
<html lang="en"     class="pb-page"  data-request-id="0be5f58d-a5be-43f3-a44c-07324c98ea8c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.0c02054;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2021.64.issue-14"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches" /></meta><meta name="dc.Creator" content="Yanjun  Zheng" /></meta><meta name="dc.Creator" content="Kutty Selva  Nandakumar" /></meta><meta name="dc.Creator" content="Kui  Cheng" /></meta><meta name="dc.Description" content="Chimeric antigen receptor T cell therapy has demonstrated antileukemia efficacy. However, this therapeutic approach is hampered by severe cytokine release syndrome, which is a major impediment to i..." /></meta><meta name="Description" content="Chimeric antigen receptor T cell therapy has demonstrated antileukemia efficacy. However, this therapeutic approach is hampered by severe cytokine release syndrome, which is a major impediment to i..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 30, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c02054" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02054" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c02054" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02054" /></link>
        
    
    

<title>Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c02054" /></meta><meta property="og:title" content="Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0010.jpeg" /></meta><meta property="og:description" content="Chimeric antigen receptor T cell therapy has demonstrated antileukemia efficacy. However, this therapeutic approach is hampered by severe cytokine release syndrome, which is a major impediment to its widespread application in the clinic. The safety of this approach can be improved by engineering a rapid and reversible “off” or “on” safety switch for CAR-T cells. Cutting-edge investigations combining the advantages of genetic engineering and chemical technology have led to the invention of small-molecule-based safety switches for CAR-T cells. Small molecules such as FITC, folate, rimiducid, rapamycin, proteolysis-targeting chimera (PROTAC) compounds, and dasatinib are being investigated to design such safety switches. Optimized CAR-T cells may have enhanced therapeutic efficiency with fewer adverse effects. Herein we summarize and classify current novel small-molecule-based safety switches for CAR-T cells that aim to provide pharmacological control over the activities and toxicities associated with CAR-T cell-based cancer immunotherapies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c02054"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02054">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c02054&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c02054&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c02054&amp;href=/doi/10.1021/acs.jmedchem.0c02054" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 14</span><span class="cit-fg-pageRange">, 9577-9591</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/14" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.1c00186" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yanjun Zheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yanjun Zheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Guangdong Provincial Key Laboratory of New Drug Screening and Guangzhou Key Laboratory of Drug Research for Emerging Virus Prevention and Treatment, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yanjun++Zheng">Yanjun Zheng</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kutty Selva Nandakumar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kutty Selva Nandakumar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Guangdong Provincial Key Laboratory of New Drug Screening and Guangzhou Key Laboratory of Drug Research for Emerging Virus Prevention and Treatment, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kutty+Selva++Nandakumar">Kutty Selva Nandakumar</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-7790-8197" title="Orcid link">https://orcid.org/0000-0001-7790-8197</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Kui Cheng</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kui Cheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Guangdong Provincial Key Laboratory of New Drug Screening and Guangzhou Key Laboratory of Drug Research for Emerging Virus Prevention and Treatment, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +86 20 6164 7192. Fax: +86 20 6164 8533. Email: <a href="/cdn-cgi/l/email-protection#0e4d666b6069654e7d637b206b6a7b206d60"><span class="__cf_email__" data-cfemail="307358555e575b70435d451e5554451e535e">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kui++Cheng">Kui Cheng</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-4136-2070" title="Orcid link">https://orcid.org/0000-0002-4136-2070</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02054&amp;href=/doi/10.1021%2Facs.jmedchem.0c02054" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 14</span><span class="cit-pageRange">, 9577–9591</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 30, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 November 2020</li><li><span class="item_label"><b>Published</b> online</span>30 June 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 July 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c02054" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02054</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9577%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYanjun%2BZheng%252C%2BKutty%2BSelva%2BNandakumar%252C%2BKui%2BCheng%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D14%26contentID%3Dacs.jmedchem.0c02054%26title%3DOptimization%2Bof%2BCAR-T%2BCell-Based%2BTherapies%2BUsing%2BSmall-Molecule-Based%2BSafety%2BSwitches%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9591%26publicationDate%3DJuly%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c02054"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">952</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c02054" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yanjun&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Kutty&quot;,&quot;last_name&quot;:&quot;Selva Nandakumar&quot;},{&quot;first_name&quot;:&quot;Kui&quot;,&quot;last_name&quot;:&quot;Cheng&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;30&quot;,&quot;issue&quot;:&quot;14&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;9577-9591&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c02054&quot;},&quot;abstract&quot;:&quot;Chimeric antigen receptor T cell therapy has demonstrated antileukemia efficacy. However, this therapeutic approach is hampered by severe cytokine release syndrome, which is a major impediment to its widespread application in the clinic. The safety of this approach can be improved by engineering a rapid and reversible “off” or “on” safety switch for CAR-T cells. Cutting-edge investigations combining the advantages of genetic engineering and chemical technology have led to the invention of small-molecule-based safety switches for CAR-T cells. Small molecules such as FITC, folate, rimiducid, rapamycin, proteolysis-targeting chimera (PROTAC) compounds, and dasatinib are being investigated to design such safety switches. Optimized CAR-T cells may have enhanced therapeutic efficiency with fewer adverse effects. Herein we summarize and classify current novel small-molecule-based safety switches for CAR-T cells that aim to provide pharmacological control over the activities and toxicities associated with CAR-T cell-&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02054&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02054" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02054&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02054" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02054&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02054" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02054&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02054&amp;href=/doi/10.1021/acs.jmedchem.0c02054" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c02054" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c02054" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c02054%26sid%3Dliteratum%253Aachs%26pmid%3D34191515%26genre%3Darticle%26aulast%3DZheng%26date%3D2021%26atitle%3DOptimization%2Bof%2BCAR-T%2BCell-Based%2BTherapies%2BUsing%2BSmall-Molecule-Based%2BSafety%2BSwitches%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D14%26spage%3D9577%26epage%3D9591%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291720" title="Antigens">Antigens</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291697" title="Safety">Safety</a>,</li><li><a href="/action/doSearch?ConceptID=290808" title="Toxicity">Toxicity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/14" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/medium/jm0c02054_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02054&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Chimeric antigen receptor T cell therapy has demonstrated antileukemia efficacy. However, this therapeutic approach is hampered by severe cytokine release syndrome, which is a major impediment to its widespread application in the clinic. The safety of this approach can be improved by engineering a rapid and reversible “off” or “on” safety switch for CAR-T cells. Cutting-edge investigations combining the advantages of genetic engineering and chemical technology have led to the invention of small-molecule-based safety switches for CAR-T cells. Small molecules such as FITC, folate, rimiducid, rapamycin, proteolysis-targeting chimera (PROTAC) compounds, and dasatinib are being investigated to design such safety switches. Optimized CAR-T cells may have enhanced therapeutic efficiency with fewer adverse effects. Herein we summarize and classify current novel small-molecule-based safety switches for CAR-T cells that aim to provide pharmacological control over the activities and toxicities associated with CAR-T cell-based cancer immunotherapies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81035" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81035" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Anticancer therapy for pre-B cell acute lymphoblastic leukemia (ALL) or B cell non-Hodgkin lymphoma refractory to standard treatments has been transformed since the U.S. Food and Drug Administration approved anti-CD19 chimeric antigen receptor T cell (CAR-T cell) products as treatments for hematologic malignancies of the B-cell lineages.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Cells frequently used in adoptive T cell therapies include tumor-infiltrating lymphocytes (TILs), T cells expressing engineered T cell receptor (TCR-T cells), and CAR-T cells. Among them, CAR-T cell therapy is a promising treatment option with high response rates against hematological malignancies.<a onclick="showRef(event, 'ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5">(3−5)</a> CAR-T cells are genetically engineered to express a class of synthetic receptors. A chimeric antigen receptor (CAR) usually consists of a single-chain fragment variant (scFv), a CD3ζ region, and one or two costimulatory domains.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The scFv derived from the variable light- and heavy-chain regions of a monoclonal antibody used in this therapy specifically recognizes a tumor membrane protein. The CD3ζ endodomain includes immunoreceptor tyrosine-based activation motifs (ITAMs), which are required for signal transduction for T cell activation. Costimulatory domains provide additional costimulatory signals required for T cell activation. As shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, compared with unmodified T cells, CAR-T cells recognize surface-exposed tumor-associated antigens (TAAs) more specifically and are activated to eliminate tumor cells without any major histocompatibility complex (MHC) restriction.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/medium/jm0c02054_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of the differences between conventional CD8<sup>+</sup> T cells and CD8<sup>+</sup> CAR-T cells in killing tumor cells and the architectural evolution of CARs. Conventional CD8<sup>+</sup> T cells specifically recognize the peptide–MHC class I (pMHC-I) complex on the surface of APCs through the TCR, which transduces activation signals into the intracellular compartment through CD3, enabling the initial activation of T cells. By recognizing tumor cells through an artificially introduced single-chain fragment variant (scFv), CD3ζ domain, and costimulatory domain, CAR-T cells are activated and kill tumor cells independent of MHC restriction. The structural differences of several generations of CARs are mainly located in the transmembrane and intracellular domains. The intracellular domain of the first-generation CAR lacked the costimulatory signal domain and contained only the CD3 domain. The second-generation CARs were equipped with only one of the CD28 or 4-1BB costimulatory domains to provide the second signal for the activation of CAR-T cells. The third-generation CAR structures had two costimulatory domains. The fourth-generation CAR structure may be designed to express separate cytokine transgenes (<i>e.g.</i>, IL-12). The fifth-generation CAR is yet to be developed; it is not yet clear whether it specifically refers to the approach incorporating a truncated cytoplasmic domain of IL-2 receptor β and the transcription factor STAT3-binding motif. Abbreviations: APC, antigen-presenting cell; Costim, costimulatory domain; IL-2Rβ, IL-2 receptor β; TAA, tumor-associated antigen.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02054&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">CARs have evolved through several generations of structural design refinement. The architectural differences found in several generations of CARs are illustrated in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. The first-generation CARs were genetically engineered to combine only an scFv with a CD3ζ endodomain.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> However, the efficacy of these CARs was limited because of insufficient CAR-T cell expansion, proliferation, and survival due to the absence of costimulatory signals and insufficient cytokine production.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> To overcome these limitations, the second-generation CARs were developed by incorporating costimulatory domains such as CD28<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> or CD137 (4-1BB),<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> which provide additional signals to CAR-T cells. This improvement increased their proliferation and secretion of cytokines and delayed CAR-T cell death.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Chimeric receptors encompassing multiple costimulatory endodomains, such as CD28 and 4-1BB<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> or CD28 and OX40,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> were modifications implemented with the third-generation CARs, which are expected to have improved potency for cytokine release and cytolytic capacity. Most of the third-generation CARs achieved their intended targets, although a few studies have shown some unexpected results.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The fourth-generation CARs incorporate an additional transgene for the secretion of stimulatory cytokines. One example of fourth-generation CARs was termed “T cells redirected for universal cytokine-mediated killing” (TRUCKs), in which a gene for the inducible or constitutive expression of IL-12 was inserted. This design helps T cells release pro-inflammatory factors into the immunosuppressive tumor microenvironment and achieve superior antitumor effects.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Other cytokines were also explored for constructing such “armored” CARs, including IL-15, IL-18, and a combination of CCL19 and IL-7.<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17−19)</a> The fifth-generation CARs, also called next-generation CARs, incorporate a truncated cytoplasmic domain of IL-2 receptor β and the transcription factor STAT3-binding motif between the cytoplasmic CD28 costimulatory domain and the CD3ζ signal transduction domain that deliver cytokine signals after antigenic stimulation.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> However, investigations of the fifth-generation CARs are still in the early stages and have not yet been well-recognized. Although efforts have been made to design various CAR constructs, the contributions of the last two generations of CAR constructs to CAR-T cell effectiveness remain to be comprehensively evaluated.</div><div class="NLM_p last">CAR-T cell-based cancer immunotherapies are under intensive investigation because of their extraordinary potential for clinical application to combat B cell lymphoid malignancies. Tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) are two approved anti-CD19 CAR-T cell products for the treatment of pediatric relapsed or refractory ALL and adult relapsed or refractory large B cell lymphoma, respectively.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> However, similar to other immunotherapies, many side effects have been observed with the currently approved CAR-T cell therapy used to treat malignant hematological diseases. When genetically engineered CAR-T cells are reinfused into patients, antitumor effects may be accompanied by cytokine release syndrome (CRS), which may sometimes threaten the patient’s life. Therefore, there is a need to control the quantity of activated CAR-T cells to execute the intended clinical effects without severe systemic cytokine-derived toxicities. Incorporating a safety switch for the CAR-T cells will lead to the development of safer immunotherapies. Small-molecule compounds targeting diverse pathways are anticipated to provide a flexible measure to control CAR-T cells because they possess tunable and drug-like pharmacokinetic properties and can easily be synthesized by chemical modifications. Progress in designing safety switches for CAR-T cells has been made using fluorescein isothiocyanate (FITC), folate, rimiducid (AP1903), rapamycin, proteolysis-targeting chimera (PROTAC) compounds, and other small-molecule compounds. FITC and folate conjugated with other substances mediate the formation of a pseudoimmunological synapse. Rimiducid is a homodimerizer that induces the dimerization of caspase-9 with consequent apoptosis of CAR-T cells. Rapamycin is the other single agent that can assemble an FKBP12–rapamycin–FRB tripartite complex to “turn on” CAR-T cells. PROTAC technology that is under development offers an alternative approach to control the lysis of CARs. Dasatinib is also a single agent that can directly prevent the activation of CAR-T cells. These successful examples have encouraged scientists to search for other small-molecule compounds with better and more suitable characteristics for the design of safety switches. The ability of such safety switches to titrate the activity of CAR-T cells toward tumor cells and therefore to strictly control toxicities after administration of CAR-T cells will expand the clinical application of CAR-T cell therapy and bring dual treatment benefits for patients. Here we discuss how safety switches offer toxicity control over CAR-T cells with their distinct regulatory mechanisms. We also describe how they are developed by combining the advantages of genetic engineering and chemical methodologies.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  CAR-T Cell Therapy: Toxicity Issues Accompany Their Effectiveness</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26175" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26175" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cytokine release syndrome, typically manifested as high fever, myalgia, unstable hypotension, and even respiratory failure, is viewed as the most common toxicity associated with CAR-T cell therapies.<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24−26)</a> CRS is graded according to its severity, and the symptoms associated with CRS vary by the grade.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In clinical trials involving CAR-T cells, severe CRS has occasionally caused serious complications that necessitated termination of the trial. In patients with severe CRS, abnormal amounts of cytokines are released by activated lymphocytes and/or myeloid cells.<a onclick="showRef(event, 'ref26 ref28'); return false;" href="javascript:void(0);" class="ref ref26 ref28">(26,28)</a> Cytokines such as IFN-γ and IL-2 are released by overactivated CAR-T cells, while elevated levels of IL-6 are the result of secondary activation of macrophages by these cytokines.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> Moreover, CRS can also be induced by tumor cell pyroptosis: CAR-T cells release a large amount of perforin, which forms pores on the surface of tumor cells and causes granzyme B to enter the tumor cells, which in turn activates the caspase 3-gasdermin E pathway to induce cell pyroptosis and subsequent CRS.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Tocilizumab, a recombinant humanized anti-IL-6 antibody, was used as the pharmacological intervention for patients who experienced life-threatening CRS. When tocilizumab does not completely reverse severe CRS, corticosteroids may be included in the treatment regimen.<a onclick="showRef(event, 'ref24 ref31'); return false;" href="javascript:void(0);" class="ref ref24 ref31">(24,31)</a> Both of these treatments have been used after the development of severe CRS, but they cannot solve the inherent problem of CAR-T cell treatment-related toxicities. Thus, it is necessary to endow CAR-T cells with an ability to titrate its activity toward tumor cells precisely so that toxicities can be strictly controlled. In another case of off-target/off-tumor toxicity, CAR-T cells targeting GD2, which is abundantly present on the surface of neuroblastoma cells, led to lethal central nervous system (CNS) toxicity along with enhanced antitumor efficacy.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> This neurotoxicity has recently been termed immune effector cell-associated neurotoxicity syndrome (ICANS).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> ICANS typically presents itself as a toxic encephalopathy with several neurological symptoms that include confusion, delirium, occasional seizures, and cerebral edema.<a onclick="showRef(event, 'ref27 ref33'); return false;" href="javascript:void(0);" class="ref ref27 ref33">(27,33)</a> A compromised blood–brain barrier was associated with a higher level of cytokines in the blood and cerebrospinal fluid, in addition to endothelial activation, which was demonstrated to be a link between neurotoxicity and CRS.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><div class="NLM_p last">When the targeted tumor-associated antigen is expressed on normal host cells, CAR-T cells will attack nonmalignant cells as well, causing on-target/off-tumor toxicity. It is difficult to identify specific surface molecules, such as EGFR variant III (EGFRvIII), that exist only on the surface of tumors but not on normal cells.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Therefore, on-target/off-tumor toxicities are more likely to occur when CAR-T cells have mistakenly targeted specific antigens expressed on the surface of normal cells, such as B cells. CAR-T cells are called “living drugs” because they have unpredictable half-lives and can survive long-term in patients. Occasionally, B cell depletion was induced after CAR-T cell therapy, which required subsequent supplementation with immunoglobulins.<a onclick="showRef(event, 'ref25 ref36'); return false;" href="javascript:void(0);" class="ref ref25 ref36">(25,36)</a> Another case of on-target/off-tumor toxicity was reported in a patient with colon cancer that had metastasized to the lung and liver after administration of autologous CAR-T cells targeting the ERBB2 (Her-2/neu) antigen. This patient died because the CAR-T cells recognized low levels of ERBB2 expressed on lung epithelial cells, which triggered the release of large amounts of cytokines.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Although the incidence of graft-versus-host disease (GvHD) is low, infusion of activated allogeneic T cells still poses the risk of GvHD. Fortunately, the risk can be reduced by an infusion of donor-derived T cells and an inducible caspase-9 safety switch system.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> Since the activation and proliferation of CAR-T cells cannot be controlled <i>in vivo</i>, it is extremely important to remotely and reversibly regulate the functions of CAR-T cells using a small-molecule-based safety switch.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">3.  Small Molecules Function as Safety Switches to Reduce the Toxicity Associated with CAR-T Cell Therapy</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81445" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81445" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A variety of technologies, such as FITC-labeled antibodies, rapamycin-induced protein heterodimerization, rimiducid-induced protein homodimerization, and PROTAC-regulated protein degradation, have been employed to design novel safety switches. Such safety switches were designed by applying distinct strategies to minimize treatment-related toxicities while improving the therapeutic efficiency of CAR-T cells. Safety switches produced to date can be divided into “on” and “off” switches. “On” switches mediate the assembly of tripartite complexes: FITC and/or folate-based switches mediate the formation of tertiary complexes by acting as pseudoimmunological synapses between antigen-expressing tumor cells and CAR-T cells, and rapamycin mediates the assembly of an FKBP12–rapamycin–FRB tripartite complex. “Off” switches can be subdivided into three types: rimiducid induces caspase-9 dimerization with consequent CAR-T cell apoptosis; PROTAC compounds can control the stability of CARs; and dasatinib directly inhibits CAR-T cell activation. The structures of recently described small-molecule compounds used as safety switches and their distinct mechanisms are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Summary of Small-Molecule Safety Switches</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/medium/jm0c02054_0008.gif" alt="" id="gr9" /></img><div></div></div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">3.1.  FITC/Folate-Based Safety Switches Mediate the Assembly of Pseudoimmunological Synapses</h3><div class="NLM_p">A novel bifunctional/bispecific “switch” has been designed to maximize the antitumor activities of CAR-T cells while controlling the toxicities associated with life-threatening CRS. Appropriate small molecules have been conjugated with other components so that they function together as an intermediate bifunctional/bispecific switch. This type of safety switch contains two key modules: one is endowed with the ability of specific recognition and binding to TAA, and the other is capable of binding to the reprogrammed antigen recognition domain of the CAR. FITC and folate are commonly used to design this type of safety switch. This bifunctional/bispecific switch can turn CAR-T cells to the “on” state by serving as pseudoimmunological synapses between CAR-T cells and tumor cells in a spatiotemporal and dosage-dependent manner. It is only after administration of the small-molecule safety switch that the pseudoimmunological synapse can be formed and CAR-T cells be triggered to eradicate the target cancer cells.</div><div class="NLM_p">Fluorescein is a synthetic, exogenous fluorescent tracer for fluorescence imaging, and it is used in the treatment of malignant tumors.<a onclick="showRef(event, 'ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref40 ref41 ref42">(40−42)</a> FITC is generated by introducing an isothiocyanate group into the structure of fluorescein. FITC has the advantages of a high fluorescence quantum yield and susceptibility to microenvironmental changes without significant influence on the specificity of the conjugated antibody. Most importantly, the gene sequences of anti-FITC antibodies have been extensively investigated, facilitating the use of FITC in the design of safety switches for CAR-T cells. At present, FITC is the most widely used fluorochrome in modifying antibody fragments or conjugating with folate to synthesize FITC-based switches (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The development of additional antibodies against small molecules and elucidation of their gene sequences will provide alternative small molecules that can be use in such safety switches. When FITC conjugates with the target protein, the isothiocyanate group of FITC usually forms a thiourea bond with the primary amine group of the protein. Recently, novel approaches have been devised to conjugate FITC with antibodies. After FITC is chemically modified by compounds containing terminal alkynyl groups, it is allowed to undergo a “click” reaction with antibodies incorporating <i>p</i>-azidophenylalanine (pAzF) and then form strong antibody–fluorescent dye conjugates. The specific reactions and the general scheme are summarized in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>A.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> First, by the use of PEG4 and endo-BCN-NHS as substrates, BCN-PEG4-FITC, which introduces cycloalkynyl groups into FITC, is synthesized in a two-step reaction. Meanwhile, pAzF is incorporated into antibody fragments genetically. The antigen-binding fragments (Fabs) that have been investigated to date include but are not limited to CD19 (clone FMC63)-, CD22 (clone M971)-, and Her2 (clone 4D5)-specific monoclonal antibodies. Finally, the terminal alkynyl moiety of BCN-PEG4-FITC and the azido moiety of the antibody fragment undergo a catalyst-free click reaction to generate the FITC-based safety switch.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/medium/jm0c02054_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic diagram of the FITC/folate-based safety switch. (A) The formation of pseudoimmunological synapses between tumors and CAR-T cells is mediated by safety switches. CAR-T cells are not activated to eliminate tumors without a FITC/folate-based safety switch, even in the presence of tumor-associated antigens. FITC/folate-based safety switches are anticipated to effectively regulate the activities of CAR-T cells to manage severe CRS. (B) The FITC/folate-based safety switch mediates the formation of pseudoimmunological synapses <i>via</i> two components of binding sites. These two components can combine with predesigned antigen receptors present on the surface of CAR-T cells as well as the abnormally expressed receptors or epitopes present on the surface of tumor cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02054&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/medium/jm0c02054_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0013.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of the FITC/Folate-Based Safety Switch: (A) General Scheme for the Synthesis of Site-Specific FITC–Antibody Conjugates <i>via</i> Click Chemistry; (B) Synthesis of FITC–Folate Conjugates</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02054&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Investigators carried out <i>in vivo</i> and <i>in vitro</i> experiments to verify the efficacy of FITC-based safety switches. Comparisons between conventional CD19-specific CAR-T cells and anti-FITC switchable CAR-T (sCAR-T) cells equipped with the optimized anti-CD19 FITC-based safety switch are shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Anti-FITC CAR-T cells with 1 nM anti-CD19 AB-FITC and conventional CART-19 cells exhibited comparable activities in lysing Nalm-6 (CD19<sup>+</sup>) cells. <i>In vivo</i> experiments were carried out in a Nalm-6 xenograft model. Tumor growth was quantified by detecting the radiance in the region of interest (ROI). The results showed that anti-FITC CAR-T cells with anti-CD19 AB-FITC cleared the tumors as effectively as CD-19 CAR-T cells. In addition, the data show that the conjugation site greatly influences the therapeutic efficacy. The proximal bivalent AB-FITC switch displayed the best antitumor efficacy, and the proximal monovalent B switch was more potent than bivalent EF and random switches. Moreover, the toxicities of CAR-T cell therapy can be theoretically controlled by varying the dosing regimen of the small-molecule-based safety switch. Anti-CD19 AB-FITC at a concentration of 0.5 mg/kg caused a significant weight loss in mice, while a concentration of 0.05 mg/kg did not cause weight loss to a similar extent. In dose-escalation studies, a dose of anti-CD19 AB-FITC started at 0.05 mg/kg and increased to 0.5 mg/kg achieved equivalent tumor clearance and milder weight loss than a high starting switch dose of 0.5 mg/kg. These results provide evidence that the small-molecule-based safety switch approach may be useful for controlling severe CRS in clinical settings. FITC labeling of the Fab fragments of trastuzumab can also be applied to redirect CAR-T cells to Her2-expressing tumor cells, which are present in Her2-positive breast cancer patients. This FITC-labeled trastuzumab safety switch mediated sCAR-T cells to completely clear tumors in rodent xenograft models. The dosage regimen for mice consisted of an injection of 3 × 10<sup>7</sup> anti-FITC CAR-T cells iv followed by another iv injection of anti-Her2 Fab-FITC switch at 0.5 mg kg<sup>–1</sup> every other day up to day 14 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B).<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> The FITC-based safety switch has been demonstrated to redirect the specificity of CAR-T cells by inducing distinct spatial interactions. In fact, FITC was applied to link unique tumor-specific ligands to target different tumor markers.<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45,46)</a> Another small-molecule switch named FITC-HM-3 bifunctional molecule (FHBM) was designed to simultaneously bind dual-receptor-modified T cells and cognate tumor cells expressing both mesothelin (MSLN) and integrin αvβ3, thus endowing CAR-T cells with not only an improved ability to distinguish tumor and normal cells but also an enhanced ability to control their activity and cytotoxicity.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/medium/jm0c02054_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Comparison of the anticancer and cytotoxic effects of switchable and conventional CAR-T cells. (A) Comparison of <i>in vitro</i> cytotoxicities and <i>in vivo</i> radiance quantifications in the region of interest (ROI) of conventional CAR-T cells and anti-FITC CAR-T cells with an optimized anti-CD19 AB-FITC switch. Reproduced from ref <a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a>. Published by the National Academy of Sciences. (B) Comparison of <i>in vivo</i> antitumor efficacies and <i>in vitro</i> cytotoxicities of conventional anti-Her2 CAR-T and sCAR-T cells. Reproduced with permission from ref <a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a>. Copyright 2016 Wiley-VCH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02054&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Folate (or folic acid), which is a to water-soluble B vitamin, is a low-molecular-weight compound with low immunogenicity. It occupies an important place in the design of this type of safety switch. Cancer therapeutics using folate as a targeting ligand have attracted significant interest, including folate-attached cytotoxic drugs and folate-laden nanoformulations.<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48,49)</a> Abnormal proliferation of malignant tumors requires large amounts of folate because it is an important precursor for nucleic acid biosynthesis and methylation. Hence, tumor cells rely on endocytosis mediated by the folate-binding protein folate receptor (FR) to actively absorb exogenous folate into the cytoplasm to maintain elevated metabolic needs. Among all of the isoforms of FR, FRα is expressed in a restricted manner within normal tissues, such as relatively low level expression on the apical (luminal) cell membrane of various epithelial tissues, but this isoform is expressed in endometrial cancer, ovarian cancer, cervical adenocarcinoma, nonsmall cell lung cancer, and malignant mesothelioma (MM).<a onclick="showRef(event, 'ref50 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref50 ref51 ref52">(50−52)</a> Hence, the differential distribution of FRα in normal and tumor tissues together with the high affinity and stability of folate make FRα and folate potential targets for the design of safety switches</div><div class="NLM_p">Folate-based safety switches were designed to mitigate the toxicities associated with CAR-T cell therapy. Unlike antibody fragments that are genetically encoded to incorporate an azido moiety where click reactions can occur, the humanized catalytic antibody h38C2 contains an unprotonated lysine Lys residue, which is adapted for site-specific conjugation with small molecules.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> The Lys99 residue can be used to chemically program antibodies by forming a stable amide bond with small-molecule compounds containing β-lactam functions. More recently, a new switchable CAR-T treatment platform based on chemically programmed antibody fragments (cp-Fab) was developed by modifying the Fab fragments with a trifunctional β-lactam–biotin–folate compound.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> This novel safety switch system was called cp-Fab/CAR-T. The first type of cp-Fab was produced by fusion of a GCN4 polypeptide fragment to the light- or heavy-chain terminus of h38C2 Fab followed by coupling with folate. The second type of cp-Fab was formed by conjugation of folate with the GCN4 polypeptide followed by coupling with the wild-type h38C2 Fab scaffold. The GCN4 polypeptide fragment binds to scFv 52SR4-based CAR-T cells, and folate binds to FRα that is overexpressed on cancer cells.</div><div class="NLM_p">Unlike switches composed of a tumor-targeting antibody, safety switches using small-molecule ligands that recognize and bind to folate receptors overexpressed on tumor cells are more practical and readily available. In another approach, a FITC–folate conjugate was developed as a bifunctional small-molecule switch. The FITC–folate conjugate was synthesized by condensing folate with an ethylenediamine linker followed by direct coupling to FITC through a second condensation reaction (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>B).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> This small-molecule switch is bispecific for FR-positive cells and anti-FITC CAR-T cells.</div><div class="NLM_p">FRα is also a suitable marker for nonsmall cell lung cancers because of its high expression in tumor tissues.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Therefore, the FITC–folate conjugate is expected to function as an intermediate switch to reduce the toxicity while increasing the efficacy of CAR-T cells to treat nonsmall cell lung cancer.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><div class="NLM_p last">Indeed, FITC could redirect CAR-T cells toward various antigen epitopes of cancer cells by conjugation with different substrates, thereby eliminating the need to re-engineer CAR-T cells. In addition, the wealth of existing studies on anti-FITC antibodies and the high affinity of FITC to these antibodies provide advantages to the switch design that cannot be ignored. Although this type of small-molecule-based safety switch theoretically improves the safety profiles of CAR-T cells, the antitumor effect of the modified cells was not always better than that of the unmodified CAR-T cells. Therefore, additional designs and techniques need to be developed to navigate trade-offs between the safety and efficiency profiles of such treatment options.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">3.2.  Rapamycin Induces the Assembly of FKBP12 and the FRB Binding Domain to Control the Activation of CAR-T Cells</h3><div class="NLM_p">T cells are activated by recognition of the antigenic peptide–MHC (p-MHC) complex present on the surface of APCs along with interactions with other receptors and ligands that provide secondary stimulatory signals. Genetically engineered CAR-T cells possess an extracellular antigen recognition domain and an intracellular signaling domain. Another strategy for generating small-molecule-based switches is to split these two structures and rejoin them in the presence of small-molecule drugs. Chemical inducer of dimerization (CID) has emerged as a potent tool for controlling protein dimerization. In this context, rapamycin and analogues of rapamycin (rapalogues) can be used as CIDs to assemble domains introduced into CAR structures. Rapamycin exerts potent immunosuppressive properties apart from its promising antitumor functions by inhibiting mTOR (TORC1).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> To improve the pharmacological properties of rapamycin, various rapalogues were synthesized by structural modification of the C8 or C40 hydroxyl group, six-membered pipecolate ring, and cyclohexane ring present in rapamycin.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Among them, AP21967 is a derivative of the C16 structure modified by methylindole with less undesirable immunosuppressive activities.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Rapamycin simultaneously occupies two different hydrophobic binding pockets of two proteins: human FK506-binding protein (FKBP12) and the FKBP12-rapamycin-binding (FRB) domain of FKBP-rapamycin-associated protein (FRAP).<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> AP21967 dimerizes the T2089L mutant of the FRB domain of FRAP and the FKBP12 domain. Rapamycin, after binding to the FKBP12 and FRB domains, can directly induce heterodimerization of these two binding domains.<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60,61)</a> Thus, inserting the FKBP12–rapamycin–FRAP/FRB tripartite complex into the structure of CAR can constitute a small-molecule-based safety switch to control CAR-T cell activities. The specific insertion site can be varied flexibly according to the design ideas. In the presence of rapamycin, the chimeric antigen receptor executes both antigen recognition and signaling functions. However, in the absence of rapamycin, the antigen-binding subunit and the intracellular signaling subunit are disconnected, keeping CAR-T cells in the “off” state even though the scFv fragments of CAR-T cells bind to the target antigens on the surface of tumor cells (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). This type of safety switch allows CAR-T cells to be specifically regulated after being injected into the patient’s body, which means that the activity can be gradually titrated to the appropriate therapeutic level to avoid serious adverse reactions.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/medium/jm0c02054_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Schematic representation of rapamycin as a molecular switch. Comparisons of the cytotoxicities and anticancer effects of modified CD19-DARIC T cells and conventional CAR-T cells are shown. (A) In the absence of rapamycin, the antigen recognition domain is separated from the signal transduction domain of the CAR structure. The formation of the tripartite complex bridges the antigen recognition and signal transduction domains, restoring the CAR structure as a whole molecule. Thus, rapamycin can be used to regulate the activities of CAR-T cells remotely to avoid potentially fatal toxic effects. (B) (left) The cytotoxicity of CD19-DARIC T cells was comparable to that of conventional CD19-CAR-T cells. (right) Bioluminescence data showing superior <i>in vivo</i> activity of CD19-DARIC T cells with non-immunosuppressive rapamycin concentrations compared with conventional CD19-CAR-T cells. Reproduced with permission from ref <a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a>. Copyright 2019 American Society for Clinical Investigation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02054&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Inserting fusion proteins of FRB and FKBP12 into the intracellular region separates the extracellular scFv antigen-binding domain from the CD3ζ downstream signaling subunit and costimulatory domain. “On-switch” CARs adopt a split-receptor design that mediates heterodimerization by rapamycin or a rapalogue and possess a dual role, <i>i.e.</i>, achieving maximum reduction in toxicity while generating strong antigen-induced signals.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> The optimal conformation of the two fusion proteins (FKBP and FRB*) was determined by changing the domain composition and the order of the CAR splitting parts and orthogonally combining these disparate parts. A dimerizing-agent-regulated immunoreceptor complex (DARIC) was generated by insertion of the FKBP12–rapamycin–FRAP/FRB tripartite complex into the extracellular domain of the second-generation CD19-CAR.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> This study also evaluated the <i>in vivo</i> antitumor efficacy of CD19-DARIC T cells in comparison to that of conventional CD19-CAR-T cells. Compared with conventional CD19-CAR T cells, CD19-DARIC T cells in the presence of rapamycin or the analogue compound AP21967 exhibited equivalent levels (∼80%) of cytotoxicity in a fluorescence-activated cell sorting (FACS)-based analysis and superior tumor clearance in a bioluminescence analysis (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). In another attempt to mitigate the toxicity, this small-molecule-based switch strategy was applied to a novel CAR architecture based on an FcεRI receptor scaffold.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> These cellular products, called controllable transient CAR T-cells, were expected to have improved safety profiles because of the use of rapamycin or its analogues to control the function and cytotoxicity of CAR-T cells. Because rapamycin can join FKBP12 and FRB, it can also mediate apoptosis by inducing caspase-9 dimerization (see <a class="ref internalNav" href="#sec3_3" aria-label="section 3.3">section 3.3</a>) as long as the inducible caspase-9 system contains FKBP12 and FRB domains. For example, rapamycin was used to dimerize rapamycin-induced caspase-9 (iRC9) by linking the FKBP12 domain of one iRC9 and the FRB domain of another iRC9 and to induce apoptosis of CAR-T cells in a rapamycin-dependent manner.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div><div class="NLM_p last">However, rapamycin and its analogues are not panaceae for eliminating toxicities because of the following concerns: First, FKBP12- and FRB-fused proteins are not exclusive receptors for rapamycin and its analogues. Competition with endogenous FKBP12 and the mTOR complex may lead to unpredictable CAR functions and interfere with accurate control of the dose of rapamycin and its analogues. Second, rapamycin exhibits potent immunosuppressive activity, which contradicts the underlying concept of CAR-T cell therapy to enhance the activity of the immune system <i>in vivo</i>. Therefore, rapamycin may partially reduce the robust therapeutic effects of CAR-T cells. This is supported by the observation that traditional CAR-T cell activity was slightly suppressed after the administration of rapamycin. Notably, there are rapalogues that have lower immunosuppressive activity than rapamycin.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Therefore, these agents may be used as alternatives to rapamycin. However, few studies have investigated their safety, efficacy, and clinical applications.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">3.3.  Rimiducid Induces Caspase-9 Dimerization and Promotes Apoptosis of Excessively Activated CAR-T Cells</h3><div class="NLM_p">Genetically targeted T cells combined with suicide genes possess considerable practical utility, and this method has been tested in several clinical trials. To date, approaches introducing a suicide gene can be categorized according to the dimer and CID. CIDs such as rimiducid (AP1903) and ganciclovir can induce apoptosis of CAR-T cells when CAR structures include a suicide-gene-encoding fusion protein. A human cell surface polypeptide CD20 antigen was used not only as a selection marker but also as a suicide gene, which can be triggered by rituximab (anti-CD20 monoclonal antibody) to execute its protective function.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> We herein mainly focus on introducing a suicide gene system using small-molecule-based safety switches. The suicide gene system using ganciclovir and herpes simplex virus thymidine kinase (HSV-TK) has drawbacks compared with those using rimiducid and inducible caspase-9. Ganciclovir is a phosphorylated purine nucleotide analogue that interferes with DNA synthesis and kills dividing cells, but it requires several days before therapeutic benefits are gained.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Moreover, HSV-TK is an exogenous virus-derived protein with potential high immunogenicity, which may induce undesirable immune responses and lead to premature elimination.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Thus, we mainly discuss the extensive studies and promising clinical benefits of safety switches composed of rimiducid and inducible caspase-9. To avoid undesired severe toxicities, the inducible caspase-9 safety switch system was developed as a practical approach with a defined clinical profile. This system could promptly terminate the therapeutic activity of CAR-T cells through small-molecule-induced apoptosis.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> This system fuses modified human caspase-9 to human FK506-binding proteins (FKBPs) and uses rimiducid/AP20187 as the chemical inducer of dimerization.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Rimiducid acts as a dimerizer by cross-linking the F36V variant of the FKBP12 (FKBP12-F36V) domain. AP20187 is similar to rimiducid and can homodimerize FKBP12-F36V. These two small molecules are different from AP21967, which dimerizes the T2089L mutant of the FRB and FKBP domains (see <a class="ref internalNav" href="#sec3_2" aria-label="section 3.2">section 3.2</a>). Rimiducid/AP20187 can mediate the conditional dimerization of inducible caspase-9 with subsequent activation of caspases 3, 6, and 7, causing apoptosis of cells expressing the fusion protein (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A).</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/medium/jm0c02054_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Schematic diagram of the iCas9 system and the <i>in vivo</i> antitumor activity. (A) Schematic diagram of the iCas9 system inducing apoptosis of CAR-T cells. Rimiducid and iCas9 are part of a potent suicide gene system that efficiently induces apoptosis of CAR-T cells in the case of CRS. iCas9 is a fusion protein composed of FKBP12-F36V (an F36V mutant of FK506-binding protein) and ΔCaspase9. Rimiducid is a small-molecule dimerizing agent that can bind to FKBP12-F36V with high affinity. Once rimiducid induces homodimerization of iCas9, the caspase cascade is triggered to activate caspase 3, 6, and 7, leading to apoptosis of CAR-T cells. (B) Summary of the bioluminescence signal in severe combined immunodeficient (SCID) mice engrafted either ip or sc with 3 × 10<sup>6</sup> Daudi cells labeled with FFLuc. Reproduced with permission from ref <a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a>. Copyright 2010 Springer Nature.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02054&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">There are numerous examples of safety switches using this approach. AP20187, an effective CID <i>in vitro</i>, can modulate CD-19 CAR-T cell toxicities by inducing the dimerization of mutant human caspase 9 and subsequent apoptosis of T cells.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Novel CD19 CAR-T cells that coinsert the interleukin-15 (IL-15) gene and an inducible caspase-9-based suicide gene can balance the potentially increased risk of direct toxicity and the improved antilymphoma/leukemia effects. In these iC9/CAR.19/IL15<sup>+</sup> T cells, investigators were able to manage uncontrolled proliferation after the introduction of IL-15 by pharmacologically activating the caspase-9-based safety switch.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> As demonstrated in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B, iC9/CAR.19/IL15<sup>+</sup> T cells showed improved <i>in vivo</i> antitumor effects. There was a 4.7–5.4-fold reduction in the tumor burden in animals treated with iC9/CAR.19/IL15<sup>+</sup> T cells compared with the group treated with CAR.19<sup>+</sup> T cells [(1.7 ± 5) × 10<sup>8</sup> to (9.3 ± 1.6) × 10<sup>8</sup> cells by day 38]. In a separate series of experiments, a CD20 chimeric antigen receptor and a suicide switch consisting of inducible caspase-9 and rimiducid or AP20187 (B/B homodimerizer) were introduced into CAR-T cells. These CAR-T cells with the safety switch were efficiently removed both <i>in vivo</i> and <i>in vitro</i> and improved the efficacy and safety of adoptive T cell immunotherapy for lymphoma.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Bellicum Pharmaceuticals has applied the CID technology with inducible caspase-9 and MyD88/CD40 to build safety and GO switches, respectively. The inducible caspase-9 system was applied to trigger T cell apoptosis in the context of HSCT therapy, and the inducible MyD88/CD40 switch was used to trigger T cell activation and proliferation in CAR-T cell therapy.<a onclick="showRef(event, 'ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref74 ref75">(74,75)</a> The feasibility of deploying rimiducid as an iC9 safety switch to control severe CRS also been tested in patients. As listed in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, the inducible caspase-9 safety switch system has undergone multiple clinical trials. The safety profile of CAR-T cell therapy modified by rimiducid–inducible caspase-9 was validated in five recipients who received a stem cell transplant for relapsed acute leukemia.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Treatment in 12 haploidentical hematopoietic stem cell transplant (haplo-HSCT) patients also proved that administration of rimiducid can control GvHD and severe CRS by eliminating iC9-T cells.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Long-term follow-up of 10 patients after haplo-HSCT showed that a single administration of rimiducid can provide permanent control of graft-versus-host disease (GvHD) without impeding immune reconstitution.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> More surprisingly, the allo-depleted T cells containing the iC9 safety gene benefited the patients by their long-term persistence, immune recovery, and resistance to opportunistic infections.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Clinical Trials of the iCas9 System Used for Safety Switch</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">CAR-T cells</th><th class="colsep0 rowsep0" align="center">test no.</th><th class="colsep0 rowsep0" align="center">year</th><th class="colsep0 rowsep0" align="center">phase</th><th class="colsep0 rowsep0" align="center">no. of participants</th><th class="colsep0 rowsep0" align="center">conditions</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iC9-CAR19</td><td class="colsep0 rowsep0" align="left">NCT03016377</td><td class="colsep0 rowsep0" align="left">2018</td><td class="colsep0 rowsep0" align="left">I, II</td><td class="colsep0 rowsep0" align="left">54</td><td class="colsep0 rowsep0" align="left">ALL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iC9-CAR19</td><td class="colsep0 rowsep0" align="left">NCT03594162</td><td class="colsep0 rowsep0" align="left">2018</td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="left">ALL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iC9-CAR19</td><td class="colsep0 rowsep0" align="left">NCT03696784</td><td class="colsep0 rowsep0" align="left">2019</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">lymphoma</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iC9.GD2.IL-15</td><td class="colsep0 rowsep0" align="left">NCT03721068</td><td class="colsep0 rowsep0" align="left">2019</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">neuroblastoma</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P-BCMA-101</td><td class="colsep0 rowsep0" align="left">NCT03741127</td><td class="colsep0 rowsep0" align="left">2018</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">MM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P-BCMA-101</td><td class="colsep0 rowsep0" align="left">NCT03288493</td><td class="colsep0 rowsep0" align="left">2017</td><td class="colsep0 rowsep0" align="left">I, II</td><td class="colsep0 rowsep0" align="left">220</td><td class="colsep0 rowsep0" align="left">MM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CD19-CAR-T</td><td class="colsep0 rowsep0" align="left">NCT03373071</td><td class="colsep0 rowsep0" align="left">2017</td><td class="colsep0 rowsep0" align="left">I, II</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">ALL, CD19-NHL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P-PSMA-101</td><td class="colsep0 rowsep0" align="left">NCT04249947</td><td class="colsep0 rowsep0" align="left">2020</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">prostatic neoplasms</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">anti-SLAMF7</td><td class="colsep0 rowsep0" align="left">NCT03958656</td><td class="colsep0 rowsep0" align="left">2019</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="left">MM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">anti-GD2</td><td class="colsep0 rowsep0" align="left">NCT02107963</td><td class="colsep0 rowsep0" align="left">2014</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">sarcoma</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iC9-GD2</td><td class="colsep0 rowsep0" align="left">NCT01822652</td><td class="colsep0 rowsep0" align="left">2013</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">neuroblastoma</td></tr></tbody></table></div></div><div class="NLM_p last">Another study showed that rimiducid-activated dimerization not only induced CAR-T cell apoptosis but also introduced new applications for CAR modification. For instance, designing novel rimiducid-regulatable domains may make it possible to provide an alternate activation signal in CAR-T cells. Rimiducid-induced dimerization of inducible MyD88/CD40 (iMC) led to activation of downstream TLR and CD40 costimulatory signaling pathways. As a consequence, rimiducid administration enhanced survival and promoted proliferation of CAR-T cells, while cells could become anergic after rimiducid was withdrawn.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> The data from the above studies and the proposed mechanisms demonstrate the need for additional experiments to compare the therapeutic effects of conventional CAR-T cells with those modified with the iCas9 or iMC system. Altogether, most of these safety switches can induce ∼90% CAR-T cell apoptosis within 2 h, and therefore, rimiducid may be regarded as a potent “off” safety switch with a definite effect on inducing CAR-T cell apoptosis. However, although these safety switches are highly effective and have undergone numerous clinical trials, the major limitation is the irreversible depletion of CAR-T cells from circulation. This could result in loss of therapeutic efficacy, which may require reinfusion of CAR-T cells.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">3.4.  PROTAC Technology Controls the Lysis and Degradation of CARs</h3><div class="NLM_p">CAR-T cells remain in an activated state as long as CARs recognize and bind to predetermined tumor-associated antigens present on the surface of target tumor cells. Therefore, the quantities of CARs expressed on the surface of T cells are a key indicator to quantify the anticancer activities and potential toxicities of CAR-T cells. Remote and reversible regulation of surface presentation of CARs by precise control of their degradation represents a novel approach in designing a safety switch. Currently, a new technology named proteolysis-targeting chimera (PROTAC) has emerged as a potent therapeutic intervention to degrade specific proteins within cells.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> The N- and C-terminal residues of cellular proteins are major determinants of N- and C-degrons, respectively, which are signals controlling the degradation and stability of proteins.<a onclick="showRef(event, 'ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref79 ref80">(79,80)</a> Proteins of interest containing degrons are degraded mainly through the ubiquitin (Ub)–proteasome system (UPS), in which E3 ubiquitin ligase promotes protein ubiquitination and the proteasome subsequently executes protein degradation.<a onclick="showRef(event, 'ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref81 ref82">(81,82)</a> Because CAR is an artificial and synthetic protein, by incorporation of a degron into CAR it should be theoretically feasible to degrade the entire CAR protein once the degron is recognized by a proteolytic enzyme (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Various novel small molecules have been used to control the degradation of CAR <i>via</i> different methods.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/medium/jm0c02054_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Schematic diagram of PROTAC technology controlling CAR degradation through the ubiquitin–proteasome system. (A) Asunaprevir, known as an HCV NS3 protease inhibitor, inhibits HCV NS3 protease from cleaving the degron from CAR. Thus, the degron together with CAR is degraded by the proteasome. (B) Administration of ARV771 or ARV825 induces CAR degradation by the E3 ligase–proteasome pathway. (C) Shield-1 displaces and exposes the degron to the proteasome by competitively binding to FKBP12-F36V. Abbreviations: Costim, costimulatory; BD, bromodomain; E2, E2 ligase; E3, E3 ligase; Ub, ubiquitin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02054&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The SWIFF-CAR system, in which an off switch is integrated into the CAR construct, was designed to regulate the expression of CAR on the cell surface reversibly at the protein level.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> This novel CAR construct has three main components: a protease target site, HCV NS3 protease, and a degradation moiety (degron) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). Asunaprevir, an HCV NS3 protease inhibitor, controls the self-cleaving moiety, and the HCV NS3 protease/degron component was incorporated into the CAR architecture. In the presence of asunaprevir, it inhibits the cleavage of the degron from the CAR by the HCV NS3 protease. Therefore, while active HCV NS3 protease activity promoted the membrane expression of a functional CAR, the administration of protease inhibitor acted as an “off” signal, prompting the proteasome degradation of the full CAR–protease–degron structure. Administration of ARV771 or ARV825, PROTAC compounds against bromodomain (BD), regulate a second safety switch system by degrading the BD-containing CAR protein (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B).<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> This safety switch controls both cytokine secretion and lytic activity of CAR-T cells. ARV-771 and ARV-825 are heterobifunctional compounds comprising an alkyl linker and a BETP-binding moiety, Von Hippel–Lindau (VHL) for ARV-771 and the E3 ligase cereblon-binding moiety for ARV-825.<a onclick="showRef(event, 'ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref84 ref85">(84,85)</a> The ligand-induced degradation (LID) domain can be fused to the CAR construct to modulate its characteristics. Shield-1, a small-molecule ligand, was designed to displace and expose the cryptic degron present within the LID domain, which initiates proteasomal degradation of the CAR–LID fusion protein and downregulation of the surface expression of CARs.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></div><div class="NLM_p last">However, application of the PROTAC technology to control the lysis and degradation of CARs is more complicated. First, the slow onset of small-molecule-induced degradation of CAR might not be sufficient to reverse severe and acute CRS rapidly. Theoretically, the degradation of CAR protein and the restoration of CAR expression are reversible. However, most of the studies to date have been carried out <i>in vitro</i> only, except for a single <i>in vivo</i> experiment that proved the inhibitory function of PROTAC compounds on CAR expression. Thus, the feasibility of this PROTAC-based safety switch approach needs additional investigation in the near future. Nonetheless, PROTAC-technology-mediated CAR degradation still holds promise as a means to control toxicities because of its flexible and innovative properties.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">3.5.  Dasatinib Directly Prevents CAR-T Cell Activation</h3><div class="NLM_p last">Existing drugs can be used as pharmacological safety switches to temporarily inactivate CAR-T cells to control their toxicities. Moreover, the antitumor effects can be restored after discontinuing the safety switch drugs. Dasatinib, a small-molecule multityrosine kinase inhibitor against BCR-ABL and SRC, suppresses TCR-mediated signal transduction, cellular proliferation, cytokine production, and <i>in vivo</i> T-cell responses by inhibiting lymphocyte-specific protein tyrosine kinase (Lck).<a onclick="showRef(event, 'ref87 ref88'); return false;" href="javascript:void(0);" class="ref ref87 ref88">(87,88)</a> Therefore, dasatinib is a potential drug of choice as a pharmacological safety switch to attenuate the toxicities of CAR-T cells without compromising their therapeutic efficacy. Inhibition of the autophosphorylation of Lck by dasatinib reduces Lck-mediated phosphorylation of CD3ζ and the ζ-chain of T cell receptor-associated protein kinase 70 (ZAP70) by ∼90%, which further reduces signaling in CAR constructs.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Therefore, dasatinib is potentially effective for all CAR structures because CD3ζ is an immobile part of the signal transduction module present in all types of CAR constructs. The effects of dasatinib on antigen-induced T cell activation, proliferation, and cytokine production have been assessed in preclinical studies, and the results provide evidence that dasatinib can act as a potent pharmacological off switch to control severe CRS and may also contribute to the treatment of ICANS.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> However, the inhibitory effect of dasatinib is not as robust in activated CAR-T cells, which might result in inferior toxicity control.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Moreover, dasatinib is a nonspecific immunosuppressive drug that can suppress all T cells, including T helper cells.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Since dasatinib is not specifically designed as a small-molecule safety switch but used only as an immunosuppressive drug, it is controversial whether it could be called a small-molecule safety switch for CAR-T cells. Overall, notwithstanding its limitations, dasatinib can still potentially be used because of its safety profile.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">4.  Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70040" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70040" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Adoptive T-cell immunotherapy based on the forced expression of genetically engineered antigen receptors presents significant clinical promise in the treatment of malignant hematological tumors. Ongoing investigations on CAR-T cell therapies are mainly focused on improving the clinical efficacy, mitigating antigen escape, and enhancing the specificity of CAR-T cells. In order to achieve these goals, various modifications are introduced into chimeric antigen receptor constructs. Fourth-generation CARs have been developed that can deliver cytokines or chemokines to confer resistance to the immune-suppressive tumor microenvironment. In addition, dual and triple CARs are being developed to simultaneously bind to two or three tumor antigens to improve their specificity to tumor cells.</div><div class="NLM_p">Despite the excellent clinical profiles of CAR-T cell therapy, it is still difficult to attain the optimal therapeutic levels without causing severe toxicities when the tumor load is unpredictable and the activity of T cells is uncontrolled. Severe CRS remains a potentially fatal side effect of CAR-T cell therapy. As a part of the improvement of this therapeutic approach, sufficient attention should be paid to managing the CAR-T cell safety profile. To control the toxicity, severe CRS needs to be monitored appropriately using the CRS grading system as a guide and modulated precisely using small-molecule-based safety switches. CAR-T cells equipped with small-molecule compounds should have definite pharmacodynamic and pharmacokinetic properties. Thus, small molecules are expected to endow CAR-T cells with functional flexibility by artificially switching between the “on” and “off” states. Additionally, small molecules can also be delivered selectively to target tissues using drug-directed transport technology, which will help further mitigate the on-target/off-tumor toxicity issues. Small-molecule compounds such as FITC, folate, rapamycin, rimiducid, and PROTAC compounds have been successfully adapted to design novel safety switches for CAR-T cells to reduce life-threatening CRS through various mechanisms (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Nonetheless, most of the small-molecule-based safety switches have not yet been tested clinically in the context of CAR-T cell-based therapies, and therefore, it remains to be seen how effective they could be in enhancing safety while reducing toxicity.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/medium/jm0c02054_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Schematic diagram depicting distinct mechanisms of small-molecule compounds applied in safety switches. FITC–folate conjugates act as safety switches that induce the formation of pseudoimmunological synapses between tumors and CAR-T cells. Rapamycin mediates assembly of the FKBP12–rapamycin–FRB tripartite complex that bridges the extracellular antigen recognition domain with costimulatory and CD3ζ domains. Rimiducid binds to FKBP12-F36V and induces caspase-9 dimerization with consequent apoptosis of CAR-T cells. PROTAC compounds in conjunction with degrons control the surface expression levels of CARs by inducing degradation of CARs. Dasatinib prevents the activation of CAR-T cells by inhibiting the phosphorylation of Lck, CD3ζ, and ZAP70 molecules. Costim, costimulatory domain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02054&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In the future, small-molecule compounds are expected to be equipped with the following properties for safety switch design. First, the small molecules should be safe enough and preferably have low immunogenicity to avoid superfluous treatment-related toxicities and also be directed toward endogenous targets so that they do not compete with endogenous substances for binding sites. Second, the small molecules should maintain the stability and invariability of the chemical structure in the biological environment until their function is accomplished. Finally, the small molecules are supposed to titrate the activities of CAR-T cells toward tumor cells in a dose-dependent manner, and the activities of CAR-T cells with safety switches should be as potent as those of standard CAR-T cells. The combination of chemical methodologies and tools with genetic engineering techniques is expected to facilitate CAR-T cell-based immunotherapies and provide new applications for small-molecule compounds. In summary, equipping CAR-T cells with robust small-molecule-based safety switches that fulfill the criteria of titrating CAR-T cell activities against tumor cells in a nonlethal and spatiotemporal manner will eventually promote enormous progress with CAR-T cell-based therapies.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c02054" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21838" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21838" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kui Cheng</span> - <span class="hlFld-Affiliation affiliation">Guangdong Provincial Key Laboratory
of New Drug Screening and Guangzhou Key Laboratory of Drug Research
for Emerging Virus Prevention and Treatment, School of Pharmaceutical
Sciences, Southern Medical University, Guangzhou 510515, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-4136-2070" title="Orcid link">https://orcid.org/0000-0002-4136-2070</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#87c4efe2e9e0ecc7f4eaf2a9e2e3f2a9e4e9"><span class="__cf_email__" data-cfemail="b3f0dbd6ddd4d8f3c0dec69dd6d7c69dd0dd">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanjun Zheng</span> - <span class="hlFld-Affiliation affiliation">Guangdong Provincial Key Laboratory
of New Drug Screening and Guangzhou Key Laboratory of Drug Research
for Emerging Virus Prevention and Treatment, School of Pharmaceutical
Sciences, Southern Medical University, Guangzhou 510515, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kutty Selva Nandakumar</span> - <span class="hlFld-Affiliation affiliation">Guangdong Provincial Key Laboratory
of New Drug Screening and Guangzhou Key Laboratory of Drug Research
for Emerging Virus Prevention and Treatment, School of Pharmaceutical
Sciences, Southern Medical University, Guangzhou 510515, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-7790-8197" title="Orcid link">https://orcid.org/0000-0001-7790-8197</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.Z. and K.C. wrote the original draft. K.S.N. reviewed and edited the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34776" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34776" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Yanjun Zheng</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02054&amp;id=BIO-d7e924-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yanjun Zheng</b> obtained her B.S. in pharmacy from the University of South China in 2020. Since then, she has been pursuing a Ph.D. in medicinal chemistry at Southern Medical University in China. Her research interests mainly focus on the design and development of novel potent small-molecule-based safety switches for CAR-T cells and the incorporation of chemical methodologies into genetic engineering techniques to improve the therapeutic profile of cellular products.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Kutty Selva Nandakumar</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02054&amp;id=BIO-d7e929-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Kutty Selva Nandakumar</b> obtained his Ph.D. in immunology from Madurai Kamaraj University in India in 1996 and his D.Sc. in medical inflammation science from Lund University in Sweden in 2006. He received his postdoctoral training in tumor immunology at the Center for Cellular and Molecular Biology in India and in rheumatoid arthritis at Lund University from 1996 to 2001. He worked at Lund University and the Karolinska Institute in Sweden for more than 10 years, up to the level of associate professor. In 2016 he became a professor in the School of Pharmacy at Southern Medical University. His current research focuses on exploring pathogenic pathways and developing therapeutics for inflammatory diseases. He has published more than 155 scientific papers and is a coinventor of four PCT international patents.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Kui Cheng</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02054&amp;id=BIO-d7e934-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Kui Cheng</b> received a joint Ph.D. in biology from Nanjing University and the University of Colorado Boulder and carried out his postdoctoral research in chemical biology at the University of Colorado from 2011 to 2014. Subsequently, he worked at Tsinghua University as an assistant researcher. In 2016 he moved to the School of Pharmaceutical Sciences at Southern Medical University and was appointed as a professor. His current research focuses on small molecules used in cancer immunotherapy, such as the discovery and development of new drug-inducing Toll-like receptor modulators, PD-1/PD-L1 blocking agents, and safety switches for CAR-T cells. He has published more than 20 scientific papers in peer-reviewed journals and has applied for four U.S. patents, two of which have been authorized.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71175" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71175" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the National Natural Science Foundation of China (81773558, 82073689), the Natural Science Foundation of Guangdong Province (2020A151501518, 2018B030312010), and the Science and Technology Program of Guangzhou (201904010380) for financial support for this work.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">CAR-T cell</td><td class="NLM_def"><p class="first last">chimeric antigen receptor T-cell</p></td></tr><tr><td class="NLM_term">PROTAC</td><td class="NLM_def"><p class="first last">proteolysis-targeting chimera</p></td></tr><tr><td class="NLM_term">ALL</td><td class="NLM_def"><p class="first last">acute lymphoblastic leukemia</p></td></tr><tr><td class="NLM_term">TIL</td><td class="NLM_def"><p class="first last">tumor infiltrating lymphocyte</p></td></tr><tr><td class="NLM_term">TCR</td><td class="NLM_def"><p class="first last">T cell receptor</p></td></tr><tr><td class="NLM_term">scFv</td><td class="NLM_def"><p class="first last">single-chain fragment variant</p></td></tr><tr><td class="NLM_term">TAA</td><td class="NLM_def"><p class="first last">tumor-associated antigen</p></td></tr><tr><td class="NLM_term">MHC</td><td class="NLM_def"><p class="first last">major histocompatibility complex</p></td></tr><tr><td class="NLM_term">APC</td><td class="NLM_def"><p class="first last">antigen-presenting cell</p></td></tr><tr><td class="NLM_term">pMHC-I</td><td class="NLM_def"><p class="first last">peptide–MHC class I</p></td></tr><tr><td class="NLM_term">Costim</td><td class="NLM_def"><p class="first last">costimulatory domain</p></td></tr><tr><td class="NLM_term">IL-2Rβ</td><td class="NLM_def"><p class="first last">IL-2 receptor β</p></td></tr><tr><td class="NLM_term">ITAM</td><td class="NLM_def"><p class="first last">immunoreceptor tyrosine-based activation motif</p></td></tr><tr><td class="NLM_term">CRS</td><td class="NLM_def"><p class="first last">cytokine release syndrome</p></td></tr><tr><td class="NLM_term">EGFRvIII</td><td class="NLM_def"><p class="first last">EGFR variant III</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">GvHD</td><td class="NLM_def"><p class="first last">graft-versus-host disease</p></td></tr><tr><td class="NLM_term">FITC</td><td class="NLM_def"><p class="first last">fluorescein isothiocyanate</p></td></tr><tr><td class="NLM_term">pAzF</td><td class="NLM_def"><p class="first last"><i>p</i>-azidophenylalanine</p></td></tr><tr><td class="NLM_term">ROI</td><td class="NLM_def"><p class="first last">region of interest</p></td></tr><tr><td class="NLM_term">MSLN</td><td class="NLM_def"><p class="first last">mesothelin</p></td></tr><tr><td class="NLM_term">FR</td><td class="NLM_def"><p class="first last">folate receptor</p></td></tr><tr><td class="NLM_term">FKBP</td><td class="NLM_def"><p class="first last">FK506-binding protein</p></td></tr><tr><td class="NLM_term">FRAP</td><td class="NLM_def"><p class="first last">FKBP-rapamycin-associated protein</p></td></tr><tr><td class="NLM_term">FRB</td><td class="NLM_def"><p class="first last">FKBP12-rapamycin-binding</p></td></tr><tr><td class="NLM_term">CID</td><td class="NLM_def"><p class="first last">chemical inducers of dimerization</p></td></tr><tr><td class="NLM_term">HSV-TK</td><td class="NLM_def"><p class="first last">herpes simplex virus thymidine kinase</p></td></tr><tr><td class="NLM_term">CARD</td><td class="NLM_def"><p class="first last">caspase recruitment domain</p></td></tr><tr><td class="NLM_term">IL-15</td><td class="NLM_def"><p class="first last">interleukin-15</p></td></tr><tr><td class="NLM_term">haplo-HSCT</td><td class="NLM_def"><p class="first last">haploidentical hematopoietic stem cell transplant</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60478" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60478" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 91 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, V.</span></span> <span> </span><span class="NLM_article-title">Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2017.156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fnrclinonc.2017.156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=28975930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FltV2ksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=11-12&issue=1&author=V.+Prasad&title=Immunotherapy%3A+Tisagenlecleucel+-+the+first+approved+CAR-T-cell+therapy%3A+implications+for+payers+and+policy+makers&doi=10.1038%2Fnrclinonc.2017.156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers</span></div><div class="casAuthors">Prasad Vinay</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Clinical oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRQ-hrFX0bM7nRxY89Cm6SyfW6udTcc2eYfeO7hS5Sn17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FltV2ksg%253D%253D&md5=92bc7bd66ed2ce17917f8aec564c41ea</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2017.156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2017.156%26sid%3Dliteratum%253Aachs%26aulast%3DPrasad%26aufirst%3DV.%26atitle%3DImmunotherapy%253A%2520Tisagenlecleucel%2520-%2520the%2520first%2520approved%2520CAR-T-cell%2520therapy%253A%2520implications%2520for%2520payers%2520and%2520policy%2520makers%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D15%26issue%3D1%26spage%3D11%26epage%3D12%26doi%3D10.1038%2Fnrclinonc.2017.156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yip, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, R.</span></span> <span> </span><span class="NLM_article-title">The market for chimeric antigen receptor T cell therapies</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fnrd.2017.266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29375140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVeqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=161-162&author=A.+Yipauthor=R.+Webster&title=The+market+for+chimeric+antigen+receptor+T+cell+therapies&doi=10.1038%2Fnrd.2017.266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The market for chimeric antigen receptor T cell therapies</span></div><div class="casAuthors">Yip, Amy; Webster, Rachel M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-162</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">This article discusses the market for chimeric antigen receptor (CAR) T cell therapies, focusing on haematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCffdVEf0fN7Vg90H21EOLACvtfcHk0lhghYudQ3VuEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVeqtL0%253D&md5=d3f333b2d8a340be05f621ae355c25fa</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.266%26sid%3Dliteratum%253Aachs%26aulast%3DYip%26aufirst%3DA.%26aulast%3DWebster%26aufirst%3DR.%26atitle%3DThe%2520market%2520for%2520chimeric%2520antigen%2520receptor%2520T%2520cell%2520therapies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D161%26epage%3D162%26doi%3D10.1038%2Fnrd.2017.266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrusciel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban-Wojciuk, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcimowicz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurkowiak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gliwinski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marjanski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rzyman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biernat, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadziuszko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montesano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marek-Trzonkowska, N.</span></span> <span> </span><span class="NLM_article-title">Adoptive Cell Therapy-harnessing antigen-specific T cells to target solid tumours</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">683</span>, <span class="refDoi"> DOI: 10.3390/cancers12030683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.3390%2Fcancers12030683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVShtrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=683&author=E.+Chruscielauthor=Z.+Urban-Wojciukauthor=L.+Arcimowiczauthor=M.+Kurkowiakauthor=J.+Kowalskiauthor=M.+Gliwinskiauthor=T.+Marjanskiauthor=W.+Rzymanauthor=W.+Biernatauthor=R.+Dziadziuszkoauthor=C.+Montesanoauthor=R.+Bernardiniauthor=N.+Marek-Trzonkowska&title=Adoptive+Cell+Therapy-harnessing+antigen-specific+T+cells+to+target+solid+tumours&doi=10.3390%2Fcancers12030683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Adoptive cell therapy-harnessing antigen-specific T cells to target solid tumours</span></div><div class="casAuthors">Chrusciel, Elzbieta; Urban-Wojciuk, Zuzanna; Arcimowicz, Lukasz; Kurkowiak, Malgorzata; Kowalski, Jacek; Gliwinski, Mateusz; Marjanski, Tomasz; Rzyman, Witold; Biernat, Wojciech; Dziadziuszko, Rafal; Montesano, Carla; Bernardini, Roberta; Marek-Trzonkowska, Natalia</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">683</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">In recent years, much research has been focused on the field of adoptive cell therapies (ACT) that use native or genetically modified T cells as therapeutic tools.  Immunotherapy with T cells expressing chimeric antigen receptors (CARs) demonstrated great success in the treatment of haematol. malignancies, whereas adoptive transfer of autologous tumor infiltrating lymphocytes (TILs) proved to be highly effective in metastatic melanoma.  These encouraging results initiated many studies where ACT was tested as a treatment for various solid tumors.  In this review, we provide an overview of the challenges of T cell-based immunotherapies of solid tumors.  We describe alternative approaches for choosing the most efficient T cells for cancer treatment in terms of their tumor-specificity and phenotype.  Finally, we present strategies for improvement of anti-tumor potential of T cells, including combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhn1-ZN5FDW7Vg90H21EOLACvtfcHk0lhBzPRTt95WSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVShtrjM&md5=8593ca5d44dddfe51069aafd9310e706</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3390%2Fcancers12030683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12030683%26sid%3Dliteratum%253Aachs%26aulast%3DChrusciel%26aufirst%3DE.%26aulast%3DUrban-Wojciuk%26aufirst%3DZ.%26aulast%3DArcimowicz%26aufirst%3DL.%26aulast%3DKurkowiak%26aufirst%3DM.%26aulast%3DKowalski%26aufirst%3DJ.%26aulast%3DGliwinski%26aufirst%3DM.%26aulast%3DMarjanski%26aufirst%3DT.%26aulast%3DRzyman%26aufirst%3DW.%26aulast%3DBiernat%26aufirst%3DW.%26aulast%3DDziadziuszko%26aufirst%3DR.%26aulast%3DMontesano%26aufirst%3DC.%26aulast%3DBernardini%26aufirst%3DR.%26aulast%3DMarek-Trzonkowska%26aufirst%3DN.%26atitle%3DAdoptive%2520Cell%2520Therapy-harnessing%2520antigen-specific%2520T%2520cells%2520to%2520target%2520solid%2520tumours%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26spage%3D683%26doi%3D10.3390%2Fcancers12030683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maude, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aplenc, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacey, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahnke, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melenhorst, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rheingold, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teachey, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grupp, S. A.</span></span> <span> </span><span class="NLM_article-title">Chimeric antigen receptor T cells for sustained remissions in leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">1507</span>– <span class="NLM_lpage">1517</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1407222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1056%2FNEJMoa1407222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=25317870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVSls73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=1507-1517&author=S.+L.+Maudeauthor=N.+Freyauthor=P.+A.+Shawauthor=R.+Aplencauthor=D.+M.+Barrettauthor=N.+J.+Buninauthor=A.+Chewauthor=V.+E.+Gonzalezauthor=Z.+Zhengauthor=S.+F.+Laceyauthor=Y.+D.+Mahnkeauthor=J.+J.+Melenhorstauthor=S.+R.+Rheingoldauthor=A.+Shenauthor=D.+T.+Teacheyauthor=B.+L.+Levineauthor=C.+H.+Juneauthor=D.+L.+Porterauthor=S.+A.+Grupp&title=Chimeric+antigen+receptor+T+cells+for+sustained+remissions+in+leukemia&doi=10.1056%2FNEJMoa1407222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric antigen receptor T cells for sustained remissions in leukemia</span></div><div class="casAuthors">Maude, Shannon L.; Frey, Noelle; Shaw, Pamela A.; Aplenc, Richard; Barrett, David M.; Bunin, Nancy J.; Chew, Anne; Gonzalez, Vanessa E.; Zheng, Zhaohui; Lacey, Simon F.; Mahnke, Yolanda D.; Melenhorst, Jan J.; Rheingold, Susan R.; Shen, Angela; Teachey, David T.; Levine, Bruce L.; June, Carl H.; Porter, David L.; Grupp, Stephan A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1507-1517, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies.  Chimeric antigen receptor-modified T cells targeting CD19 may overcome many limitations of conventional therapies and induce remission in patients with refractory disease.  Methods: We infused autologous T cells transduced with a CD19-directed chimeric antigen receptor (CTL019) lentiviral vector in patients with relapsed or refractory ALL at doses of 0.76 × 106 to 20.6 × 106 CTL019 cells per kg of body wt.  Patients were monitored for a response, toxic effects, and the expansion and persistence of circulating CTL019 T cells.  Results: A total of 30 children and adults received CTL019.  Complete remission was achieved in 27 patients (90%), including 2 patients with blinatumomab-refractory disease and 15 who had undergone stem-cell transplantation.  CTL019 cells proliferated in vivo and were detectable in the blood, bone marrow, and cerebrospinal fluid of patients who had a response.  Sustained remission was achieved with a 6-mo event-free survival rate of 67% (95% confidence interval [CI], 51 to 88) and an overall survival rate of 78% (95% CI, 65 to 95).  At 6 mo, the probability that a patient would have persistence of CTL019 was 68% (95% CI, 50 to 92) and the probability that a patient would have relapse-free B-cell aplasia was 73% (95% CI, 57 to 94).  All the patients had the cytokine-release syndrome.  Severe cytokine-release syndrome, which developed in 27% of the patients, was assocd. with a higher disease burden before infusion and was effectively treated with the anti-interleukin-6 receptor antibody tocilizumab.  Conclusions: Chimeric antigen receptor-modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL.  CTL019 was assocd. with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 mo were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMldO024V5VrVg90H21EOLACvtfcHk0lhBzPRTt95WSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVSls73K&md5=7f13aaa25ae118901d3bec614b07cc3a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1407222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1407222%26sid%3Dliteratum%253Aachs%26aulast%3DMaude%26aufirst%3DS.%2BL.%26aulast%3DFrey%26aufirst%3DN.%26aulast%3DShaw%26aufirst%3DP.%2BA.%26aulast%3DAplenc%26aufirst%3DR.%26aulast%3DBarrett%26aufirst%3DD.%2BM.%26aulast%3DBunin%26aufirst%3DN.%2BJ.%26aulast%3DChew%26aufirst%3DA.%26aulast%3DGonzalez%26aufirst%3DV.%2BE.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DLacey%26aufirst%3DS.%2BF.%26aulast%3DMahnke%26aufirst%3DY.%2BD.%26aulast%3DMelenhorst%26aufirst%3DJ.%2BJ.%26aulast%3DRheingold%26aufirst%3DS.%2BR.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DTeachey%26aufirst%3DD.%2BT.%26aulast%3DLevine%26aufirst%3DB.%2BL.%26aulast%3DJune%26aufirst%3DC.%2BH.%26aulast%3DPorter%26aufirst%3DD.%2BL.%26aulast%3DGrupp%26aufirst%3DS.%2BA.%26atitle%3DChimeric%2520antigen%2520receptor%2520T%2520cells%2520for%2520sustained%2520remissions%2520in%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D1507%26epage%3D1517%26doi%3D10.1056%2FNEJMoa1407222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svoboda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasta, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mato, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anak, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogdon, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruteanu-Malinici, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhoj, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landsburg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacey, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melenhorst, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, C. H.</span></span> <span> </span><span class="NLM_article-title">Chimeric antigen receptor T cells in refractory B-Cell lymphomas</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">2545</span>– <span class="NLM_lpage">2554</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1708566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1056%2FNEJMoa1708566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29226764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=2545-2554&author=S.+J.+Schusterauthor=J.+Svobodaauthor=E.+A.+Chongauthor=S.+D.+Nastaauthor=A.+R.+Matoauthor=O.+Anakauthor=J.+L.+Brogdonauthor=I.+Pruteanu-Maliniciauthor=V.+Bhojauthor=D.+Landsburgauthor=M.+Wasikauthor=B.+L.+Levineauthor=S.+F.+Laceyauthor=J.+J.+Melenhorstauthor=D.+L.+Porterauthor=C.+H.+June&title=Chimeric+antigen+receptor+T+cells+in+refractory+B-Cell+lymphomas&doi=10.1056%2FNEJMoa1708566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric antigen receptor T cells in refractory B-cell lymphomas</span></div><div class="casAuthors">Schuster, Stephen J.; Svoboda, Jakub; Chong, Elise A.; Nasta, Sunita D.; Mato, Anthony R.; Anak, Ozlem; Brogdon, Jennifer L.; Pruteanu-Malinici, Iulian; Bhoj, Vijay; Landsburg, Daniel; Wasik, Mariusz; Levine, Bruce L.; Lacey, Simon F.; Melenhorst, Jan J.; Porter, David L.; June, Carl H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2545-2554</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Patients with diffuse large B-cell lymphoma or follicular lymphoma that is refractory to or that relapses after immunochemotherapy and transplantation have a poor prognosis.  High response rates have been reported with the use of T cells modified by chimeric antigen receptor (CAR) that target CD19 in B-cell cancers, although data regarding B-cell lymphomas are limited. methods We used autologous T cells that express a CD19-directed CAR (CTL019) to treat patients with diffuse large B-cell lymphoma or follicular lymphoma that had relapsed or was refractory to previous treatments.  Patients were monitored for response to treatment, toxic effects, the expansion and persistence of CTL019 cells in vivo, and immune recovery. results A total of 28 adult patients with lymphoma received CTL019 cells, and 18 of 28 had a response (64%; 95% confidence interval [CI], 44 to 81).  Complete remission occurred in 6 of 14 patients with diffuse large B-cell lymphoma (43%; 95% CI, 18 to 71) and 10 of 14 patients with follicular lymphoma (71%; 95% CI, 42 to 92).  CTL019 cells proliferated in vivo and were detectable in the blood and bone marrow of patients who had a response and patients who did not have a response.  Sustained remissions were achieved, and at a median follow-up of 28.6 mo, 86% of patients with diffuse large B-cell lymphoma who had a response (95% CI, 33 to 98) and 89% of patients with follicular lymphoma who had a response (95% CI, 43 to 98) had maintained the response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZL6YpNA3zJbVg90H21EOLACvtfcHk0lhPWOiUD-7Q2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGjtbs%253D&md5=ccaf409a1f47453d2b95ba8376fcf035</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1708566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1708566%26sid%3Dliteratum%253Aachs%26aulast%3DSchuster%26aufirst%3DS.%2BJ.%26aulast%3DSvoboda%26aufirst%3DJ.%26aulast%3DChong%26aufirst%3DE.%2BA.%26aulast%3DNasta%26aufirst%3DS.%2BD.%26aulast%3DMato%26aufirst%3DA.%2BR.%26aulast%3DAnak%26aufirst%3DO.%26aulast%3DBrogdon%26aufirst%3DJ.%2BL.%26aulast%3DPruteanu-Malinici%26aufirst%3DI.%26aulast%3DBhoj%26aufirst%3DV.%26aulast%3DLandsburg%26aufirst%3DD.%26aulast%3DWasik%26aufirst%3DM.%26aulast%3DLevine%26aufirst%3DB.%2BL.%26aulast%3DLacey%26aufirst%3DS.%2BF.%26aulast%3DMelenhorst%26aufirst%3DJ.%2BJ.%26aulast%3DPorter%26aufirst%3DD.%2BL.%26aulast%3DJune%26aufirst%3DC.%2BH.%26atitle%3DChimeric%2520antigen%2520receptor%2520T%2520cells%2520in%2520refractory%2520B-Cell%2520lymphomas%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D2545%26epage%3D2554%26doi%3D10.1056%2FNEJMoa1708566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">Engineering CAR-T cells</span>. <i>Biomarker Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">22</span>, <span class="refDoi"> DOI: 10.1186/s40364-017-0102-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1186%2Fs40364-017-0102-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=28652918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BC1cjitFSgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=22&author=C.+Zhangauthor=J.+Liuauthor=J.+F.+Zhongauthor=X.+Zhang&title=Engineering+CAR-T+cells&doi=10.1186%2Fs40364-017-0102-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering CAR-T cells</span></div><div class="casAuthors">Zhang Cheng; Liu Jun; Zhang Xi; Zhong Jiang F</div><div class="citationInfo"><span class="NLM_cas:title">Biomarker research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">22</span>
        ISSN:<span class="NLM_cas:issn">2050-7771</span>.
    </div><div class="casAbstract">Chimeric antigen receptor redirected T cells (CAR-T cells) have achieved inspiring outcomes in patients with B cell malignancies, and are now being investigated in other hematologic malignancies and solid tumors.  CAR-T cells are generated by the T cells from patients' or donors' blood.  After the T cells are expanded and genetically modified, they are reinfused into the patients.  However, many challenges still need to be resolved in order for this technology to gain widespread adoption.  In this review, we first discuss the structure and evolution of chimeric antigen receptors.  We then report on the tools used for production of CAR-T cells.  Finally, we address the challenges posed by CAR-T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgIN211pEHHq-9TkgmBqTqfW6udTcc2eY5oVE3Ko9WHrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjitFSgtg%253D%253D&md5=1f2973140d40b7b5a2164b40229e874e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1186%2Fs40364-017-0102-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40364-017-0102-y%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhong%26aufirst%3DJ.%2BF.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DEngineering%2520CAR-T%2520cells%26jtitle%3DBiomarker%2520Res.%26date%3D2017%26volume%3D5%26spage%3D22%26doi%3D10.1186%2Fs40364-017-0102-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotti, G.</span></span> <span> </span><span class="NLM_article-title">Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy</span>. <i>Expert Opin. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">873</span>, <span class="refDoi"> DOI: 10.1517/14712598.2011.573476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1517%2F14712598.2011.573476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=21463133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFOnsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=855-873&author=C.+A.+Ramosauthor=G.+Dotti&title=Chimeric+antigen+receptor+%28CAR%29-engineered+lymphocytes+for+cancer+therapy&doi=10.1517%2F14712598.2011.573476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy</span></div><div class="casAuthors">Ramos, Carlos A.; Dotti, Gianpietro</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">855-873</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Chimeric antigen receptors (CARs) usually combine the antigen binding site of a monoclonal antibody with the signal activating machinery of a T cell, freeing antigen recognition from MHC restriction and thus breaking one of the barriers to more widespread application of cellular therapy.  Similar to treatment strategies employing monoclonal antibodies, T cells expressing CARs are highly targeted, but addnl. offer the potential benefits of active trafficking to tumor sites, in vivo expansion and long-term persistence.  Furthermore, gene transfer allows the introduction of countermeasures to tumor immune evasion and of safety mechanisms.Areas covered: The basic structure of so-called first and later generation CARs and their potential advantages over other immune therapy systems.  How these mols. can be grafted into immune cells (including retroviral and non-retroviral transduction methods) and strategies to improve the in vivo persistence and function of immune cells expressing CARs.  Examples of tumor-assocd. antigens that have been targeted in preclin. models and clin. experience with these modified cells.  Safety issues surrounding CAR gene transfer into T cells and potential solns. to them.Expert opinion: Because of recent advances in immunol., genetics and cell processing, CAR-modified T cells will likely play an increasing role in the cellular therapy of cancer, chronic infections and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5rBLFV7PoYLVg90H21EOLACvtfcHk0liH6iRFdGG0Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFOnsrw%253D&md5=b09ede2a6e2b1d25d532953f2fba5514</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1517%2F14712598.2011.573476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.2011.573476%26sid%3Dliteratum%253Aachs%26aulast%3DRamos%26aufirst%3DC.%2BA.%26aulast%3DDotti%26aufirst%3DG.%26atitle%3DChimeric%2520antigen%2520receptor%2520%2528CAR%2529-engineered%2520lymphocytes%2520for%2520cancer%2520therapy%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2011%26volume%3D11%26spage%3D855%26epage%3D873%26doi%3D10.1517%2F14712598.2011.573476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eshhar, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waks, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, D. G.</span></span> <span> </span><span class="NLM_article-title">Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">720</span>– <span class="NLM_lpage">724</span>, <span class="refDoi"> DOI: 10.1073/pnas.90.2.720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1073%2Fpnas.90.2.720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=8421711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADyaK3sXitVCkurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=720-724&author=Z.+Eshharauthor=T.+Waksauthor=G.+Grossauthor=D.+G.+Schindler&title=Specific+activation+and+targeting+of+cytotoxic+lymphocytes+through+chimeric+single+chains+consisting+of+antibody-binding+domains+and+the+gamma+or+zeta+subunits+of+the+immunoglobulin+and+T-cell+receptors&doi=10.1073%2Fpnas.90.2.720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors</span></div><div class="casAuthors">Eshhar, Zelig; Waks, Tova; Gross, Gideon; Schindler, Daniel G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">720-4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The generation of tumor-specific lymphocytes and their use in adoptive immunotherapy is limited to a few malignancies because most spontaneous tumors are very weak or not at all immunogenic.  On the other hand, many antitumor antibodies have been described which bind tumor-assocd. antigens shared among tumors of the same histol.  Combining the variable regions (Fv) of an antibody with the const. regions of the T-cell receptor (TCR) chains results in chimeric genes endowing T lymphocytes with antibody-type specificity, potentially allowing cellular adoptive immunotherapy against types of tumors not previously possible.  To generalize and extend this approach to addnl. lymphocyte-activating mols., the designed and constructed chimeric genes composed of a single-chain Fv domain (scFv) of an antibody linked with γ or ζ chains, the common signal-transducing subunits of the Ig receptor and the TCR.  Such chimeric genes contg. the Fv region of an anti-trinitophenyl antibody could be expressed as functional surface receptors in a cytolytic T-cell hybridoma.  They triggered interleukin 2 secretion upon encountering antigen and mediated non-major-histocompatibility-complex-restricted hapten-specific target cell lysis.  Such chimeric receptors can be exploited to provide T cells and other effector lymphocytes, such as natural killer cells, with antibody-type recognition directly coupled to cellular activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYNQLwO2EOMrVg90H21EOLACvtfcHk0liH6iRFdGG0Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXitVCkurY%253D&md5=224226a20d25ffc9cf4ce40257d14c53</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.90.2.720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.90.2.720%26sid%3Dliteratum%253Aachs%26aulast%3DEshhar%26aufirst%3DZ.%26aulast%3DWaks%26aufirst%3DT.%26aulast%3DGross%26aufirst%3DG.%26aulast%3DSchindler%26aufirst%3DD.%2BG.%26atitle%3DSpecific%2520activation%2520and%2520targeting%2520of%2520cytotoxic%2520lymphocytes%2520through%2520chimeric%2520single%2520chains%2520consisting%2520of%2520antibody-binding%2520domains%2520and%2520the%2520gamma%2520or%2520zeta%2520subunits%2520of%2520the%2520immunoglobulin%2520and%2520T-cell%2520receptors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1993%26volume%3D90%26spage%3D720%26epage%3D724%26doi%3D10.1073%2Fpnas.90.2.720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadelain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brentjens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riviere, I.</span></span> <span> </span><span class="NLM_article-title">The promise and potential pitfalls of chimeric antigen receptors</span>. <i>Curr. Opin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1016/j.coi.2009.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.coi.2009.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=19327974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVCgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=215-223&author=M.+Sadelainauthor=R.+Brentjensauthor=I.+Riviere&title=The+promise+and+potential+pitfalls+of+chimeric+antigen+receptors&doi=10.1016%2Fj.coi.2009.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The promise and potential pitfalls of chimeric antigen receptors</span></div><div class="casAuthors">Sadelain, Michel; Brentjens, Renier; Riviere, Isabelle</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">215-223</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  One important purpose of T cell engineering is to generate tumor-targeted T cells through the genetic transfer of antigen-specific receptors, which consist of either physiol., MHC-restricted T cell receptors (TCRs) or non MHC-restricted chimeric antigen receptors (CARs).  CARs combine antigen-specificity and T cell activating properties in a single fusion mol.  First generation CARs, which included as their signaling domain the cytoplasmic region of the CD3ζ or Fc receptor γ chain, effectively redirected T cell cytotoxicity but failed to enable T cell proliferation and survival upon repeated antigen exposure.  Receptors encompassing both CD28 and CD3ζ are the prototypes for second generation CARs, which are now rapidly expanding to a diverse array of receptors with different functional properties.  First generation CARs have been tested in phase I clin. studies in patients with ovarian cancer, renal cancer, lymphoma, and neuroblastoma, where they have induced modest responses.  Second generation CARs, which are just now entering the clin. arena in the B cell malignancies and other cancers, will provide a more significant test for this approach.  If the immunogenicity of CARs can be averted, the versatility of their design and HLA-independent antigen recognition will make CARs tools of choice for T cell engineering for the development of targeted cancer immunotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-UZMlP4fPebVg90H21EOLACvtfcHk0liH6iRFdGG0Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVCgtLc%253D&md5=ab5443309173bbde22c679dc2f5090e8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.coi.2009.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coi.2009.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DSadelain%26aufirst%3DM.%26aulast%3DBrentjens%26aufirst%3DR.%26aulast%3DRiviere%26aufirst%3DI.%26atitle%3DThe%2520promise%2520and%2520potential%2520pitfalls%2520of%2520chimeric%2520antigen%2520receptors%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2009%26volume%3D21%26spage%3D215%26epage%3D223%26doi%3D10.1016%2Fj.coi.2009.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savoldo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mims, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrum, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamble, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollard, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grilley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heslop, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotti, G.</span></span> <span> </span><span class="NLM_article-title">CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">1822</span>– <span class="NLM_lpage">1826</span>, <span class="refDoi"> DOI: 10.1172/JCI46110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1172%2FJCI46110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=21540550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvFKnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=1822-1826&author=B.+Savoldoauthor=C.+A.+Ramosauthor=E.+Liuauthor=M.+P.+Mimsauthor=M.+J.+Keatingauthor=G.+Carrumauthor=R.+T.+Kambleauthor=C.+M.+Bollardauthor=A.+P.+Geeauthor=Z.+Meiauthor=H.+Liuauthor=B.+Grilleyauthor=C.+M.+Rooneyauthor=H.+E.+Heslopauthor=M.+K.+Brennerauthor=G.+Dotti&title=CD28+costimulation+improves+expansion+and+persistence+of+chimeric+antigen+receptor-modified+T+cells+in+lymphoma+patients&doi=10.1172%2FJCI46110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients</span></div><div class="casAuthors">Savoldo, Barbara; Ramos, Carlos Almeida; Liu, Enli; Mims, Martha P.; Keating, Michael J.; Carrum, George; Kamble, Rammurti T.; Bollard, Catherine M.; Gee, Adrian P.; Mei, Zhuyong; Liu, Hao; Grilley, Bambi; Rooney, Cliona M.; Heslop, Helen E.; Brenner, Malcolm K.; Dotti, Gianpietro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1822-1826</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Targeted T cell immunotherapies using engineered T lymphocytes expressing tumor-directed chimeric antigen receptors (CARs) are designed to benefit patients with cancer.  Although incorporation of costimulatory endodomains within these CARs increases the proliferation of CAR-redirected T lymphocytes, it has proven difficult to draw definitive conclusions about the specific effects of costimulatory endodomains on the expansion, persistence, and antitumor effectiveness of CAR-redirected T cells in human subjects, owing to the lack of side-by-side comparisons with T cells bearing only a single signaling domain.  We therefore designed a study that allowed us to directly measure the consequences of adding a costimulatory endodomain to CAR-redirected T cells.  Patients with B cell lymphomas were simultaneously infused with 2 autologous T cell products expressing CARs with the same specificity for the CD19 antigen, present on most B cell malignancies.  One CAR encoded both the costimulatory CD28 and the ζ-endodomains, while the other encoded only the ζ-endodomain.  CAR+ T cells contg. the CD28 endodomain showed strikingly enhanced expansion and persistence compared with CAR+ T cells lacking this endodomain.  These results demonstrate the superiority of CARs with dual signal domains and confirm a method of comparing CAR-modified T cells within individual patients, thereby avoiding patient-to-patient variability and accelerating the development of optimal T cell immunotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK9WGbnfmoGrVg90H21EOLACvtfcHk0liU2qpqf4Qwqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvFKnt7o%253D&md5=7ec0c6af57071880831b0a7fa17caa7b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1172%2FJCI46110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI46110%26sid%3Dliteratum%253Aachs%26aulast%3DSavoldo%26aufirst%3DB.%26aulast%3DRamos%26aufirst%3DC.%2BA.%26aulast%3DLiu%26aufirst%3DE.%26aulast%3DMims%26aufirst%3DM.%2BP.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DCarrum%26aufirst%3DG.%26aulast%3DKamble%26aufirst%3DR.%2BT.%26aulast%3DBollard%26aufirst%3DC.%2BM.%26aulast%3DGee%26aufirst%3DA.%2BP.%26aulast%3DMei%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DGrilley%26aufirst%3DB.%26aulast%3DRooney%26aufirst%3DC.%2BM.%26aulast%3DHeslop%26aufirst%3DH.%2BE.%26aulast%3DBrenner%26aufirst%3DM.%2BK.%26aulast%3DDotti%26aufirst%3DG.%26atitle%3DCD28%2520costimulation%2520improves%2520expansion%2520and%2520persistence%2520of%2520chimeric%2520antigen%2520receptor-modified%2520T%2520cells%2520in%2520lymphoma%2520patients%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26spage%3D1822%26epage%3D1826%26doi%3D10.1172%2FJCI46110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milone, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binder, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teachey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samanta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakhal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloss, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danet-Desnoyers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campana, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grupp, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, C. H.</span></span> <span> </span><span class="NLM_article-title">Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1453</span>– <span class="NLM_lpage">1464</span>, <span class="refDoi"> DOI: 10.1038/mt.2009.83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fmt.2009.83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=19384291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=1453-1464&author=M.+C.+Miloneauthor=J.+D.+Fishauthor=C.+Carpenitoauthor=R.+G.+Carrollauthor=G.+K.+Binderauthor=D.+Teacheyauthor=M.+Samantaauthor=M.+Lakhalauthor=B.+Glossauthor=G.+Danet-Desnoyersauthor=D.+Campanaauthor=J.+L.+Rileyauthor=S.+A.+Gruppauthor=C.+H.+June&title=Chimeric+receptors+containing+CD137+signal+transduction+domains+mediate+enhanced+survival+of+T+cells+and+increased+antileukemic+efficacy+in+vivo&doi=10.1038%2Fmt.2009.83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo</span></div><div class="casAuthors">Milone, Michael C.; Fish, Jonathan D.; Carpenito, Carmine; Carroll, Richard G.; Binder, Gwendolyn K.; Teachey, David; Samanta, Minu; Lakhal, Mehdi; Gloss, Brian; Danet-Desnoyers, Gwenn; Campana, Dario; Riley, James L.; Grupp, Stephan A.; June, Carl H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1453-1464</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Persistence of T cells engineered with chimeric antigen receptors (CARs) has been a major barrier to use of these cells for molecularly targeted adoptive immunotherapy.  To address this issue, we created a series of CARs that contain the T cell receptor-ζ (TCR-ζ) signal transduction domain with the CD28 and/or CD137 (4-1BB) intracellular domains in tandem.  After short-term expansion, primary human T cells were subjected to lentiviral gene transfer, resulting in large nos. of cells with >85% CAR expression.  In an immunodeficient mouse xenograft model of primary human pre-B-cell acute lymphoblastic leukemia, human T cells expressing anti-CD19 CARs contg. CD137 exhibited the greatest antileukemic efficacy and prolonged (>6 mo) survival in vivo, and were significantly more effective than cells expressing CARs contg. TCR-ζ alone or CD28-ζ signaling receptors.  We uncovered a previously unrecognized, antigen-independent effect of CARs expressing the CD137 cytoplasmic domain that likely contributes to the enhanced antileukemic efficacy and survival in tumor bearing mice.  Furthermore, our studies revealed significant discrepancies between in vitro and in vivo surrogate measures of CAR efficacy.  Together these results suggest that incorporation of the CD137 signaling domain in CARs should improve the persistence of CARs in the hematol. malignancies and hence maximize their antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOdpTM_J3qa7Vg90H21EOLACvtfcHk0liU2qpqf4Qwqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVWqsLk%253D&md5=29d09c68851cdfd2953ac10dfcfb8be9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fmt.2009.83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2009.83%26sid%3Dliteratum%253Aachs%26aulast%3DMilone%26aufirst%3DM.%2BC.%26aulast%3DFish%26aufirst%3DJ.%2BD.%26aulast%3DCarpenito%26aufirst%3DC.%26aulast%3DCarroll%26aufirst%3DR.%2BG.%26aulast%3DBinder%26aufirst%3DG.%2BK.%26aulast%3DTeachey%26aufirst%3DD.%26aulast%3DSamanta%26aufirst%3DM.%26aulast%3DLakhal%26aufirst%3DM.%26aulast%3DGloss%26aufirst%3DB.%26aulast%3DDanet-Desnoyers%26aufirst%3DG.%26aulast%3DCampana%26aufirst%3DD.%26aulast%3DRiley%26aufirst%3DJ.%2BL.%26aulast%3DGrupp%26aufirst%3DS.%2BA.%26aulast%3DJune%26aufirst%3DC.%2BH.%26atitle%3DChimeric%2520receptors%2520containing%2520CD137%2520signal%2520transduction%2520domains%2520mediate%2520enhanced%2520survival%2520of%2520T%2520cells%2520and%2520increased%2520antileukemic%2520efficacy%2520in%2520vivo%26jtitle%3DMol.%2520Ther.%26date%3D2009%26volume%3D17%26spage%3D1453%26epage%3D1464%26doi%3D10.1038%2Fmt.2009.83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Govers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebestyen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roszik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Brakel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrevoets, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szoor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panoutsopoulou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broertjes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vereb, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szollosi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debets, R.</span></span> <span> </span><span class="NLM_article-title">TCRs genetically linked to CD28 and CD3epsilon do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>193</i></span>,  <span class="NLM_fpage">5315</span>– <span class="NLM_lpage">5326</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1302074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.4049%2Fjimmunol.1302074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=25320284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyjtbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2014&pages=5315-5326&author=C.+Goversauthor=Z.+Sebestyenauthor=J.+Roszikauthor=M.+van+Brakelauthor=C.+Berrevoetsauthor=A.+Szoorauthor=K.+Panoutsopoulouauthor=M.+Broertjesauthor=T.+Vanauthor=G.+Verebauthor=J.+Szollosiauthor=R.+Debets&title=TCRs+genetically+linked+to+CD28+and+CD3epsilon+do+not+mispair+with+endogenous+TCR+chains+and+mediate+enhanced+T+cell+persistence+and+anti-melanoma+activity&doi=10.4049%2Fjimmunol.1302074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">TCRs Genetically Linked to CD28 and CD3ε Do Not Mispair with Endogenous TCR Chains and Mediate Enhanced T Cell Persistence and Anti-Melanoma Activity</span></div><div class="casAuthors">Govers, Coen; Sebestyen, Zsolt; Roszik, Janos; van Brakel, Mandy; Berrevoets, Cor; Szoeor, Arpad; Panoutsopoulou, Konstantina; Broertjes, Marieke; Van, Tan; Vereb, Gyoergy; Szoellosi, Janos; Debets, Reno</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5315-5326</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Adoptive transfer of T cells that are gene engineered to express a defined TCR represents a feasible and promising therapy for patients with tumors.  However, TCR gene therapy is hindered by the transient presence and effectiveness of transferred T cells, which are anticipated to be improved by adequate T cell costimulation.  In this article, we report the identification and characterization of a novel two-chain TCR linked to CD28 and CD3ε (i.e., TCR:28ε).  This modified TCR demonstrates enhanced binding of peptide-MHC and mediates enhanced T cell function following stimulation with peptide compared with wild-type TCR.  Surface expression of TCR:28ε depends on the transmembrane domain of CD28, whereas T cell functions depend on the intracellular domains of both CD28 and CD3ε, with IL-2 prodn. showing dependency on CD28:LCK binding.  TCR:28ε, but not wild-type TCR, induces detectable immune synapses in primary human T cells, and such immune synapses show significantly enhanced accumulation of TCR transgenes and markers of early TCR signaling, such as phosphorylated LCK and ERK.  Importantly, TCR:28ε does not show signs of off-target recognition, as evidenced by lack of TCR mispairing, as well as preserved specificity.  Notably, when testing TCR:28ε in immune-competent mice, we obsd. a drastic increase in T cell survival, which was accompanied by regression of large melanomas with limited recurrence.  Our data argue that TCR transgenes that contain CD28, and, thereby, may provide T cell costimulation in an immune-suppressive environment, represent candidate receptors to treat patients with tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQAd2X83-fFrVg90H21EOLACvtfcHk0lh44XCXY8k-Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyjtbrO&md5=b71212b64adedea30d15ffdb7df605e6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1302074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1302074%26sid%3Dliteratum%253Aachs%26aulast%3DGovers%26aufirst%3DC.%26aulast%3DSebestyen%26aufirst%3DZ.%26aulast%3DRoszik%26aufirst%3DJ.%26aulast%3Dvan%2BBrakel%26aufirst%3DM.%26aulast%3DBerrevoets%26aufirst%3DC.%26aulast%3DSzoor%26aufirst%3DA.%26aulast%3DPanoutsopoulou%26aufirst%3DK.%26aulast%3DBroertjes%26aufirst%3DM.%26aulast%3DVan%26aufirst%3DT.%26aulast%3DVereb%26aufirst%3DG.%26aulast%3DSzollosi%26aufirst%3DJ.%26aulast%3DDebets%26aufirst%3DR.%26atitle%3DTCRs%2520genetically%2520linked%2520to%2520CD28%2520and%2520CD3epsilon%2520do%2520not%2520mispair%2520with%2520endogenous%2520TCR%2520chains%2520and%2520mediate%2520enhanced%2520T%2520cell%2520persistence%2520and%2520anti-melanoma%2520activity%26jtitle%3DJ.%2520Immunol.%26date%3D2014%26volume%3D193%26spage%3D5315%26epage%3D5326%26doi%3D10.4049%2Fjimmunol.1302074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carpenito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milone, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonet, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakhal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suhoski, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varela-Rohena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haines, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitjan, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albelda, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, C. H.</span></span> <span> </span><span class="NLM_article-title">Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">3360</span>– <span class="NLM_lpage">3365</span>, <span class="refDoi"> DOI: 10.1073/pnas.0813101106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1073%2Fpnas.0813101106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=19211796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivF2jsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=3360-3365&author=C.+Carpenitoauthor=M.+C.+Miloneauthor=R.+Hassanauthor=J.+C.+Simonetauthor=M.+Lakhalauthor=M.+M.+Suhoskiauthor=A.+Varela-Rohenaauthor=K.+M.+Hainesauthor=D.+F.+Heitjanauthor=S.+M.+Albeldaauthor=R.+G.+Carrollauthor=J.+L.+Rileyauthor=I.+Pastanauthor=C.+H.+June&title=Control+of+large%2C+established+tumor+xenografts+with+genetically+retargeted+human+T+cells+containing+CD28+and+CD137+domains&doi=10.1073%2Fpnas.0813101106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains</span></div><div class="casAuthors">Carpenito, Carmine; Milone, Michael C.; Hassan, Raffit; Simonet, Jacqueline C.; Lakhal, Mehdi; Suhoski, Megan M.; Varela-Rohena, Angel; Haines, Kathleen M.; Heitjan, Daniel F.; Albelda, Steven M.; Carroll, Richard G.; Riley, James L.; Pastan, Ira; June, Carl H.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3360-3365</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Mesothelin is a cell-surface mol. over-expressed on a large fraction of carcinomas, and thus is an attractive target of immunotherapy.  A molecularly targeted therapy for these cancers was created by engineering T cells to express a chimeric receptor with high affinity for human mesothelin.  Lentiviral vectors were used to express a single-chain variable fragment that binds mesothelin and that is fused to signaling domains derived from T-cell receptor zeta, CD28, and CD137 (4-1BB).  When stimulated by mesothelin, lentivirally transduced T cells were induced to proliferate, express the antiapoptotic gene Bcl-XL, and secrete multiple cytokines, all features characteristic of central memory T cells.  When transferred intratumorally or i.v. into NOD/scid/IL2rγ-/- mice engrafted with large pre-established tumors, the engineered T cells reduced the tumor burden, and in some cases resulted in complete eradication of the tumors at low effector-to-target ratios.  Incorporation of the CD137 signaling domain specifically reprogrammed cells for multifunctional cytokine secretion and enhanced persistence of T cells.  These findings have important implications for adoptive immunotherapy of cancer, esp. in the context of poorly immunogenic tumors.  Genetically redirected T cells have promise of targeting T lymphocytes to tumor antigens, confer resistance to the tumor microenvironment, and providing immunosurveillance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1x8gxtesA8rVg90H21EOLACvtfcHk0lh44XCXY8k-Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivF2jsbw%253D&md5=9c2e1243ffc503022d04ed1fa465fa82</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0813101106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0813101106%26sid%3Dliteratum%253Aachs%26aulast%3DCarpenito%26aufirst%3DC.%26aulast%3DMilone%26aufirst%3DM.%2BC.%26aulast%3DHassan%26aufirst%3DR.%26aulast%3DSimonet%26aufirst%3DJ.%2BC.%26aulast%3DLakhal%26aufirst%3DM.%26aulast%3DSuhoski%26aufirst%3DM.%2BM.%26aulast%3DVarela-Rohena%26aufirst%3DA.%26aulast%3DHaines%26aufirst%3DK.%2BM.%26aulast%3DHeitjan%26aufirst%3DD.%2BF.%26aulast%3DAlbelda%26aufirst%3DS.%2BM.%26aulast%3DCarroll%26aufirst%3DR.%2BG.%26aulast%3DRiley%26aufirst%3DJ.%2BL.%26aulast%3DPastan%26aufirst%3DI.%26aulast%3DJune%26aufirst%3DC.%2BH.%26atitle%3DControl%2520of%2520large%252C%2520established%2520tumor%2520xenografts%2520with%2520genetically%2520retargeted%2520human%2520T%2520cells%2520containing%2520CD28%2520and%2520CD137%2520domains%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D3360%26epage%3D3365%26doi%3D10.1073%2Fpnas.0813101106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hombach, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abken, H.</span></span> <span> </span><span class="NLM_article-title">Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation</span>. <i>Hum. Gene Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.1089/hum.2012.247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1089%2Fhum.2012.247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=23350854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktleltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=259-269&author=A.+A.+Hombachauthor=M.+Chmielewskiauthor=G.+Rapplauthor=H.+Abken&title=Adoptive+immunotherapy+with+redirected+T+cells+produces+CCR7-+cells+that+are+trapped+in+the+periphery+and+benefit+from+combined+CD28-OX40+costimulation&doi=10.1089%2Fhum.2012.247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Adoptive Immunotherapy with Redirected T Cells Produces CCR7- Cells That Are Trapped in the Periphery and Benefit from Combined CD28-OX40 Costimulation</span></div><div class="casAuthors">Hombach, Andreas A.; Chmielewski, Markus; Rappl, Gunter; Abken, Hinrich</div><div class="citationInfo"><span class="NLM_cas:title">Human Gene Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">259-269</span>CODEN:
                <span class="NLM_cas:coden">HGTHE3</span>;
        ISSN:<span class="NLM_cas:issn">1043-0342</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Adoptive therapy of cancer with genetically redirected T cells showed spectacular efficacy in recent trials.  A body of preclin. and clin. data indicate that young effector and central memory T cells perform superior in a primary antitumor response; repetitive antigen engagement, however, drives T-cell maturation to terminally differentiated cells assocd. with the loss of CCR7, which enables T cells to persist in peripheral tissues.  In this work, we explored the antitumor efficacy of CCR7- T cells when redirected in an antigen-dependent fashion by a chimeric antigen receptor (CAR) toward tumors in the periphery.  CAR-engineered CCR7- T cells more efficiently accumulated at the tumor site, secreted more IFN-γ, expressed higher amts. of cytotoxic mols., and showed superior tumor cell lysis compared to the younger CCR7+ cells.  CCR7- T cells, however, were more prone to spontaneous and activation-induced cell death, which could be counteracted by simultaneous CD28 and OX40 (CD134) costimulation.  Consequently, the combined CD28-ζ-OX40 signaling CAR rescued CCR7- T cells from apoptosis, which then produced more efficient antitumor efficacy than CCR7+ T cells redirected by the same CAR.  Data suggest that T-cell therapy will benefit from combined CD28-ζ-OX40 stimulation in the long-term by rescuing continuously generated CCR7- T cells for an antitumor attack.  Hombach and colleagues explore the antitumor efficacy of T cells lacking chemokine receptor CCR7 (CCR7- T cells) redirected by a chimeric antigen receptor (CAR) toward peripheral tumors.  Although antigen-specific CAR-engineered CCR7- T cells were more prone to spontaneous and activation-induced cell death, they accumulated more efficiently at tumor sites, secreted more interferon-γ, expressed higher amts. of cytotoxic mols., and showed superior tumor cell lysis.  CCR7- T cell activation-induced cell death was counteracted when cells were instead redirected by a combined CD28 and OX40 costimulatory CAR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ7M6v2CO6VrVg90H21EOLACvtfcHk0lhhsXWCL6zWug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktleltbk%253D&md5=fbb4d165116b00036bf9c7861f9fa70c</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1089%2Fhum.2012.247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fhum.2012.247%26sid%3Dliteratum%253Aachs%26aulast%3DHombach%26aufirst%3DA.%2BA.%26aulast%3DChmielewski%26aufirst%3DM.%26aulast%3DRappl%26aufirst%3DG.%26aulast%3DAbken%26aufirst%3DH.%26atitle%3DAdoptive%2520immunotherapy%2520with%2520redirected%2520T%2520cells%2520produces%2520CCR7-%2520cells%2520that%2520are%2520trapped%2520in%2520the%2520periphery%2520and%2520benefit%2520from%2520combined%2520CD28-OX40%2520costimulation%26jtitle%3DHum.%2520Gene%2520Ther.%26date%3D2013%26volume%3D24%26spage%3D259%26epage%3D269%26doi%3D10.1089%2Fhum.2012.247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abate-Daga, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagisetty, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gattinoni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miermont, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teper, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudloff, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Restifo, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, R. A.</span></span> <span> </span><span class="NLM_article-title">A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer</span>. <i>Hum. Gene Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1003</span>– <span class="NLM_lpage">1012</span>, <span class="refDoi"> DOI: 10.1089/hum.2013.209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1089%2Fhum.2013.209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=24694017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitV2ntrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=1003-1012&issue=12&author=D.+Abate-Dagaauthor=K.+H.+Lagisettyauthor=E.+Tranauthor=Z.+Zhengauthor=L.+Gattinoniauthor=Z.+Yuauthor=W.+R.+Burnsauthor=A.+M.+Miermontauthor=Y.+Teperauthor=U.+Rudloffauthor=N.+P.+Restifoauthor=S.+A.+Feldmanauthor=S.+A.+Rosenbergauthor=R.+A.+Morgan&title=A+novel+chimeric+antigen+receptor+against+prostate+stem+cell+antigen+mediates+tumor+destruction+in+a+humanized+mouse+model+of+pancreatic+cancer&doi=10.1089%2Fhum.2013.209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Chimeric Antigen Receptor Against Prostate Stem Cell Antigen Mediates Tumor Destruction in a Humanized Mouse Model of Pancreatic Cancer</span></div><div class="casAuthors">Abate-Daga, Daniel; Lagisetty, Kiran H.; Tran, Eric; Zheng, Zhili; Gattinoni, Luca; Yu, Zhiya; Burns, William R.; Miermont, Anne M.; Teper, Yaroslav; Rudloff, Udo; Restifo, Nicholas P.; Feldman, Steven A.; Rosenberg, Steven A.; Morgan, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Human Gene Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1003-1012</span>CODEN:
                <span class="NLM_cas:coden">HGTHE3</span>;
        ISSN:<span class="NLM_cas:issn">1043-0342</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Despite advances in the understanding of its mol. pathophysiol., pancreatic cancer remains largely incurable, highlighting the need for novel therapies.  We developed a chimeric antigen receptor (CAR) specific for prostate stem cell antigen (PSCA), a glycoprotein that is overexpressed in pancreatic cancer starting at early stages of malignant transformation.  To optimize the CAR design, we used antigen-recognition domains derived from mouse or human antibodies, and intracellular signaling domains contg. one or two T cell costimulatory elements, in addn. to CD3zeta.  Comparing multiple constructs established that the CAR based on human monoclonal antibody Ha1-4.117 had the greatest reactivity in vitro.  To further analyze this CAR, we developed a human pancreatic cancer xenograft model and adoptively transferred CAR-engineered T cells into animals with established tumors.  CAR-engineered human lymphocytes induced significant antitumor activity, and unlike what has been described for other CARs, a second-generation CAR (contg. CD28 cosignaling domain) induced a more potent antitumor effect than a third-generation CAR (contg. CD28 and 41BB cosignaling domains).  While our results provide evidence to support PSCA as a target antigen for CAR-based immunotherapy of pancreatic cancer, the expression of PSCA on selected normal tissues could be a source of limiting toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouotN47Usys7Vg90H21EOLACvtfcHk0lhhsXWCL6zWug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitV2ntrnI&md5=5ea2fc25cee4a24f71109e115920c847</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1089%2Fhum.2013.209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fhum.2013.209%26sid%3Dliteratum%253Aachs%26aulast%3DAbate-Daga%26aufirst%3DD.%26aulast%3DLagisetty%26aufirst%3DK.%2BH.%26aulast%3DTran%26aufirst%3DE.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DGattinoni%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DBurns%26aufirst%3DW.%2BR.%26aulast%3DMiermont%26aufirst%3DA.%2BM.%26aulast%3DTeper%26aufirst%3DY.%26aulast%3DRudloff%26aufirst%3DU.%26aulast%3DRestifo%26aufirst%3DN.%2BP.%26aulast%3DFeldman%26aufirst%3DS.%2BA.%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26aulast%3DMorgan%26aufirst%3DR.%2BA.%26atitle%3DA%2520novel%2520chimeric%2520antigen%2520receptor%2520against%2520prostate%2520stem%2520cell%2520antigen%2520mediates%2520tumor%2520destruction%2520in%2520a%2520humanized%2520mouse%2520model%2520of%2520pancreatic%2520cancer%26jtitle%3DHum.%2520Gene%2520Ther.%26date%3D2014%26volume%3D25%26issue%3D12%26spage%3D1003%26epage%3D1012%26doi%3D10.1089%2Fhum.2013.209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chmielewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abken, H.</span></span> <span> </span><span class="NLM_article-title">TRUCKs: the fourth generation of CARs</span>. <i>Expert Opin. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1145</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1517/14712598.2015.1046430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1517%2F14712598.2015.1046430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=25985798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFyqsrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=1145-1154&author=M.+Chmielewskiauthor=H.+Abken&title=TRUCKs%3A+the+fourth+generation+of+CARs&doi=10.1517%2F14712598.2015.1046430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">TRUCKs: the fourth generation of CARs</span></div><div class="casAuthors">Chmielewski, Markus; Abken, Hinrich</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1145-1154</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: Adoptive cell therapy of malignant diseases takes advantage of the cellular immune system to recognize and destroy cancer cells.  This is impressively demonstrated by redirecting T cells with a chimeric antigen receptor (CAR) towards CD19, inducing complete and lasting remission of leukemia in more than two-thirds of patients in early phase trials.  Areas covered: We outline how the CAR strategy is highly specific in redirecting T cells towards pre-defined target cells, however, reaches its limits when targeting solid tumors with a tremendous phenotypic heterogeneity.  After initial tumor redn. by CAR T cells, antigen-neg. cancer cells not recognized by CAR may give rise to tumor relapse.  The situation may be overcome by CAR-mediated activation of T cells in the tumor, releasing inducible IL-12 which augments T-cell activation and attracts and activates innate immune cells to eliminate antigen-neg. cancer cells in the targeted lesion.  Expert opinion: CAR T cells with a transgenic 'payload', so-called TRUCK T cells or the 'fourth-generation' CAR T cells, are worthwhile to explore to shape the tumor environment by the inducible release of transgenic immune modifiers.  Such TRUCK T cells are moreover envisioned to be applied in fields beyond cancer therapy including the therapy of virus infections, auto-immune diseases or metabolic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ_GDRaZwN1LVg90H21EOLACvtfcHk0lgs8e6U8sZoHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFyqsrvN&md5=159cc23be6bbcf0b17c107ca08e3c9a0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1517%2F14712598.2015.1046430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.2015.1046430%26sid%3Dliteratum%253Aachs%26aulast%3DChmielewski%26aufirst%3DM.%26aulast%3DAbken%26aufirst%3DH.%26atitle%3DTRUCKs%253A%2520the%2520fourth%2520generation%2520of%2520CARs%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2015%26volume%3D15%26spage%3D1145%26epage%3D1154%26doi%3D10.1517%2F14712598.2015.1046430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alizadeh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecoraro, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ann, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C. E.</span></span> <span> </span><span class="NLM_article-title">IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-18-0466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1158%2F2326-6066.CIR-18-0466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=30890531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVyjurnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=759-772&issue=5&author=D.+Alizadehauthor=R.+A.+Wongauthor=X.+Yangauthor=D.+Wangauthor=J.+R.+Pecoraroauthor=C.+F.+Kuoauthor=B.+Aguilarauthor=Y.+Qiauthor=D.+K.+Annauthor=R.+Starrauthor=R.+Urakauthor=X.+Wangauthor=S.+J.+Formanauthor=C.+E.+Brown&title=IL15+enhances+CAR-T+cell+antitumor+activity+by+reducing+mTORC1+activity+and+preserving+their+stem+cell+memory+phenotype&doi=10.1158%2F2326-6066.CIR-18-0466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype</span></div><div class="casAuthors">Alizadeh, Darya; Wong, Robyn A.; Yang, Xin; Wang, Dongrui; Pecoraro, Joseph R.; Kuo, Cheng-Fu; Aguilar, Brenda; Qi, Yue; Ann, David K.; Starr, Renate; Urak, Ryan; Wang, Xiuli; Forman, Stephen J.; Brown, Christine E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">759-772</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Improvements in the quality and fitness of chimeric antigen receptor (CAR)-engineered T cells, through CAR design or manufg. optimizations, could enhance the therapeutic potential of CAR-T cells.  One parameter influencing the effectiveness of CAR-T cell therapy is the differentiation status of the final product: CAR-T cells that are less-differentiated and less exhausted are more therapeutically effective.  In the current study, we demonstrate that CAR-T cells expanded in IL15 (CAR-T/IL15) preserve a less-differentiated stem cell memory (Tscm) phenotype, defined by expression of CD62L+CD45RA+ CCR7+, as compared with cells cultured in IL2 (CAR-T/IL2).  CAR-T/IL15 cells exhibited reduced expression of exhaustion markers, higher antiapoptotic properties, and increased proliferative capacity upon antigen challenge.  Furthermore, CAR-T/IL15 cells exhibited decreased mTORC1 activity, reduced expression of glycolytic enzymes and improved mitochondrial fitness.  CAR-T/IL2 cells cultured in rapamycin (mTORC1 inhibitor) shared phenotypic features with CAR-T/IL15 cells, suggesting that IL15-mediated redn. of mTORC1 activity is responsible for preserving the Tscm phenotype.  CAR-T/IL15 cells promoted superior antitumor responses in vivo in comparison with CAR-T/IL2 cells.  Inclusion of cytokines IL7 and/or IL21 in addn. to IL15 reduced the beneficial effects of IL15 on CAR-T phenotype and antitumor potency.  Our findings show that IL15 preserves the CAR-T cell Tscm phenotype and improves their metabolic fitness, which results in superior in vivo antitumor activity, thus opening an avenue that may improve future adoptive T-cell therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-D-xwBOvnrrVg90H21EOLACvtfcHk0lgs8e6U8sZoHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVyjurnK&md5=f8aa1f5d992abbcac9fbc8c6826afabc</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-18-0466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-18-0466%26sid%3Dliteratum%253Aachs%26aulast%3DAlizadeh%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DR.%2BA.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DPecoraro%26aufirst%3DJ.%2BR.%26aulast%3DKuo%26aufirst%3DC.%2BF.%26aulast%3DAguilar%26aufirst%3DB.%26aulast%3DQi%26aufirst%3DY.%26aulast%3DAnn%26aufirst%3DD.%2BK.%26aulast%3DStarr%26aufirst%3DR.%26aulast%3DUrak%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DForman%26aufirst%3DS.%2BJ.%26aulast%3DBrown%26aufirst%3DC.%2BE.%26atitle%3DIL15%2520enhances%2520CAR-T%2520cell%2520antitumor%2520activity%2520by%2520reducing%2520mTORC1%2520activity%2520and%2520preserving%2520their%2520stem%2520cell%2520memory%2520phenotype%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2019%26volume%3D7%26issue%3D5%26spage%3D759%26epage%3D772%26doi%3D10.1158%2F2326-6066.CIR-18-0466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeku, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijewarnasuriya, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Leeuwen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purdon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniyan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brentjens, R. J.</span></span> <span> </span><span class="NLM_article-title">Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2130</span>– <span class="NLM_lpage">2141</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2018.04.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.celrep.2018.04.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29768210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsFygt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=2130-2141&issue=7&author=M.+P.+Avanziauthor=O.+Yekuauthor=X.+Liauthor=D.+P.+Wijewarnasuriyaauthor=D.+G.+van+Leeuwenauthor=K.+Cheungauthor=H.+Parkauthor=T.+J.+Purdonauthor=A.+F.+Daniyanauthor=M.+H.+Spitzerauthor=R.+J.+Brentjens&title=Engineered+tumor-targeted+T+cells+mediate+enhanced+anti-tumor+efficacy+both+directly+and+through+activation+of+the+endogenous+immune+system&doi=10.1016%2Fj.celrep.2018.04.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System</span></div><div class="casAuthors">Avanzi, Mauro P.; Yeku, Oladapo; Li, Xinghuo; Wijewarnasuriya, Dinali P.; van Leeuwen, Dayenne G.; Cheung, Kenneth; Park, Hyebin; Purdon, Terence J.; Daniyan, Anthony F.; Spitzer, Matthew H.; Brentjens, Renier J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2130-2141</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Chimeric antigen receptor (CAR) T cell therapy has proven clin. beneficial against B cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma.  However, suboptimal clin. outcomes have been assocd. with decreased expansion and persistence of adoptively transferred CAR T cells, antigen-neg. relapses, and impairment by an immunosuppressive tumor microenvironment.  Improvements in CAR T cell design are required to enhance clin. efficacy, as well as broaden the applicability of this technol.  Here, we demonstrate that interleukin-18 (IL-18)-secreting CAR T cells exhibit enhanced in vivo expansion and persistence and significantly increase long-term survival in syngeneic mouse models of both hematol. and solid malignancies.  In addn., we demonstrate that IL-18-secreting CAR T cells are capable of modulating the tumor microenvironment, as well as enhancing an effective endogenous anti-tumor immune response.  IL-18-secreting CAR T cells represent a promising strategy to enhance the clin. outcomes of adoptive T cell therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqscfnTMdvtA7Vg90H21EOLACvtfcHk0lgZtWO60ZjAhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsFygt7o%253D&md5=0b3d391a36296cb5c86ef66d7d7f31ba</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2018.04.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2018.04.051%26sid%3Dliteratum%253Aachs%26aulast%3DAvanzi%26aufirst%3DM.%2BP.%26aulast%3DYeku%26aufirst%3DO.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWijewarnasuriya%26aufirst%3DD.%2BP.%26aulast%3Dvan%2BLeeuwen%26aufirst%3DD.%2BG.%26aulast%3DCheung%26aufirst%3DK.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DPurdon%26aufirst%3DT.%2BJ.%26aulast%3DDaniyan%26aufirst%3DA.%2BF.%26aulast%3DSpitzer%26aufirst%3DM.%2BH.%26aulast%3DBrentjens%26aufirst%3DR.%2BJ.%26atitle%3DEngineered%2520tumor-targeted%2520T%2520cells%2520mediate%2520enhanced%2520anti-tumor%2520efficacy%2520both%2520directly%2520and%2520through%2520activation%2520of%2520the%2520endogenous%2520immune%2520system%26jtitle%3DCell%2520Rep.%26date%3D2018%26volume%3D23%26issue%3D7%26spage%3D2130%26epage%3D2141%26doi%3D10.1016%2Fj.celrep.2018.04.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamada, K.</span></span> <span> </span><span class="NLM_article-title">IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">346</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1038/nbt.4086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fnbt.4086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29505028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVOlu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=346-351&issue=4&author=K.+Adachiauthor=Y.+Kanoauthor=T.+Nagaiauthor=N.+Okuyamaauthor=Y.+Sakodaauthor=K.+Tamada&title=IL-7+and+CCL19+expression+in+CAR-T+cells+improves+immune+cell+infiltration+and+CAR-T+cell+survival+in+the+tumor&doi=10.1038%2Fnbt.4086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor</span></div><div class="casAuthors">Adachi, Keishi; Kano, Yosuke; Nagai, Tomohiko; Okuyama, Namiko; Sakoda, Yukimi; Tamada, Koji</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">346-351</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Infiltration, accumulation, and survival of chimeric antigen receptor T (CAR-T) cells in solid tumors is crucial for tumor clearance.  We engineered CAR-T cells to express interleukin (IL)-7 and CCL19 (7 × 19 CAR-T cells), as these factors are essential for the maintenance of T-cell zones in lymphoid organs.  In mice, 7 × 19 CAR-T cells achieved complete regression of pre-established solid tumors and prolonged mouse survival, with superior anti-tumor activity compared to conventional CAR-T cells.  Histopathol. analyses showed increased infiltration of dendritic cells (DC) and T cells into tumor tissues following 7 × 19 CAR-T cell therapy.  Depletion of recipient T cells before 7 × 19 CAR-T cell administration dampened the therapeutic effects of 7 × 19 CAR-T cell treatment, suggesting that CAR-T cells and recipient immune cells collaborated to exert anti-tumor activity.  Following treatment of mice with 7 × 19 CAR-T cells, both recipient conventional T cells and administered CAR-T cells generated memory responses against tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYltatjh4Ir7Vg90H21EOLACvtfcHk0lj5wCaBirnW8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVOlu74%253D&md5=86ffd1f1dd5fbbbc7a64d346d4e6080f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnbt.4086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.4086%26sid%3Dliteratum%253Aachs%26aulast%3DAdachi%26aufirst%3DK.%26aulast%3DKano%26aufirst%3DY.%26aulast%3DNagai%26aufirst%3DT.%26aulast%3DOkuyama%26aufirst%3DN.%26aulast%3DSakoda%26aufirst%3DY.%26aulast%3DTamada%26aufirst%3DK.%26atitle%3DIL-7%2520and%2520CCL19%2520expression%2520in%2520CAR-T%2520cells%2520improves%2520immune%2520cell%2520infiltration%2520and%2520CAR-T%2520cell%2520survival%2520in%2520the%2520tumor%26jtitle%3DNat.%2520Biotechnol.%26date%3D2018%26volume%3D36%26issue%3D4%26spage%3D346%26epage%3D351%26doi%3D10.1038%2Fnbt.4086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kagoya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anczurowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saso, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minden, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, N.</span></span> <span> </span><span class="NLM_article-title">A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">352</span>– <span class="NLM_lpage">359</span>, <span class="refDoi"> DOI: 10.1038/nm.4478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fnm.4478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29400710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=352-359&author=Y.+Kagoyaauthor=S.+Tanakaauthor=T.+Guoauthor=M.+Anczurowskiauthor=C.+H.+Wangauthor=K.+Sasoauthor=M.+O.+Butlerauthor=M.+D.+Mindenauthor=N.+Hirano&title=A+novel+chimeric+antigen+receptor+containing+a+JAK-STAT+signaling+domain+mediates+superior+antitumor+effects&doi=10.1038%2Fnm.4478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects</span></div><div class="casAuthors">Kagoya, Yuki; Tanaka, Shinya; Guo, Tingxi; Anczurowski, Mark; Wang, Chung-Hsi; Saso, Kayoko; Butler, Marcus O.; Minden, Mark D.; Hirano, Naoto</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">352-359</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The adoptive transfer of T cells engineered with a chimeric antigen receptor (CAR) (hereafter referred to as CAR-T cells) specific for the B lymphocyte antigen CD19 has shown impressive clin. responses in patients with refractory B cell malignancies.  However, the therapeutic effects of CAR-T cells that target other malignancies have not yet resulted in significant clin. benefit.  Although inefficient tumor trafficking and various immunosuppressive mechanisms can impede CAR-T cell effector responses, the signals delivered by the current CAR constructs may still be insufficient to fully activate antitumor T cell functions.  Optimal T cell activation and proliferation requires multiple signals, including T cell receptor (TCR) engagement (signal 1), co-stimulation (signal 2) and cytokine engagement (signal 3).  However, CAR constructs currently being tested in the clinic contain a CD3z (TCR signaling) domain and co-stimulatory domain(s) but not a domain that transmits signal 3 (refs. 13, 14, 15, 16, 17, 18).  Here we have developed a novel CAR construct capable of inducing cytokine signaling after antigen stimulation.  This new-generation CD19 CAR encodes a truncated cytoplasmic domain from the interleukin (IL)-2 receptor β-chain (IL-2Rβ) and a STAT3-binding tyrosine-X-X-glutamine (YXXQ) motif, together with the TCR signaling (CD3z) and co-stimulatory (CD28) domains (hereafter referred to as 28-ΔIL2RB-z(YXXQ)).  The 28-ΔIL2RB-z(YXXQ) CAR-T cells showed antigen-dependent activation of the JAK kinase and of the STAT3 and STAT5 transcription factors signaling pathways, which promoted their proliferation and prevented terminal differentiation in vitro.  The 28-ΔIL2RB-z(YXXQ) CAR-T cells demonstrated superior in vivo persistence and antitumor effects in models of liq. and solid tumors as compared with CAR-T cells expressing a CD28 or 4-1BB co-stimulatory domain alone.  Taken together, these results suggest that our new-generation CAR has the potential to demonstrate superior antitumor effects with minimal toxicity in the clinic and that clin. translation of this novel CAR is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNT3m_IKkclrVg90H21EOLACvtfcHk0lj5wCaBirnW8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCiu7o%253D&md5=21137ad18d890e713d4a329350995cf3</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnm.4478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4478%26sid%3Dliteratum%253Aachs%26aulast%3DKagoya%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DAnczurowski%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DC.%2BH.%26aulast%3DSaso%26aufirst%3DK.%26aulast%3DButler%26aufirst%3DM.%2BO.%26aulast%3DMinden%26aufirst%3DM.%2BD.%26aulast%3DHirano%26aufirst%3DN.%26atitle%3DA%2520novel%2520chimeric%2520antigen%2520receptor%2520containing%2520a%2520JAK-STAT%2520signaling%2520domain%2520mediates%2520superior%2520antitumor%2520effects%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D352%26epage%3D359%26doi%3D10.1038%2Fnm.4478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tokarew, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogonek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endres, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Bergwelt-Baildon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobold, S.</span></span> <span> </span><span class="NLM_article-title">Teaching an old dog new tricks: next-generation CAR T cells</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1038/s41416-018-0325-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fs41416-018-0325-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=30413825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFOjt7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2019&pages=26-37&author=N.+Tokarewauthor=J.+Ogonekauthor=S.+Endresauthor=M.+von+Bergwelt-Baildonauthor=S.+Kobold&title=Teaching+an+old+dog+new+tricks%3A+next-generation+CAR+T+cells&doi=10.1038%2Fs41416-018-0325-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Teaching an old dog new tricks: next-generation CAR T cells</span></div><div class="casAuthors">Tokarew, Nicholas; Ogonek, Justyna; Endres, Stefan; von Bergwelt-Baildon, Michael; Kobold, Sebastian</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-37</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Adoptive T cell therapy (ACT) refers to the therapeutic use of T cells.  T cells genetically engineered to express chimeric antigen receptors (CAR) constitute the most clin. advanced form of ACT approved to date for the treatment of CD19-pos. leukemias and lymphomas.  CARs are synthetic receptors that are able to confer antigen-binding and activating functions on T cells with the aim of therapeutically targeting cancer cells.  Several factors are essential for CAR T cell therapy to be effective, such as recruitment, activation, expansion and persistence of bioengineered T cells at the tumor site.  Despite the advances made in CAR T cell therapy, however, most tumor entities still escape immune detection and elimination.  A no. of strategies counteracting these problems will need to be addressed in order to render T cell therapy effective in more situations than currently possible.  Non-haematol. tumors are also the subject of active investigation, but ACT has so far shown only marginal success rates in these cases.  New approaches are needed to enhance the ability of ACT to target solid tumors without increasing toxicity, by improving recognition, infiltration, and persistence within tumors, as well as an enhanced resistance to the suppressive tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr56iJiHa1nxbVg90H21EOLACvtfcHk0lgH0Va2L7cQtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFOjt7fL&md5=d0ac6d54dbe5511e3e75245f935517ea</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fs41416-018-0325-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41416-018-0325-1%26sid%3Dliteratum%253Aachs%26aulast%3DTokarew%26aufirst%3DN.%26aulast%3DOgonek%26aufirst%3DJ.%26aulast%3DEndres%26aufirst%3DS.%26aulast%3Dvon%2BBergwelt-Baildon%26aufirst%3DM.%26aulast%3DKobold%26aufirst%3DS.%26atitle%3DTeaching%2520an%2520old%2520dog%2520new%2520tricks%253A%2520next-generation%2520CAR%2520T%2520cells%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2019%26volume%3D120%26spage%3D26%26epage%3D37%26doi%3D10.1038%2Fs41416-018-0325-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waller, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borchmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuirk, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jäger, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaglowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreadis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westin, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleury, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachanova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mielke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magenau, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holte, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacaud, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anak, Ö.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salles, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maziarz, R. T.</span></span> <span> </span><span class="NLM_article-title">Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1804980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1056%2FNEJMoa1804980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=30501490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=45-56&issue=1&author=S.+J.+Schusterauthor=M.+R.+Bishopauthor=C.+S.+Tamauthor=E.+K.+Wallerauthor=P.+Borchmannauthor=J.+P.+McGuirkauthor=U.+J%C3%A4gerauthor=S.+Jaglowskiauthor=C.+Andreadisauthor=J.+R.+Westinauthor=I.+Fleuryauthor=V.+Bachanovaauthor=S.+R.+Foleyauthor=P.+J.+Hoauthor=S.+Mielkeauthor=J.+M.+Magenauauthor=H.+Holteauthor=S.+Pantanoauthor=L.+B.+Pacaudauthor=R.+Awasthiauthor=J.+Chuauthor=%C3%96.+Anakauthor=G.+Sallesauthor=R.+T.+Maziarz&title=Tisagenlecleucel+in+adult+relapsed+or+refractory+diffuse+large+B-cell+lymphoma&doi=10.1056%2FNEJMoa1804980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma</span></div><div class="casAuthors">Schuster, Stephen J.; Bishop, Michael R.; Tam, Constantine S.; Waller, Edmund K.; Borchmann, Peter; McGuirk, Joseph P.; Jager, Ulrich; Jaglowski, Samantha; Andreadis, Charalambos; Westin, Jason R.; Fleury, Isabelle; Bachanova, Veronika; Foley, S. Ronan; Ho, P. Joy; Mielke, Stephan; Magenau, John M.; Holte, Harald; Pantano, Serafino; Pacaud, Lida B.; Awasthi, Rakesh; Chu, Jufen; Anak, Ozlem; Salles, Gilles; Maziarz, Richard T.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-56</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis.  The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, phase 2a study.  We conducted an international, phase 2, pivotal study of centrally manufd. tisagenlecleucel involving adult patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for or had disease progression after autologous hematopoietic stem-cell transplantation.  The primary end point was the best overall response rate (i.e., the percentage of patients who had a complete or partial response), as judged by an independent review committee.  A total of 93 patients received an infusion and were included in the evaluation of efficacy.  The median time from infusion to data cutoff was 14 mo (range, 0.1 to 26).  The best overall response rate was 52% (95% confidence interval, 41 to 62); 40% of the patients had complete responses, and 12% had partial responses.  Response rates were consistent across prognostic subgroups.  At 12 mo after the initial response, the rate of relapse-free survival was estd. to be 65% (79% among patients with a complete response).  The most common grade 3 or 4 adverse events of special interest included cytokine release syndrome (22%), neurol. events (12%), cytopenias lasting more than 28 days (32%), infections (20%), and febrile neutropenia (14%).  Three patients died from disease progression within 30 days after infusion.  No deaths were attributed to tisagenlecleucel, cytokine release syndrome, or cerebral edema.  No differences between response groups in tumor expression of CD19 or immune checkpoint-related proteins were found.  In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYUl7vblDrEbVg90H21EOLACvtfcHk0lgH0Va2L7cQtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtbc%253D&md5=b8ead75d6b00fbb05cbe0416763d9314</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1804980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1804980%26sid%3Dliteratum%253Aachs%26aulast%3DSchuster%26aufirst%3DS.%2BJ.%26aulast%3DBishop%26aufirst%3DM.%2BR.%26aulast%3DTam%26aufirst%3DC.%2BS.%26aulast%3DWaller%26aufirst%3DE.%2BK.%26aulast%3DBorchmann%26aufirst%3DP.%26aulast%3DMcGuirk%26aufirst%3DJ.%2BP.%26aulast%3DJ%25C3%25A4ger%26aufirst%3DU.%26aulast%3DJaglowski%26aufirst%3DS.%26aulast%3DAndreadis%26aufirst%3DC.%26aulast%3DWestin%26aufirst%3DJ.%2BR.%26aulast%3DFleury%26aufirst%3DI.%26aulast%3DBachanova%26aufirst%3DV.%26aulast%3DFoley%26aufirst%3DS.%2BR.%26aulast%3DHo%26aufirst%3DP.%2BJ.%26aulast%3DMielke%26aufirst%3DS.%26aulast%3DMagenau%26aufirst%3DJ.%2BM.%26aulast%3DHolte%26aufirst%3DH.%26aulast%3DPantano%26aufirst%3DS.%26aulast%3DPacaud%26aufirst%3DL.%2BB.%26aulast%3DAwasthi%26aufirst%3DR.%26aulast%3DChu%26aufirst%3DJ.%26aulast%3DAnak%26aufirst%3D%25C3%2596.%26aulast%3DSalles%26aufirst%3DG.%26aulast%3DMaziarz%26aufirst%3DR.%2BT.%26atitle%3DTisagenlecleucel%2520in%2520adult%2520relapsed%2520or%2520refractory%2520diffuse%2520large%2520B-cell%2520lymphoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26issue%3D1%26spage%3D45%26epage%3D56%26doi%3D10.1056%2FNEJMoa1804980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neelapu, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locke, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lekakis, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miklos, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braunschweig, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oluwole, O. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmerman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiff, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedberg, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deol, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farooq, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McSweeney, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avivi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westin, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghobadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komanduri, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witzig, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reagan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navale, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aycock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elias, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiezorek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, W. Y.</span></span> <span> </span><span class="NLM_article-title">Axicabtagene Ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">2531</span>– <span class="NLM_lpage">2544</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1707447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1056%2FNEJMoa1707447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29226797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=2531-2544&issue=26&author=S.+S.+Neelapuauthor=F.+L.+Lockeauthor=N.+L.+Bartlettauthor=L.+J.+Lekakisauthor=D.+B.+Miklosauthor=C.+A.+Jacobsonauthor=I.+Braunschweigauthor=O.+O.+Oluwoleauthor=T.+Siddiqiauthor=Y.+Linauthor=J.+M.+Timmermanauthor=P.+J.+Stiffauthor=J.+W.+Friedbergauthor=I.+W.+Flinnauthor=A.+Goyauthor=B.+T.+Hillauthor=M.+R.+Smithauthor=A.+Deolauthor=U.+Farooqauthor=P.+McSweeneyauthor=J.+Munozauthor=I.+Aviviauthor=J.+E.+Castroauthor=J.+R.+Westinauthor=J.+C.+Chavezauthor=A.+Ghobadiauthor=K.+V.+Komanduriauthor=R.+Levyauthor=E.+D.+Jacobsenauthor=T.+E.+Witzigauthor=P.+Reaganauthor=A.+Botauthor=J.+Rossiauthor=L.+Navaleauthor=Y.+Jiangauthor=J.+Aycockauthor=M.+Eliasauthor=D.+Changauthor=J.+Wiezorekauthor=W.+Y.+Go&title=Axicabtagene+Ciloleucel+CAR+T-Cell+therapy+in+refractory+large+B-cell+lymphoma&doi=10.1056%2FNEJMoa1707447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma</span></div><div class="casAuthors">Neelapu, S. S.; Locke, F. L.; Bartlett, N. L.; Lekakis, L. J.; Miklos, D. B.; Jacobson, C. A.; Braunschweig, I.; Oluwole, O. O.; Siddiqi, T.; Lin, Y.; Timmerman, J. M.; Stiff, P. J.; Friedberg, J. W.; Flinn, I. W.; Goy, A.; Hill, B. T.; Smith, M. R.; Deol, A.; Farooq, U.; McSweeney, P.; Munoz, J.; Avivi, I.; Castro, J. E.; Westin, J. R.; Chavez, J. C.; Ghobadi, A.; Komanduri, K. V.; Levy, R.; Jacobsen, E. D.; Witzig, T. E.; Reagan, P.; Bot, A.; Rossi, J.; Navale, L.; Jiang, Y.; Aycock, J.; Elias, M.; Chang, D.; Wiezorek, J.; Go, W. Y.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2531-2544</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after the failure of conventional therapy.  In this multicenter, phase 2 trial, we enrolled 111 patients with diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, or transformed follicular lymphoma who had refractory disease despite undergoing recommended prior therapy.  Patients received a target dose of 2 x106 anti-CD19 CAR T cells per kg of body wt. after receiving a conditioning regimen of low-dose cyclophosphamide and fludarabine.  The primary end point was the rate of objective response (calcd. as the combined rates of complete response and partial response).  Secondary end points included overall survival, safety, and biomarker assessments. results Among the 111 patients who were enrolled, axi-cel was successfully manufd. for 110 (99%) and administered to 101 (91%).  The objective response rate was 82%, and the complete response rate was 54%.  With a median follow-up of 15.4 mo, 42% of the patients continued to have a response, with 40% continuing to have a complete response.  The overall rate of survival at 18 mo was 52%.  The most common adverse events of grade 3 or higher during treatment were neutropenia (in 78% of the patients), anemia (in 43%), and thrombocytopenia (in 38%).  Grade 3 or higher cytokine release syndrome and neurol. events occurred in 13% and 28% of the patients, resp.  Three of the patients died during treatment.  Higher CAR T-cell levels in blood were assocd. with response. conclusions In this multicenter study, patients with refractory large B-cell lymphoma who received CAR T-cell therapy with axi-cel had high levels of durable response, with a safety profile that included myelosuppression, the cytokine release syndrome, and neurol. events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPvC_XgxwBMbVg90H21EOLACvtfcHk0ljamjUBAiHCnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGjtbw%253D&md5=fb9e690e5a97b82f7438a57560eae470</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1707447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1707447%26sid%3Dliteratum%253Aachs%26aulast%3DNeelapu%26aufirst%3DS.%2BS.%26aulast%3DLocke%26aufirst%3DF.%2BL.%26aulast%3DBartlett%26aufirst%3DN.%2BL.%26aulast%3DLekakis%26aufirst%3DL.%2BJ.%26aulast%3DMiklos%26aufirst%3DD.%2BB.%26aulast%3DJacobson%26aufirst%3DC.%2BA.%26aulast%3DBraunschweig%26aufirst%3DI.%26aulast%3DOluwole%26aufirst%3DO.%2BO.%26aulast%3DSiddiqi%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DTimmerman%26aufirst%3DJ.%2BM.%26aulast%3DStiff%26aufirst%3DP.%2BJ.%26aulast%3DFriedberg%26aufirst%3DJ.%2BW.%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DHill%26aufirst%3DB.%2BT.%26aulast%3DSmith%26aufirst%3DM.%2BR.%26aulast%3DDeol%26aufirst%3DA.%26aulast%3DFarooq%26aufirst%3DU.%26aulast%3DMcSweeney%26aufirst%3DP.%26aulast%3DMunoz%26aufirst%3DJ.%26aulast%3DAvivi%26aufirst%3DI.%26aulast%3DCastro%26aufirst%3DJ.%2BE.%26aulast%3DWestin%26aufirst%3DJ.%2BR.%26aulast%3DChavez%26aufirst%3DJ.%2BC.%26aulast%3DGhobadi%26aufirst%3DA.%26aulast%3DKomanduri%26aufirst%3DK.%2BV.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DJacobsen%26aufirst%3DE.%2BD.%26aulast%3DWitzig%26aufirst%3DT.%2BE.%26aulast%3DReagan%26aufirst%3DP.%26aulast%3DBot%26aufirst%3DA.%26aulast%3DRossi%26aufirst%3DJ.%26aulast%3DNavale%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DAycock%26aufirst%3DJ.%26aulast%3DElias%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DD.%26aulast%3DWiezorek%26aufirst%3DJ.%26aulast%3DGo%26aufirst%3DW.%2BY.%26atitle%3DAxicabtagene%2520Ciloleucel%2520CAR%2520T-Cell%2520therapy%2520in%2520refractory%2520large%2520B-cell%2520lymphoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26issue%3D26%26spage%3D2531%26epage%3D2544%26doi%3D10.1056%2FNEJMoa1707447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brudno, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochenderfer, J. N.</span></span> <span> </span><span class="NLM_article-title">Toxicities of chimeric antigen receptor T cells: recognition and management</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">3321</span>– <span class="NLM_lpage">3330</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-04-703751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1182%2Fblood-2016-04-703751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=27207799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1entL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=3321-3330&author=J.+N.+Brudnoauthor=J.+N.+Kochenderfer&title=Toxicities+of+chimeric+antigen+receptor+T+cells%3A+recognition+and+management&doi=10.1182%2Fblood-2016-04-703751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Toxicities of chimeric antigen receptor T cells: recognition and management</span></div><div class="casAuthors">Brudno, Jennifer N.; Kochenderfer, James N.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3321-3330</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Chimeric antigen receptor (CAR) T cells can produce durable remissions in hematol. malignancies that are not responsive to std. therapies.  Yet the use of CAR T cells is limited by potentially severe toxicities.  Early case reports of unexpected organ damage and deaths following CAR T-cell therapy first highlighted the possible dangers of this new treatment.  CAR T cells can potentially damage normal tissues by specifically targeting a tumor-assocd. antigen that is also expressed on those tissues.  Cytokine release syndrome (CRS), a systemic inflammatory response caused by cytokines released by infused CAR T cells can lead to widespread reversible organ dysfunction.  CRS is the most common type of toxicity caused by CAR T cells.  Neurol. toxicity due to CAR T cells might in some cases have a different pathophysiol. than CRS and requires different management.  Aggressive supportive care is necessary for all patients experiencing CAR T-cell toxicities, with early intervention for hypotension and treatment of concurrent infections being essential.  Interleukin-6 receptor blockade with tocilizumab remains the mainstay pharmacol. therapy for CRS, though indications for administration vary among centers.  Corticosteroids should be reserved for neurol. toxicities and CRS not responsive to tocilizumab.  Pharmacol. management is complicated by the risk of immunosuppressive therapy abrogating the antimalignancy activity of the CAR T cells.  This review describes the toxicities caused by CAR T cells and reviews the published approaches used to manage toxicities.  We present guidelines for treating patients experiencing CRS and other adverse events following CAR T-cell therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDOudIS6qIB7Vg90H21EOLACvtfcHk0ljSjr8BIlbmwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1entL%252FE&md5=ddb69cbba2280cf8cb0bc406296f496e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-04-703751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-04-703751%26sid%3Dliteratum%253Aachs%26aulast%3DBrudno%26aufirst%3DJ.%2BN.%26aulast%3DKochenderfer%26aufirst%3DJ.%2BN.%26atitle%3DToxicities%2520of%2520chimeric%2520antigen%2520receptor%2520T%2520cells%253A%2520recognition%2520and%2520management%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D3321%26epage%3D3330%26doi%3D10.1182%2Fblood-2016-04-703751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kochenderfer, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spaner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maric, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetler-Stevenson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherry, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kammula, U. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devillier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurencot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. A.</span></span> <span> </span><span class="NLM_article-title">B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">2709</span>– <span class="NLM_lpage">2720</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-10-384388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1182%2Fblood-2011-10-384388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=22160384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFalt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=2709-2720&author=J.+N.+Kochenderferauthor=M.+E.+Dudleyauthor=S.+A.+Feldmanauthor=W.+H.+Wilsonauthor=D.+E.+Spanerauthor=I.+Maricauthor=M.+Stetler-Stevensonauthor=G.+Q.+Phanauthor=M.+S.+Hughesauthor=R.+M.+Sherryauthor=J.+C.+Yangauthor=U.+S.+Kammulaauthor=L.+Devillierauthor=R.+Carpenterauthor=D.+A.+Nathanauthor=R.+A.+Morganauthor=C.+Laurencotauthor=S.+A.+Rosenberg&title=B-cell+depletion+and+remissions+of+malignancy+along+with+cytokine-associated+toxicity+in+a+clinical+trial+of+anti-CD19+chimeric-antigen-receptor-transduced+T+cells&doi=10.1182%2Fblood-2011-10-384388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells</span></div><div class="casAuthors">Kochenderfer, James N.; Dudley, Mark E.; Feldman, Steven A.; Wilson, Wyndham H.; Spaner, David E.; Maric, Irina; Stetler-Stevenson, Maryalice; Phan, Giao Q.; Hughes, Marybeth S.; Sherry, Richard M.; Yang, James C.; Kammula, Udai S.; Devillier, Laura; Carpenter, Robert; Nathan, Debbie-Ann N.; Morgan, Richard A.; Laurencot, Carolyn; Rosenberg, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2709-2720</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">We conducted a clin. trial to assess adoptive transfer of T cells genetically modified to express an anti-CD19 chimeric Ag receptor (CAR).  Our clin. protocol consisted of chemotherapy followed by an infusion of anti-CD19-CAR-transduced T cells and a course of IL-2.  Six of the 8 patients treated on our protocol obtained remissions of their advanced, progressive B-cell malignancies.  Four of the 8 patients treated on the protocol had long-term depletion of normal polyclonal CD19+ B-lineage cells.  Cells contg. the anti-CD19 CAR gene were detected in the blood of all patients.  Four of the 8 treated patients had prominent elevations in serum levels of the inflammatory cytokines IFNγ and TNF.  The severity of acute toxicities experienced by the patients correlated with serum IFNγ and TNF levels.  The infused anti-CD19-CAR-transduced T cells were a possible source of these inflammatory cytokines because we demonstrated peripheral blood T cells that produced TNF and IFNγ ex vivo in a CD19-specific manner after anti-CD19-CAR-transduced T-cell infusions.  Anti-CD19-CAR-transduced T cells have great promise to improve the treatment of B-cell malignancies because of a potent ability to eradicate CD19+ cells in vivo; however, reversible cytokine-assocd. toxicities occurred after CAR-transduced T-cell infusions.  This.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmC2cqDf7ufrVg90H21EOLACvtfcHk0liMYKglf_I3qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFalt7o%253D&md5=30012c2bbd452b6846353eac1ae2e691</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-10-384388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-10-384388%26sid%3Dliteratum%253Aachs%26aulast%3DKochenderfer%26aufirst%3DJ.%2BN.%26aulast%3DDudley%26aufirst%3DM.%2BE.%26aulast%3DFeldman%26aufirst%3DS.%2BA.%26aulast%3DWilson%26aufirst%3DW.%2BH.%26aulast%3DSpaner%26aufirst%3DD.%2BE.%26aulast%3DMaric%26aufirst%3DI.%26aulast%3DStetler-Stevenson%26aufirst%3DM.%26aulast%3DPhan%26aufirst%3DG.%2BQ.%26aulast%3DHughes%26aufirst%3DM.%2BS.%26aulast%3DSherry%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DKammula%26aufirst%3DU.%2BS.%26aulast%3DDevillier%26aufirst%3DL.%26aulast%3DCarpenter%26aufirst%3DR.%26aulast%3DNathan%26aufirst%3DD.%2BA.%26aulast%3DMorgan%26aufirst%3DR.%2BA.%26aulast%3DLaurencot%26aufirst%3DC.%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26atitle%3DB-cell%2520depletion%2520and%2520remissions%2520of%2520malignancy%2520along%2520with%2520cytokine-associated%2520toxicity%2520in%2520a%2520clinical%2520trial%2520of%2520anti-CD19%2520chimeric-antigen-receptor-transduced%2520T%2520cells%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D2709%26epage%3D2720%26doi%3D10.1182%2Fblood-2011-10-384388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grupp, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackall, C. L.</span></span> <span> </span><span class="NLM_article-title">Current concepts in the diagnosis and management of cytokine release syndrome</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">195</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-05-552729</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1182%2Fblood-2014-05-552729" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=24876563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1WktbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=188-195&author=D.+W.+Leeauthor=R.+Gardnerauthor=D.+L.+Porterauthor=C.+U.+Louisauthor=N.+Ahmedauthor=M.+Jensenauthor=S.+A.+Gruppauthor=C.+L.+Mackall&title=Current+concepts+in+the+diagnosis+and+management+of+cytokine+release+syndrome&doi=10.1182%2Fblood-2014-05-552729"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Current concepts in the diagnosis and management of cytokine release syndrome</span></div><div class="casAuthors">Lee, Daniel W.; Gardner, Rebecca; Porter, David L.; Louis, Chrystal U.; Ahmed, Nabil; Jensen, Michael; Grupp, Stephan A.; Mackall, Crystal L.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">188-195</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  As immune-based therapies for cancer become potent, more effective, and more widely available, optimal management of their unique toxicities becomes increasingly important.  Cytokine release syndrome (CRS) is a potentially life-threatening toxicity that has been obsd. following administration of natural and bispecific antibodies and, more recently, following adoptive T-cell therapies for cancer.  CRS is assocd. with elevated circulating levels of several cytokines including interleukin (IL)-6 and interferon γ, and uncontrolled studies demonstrate that immunosuppression using tocilizumab, an anti-IL-6 receptor antibody, with or without corticosteroids, can reverse the syndrome.  However, because early and aggressive immunosuppression could limit the efficacy of the immunotherapy, current approaches seek to limit administration of immunosuppressive therapy to patients at risk for life-threatening consequences of the syndrome.  This report presents a novel system to grade the severity of CRS in individual patients and a treatment algorithm for management of CRS based on severity.  The goal of our approach is to maximize the chance for therapeutic benefit from the immunotherapy while minimizing the risk for life threatening complications of CRS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG59RbNPGZCrVg90H21EOLACvtfcHk0liMYKglf_I3qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1WktbrM&md5=2eec294eaa6681177a18221634e3edda</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-05-552729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-05-552729%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DD.%2BW.%26aulast%3DGardner%26aufirst%3DR.%26aulast%3DPorter%26aufirst%3DD.%2BL.%26aulast%3DLouis%26aufirst%3DC.%2BU.%26aulast%3DAhmed%26aufirst%3DN.%26aulast%3DJensen%26aufirst%3DM.%26aulast%3DGrupp%26aufirst%3DS.%2BA.%26aulast%3DMackall%26aufirst%3DC.%2BL.%26atitle%3DCurrent%2520concepts%2520in%2520the%2520diagnosis%2520and%2520management%2520of%2520cytokine%2520release%2520syndrome%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D188%26epage%3D195%26doi%3D10.1182%2Fblood-2014-05-552729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santomasso, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locke, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghobadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turtle, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brudno, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maus, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mead, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eldjerou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peggs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPersio, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Brink, M. R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komanduri, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grupp, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neelapu, S. S.</span></span> <span> </span><span class="NLM_article-title">ASBMT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells</span>. <i>Biol. Blood Marrow Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">625</span>– <span class="NLM_lpage">638</span>, <span class="refDoi"> DOI: 10.1016/j.bbmt.2018.12.758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.bbmt.2018.12.758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=30592986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1aksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=625-638&issue=4&author=D.+W.+Leeauthor=B.+D.+Santomassoauthor=F.+L.+Lockeauthor=A.+Ghobadiauthor=C.+J.+Turtleauthor=J.+N.+Brudnoauthor=M.+V.+Mausauthor=J.+H.+Parkauthor=E.+Meadauthor=S.+Pavleticauthor=W.+Y.+Goauthor=L.+Eldjerouauthor=R.+A.+Gardnerauthor=N.+Freyauthor=K.+J.+Curranauthor=K.+Peggsauthor=M.+Pasquiniauthor=J.+F.+DiPersioauthor=M.+R.+M.+van+den+Brinkauthor=K.+V.+Komanduriauthor=S.+A.+Gruppauthor=S.+S.+Neelapu&title=ASBMT+consensus+grading+for+cytokine+release+syndrome+and+neurologic+toxicity+associated+with+immune+effector+cells&doi=10.1016%2Fj.bbmt.2018.12.758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">ASBMT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells</span></div><div class="casAuthors">Lee, Daniel W.; Santomasso, Bianca D.; Locke, Frederick L.; Ghobadi, Armin; Turtle, Cameron J.; Brudno, Jennifer N.; Maus, Marcela V.; Park, Jae H.; Mead, Elena; Pavletic, Steven; Go, William Y.; Eldjerou, Lamis; Gardner, Rebecca A.; Frey, Noelle; Curran, Kevin J.; Peggs, Karl; Pasquini, Marcelo; Di Persio, John F.; van den Brink, Marcel R. M.; Komanduri, Krishna V.; Grupp, Stephan A.; Neelapu, Sattva S.</div><div class="citationInfo"><span class="NLM_cas:title">Biology of Blood and Marrow Transplantation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">625-638</span>CODEN:
                <span class="NLM_cas:coden">BBMTF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-8791</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Chimeric antigen receptor (CAR) T cell therapy is rapidly emerging as one of the most promising therapies for hematol. malignancies.  Two CAR T products were recently approved in the United States and Europe for the treatment of patients up to age 25 years with relapsed or refractory B cell acute lymphoblastic leukemia and/or adults with large B cell lymphoma.  These therapies are assocd. with unique toxicities of cytokine release syndrome (CRS) and neurol. toxicity.  The assessment and grading of these toxicities vary considerably across clin. trials and across institutions, making it difficult to compare the safety of different products and hindering the ability to develop optimal strategies for management of these toxicities.  Therefore, in an effort to harmonize the definitions and grading systems for CRS and neurotoxicity, experts from all aspects of the field met on June 20 and 21, 2018, at a meeting supported by the American Society for Blood and Marrow Transplantation (ASBMT) in Arlington, VA.  Here we report the consensus recommendations of that group and propose new definitions and grading for CRS and neurotoxicity that are objective, easy to apply, and ultimately more accurately categorize the severity of these toxicities.  The goal is to provide a uniform consensus grading system for CRS and neurotoxicity assocd. with immune effector cell therapies, for use across clin. trials and in the postapproval clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHSdFF-1LsELVg90H21EOLACvtfcHk0ljzDstEUQX3Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1aksbw%253D&md5=3dfa0271be9d48f99a8bee88c50686cb</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bbmt.2018.12.758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbmt.2018.12.758%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DD.%2BW.%26aulast%3DSantomasso%26aufirst%3DB.%2BD.%26aulast%3DLocke%26aufirst%3DF.%2BL.%26aulast%3DGhobadi%26aufirst%3DA.%26aulast%3DTurtle%26aufirst%3DC.%2BJ.%26aulast%3DBrudno%26aufirst%3DJ.%2BN.%26aulast%3DMaus%26aufirst%3DM.%2BV.%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DMead%26aufirst%3DE.%26aulast%3DPavletic%26aufirst%3DS.%26aulast%3DGo%26aufirst%3DW.%2BY.%26aulast%3DEldjerou%26aufirst%3DL.%26aulast%3DGardner%26aufirst%3DR.%2BA.%26aulast%3DFrey%26aufirst%3DN.%26aulast%3DCurran%26aufirst%3DK.%2BJ.%26aulast%3DPeggs%26aufirst%3DK.%26aulast%3DPasquini%26aufirst%3DM.%26aulast%3DDiPersio%26aufirst%3DJ.%2BF.%26aulast%3Dvan%2Bden%2BBrink%26aufirst%3DM.%2BR.%2BM.%26aulast%3DKomanduri%26aufirst%3DK.%2BV.%26aulast%3DGrupp%26aufirst%3DS.%2BA.%26aulast%3DNeelapu%26aufirst%3DS.%2BS.%26atitle%3DASBMT%2520consensus%2520grading%2520for%2520cytokine%2520release%2520syndrome%2520and%2520neurologic%2520toxicity%2520associated%2520with%2520immune%2520effector%2520cells%26jtitle%3DBiol.%2520Blood%2520Marrow%2520Transplant.%26date%3D2019%26volume%3D25%26issue%3D4%26spage%3D625%26epage%3D638%26doi%3D10.1016%2Fj.bbmt.2018.12.758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davila, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riviere, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartido, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borquez-Ojeda, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olszewska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasielewska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinglot, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youssif, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintanilla, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernal, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhassira, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roboz, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maslak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frattini, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giralt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadelain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brentjens, R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">224</span>),  <span class="NLM_fpage">224ra25</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3008226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1126%2Fscitranslmed.3008226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=24553386" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=224ra25&issue=224&author=M.+L.+Davilaauthor=I.+Riviereauthor=X.+Wangauthor=S.+Bartidoauthor=J.+Parkauthor=K.+Curranauthor=S.+S.+Chungauthor=J.+Stefanskiauthor=O.+Borquez-Ojedaauthor=M.+Olszewskaauthor=J.+Quauthor=T.+Wasielewskaauthor=Q.+Heauthor=M.+Finkauthor=H.+Shinglotauthor=M.+Youssifauthor=M.+Satterauthor=Y.+Wangauthor=J.+Hoseyauthor=H.+Quintanillaauthor=E.+Haltonauthor=Y.+Bernalauthor=D.+C.+Bouhassiraauthor=M.+E.+Arcilaauthor=M.+Gonenauthor=G.+J.+Robozauthor=P.+Maslakauthor=D.+Douerauthor=M.+G.+Frattiniauthor=S.+Giraltauthor=M.+Sadelainauthor=R.+Brentjens&title=Efficacy+and+toxicity+management+of+19%E2%80%9328z+CAR+T+cell+therapy+in+B+cell+acute+lymphoblastic+leukemia&doi=10.1126%2Fscitranslmed.3008226"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3008226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3008226%26sid%3Dliteratum%253Aachs%26aulast%3DDavila%26aufirst%3DM.%2BL.%26aulast%3DRiviere%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DBartido%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DChung%26aufirst%3DS.%2BS.%26aulast%3DStefanski%26aufirst%3DJ.%26aulast%3DBorquez-Ojeda%26aufirst%3DO.%26aulast%3DOlszewska%26aufirst%3DM.%26aulast%3DQu%26aufirst%3DJ.%26aulast%3DWasielewska%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DFink%26aufirst%3DM.%26aulast%3DShinglot%26aufirst%3DH.%26aulast%3DYoussif%26aufirst%3DM.%26aulast%3DSatter%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHosey%26aufirst%3DJ.%26aulast%3DQuintanilla%26aufirst%3DH.%26aulast%3DHalton%26aufirst%3DE.%26aulast%3DBernal%26aufirst%3DY.%26aulast%3DBouhassira%26aufirst%3DD.%2BC.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DGonen%26aufirst%3DM.%26aulast%3DRoboz%26aufirst%3DG.%2BJ.%26aulast%3DMaslak%26aufirst%3DP.%26aulast%3DDouer%26aufirst%3DD.%26aulast%3DFrattini%26aufirst%3DM.%2BG.%26aulast%3DGiralt%26aufirst%3DS.%26aulast%3DSadelain%26aufirst%3DM.%26aulast%3DBrentjens%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520toxicity%2520management%2520of%252019%25E2%2580%259328z%2520CAR%2520T%2520cell%2520therapy%2520in%2520B%2520cell%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2014%26volume%3D6%26issue%3D224%26spage%3D224ra25%26doi%3D10.1126%2Fscitranslmed.3008226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camisa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbiera, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purevdorj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genua, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanvito, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponzoni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doglioni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristofori, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traversari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordignon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostuni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casucci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondanza, A.</span></span> <span> </span><span class="NLM_article-title">Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">739</span>– <span class="NLM_lpage">748</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0036-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fs41591-018-0036-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29808007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=739-748&issue=6&author=M.+Norelliauthor=B.+Camisaauthor=G.+Barbieraauthor=L.+Falconeauthor=A.+Purevdorjauthor=M.+Genuaauthor=F.+Sanvitoauthor=M.+Ponzoniauthor=C.+Doglioniauthor=P.+Cristoforiauthor=C.+Traversariauthor=C.+Bordignonauthor=F.+Ciceriauthor=R.+Ostuniauthor=C.+Boniniauthor=M.+Casucciauthor=A.+Bondanza&title=Monocyte-derived+IL-1+and+IL-6+are+differentially+required+for+cytokine-release+syndrome+and+neurotoxicity+due+to+CAR+T+cells&doi=10.1038%2Fs41591-018-0036-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells</span></div><div class="casAuthors">Norelli, Margherita; Camisa, Barbara; Barbiera, Giulia; Falcone, Laura; Purevdorj, Ayurzana; Genua, Marco; Sanvito, Francesca; Ponzoni, Maurilio; Doglioni, Claudio; Cristofori, Patrizia; Traversari, Catia; Bordignon, Claudio; Ciceri, Fabio; Ostuni, Renato; Bonini, Chiara; Casucci, Monica; Bondanza, Attilio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">739-748</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">In the clinic, chimeric antigen receptor-modified T (CAR T) cell therapy is frequently assocd. with life-threatening cytokine-release syndrome (CRS) and neurotoxicity.  Understanding the nature of these pathologies and developing treatments for them are hampered by the lack of appropriate animal models.  Herein, we describe a mouse model recapitulating key features of CRS and neurotoxicity.  In humanized mice with high leukemia burden, CAR T cell-mediated clearance of cancer triggered high fever and elevated IL-6 levels, which are hallmarks of CRS.  Human monocytes were the major source of IL-1 and IL-6 during CRS.  Accordingly, the syndrome was prevented by monocyte depletion or by blocking IL-6 receptor with tocilizumab.  Nonetheless, tocilizumab failed to protect mice from delayed lethal neurotoxicity, characterized by meningeal inflammation.  Instead, the IL-1 receptor antagonist anakinra abolished both CRS and neurotoxicity, resulting in substantially extended leukemia-free survival.  These findings offer a therapeutic strategy to tackle neurotoxicity and open new avenues to safer CAR T cell therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq700n-_pyK5rVg90H21EOLACvtfcHk0ljOinT1GNmFyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbjN&md5=6ee5e872943b103cbe0bcf56ef3d5efb</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0036-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0036-4%26sid%3Dliteratum%253Aachs%26aulast%3DNorelli%26aufirst%3DM.%26aulast%3DCamisa%26aufirst%3DB.%26aulast%3DBarbiera%26aufirst%3DG.%26aulast%3DFalcone%26aufirst%3DL.%26aulast%3DPurevdorj%26aufirst%3DA.%26aulast%3DGenua%26aufirst%3DM.%26aulast%3DSanvito%26aufirst%3DF.%26aulast%3DPonzoni%26aufirst%3DM.%26aulast%3DDoglioni%26aufirst%3DC.%26aulast%3DCristofori%26aufirst%3DP.%26aulast%3DTraversari%26aufirst%3DC.%26aulast%3DBordignon%26aufirst%3DC.%26aulast%3DCiceri%26aufirst%3DF.%26aulast%3DOstuni%26aufirst%3DR.%26aulast%3DBonini%26aufirst%3DC.%26aulast%3DCasucci%26aufirst%3DM.%26aulast%3DBondanza%26aufirst%3DA.%26atitle%3DMonocyte-derived%2520IL-1%2520and%2520IL-6%2520are%2520differentially%2520required%2520for%2520cytokine-release%2520syndrome%2520and%2520neurotoxicity%2520due%2520to%2520CAR%2520T%2520cells%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26issue%3D6%26spage%3D739%26epage%3D748%26doi%3D10.1038%2Fs41591-018-0036-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span> <span> </span><span class="NLM_article-title">Gasdermin E-mediated Target Cell Pyroptosis by CAR T Cells Triggers Cytokine Release Syndrome</span>. <i>Sci. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">43</span>), <span class="NLM_elocation-id">eaax7969</span> <span class="refDoi"> DOI: 10.1126/sciimmunol.aax7969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1126%2Fsciimmunol.aax7969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=31953257" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&issue=43&author=Y.+Liuauthor=Y.+Fangauthor=X.+Chenauthor=Z.+Wangauthor=X.+Liangauthor=T.+Zhangauthor=M.+Liuauthor=N.+Zhouauthor=J.+Lvauthor=K.+Tangauthor=J.+Xieauthor=Y.+Gaoauthor=F.+Chengauthor=Y.+Zhouauthor=Z.+Zhangauthor=Y.+Huauthor=X.+Zhangauthor=Q.+Gaoauthor=Y.+Zhangauthor=B.+Huang&title=Gasdermin+E-mediated+Target+Cell+Pyroptosis+by+CAR+T+Cells+Triggers+Cytokine+Release+Syndrome&doi=10.1126%2Fsciimmunol.aax7969"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1126%2Fsciimmunol.aax7969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciimmunol.aax7969%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DLv%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DK.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DB.%26atitle%3DGasdermin%2520E-mediated%2520Target%2520Cell%2520Pyroptosis%2520by%2520CAR%2520T%2520Cells%2520Triggers%2520Cytokine%2520Release%2520Syndrome%26jtitle%3DSci.%2520Immunol.%26date%3D2020%26volume%3D5%26issue%3D43%26doi%3D10.1126%2Fsciimmunol.aax7969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maude, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teachey, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grupp, S. A.</span></span> <span> </span><span class="NLM_article-title">Managing cytokine release syndrome associated with novel T cell-engaging therapies</span>. <i>Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1097/PPO.0000000000000035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1097%2FPPO.0000000000000035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=24667956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=119-122&issue=2&author=S.+L.+Maudeauthor=D.+Barrettauthor=D.+T.+Teacheyauthor=S.+A.+Grupp&title=Managing+cytokine+release+syndrome+associated+with+novel+T+cell-engaging+therapies&doi=10.1097%2FPPO.0000000000000035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies</span></div><div class="casAuthors">Maude, Shannon L.; Barrett, David; Teachey, David T.; Grupp, Stephan A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Journal (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-122</span>CODEN:
                <span class="NLM_cas:coden">CAJOCB</span>;
        ISSN:<span class="NLM_cas:issn">1528-9117</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Chimeric antigen receptor (CAR)-modified T cells and bispecific T cell-engaging antibodies have demonstrated dramatic clin. responses in recent clin. trials.  The hallmark of these novel highly active immunotherapies is nonphysiol. T cell activation, which has correlated not only with greatly increased efficacy but also with notable toxicity in some cases.  We and others have obsd. a cytokine release syndrome (CRS), which correlates with both toxicity and efficacy in patients receiving T cell-engaging therapies.  In addn. to elevations in effector cytokines, such as interferon-γ, cytokines assocd. with hemophagocytic lymphohistiocytosis or macrophage activation syndrome, such as interleukin (IL)-10 and IL-6, may also be markedly elevated.  Whereas corticosteroids may control some of these toxicities, their potential to block T cell activation and abrogate clin. benefit is a concern.  Detailed studies of T cell proliferation and the resultant immune activation produced by these novel therapies have led to more targeted approaches that have the potential to provide superior toxicity control without compromising efficacy.  One approach we have developed targets IL-6, a prominent cytokine in CRS, using the IL-6R antagonist tocilizumab.  We will review the pathophysiol. and management options for CRS assocd. with T cell-engaging therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokoUPADluSbrVg90H21EOLACvtfcHk0ljOinT1GNmFyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOqtro%253D&md5=b7707b5d7f22159b72a233f2bf380ddd</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1097%2FPPO.0000000000000035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPPO.0000000000000035%26sid%3Dliteratum%253Aachs%26aulast%3DMaude%26aufirst%3DS.%2BL.%26aulast%3DBarrett%26aufirst%3DD.%26aulast%3DTeachey%26aufirst%3DD.%2BT.%26aulast%3DGrupp%26aufirst%3DS.%2BA.%26atitle%3DManaging%2520cytokine%2520release%2520syndrome%2520associated%2520with%2520novel%2520T%2520cell-engaging%2520therapies%26jtitle%3DCancer%2520J.%26date%3D2014%26volume%3D20%26issue%3D2%26spage%3D119%26epage%3D122%26doi%3D10.1097%2FPPO.0000000000000035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez-Cruz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moghimi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershenson, Z. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mourelatos, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grupp, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milone, M. C.</span></span> <span> </span><span class="NLM_article-title">High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-17-0211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1158%2F2326-6066.CIR-17-0211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29180536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVSltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=36-46&issue=1&author=S.+A.+Richmanauthor=S.+Nunez-Cruzauthor=B.+Moghimiauthor=L.+Z.+Liauthor=Z.+T.+Gershensonauthor=Z.+Mourelatosauthor=D.+M.+Barrettauthor=S.+A.+Gruppauthor=M.+C.+Milone&title=High-affinity+GD2-specific+CAR+T+cells+induce+fatal+encephalitis+in+a+preclinical+neuroblastoma+model&doi=10.1158%2F2326-6066.CIR-17-0211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model</span></div><div class="casAuthors">Richman, Sarah A.; Nunez-Cruz, Selene; Moghimi, Babak; Li, Lucy Z.; Gershenson, Zachary T.; Mourelatos, Zissimos; Barrett, David M.; Grupp, Stephan A.; Milone, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-46</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The GD2 ganglioside, which is abundant on the surface of neuroblastoma cells, is targeted by an FDA-approved therapeutic monoclonal antibody and is an attractive tumor-assocd. antigen for cellular immunotherapy.  Chimeric antigen receptor (CAR)-modified T cells can have potent antitumor activity in B-cell malignancies, and trials to harness this cytolytic activity toward GD2 in neuroblastoma are under way.  In an effort to enhance the antitumor activity of CAR T cells that target GD2, we generated variant CAR constructs predicted to improve the stability and the affinity of the GD2-binding, 14G2a-based, single-chain variable fragment (scFv) of the CAR and compared their properties in vivo.  We included the E101K mutation of GD2 scFv (GD2-E101K) that has enhanced antitumor activity against a GD2+ human neuroblastoma xenograft in vivo.  However, this enhanced antitumor efficacy in vivo was concomitantly assocd. with lethal central nervous system (CNS) toxicity comprised of extensive CAR T-cell infiltration and proliferation within the brain and neuronal destruction.  The encephalitis was localized to the cerebellum and basal regions of the brain that display low amts. of GD2.  Our results highlight the challenges assocd. with target antigens that exhibit shared expression on crit. normal tissues.  Despite the success of GD2-specific antibody therapies in the treatment of neuroblastoma, the fatal neurotoxicity of GD2-specific CAR T-cell therapy obsd. in our studies suggests that GD2 may be a difficult target antigen for CAR T-cell therapy without addnl. strategies that can control CAR T-cell function within the CNS.  Cancer Immunol Res; 6(1); 36-46. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ_8y4apr5j7Vg90H21EOLACvtfcHk0lhlZziKYzEbWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVSltA%253D%253D&md5=2fc2a027a315681db5e608e421c005f8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-17-0211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-17-0211%26sid%3Dliteratum%253Aachs%26aulast%3DRichman%26aufirst%3DS.%2BA.%26aulast%3DNunez-Cruz%26aufirst%3DS.%26aulast%3DMoghimi%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DL.%2BZ.%26aulast%3DGershenson%26aufirst%3DZ.%2BT.%26aulast%3DMourelatos%26aufirst%3DZ.%26aulast%3DBarrett%26aufirst%3DD.%2BM.%26aulast%3DGrupp%26aufirst%3DS.%2BA.%26aulast%3DMilone%26aufirst%3DM.%2BC.%26atitle%3DHigh-affinity%2520GD2-specific%2520CAR%2520T%2520cells%2520induce%2520fatal%2520encephalitis%2520in%2520a%2520preclinical%2520neuroblastoma%2520model%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2018%26volume%3D6%26issue%3D1%26spage%3D36%26epage%3D46%26doi%3D10.1158%2F2326-6066.CIR-17-0211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neelapu, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kebriaei, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locke, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komanduri, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulbis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loghin, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Groot, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezvani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shpall, E. J.</span></span> <span> </span><span class="NLM_article-title">Chimeric antigen receptor T-cell therapy - assessment and management of toxicities</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2017.148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fnrclinonc.2017.148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=28925994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWnur%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=47-62&issue=1&author=S.+S.+Neelapuauthor=S.+Tummalaauthor=P.+Kebriaeiauthor=W.+Wierdaauthor=C.+Gutierrezauthor=F.+L.+Lockeauthor=K.+V.+Komanduriauthor=Y.+Linauthor=N.+Jainauthor=N.+Daverauthor=J.+Westinauthor=A.+M.+Gulbisauthor=M.+E.+Loghinauthor=J.+F.+de+Grootauthor=S.+Adkinsauthor=S.+E.+Davisauthor=K.+Rezvaniauthor=P.+Hwuauthor=E.+J.+Shpall&title=Chimeric+antigen+receptor+T-cell+therapy+-+assessment+and+management+of+toxicities&doi=10.1038%2Fnrclinonc.2017.148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric antigen receptor T-cell therapy - assessment and management of toxicities</span></div><div class="casAuthors">Neelapu, Sattva S.; Tummala, Sudhakar; Kebriaei, Partow; Wierda, William; Gutierrez, Cristina; Locke, Frederick L.; Komanduri, Krishna V.; Lin, Yi; Jain, Nitin; Daver, Naval; Westin, Jason; Gulbis, Alison M.; Loghin, Monica E.; de Groot, John F.; Adkins, Sherry; Davis, Suzanne E.; Rezvani, Katayoun; Hwu, Patrick; Shpall, Elizabeth J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-62</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Immunotherapy using T cells genetically engineered to express a chimeric antigen receptor (CAR) is rapidly emerging as a promising new treatment for haematol. and non-haematol. malignancies.  CAR-T-cell therapy can induce rapid and durable clin. responses, but is assocd. with unique acute toxicities, which can be severe or even fatal.  Cytokine-release syndrome (CRS), the most commonly obsd. toxicity, can range in severity from low-grade constitutional symptoms to a high-grade syndrome assocd. with life-threatening multiorgan dysfunction; rarely, severe CRS can evolve into fulminant haemophagocytic lymphohistiocytosis (HLH).  Neurotoxicity, termed CAR-T-cell-related encephalopathy syndrome (CRES), is the second most-common adverse event, and can occur concurrently with or after CRS.  Intensive monitoring and prompt management of toxicities is essential to minimize the morbidity and mortality assocd. with this potentially curative therapeutic approach; however, algorithms for accurate and consistent grading and management of the toxicities are lacking.  To address this unmet need, we formed a CAR-T-cell-therapy-assocd. TOXicity (CARTOX) Working Group, comprising investigators from multiple institutions and medical disciplines who have experience in treating patients with various CAR-T-cell therapy products.  Herein, we describe the multidisciplinary approach adopted at our institutions, and provide recommendations for monitoring, grading, and managing the acute toxicities that can occur in patients treated with CAR-T-cell therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8WOainkYsd7Vg90H21EOLACvtfcHk0lhlZziKYzEbWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWnur%252FN&md5=846c1202a25d0103715504274fe91ec4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2017.148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2017.148%26sid%3Dliteratum%253Aachs%26aulast%3DNeelapu%26aufirst%3DS.%2BS.%26aulast%3DTummala%26aufirst%3DS.%26aulast%3DKebriaei%26aufirst%3DP.%26aulast%3DWierda%26aufirst%3DW.%26aulast%3DGutierrez%26aufirst%3DC.%26aulast%3DLocke%26aufirst%3DF.%2BL.%26aulast%3DKomanduri%26aufirst%3DK.%2BV.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DJain%26aufirst%3DN.%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DWestin%26aufirst%3DJ.%26aulast%3DGulbis%26aufirst%3DA.%2BM.%26aulast%3DLoghin%26aufirst%3DM.%2BE.%26aulast%3Dde%2BGroot%26aufirst%3DJ.%2BF.%26aulast%3DAdkins%26aufirst%3DS.%26aulast%3DDavis%26aufirst%3DS.%2BE.%26aulast%3DRezvani%26aufirst%3DK.%26aulast%3DHwu%26aufirst%3DP.%26aulast%3DShpall%26aufirst%3DE.%2BJ.%26atitle%3DChimeric%2520antigen%2520receptor%2520T-cell%2520therapy%2520-%2520assessment%2520and%2520management%2520of%2520toxicities%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D15%26issue%3D1%26spage%3D47%26epage%3D62%26doi%3D10.1038%2Fnrclinonc.2017.148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gust, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taraseviciute, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turtle, C. J.</span></span> <span> </span><span class="NLM_article-title">Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1091</span>– <span class="NLM_lpage">1101</span>, <span class="refDoi"> DOI: 10.1007/s40263-018-0582-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1007%2Fs40263-018-0582-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=30387077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BB3cvlvFSjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=1091-1101&issue=12&author=J.+Gustauthor=A.+Taraseviciuteauthor=C.+J.+Turtle&title=Neurotoxicity+Associated+with+CD19-Targeted+CAR-T+Cell+Therapies&doi=10.1007%2Fs40263-018-0582-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies</span></div><div class="casAuthors">Gust Juliane; Gust Juliane; Taraseviciute Agne; Turtle Cameron J; Turtle Cameron J</div><div class="citationInfo"><span class="NLM_cas:title">CNS drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1091-1101</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Neurotoxicity is an important and common complication of chimeric antigen receptor-T cell therapies.  Acute neurologic signs and/or symptoms occur in a significant proportion of patients treated with CD19-directed chimeric antigen receptor-T cells for B-cell malignancies.  Clinical manifestations include headache, confusion, delirium, language disturbance, seizures and rarely, acute cerebral edema.  Neurotoxicity is associated with cytokine release syndrome, which occurs in the setting of in-vivo chimeric antigen receptor-T cell activation and proliferation.  The mechanisms that lead to neurotoxicity remain unknown, but data from patients and animal models suggest there is compromise of the blood-brain barrier, associated with high levels of cytokines in the blood and cerebrospinal fluid, as well as endothelial activation.  Corticosteroids, interleukin-6-targeted therapies, and supportive care are frequently used to manage patients with neurotoxicity, but high-quality evidence of their efficacy is lacking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvASt5-xt-3iXXDYhVZBdlfW6udTcc2eat4VqjMzhNEbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvlvFSjsw%253D%253D&md5=29d8f967df80e956b2be7adb3ddb4905</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs40263-018-0582-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-018-0582-9%26sid%3Dliteratum%253Aachs%26aulast%3DGust%26aufirst%3DJ.%26aulast%3DTaraseviciute%26aufirst%3DA.%26aulast%3DTurtle%26aufirst%3DC.%2BJ.%26atitle%3DNeurotoxicity%2520Associated%2520with%2520CD19-Targeted%2520CAR-T%2520Cell%2520Therapies%26jtitle%3DCNS%2520Drugs%26date%3D2018%26volume%3D32%26issue%3D12%26spage%3D1091%26epage%3D1101%26doi%3D10.1007%2Fs40263-018-0582-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. J.</span></span> <span> </span><span class="NLM_article-title">EGF receptor variant III as a target antigen for tumor immunotherapy</span>. <i>Expert Rev. Vaccines</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">977</span>– <span class="NLM_lpage">985</span>, <span class="refDoi"> DOI: 10.1586/14760584.7.7.977</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1586%2F14760584.7.7.977" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=18767947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOiur7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=977-985&author=G.+Liauthor=A.+J.+Wong&title=EGF+receptor+variant+III+as+a+target+antigen+for+tumor+immunotherapy&doi=10.1586%2F14760584.7.7.977"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">EGF receptor variant III as a target antigen for tumor immunotherapy</span></div><div class="casAuthors">Li, Gordon; Wong, Albert J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Vaccines</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">977-985</span>CODEN:
                <span class="NLM_cas:coden">ERVXAX</span>;
        ISSN:<span class="NLM_cas:issn">1476-0584</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  The EGF receptor (EGFR) is the first tyrosine kinase receptor ever cloned and remains at the forefront of targeted therapies against cancer.  Currently, there are four US FDA-approved drugs and several more in Phase III studies that target the EGFR.  These drugs, while resulting in some dramatic remissions, have not resulted in strong nor consistent improvements in survival.  EGFR variant III (EGFRvIII) is the most common variant of the EGFR and is present in many different cancer types but not in normal tissue.  It results from the fusion of exon 1 to exon 8 of the EGFR gene, which results in a novel glycine at the junction.  This mutant receptor is constitutively active in these tumors and can lead directly to cancer phenotypes due to its oncogenic properties.  EGFRvIII is an attractive target antigen for cancer immunotherapy because it is not expressed in normal tissue and because cells producing EGFRvIII have an enhanced capacity for dysregulated growth, survival, invasion and angiogenesis.  In this review, we will discuss preclin. and clin. data from studies using EGFRvIII as the target antigen for immunotherapy, with a focus on the potential for greatly improved survival for patients diagnosed with glioblastoma multiforme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoylRB6S3onALVg90H21EOLACvtfcHk0liKq7Ek2iiFTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOiur7L&md5=6c5f467642becb388707ce1354a78cac</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1586%2F14760584.7.7.977&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14760584.7.7.977%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DG.%26aulast%3DWong%26aufirst%3DA.%2BJ.%26atitle%3DEGF%2520receptor%2520variant%2520III%2520as%2520a%2520target%2520antigen%2520for%2520tumor%2520immunotherapy%26jtitle%3DExpert%2520Rev.%2520Vaccines%26date%3D2008%26volume%3D7%26spage%3D977%26epage%3D985%26doi%3D10.1586%2F14760584.7.7.977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfeiffer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thalheimer, F. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danisch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wels, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modlich, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stripecke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoeyen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchholz, C. J.</span></span> <span> </span><span class="NLM_article-title">In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e9158</span>, <span class="refDoi"> DOI: 10.15252/emmm.201809158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.15252%2Femmm.201809158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=30224381" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=e9158&author=A.+Pfeifferauthor=F.+B.+Thalheimerauthor=S.+Hartmannauthor=A.+M.+Frankauthor=R.+R.+Benderauthor=S.+Danischauthor=C.+Costaauthor=W.+S.+Welsauthor=U.+Modlichauthor=R.+Stripeckeauthor=E.+Verhoeyenauthor=C.+J.+Buchholz&title=In+vivo+generation+of+human+CD19-CAR+T+cells+results+in+B-cell+depletion+and+signs+of+cytokine+release+syndrome&doi=10.15252%2Femmm.201809158"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.15252%2Femmm.201809158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Femmm.201809158%26sid%3Dliteratum%253Aachs%26aulast%3DPfeiffer%26aufirst%3DA.%26aulast%3DThalheimer%26aufirst%3DF.%2BB.%26aulast%3DHartmann%26aufirst%3DS.%26aulast%3DFrank%26aufirst%3DA.%2BM.%26aulast%3DBender%26aufirst%3DR.%2BR.%26aulast%3DDanisch%26aufirst%3DS.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DWels%26aufirst%3DW.%2BS.%26aulast%3DModlich%26aufirst%3DU.%26aulast%3DStripecke%26aufirst%3DR.%26aulast%3DVerhoeyen%26aufirst%3DE.%26aulast%3DBuchholz%26aufirst%3DC.%2BJ.%26atitle%3DIn%2520vivo%2520generation%2520of%2520human%2520CD19-CAR%2520T%2520cells%2520results%2520in%2520B-cell%2520depletion%2520and%2520signs%2520of%2520cytokine%2520release%2520syndrome%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2018%26volume%3D10%26spage%3De9158%26doi%3D10.15252%2Femmm.201809158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurencot, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. A.</span></span> <span> </span><span class="NLM_article-title">Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">851</span>, <span class="refDoi"> DOI: 10.1038/mt.2010.24</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fmt.2010.24" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=20179677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitlaitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=843-851&author=R.+A.+Morganauthor=J.+C.+Yangauthor=M.+Kitanoauthor=M.+E.+Dudleyauthor=C.+M.+Laurencotauthor=S.+A.+Rosenberg&title=Case+report+of+a+serious+adverse+event+following+the+administration+of+T+cells+transduced+with+a+chimeric+antigen+receptor+recognizing+ERBB2&doi=10.1038%2Fmt.2010.24"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2</span></div><div class="casAuthors">Morgan, Richard A.; Yang, James C.; Kitano, Mio; Dudley, Mark E.; Laurencot, Carolyn M.; Rosenberg, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">843-851</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In an attempt to treat cancer patients with ERBB2 overexpressing tumors, we developed a chimeric antigen receptor (CAR) based on the widely used humanized monoclonal antibody (mAb) Trastuzumab (Herceptin).  An optimized CAR vector contg. CD28, 4-1BB, and CD3ζ signaling moieties was assembled in a γ-retroviral vector and used to transduce autologous peripheral blood lymphocytes (PBLs) from a patient with colon cancer metastatic to the lungs and liver, refractory to multiple std. treatments.  The gene transfer efficiency into autologous T cells was 79% CAR+ in CD3+ cells and these cells demonstrated high-specific reactivity in in vitro coculture assays.  Following completion of nonmyeloablative conditioning, the patient received 1010 cells i.v.  Within 15 min after cell infusion the patient experienced respiratory distress, and displayed a dramatic pulmonary infiltrate on chest X-ray.  She was intubated and despite intensive medical intervention the patient died 5 days after treatment.  Serum samples after cell infusion showed marked increases in interferon-γ (IFN-γ), granulocyte macrophage-colony stimulating factor (GM-CSF), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and IL-10, consistent with a cytokine storm.  We speculate that the large no. of administered cells localized to the lung immediately following infusion and were triggered to release cytokine by the recognition of low levels of ERBB2 on lung epithelial cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9wVmmJ9_IVLVg90H21EOLACvtfcHk0ljvtBrCoUC8Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitlaitb4%253D&md5=fdf1fd771d8ce6bb9c83f46e58d89db6</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fmt.2010.24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2010.24%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DR.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DKitano%26aufirst%3DM.%26aulast%3DDudley%26aufirst%3DM.%2BE.%26aulast%3DLaurencot%26aufirst%3DC.%2BM.%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26atitle%3DCase%2520report%2520of%2520a%2520serious%2520adverse%2520event%2520following%2520the%2520administration%2520of%2520T%2520cells%2520transduced%2520with%2520a%2520chimeric%2520antigen%2520receptor%2520recognizing%2520ERBB2%26jtitle%3DMol.%2520Ther.%26date%3D2010%26volume%3D18%26spage%3D843%26epage%3D851%26doi%3D10.1038%2Fmt.2010.24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anwer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaukat, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahid, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husnain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PerskY, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riaz, I. B.</span></span> <span> </span><span class="NLM_article-title">Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review</span>. <i>Immunotherapy</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.2217/imt-2016-0127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.2217%2Fimt-2016-0127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=28128714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslWgtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=123-130&author=F.+Anwerauthor=A.+A.+Shaukatauthor=U.+Zahidauthor=M.+Husnainauthor=A.+McBrideauthor=D.+PerskYauthor=M.+Limauthor=N.+Hasanauthor=I.+B.+Riaz&title=Donor+origin+CAR+T+cells%3A+graft+versus+malignancy+effect+without+GVHD%2C+a+systematic+review&doi=10.2217%2Fimt-2016-0127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review</span></div><div class="casAuthors">Anwer, Faiz; Shaukat, Al-Aman; Zahid, Umar; Husnain, Muhammad; McBride, Ali; Persky, Daniel; Lim, Melissa; Hasan, Nida; Bin Riaz, Irbaz</div><div class="citationInfo"><span class="NLM_cas:title">Immunotherapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-130</span>CODEN:
                <span class="NLM_cas:coden">IMMUCO</span>;
        ISSN:<span class="NLM_cas:issn">1750-743X</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  CD19, CD20 chimeric antigen receptor T (CAR T) cell therapy has shown promising results for the treatment of relapsed or refractory hematol. malignancies.  Best results have been reported in acute lymphoblastic leukemia patients with a complete response rate above 80%.  Patients who received donor-derived CAR T cells for the relapsed malignancy after stem cell transplantation (allogenic hematopoietic stem cell transplant) were identified from the published trials.  A total of 72 patients from seven studies were treated with donor-derived CAR T cells.  Only five out of 72 patients (6.9%) developed graft vs. host disease.  Use of donor-derived CAR T cell for relapse prophylaxis, minimal residual disease clearance or salvage from relapse is therefore highly effective, and risk of graft vs. host disease flare is very low.  Side effects include cytokine release syndrome, tumor lysis syndrome, B-cell aplasia along with CNS toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpTdR0lWIk7LVg90H21EOLACvtfcHk0ljvtBrCoUC8Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslWgtbw%253D&md5=fc7ea4bfcd96a72aa1834c1bce65cc25</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.2217%2Fimt-2016-0127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fimt-2016-0127%26sid%3Dliteratum%253Aachs%26aulast%3DAnwer%26aufirst%3DF.%26aulast%3DShaukat%26aufirst%3DA.%2BA.%26aulast%3DZahid%26aufirst%3DU.%26aulast%3DHusnain%26aufirst%3DM.%26aulast%3DMcBride%26aufirst%3DA.%26aulast%3DPerskY%26aufirst%3DD.%26aulast%3DLim%26aufirst%3DM.%26aulast%3DHasan%26aufirst%3DN.%26aulast%3DRiaz%26aufirst%3DI.%2BB.%26atitle%3DDonor%2520origin%2520CAR%2520T%2520cells%253A%2520graft%2520versus%2520malignancy%2520effect%2520without%2520GVHD%252C%2520a%2520systematic%2520review%26jtitle%3DImmunotherapy%26date%3D2017%26volume%3D9%26spage%3D123%26epage%3D130%26doi%3D10.2217%2Fimt-2016-0127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tey, S. K.</span></span> <span> </span><span class="NLM_article-title">Adoptive T-cell therapy: adverse events and safety switches</span>. <i>Clin. Transl. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">e17</span> <span class="refDoi"> DOI: 10.1038/cti.2014.11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fcti.2014.11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=25505965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12msb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&author=S.+K.+Tey&title=Adoptive+T-cell+therapy%3A+adverse+events+and+safety+switches&doi=10.1038%2Fcti.2014.11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Adoptive T-cell therapy: adverse events and safety switches</span></div><div class="casAuthors">Tey, Siok-Keen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e17/1-e17/7</span>CODEN:
                <span class="NLM_cas:coden">CTILBR</span>;
        ISSN:<span class="NLM_cas:issn">2050-0068</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">A review.  The potential of adoptive T-cell therapy in effecting complete and durable responses has been demonstrated in a no. of malignant and infectious diseases.  Ongoing progress in T-cell engineering has given cause for optimism in the broader clin. applicability of this approach.  However, the development of more potent T cells is checked by safety concerns, highlighted by the occurrence of on-target and off-target toxicities that, although uncommon, have been fatal on occasions.  Timely pharmacol. intervention is effective in the management of a majority of adverse events but adoptively transferred T cells can persist long term, along with any unwanted effects.  A recently validated cellular safety switch, inducible caspase 9 (iCasp9), has the potential to mitigate the risks of T-cell therapy by enabling the elimination of transferred T cells if required.  In hematopoietic stem cell transplantation, iCasp9-modified donor T cells can be rapidly eliminated in the event of graft-vs.-host disease.  This review presents an overview of the risks assocd. with modern T-cell therapy and the development, clin. results and potential future application of the iCasp9 safety switch.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVezTfqwEFGLVg90H21EOLACvtfcHk0ljmv6UbMg0D2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12msb7P&md5=e6373d986ab7d355a99583f6088ee581</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fcti.2014.11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcti.2014.11%26sid%3Dliteratum%253Aachs%26aulast%3DTey%26aufirst%3DS.%2BK.%26atitle%3DAdoptive%2520T-cell%2520therapy%253A%2520adverse%2520events%2520and%2520safety%2520switches%26jtitle%3DClin.%2520Transl.%2520Immunol.%26date%3D2014%26volume%3D3%26doi%3D10.1038%2Fcti.2014.11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Acerbi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broggi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anghileri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eoli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiariti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broggi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferroli, P.</span></span> <span> </span><span class="NLM_article-title">Fluorescein-guided surgery for malignant gliomas: a review</span>. <i>Neurosurg. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">547</span>– <span class="NLM_lpage">557</span>, <span class="refDoi"> DOI: 10.1007/s10143-014-0546-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1007%2Fs10143-014-0546-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=24756415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BC2cnlvVektQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2014&pages=547-557&author=F.+Acerbiauthor=C.+Cavalloauthor=M.+Broggiauthor=R.+Cordellaauthor=E.+Anghileriauthor=M.+Eoliauthor=M.+Schiaritiauthor=G.+Broggiauthor=P.+Ferroli&title=Fluorescein-guided+surgery+for+malignant+gliomas%3A+a+review&doi=10.1007%2Fs10143-014-0546-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorescein-guided surgery for malignant gliomas: a review</span></div><div class="casAuthors">Acerbi Francesco; Cavallo Claudio; Broggi Morgan; Cordella Roberto; Anghileri Elena; Eoli Marica; Schiariti Marco; Broggi Giovanni; Ferroli Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Neurosurgical review</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">547-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fluorescein is widely used as a fluorescent tracer for many applications.  Its capacity to accumulate in cerebral areas where there has been blood-brain barrier damage makes it particularly suitable as a dye for the intraoperative visualization of malignant gliomas (MGs).  In this report, we describe the results of a comprehensive review on the use of fluorescein in the surgical treatment of MGs.  A comprehensive literature search and review for English-written articles concerning the use of fluorescein in the resection of MGs has been conducted.  The search was executed through a PubMed literature search using the following keywords: malignant gliomas, glioblastomas, high-grade gliomas, YELLOW 560, total removal, dedicated filter, neurosurgery, brain tumors, intracranial tumors, and confocal microscopy.  The literature search resulted in the retrieval of 412 evidence-based articles.  Of these, 17 were found to be strictly related to the resection of MG with the aid of fluorescein.  In addition to these 17, we have included 2 articles derived from a personal database of the corresponding author (FA).  The analysis of the articles reviewed revealed three major applications of fluorescein during surgery for MGs that was documented: Fluorescein-guided resection of MGs with white-light illumination, fluorescein-guided resection of MGs with a surgical microscope equipped with a dedicated filter for fluorescein, and confocal microscopy for intraoperative histopathological analysis on MGs.  The systemic review conducted on the use of fluorescein in MGs explored the applications and the different modalities in which fluorescein has been used.  The data we have gathered indicates that fluorescein-guided surgery is a safe, effective, and convenient technique to achieve a high rate of total removal in MGs.  Further prospective comparative trials, however, are still necessary to prove the impact of fluorescein-guided surgery on both progression-free survival and overall survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSzK17LlH9Teftos8R3JUhXfW6udTcc2eZVicRo2ih9ULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnlvVektQ%253D%253D&md5=cb312c8caa694ae28d80aa28b770395f</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs10143-014-0546-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10143-014-0546-6%26sid%3Dliteratum%253Aachs%26aulast%3DAcerbi%26aufirst%3DF.%26aulast%3DCavallo%26aufirst%3DC.%26aulast%3DBroggi%26aufirst%3DM.%26aulast%3DCordella%26aufirst%3DR.%26aulast%3DAnghileri%26aufirst%3DE.%26aulast%3DEoli%26aufirst%3DM.%26aulast%3DSchiariti%26aufirst%3DM.%26aulast%3DBroggi%26aufirst%3DG.%26aulast%3DFerroli%26aufirst%3DP.%26atitle%3DFluorescein-guided%2520surgery%2520for%2520malignant%2520gliomas%253A%2520a%2520review%26jtitle%3DNeurosurg.%2520Rev.%26date%3D2014%26volume%3D37%26spage%3D547%26epage%3D557%26doi%3D10.1007%2Fs10143-014-0546-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Dam, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Themelis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crane, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harlaar, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleijhuis, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelder, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarantopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arts, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Zee, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ntziachristos, V.</span></span> <span> </span><span class="NLM_article-title">Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1315</span>– <span class="NLM_lpage">1319</span>, <span class="refDoi"> DOI: 10.1038/nm.2472</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fnm.2472" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=21926976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFylsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=1315-1319&author=G.+M.+van%0ADamauthor=G.+Themelisauthor=L.+M.+Craneauthor=N.+J.+Harlaarauthor=R.+G.+Pleijhuisauthor=W.+Kelderauthor=A.+Sarantopoulosauthor=J.+S.+de+Jongauthor=H.+J.+Artsauthor=A.+G.+van+der+Zeeauthor=J.+Bartauthor=P.+S.+Lowauthor=V.+Ntziachristos&title=Intraoperative+tumor-specific+fluorescence+imaging+in+ovarian+cancer+by+folate+receptor-alpha+targeting%3A+first+in-human+results&doi=10.1038%2Fnm.2472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results</span></div><div class="casAuthors">van Dam, Gooitzen M.; Themelis, George; Crane, Lucia M. A.; Harlaar, Niels J.; Pleijhuis, Rick G.; Kelder, Wendy; Sarantopoulos, Athanasios; de Jong, Johannes S.; Arts, Henriette J. G.; van der Zee, Ate G. J.; Bart, Joost; Low, Philip S.; Ntziachristos, Vasilis</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1315-1319</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The prognosis in advanced-stage ovarian cancer remains poor.  Tumor-specific intraoperative fluorescence imaging may improve staging and debulking efforts in cytoreductive surgery and thereby improve prognosis.  The overexpression of folate receptor-α (FR-α) in 90-95% of epithelial ovarian cancers prompted the investigation of intraoperative tumor-specific fluorescence imaging in ovarian cancer surgery using an FR-α-targeted fluorescent agent.  In patients with ovarian cancer, intraoperative tumor-specific fluorescence imaging with an FR-α-targeted fluorescent agent showcased the potential applications in patients with ovarian cancer for improved intraoperative staging and more radical cytoreductive surgery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJtb6YYXRHBrVg90H21EOLACvtfcHk0ljmv6UbMg0D2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFylsrfN&md5=04402cfbf8b9b08a2596b76d9be26ff9</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fnm.2472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2472%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BDam%26aufirst%3DG.%2BM.%26aulast%3DThemelis%26aufirst%3DG.%26aulast%3DCrane%26aufirst%3DL.%2BM.%26aulast%3DHarlaar%26aufirst%3DN.%2BJ.%26aulast%3DPleijhuis%26aufirst%3DR.%2BG.%26aulast%3DKelder%26aufirst%3DW.%26aulast%3DSarantopoulos%26aufirst%3DA.%26aulast%3Dde%2BJong%26aufirst%3DJ.%2BS.%26aulast%3DArts%26aufirst%3DH.%2BJ.%26aulast%3Dvan%2Bder%2BZee%26aufirst%3DA.%2BG.%26aulast%3DBart%26aufirst%3DJ.%26aulast%3DLow%26aufirst%3DP.%2BS.%26aulast%3DNtziachristos%26aufirst%3DV.%26atitle%3DIntraoperative%2520tumor-specific%2520fluorescence%2520imaging%2520in%2520ovarian%2520cancer%2520by%2520folate%2520receptor-alpha%2520targeting%253A%2520first%2520in-human%2520results%26jtitle%3DNat.%2520Med.%26date%3D2011%26volume%3D17%26spage%3D1315%26epage%3D1319%26doi%3D10.1038%2Fnm.2472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacivita, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span> <span> </span><span class="NLM_article-title">Developments in fluorescent probes for receptor research</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">706</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2009.03.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.drudis.2009.03.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=19573791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFyktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=706-712&author=M.+Leopoldoauthor=E.+Lacivitaauthor=F.+Berardiauthor=R.+Perrone&title=Developments+in+fluorescent+probes+for+receptor+research&doi=10.1016%2Fj.drudis.2009.03.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Developments in fluorescent probes for receptor research</span></div><div class="casAuthors">Leopoldo, Marcello; Lacivita, Enza; Berardi, Francesco; Perrone, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">13/14</span>),
    <span class="NLM_cas:pages">706-712</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Early reports on the identification of fluorescent probes for receptors date back to mid-1970s.  Fluorescent probes were initially used to visualize mol. targets in an analogous way to the use of fluorescent antibodies but with the same resoln. as isotopically labeled ligands.  In parallel to the rapid development of techniques, such as fluorescence correlation spectroscopy, multi-photon excitation fluorescence microscopy, fluorescence polarization and in vivo fluorescence imaging, fluorescent probes are becoming multifaceted tools in life science.  The present review will focus on how the design of fluorescent ligands for receptors has evolved to meet the needs of most recent fluorescence applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqOP-3fq6YUrVg90H21EOLACvtfcHk0ljIyTFil-m6vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFyktLc%253D&md5=3de8004e2782a83b6bb503e6dc6496c9</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.03.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.03.015%26sid%3Dliteratum%253Aachs%26aulast%3DLeopoldo%26aufirst%3DM.%26aulast%3DLacivita%26aufirst%3DE.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DPerrone%26aufirst%3DR.%26atitle%3DDevelopments%2520in%2520fluorescent%2520probes%2520for%2520receptor%2520research%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D706%26epage%3D712%26doi%3D10.1016%2Fj.drudis.2009.03.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazane, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugh, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonslow, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochenderfer, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span> <span> </span><span class="NLM_article-title">Versatile strategy for controlling the specificity and activity of engineered T cells</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">E450</span>– <span class="NLM_lpage">E458</span>, <span class="refDoi"> DOI: 10.1073/pnas.1524193113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1073%2Fpnas.1524193113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=26759368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC28Xns1antA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=E450-E458&author=J.+S.+Maauthor=J.+Y.+Kimauthor=S.+A.+Kazaneauthor=S.+H.+Choiauthor=H.+Y.+Yunauthor=M.+S.+Kimauthor=D.+T.+Rodgersauthor=H.+M.+Pughauthor=O.+Singerauthor=S.+B.+Sunauthor=B.+R.+Fonslowauthor=J.+N.+Kochenderferauthor=T.+M.+Wrightauthor=P.+G.+Schultzauthor=T.+S.+Youngauthor=C.+H.+Kimauthor=Y.+Cao&title=Versatile+strategy+for+controlling+the+specificity+and+activity+of+engineered+T+cells&doi=10.1073%2Fpnas.1524193113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Versatile strategy for controlling the specificity and activity of engineered T cells</span></div><div class="casAuthors">Ma, Jennifer S. Y.; Kim, Ji Young; Kazane, Stephanie A.; Choi, Sei-hyun; Yun, Hwa Young; Kim, Min Soo; Rodgers, David T.; Pugh, Holly M.; Singer, Oded; Sun, Sophie B.; Fonslow, Bryan R.; Kochenderfer, James N.; Wright, Timothy M.; Schultz, Peter G.; Young, Travis S.; Kim, Chan Hyuk; Cao, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">E450-E458</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The adoptive transfer of autologous T cells engineered to express a chimeric antigen receptor (CAR) has emerged as a promising cancer therapy.  Despite impressive clin. efficacy, the general application of current CAR-T-cell therapy is limited by serious treatment-related toxicities.  One approach to improve the safety of CAR-T cells involves making their activation and proliferation dependent upon adaptor mols. that mediate formation of the immunol. synapse between the target cancer cell and T-cell.  Here, the authors describe the design and synthesis of structurally defined semisynthetic adaptors the authors refer to as "switch" mols., in which anti-CD19 and anti-CD22 antibody fragments are site-specifically modified with FITC using genetically encoded noncanonical amino acids.  This approach allows the precise control over the geometry and stoichiometry of complex formation between CD19- or CD22-expressing cancer cells and a "universal" anti-FITC-directed CAR-T cell.  Optimization of this CAR-switch combination results in potent, dose-dependent in vivo antitumor activity in xenograft models.  The advantage of being able to titrate CAR-T-cell in vivo activity was further evidenced by reduced in vivo toxicity and the elimination of persistent B-cell aplasia in immune-competent mice.  The ability to control CAR-T cell and cancer cell interactions using intermediate switch mols. may expand the scope of engineered T-cell therapy to solid tumors, as well as indications beyond cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpyqnoedhMJbVg90H21EOLACvtfcHk0ljIyTFil-m6vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xns1antA%253D%253D&md5=8a3ca3ccfac0d66d05ec4be93323a970</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1524193113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1524193113%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DKazane%26aufirst%3DS.%2BA.%26aulast%3DChoi%26aufirst%3DS.%2BH.%26aulast%3DYun%26aufirst%3DH.%2BY.%26aulast%3DKim%26aufirst%3DM.%2BS.%26aulast%3DRodgers%26aufirst%3DD.%2BT.%26aulast%3DPugh%26aufirst%3DH.%2BM.%26aulast%3DSinger%26aufirst%3DO.%26aulast%3DSun%26aufirst%3DS.%2BB.%26aulast%3DFonslow%26aufirst%3DB.%2BR.%26aulast%3DKochenderfer%26aufirst%3DJ.%2BN.%26aulast%3DWright%26aufirst%3DT.%2BM.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DYoung%26aufirst%3DT.%2BS.%26aulast%3DKim%26aufirst%3DC.%2BH.%26aulast%3DCao%26aufirst%3DY.%26atitle%3DVersatile%2520strategy%2520for%2520controlling%2520the%2520specificity%2520and%2520activity%2520of%2520engineered%2520T%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3DE450%26epage%3DE458%26doi%3D10.1073%2Fpnas.1524193113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampton, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazagova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugh, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazane, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T. S.</span></span> <span> </span><span class="NLM_article-title">Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7520</span>– <span class="NLM_lpage">7524</span>, <span class="refDoi"> DOI: 10.1002/anie.201601902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1002%2Fanie.201601902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC28XntFGhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=7520-7524&author=Y.+Caoauthor=D.+T.+Rodgersauthor=J.+Duauthor=I.+Ahmadauthor=E.+N.+Hamptonauthor=J.+S.+Maauthor=M.+Mazagovaauthor=S.+H.+Choiauthor=H.+Y.+Yunauthor=H.+Xiaoauthor=P.+Yangauthor=X.+Luoauthor=R.+K.+Limauthor=H.+M.+Pughauthor=F.+Wangauthor=S.+A.+Kazaneauthor=T.+M.+Wrightauthor=C.+H.+Kimauthor=P.+G.+Schultzauthor=T.+S.+Young&title=Design+of+Switchable+Chimeric+Antigen+Receptor+T+Cells+Targeting+Breast+Cancer&doi=10.1002%2Fanie.201601902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer</span></div><div class="casAuthors">Cao, Yu; Rodgers, David T.; Du, Juanjuan; Ahmad, Insha; Hampton, Eric N.; Ma, Jennifer S. Y.; Mazagova, Magdalena; Choi, Sei-hyun; Yun, Hwa Young; Xiao, Han; Yang, Pengyu; Luo, Xiaozhou; Lim, Reyna K. V.; Pugh, Holly M.; Wang, Feng; Kazane, Stephanie A.; Wright, Timothy M.; Kim, Chan Hyuk; Schultz, Peter G.; Young, Travis S.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7520-7524</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Chimeric antigen receptor T (CAR-T) cells have demonstrated promising results against hematol. malignancies, but have encountered significant challenges in translation to solid tumors.  To overcome these hurdles, the authors have developed a switchable CAR-T cell platform in which the activity of the engineered cell is controlled by dosage of an antibody-based switch.  Herein, the authors apply this approach to Her2-expressing breast cancers by engineering switch mols. through site-specific incorporation of FITC or grafting of a peptide neo-epitope (PNE) into the anti-Her2 antibody trastuzumab (clone 4D5).  The authors demonstrate that both switch formats can be readily optimized to redirect CAR-T cells (specific for the corresponding FITC or PNE) to Her2-expressing tumor cells, and afford dose-titratable activation of CAR-T cells ex vivo and complete clearance of the tumor in rodent xenograft models.  This strategy may facilitate the application of immunotherapy to solid tumors by affording comparable efficacy with improved safety owing to switch-based control of the CAR-T response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptJTcWT8ddcbVg90H21EOLACvtfcHk0ljIyTFil-m6vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntFGhsLs%253D&md5=8a7805a2b6a4a66979a029671f36cf16</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fanie.201601902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201601902%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DY.%26aulast%3DRodgers%26aufirst%3DD.%2BT.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DAhmad%26aufirst%3DI.%26aulast%3DHampton%26aufirst%3DE.%2BN.%26aulast%3DMa%26aufirst%3DJ.%2BS.%26aulast%3DMazagova%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DS.%2BH.%26aulast%3DYun%26aufirst%3DH.%2BY.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DLim%26aufirst%3DR.%2BK.%26aulast%3DPugh%26aufirst%3DH.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKazane%26aufirst%3DS.%2BA.%26aulast%3DWright%26aufirst%3DT.%2BM.%26aulast%3DKim%26aufirst%3DC.%2BH.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DYoung%26aufirst%3DT.%2BS.%26atitle%3DDesign%2520of%2520Switchable%2520Chimeric%2520Antigen%2520Receptor%2520T%2520Cells%2520Targeting%2520Breast%2520Cancer%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D7520%26epage%3D7524%26doi%3D10.1002%2Fanie.201601902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasarao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanduluru, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span> <span> </span><span class="NLM_article-title">Use of a single CAR T cell and several bispecific adapters facilitates eradication of multiple antigenically different solid tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-18-1834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1158%2F0008-5472.CAN-18-1834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=30482775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos1aiu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=387-396&issue=2&author=Y.+G.+Leeauthor=I.+Marksauthor=M.+Srinivasaraoauthor=A.+K.+Kanduluruauthor=S.+M.+Mahalingamauthor=X.+Liuauthor=H.+Chuauthor=P.+S.+Low&title=Use+of+a+single+CAR+T+cell+and+several+bispecific+adapters+facilitates+eradication+of+multiple+antigenically+different+solid+tumors&doi=10.1158%2F0008-5472.CAN-18-1834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Use of a single CAR T cell and several bispecific adapters facilitates eradication of multiple antigenically different solid tumors</span></div><div class="casAuthors">Lee, Yong Gu; Marks, Isaac; Srinivasarao, Madduri; Kanduluru, Ananda Kumar; Mahalingam, Sakkarapalayam M.; Liu, Xin; Chu, Haiyan; Low, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">387-396</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Most solid tumors are comprised of multiple clones that express orthogonal antigens, suggesting that novel strategies must be developed in order to adapt chimeric antigen receptor (CAR) T-cell therapies to treat heterogeneous solid tumors.  Here, we utilized a cocktail of low-mol.-wt.bispecific adapters, each comprised of fluorescein linked to a different tumor-specific ligand, to bridge between an antifluorescein CAR on the engineered T cell and a unique antigen on the cancer cell.  This formation of an immunol. synapse between the CAR T cell and cancer cell enabled use of a single antifluorescein CAR T cell to eradicate a diversity of antigenically different solid tumors implanted concurrently in NSG mice.  Based on these data, we suggest that a carefully designed cocktail of bispecific adapters in combination with antifluorescein CAR T cells can overcome tumor antigen escape mechanisms that lead to disease recurrence following many CAR T-cell therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTEYUbvxURY7Vg90H21EOLACvtfcHk0lhL8ndUJ0r2hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos1aiu70%253D&md5=4fbae4398604a2cc0a83e07e04ad7228</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-1834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-1834%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%2BG.%26aulast%3DMarks%26aufirst%3DI.%26aulast%3DSrinivasarao%26aufirst%3DM.%26aulast%3DKanduluru%26aufirst%3DA.%2BK.%26aulast%3DMahalingam%26aufirst%3DS.%2BM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DChu%26aufirst%3DH.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DUse%2520of%2520a%2520single%2520CAR%2520T%2520cell%2520and%2520several%2520bispecific%2520adapters%2520facilitates%2520eradication%2520of%2520multiple%2520antigenically%2520different%2520solid%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26issue%3D2%26spage%3D387%26epage%3D396%26doi%3D10.1158%2F0008-5472.CAN-18-1834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favalli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandholzer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millul, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzamalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matasci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myburgh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manz, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neri, D.</span></span> <span> </span><span class="NLM_article-title">Impact of ligand size and conjugation chemistry on the performance of universal chimeric antigen receptor T-cells for tumor killing</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1775</span>– <span class="NLM_lpage">1783</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.0c00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.0c00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFWmtrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2020&pages=1775-1783&issue=7&author=C.+Pellegrinoauthor=N.+Favalliauthor=M.+Sandholzerauthor=L.+Voltaauthor=G.+Bassiauthor=J.+Millulauthor=S.+Cazzamalliauthor=M.+Matasciauthor=A.+Villaauthor=R.+Myburghauthor=M.+G.+Manzauthor=D.+Neri&title=Impact+of+ligand+size+and+conjugation+chemistry+on+the+performance+of+universal+chimeric+antigen+receptor+T-cells+for+tumor+killing&doi=10.1021%2Facs.bioconjchem.0c00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Ligand Size and Conjugation Chemistry on the Performance of Universal Chimeric Antigen Receptor T-Cells for Tumor Killing</span></div><div class="casAuthors">Pellegrino, Christian; Favalli, Nicholas; Sandholzer, Michael; Volta, Laura; Bassi, Gabriele; Millul, Jacopo; Cazzamalli, Samuele; Matasci, Mattia; Villa, Alessandra; Myburgh, Renier; Manz, Markus G.; Neri, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1775-1783</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">All Universal Chimeric Antigen Receptor T-cells (UniCAR T-cells) are T-cells which have been engineered to recognize a haptenated ligand.  Due to this feature, UniCAR T-cells have the potential to mediate a potent and selective tumor killing only in the presence of a haptenated tumor ligand, thus avoiding the long-lasting biocidal effects of conventional CAR T-cells.  We have used fluorescein-labeled versions of small org. ligands and different antibody formats specific to carbonic anhydrase IX (a tumor-assocd. antigen) in order to assess whether the killing potential of UniCAR T-cells depended on the mol. features of the haptenated mol.  Both small mol. ligands and larger antibody fragments were potent in mediating tumor cell killing over a broad concn. range.  Antibodies could be conveniently used both in IgG format and as smaller diabody fragments.  Importantly, the use of site-specific chem. modification strategies for the antibody coupling to fluorescein led to a substantial improvement of tumor cell killing performance, compared to the random modification of primary amino groups on the antibody surface.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp1I2YW_nSMrVg90H21EOLACvtfcHk0liBhybAhjYGqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFWmtrjK&md5=c4b673d38b1d6c00b1e14d49da3c2d49</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.0c00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.0c00258%26sid%3Dliteratum%253Aachs%26aulast%3DPellegrino%26aufirst%3DC.%26aulast%3DFavalli%26aufirst%3DN.%26aulast%3DSandholzer%26aufirst%3DM.%26aulast%3DVolta%26aufirst%3DL.%26aulast%3DBassi%26aufirst%3DG.%26aulast%3DMillul%26aufirst%3DJ.%26aulast%3DCazzamalli%26aufirst%3DS.%26aulast%3DMatasci%26aufirst%3DM.%26aulast%3DVilla%26aufirst%3DA.%26aulast%3DMyburgh%26aufirst%3DR.%26aulast%3DManz%26aufirst%3DM.%2BG.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DImpact%2520of%2520ligand%2520size%2520and%2520conjugation%2520chemistry%2520on%2520the%2520performance%2520of%2520universal%2520chimeric%2520antigen%2520receptor%2520T-cells%2520for%2520tumor%2520killing%26jtitle%3DBioconjugate%2520Chem.%26date%3D2020%26volume%3D31%26issue%3D7%26spage%3D1775%26epage%3D1783%26doi%3D10.1021%2Facs.bioconjchem.0c00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setrerrahmane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span> <span> </span><span class="NLM_article-title">Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">44</span>, <span class="refDoi"> DOI: 10.1186/s13045-018-0591-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1186%2Fs13045-018-0591-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29558951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVyqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=44&author=E.+Zhangauthor=J.+Guauthor=J.+Xueauthor=C.+Linauthor=C.+Liuauthor=M.+Liauthor=J.+Haoauthor=S.+Setrerrahmaneauthor=X.+Chiauthor=W.+Qiauthor=J.+Huauthor=H.+Xu&title=Accurate+control+of+dual-receptor-engineered+T+cell+activity+through+a+bifunctional+anti-angiogenic+peptide&doi=10.1186%2Fs13045-018-0591-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide</span></div><div class="casAuthors">Zhang, Erhao; Gu, Jieyi; Xue, Jianpeng; Lin, Chenyu; Liu, Chen; Li, Mengwei; Hao, Jingchao; Setrerrahmane, Sarra; Chi, Xiaowei; Qi, Weiyan; Hu, Jialiang; Xu, Hanmei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">44/1-44/14</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Chimeric antigen receptors (CARs) presented on T cell surfaces enable redirection of T cell specificity, which has enormous promise in antitumor therapy.  However, excessive activity and poor control over such engineered T cells cause significant safety challenges, such as cytokine release syndrome and organ toxicities.  To enhance the specificity and controllable activity of CAR-T cells, we report a novel switchable dual-receptor CAR-engineered T (sdCAR-T) cell and a new switch mol. of FITC-HM-3 bifunctional mol. (FHBM) in this study.  We designed a fusion mol. comprising FITC and HM-3.  HM-3, an antitumor peptide including an Arg-Gly-Asp sequence, can specifically target integrin avβ3 that is presented on some tumor cells.  Moreover, to improve the specificity of CAR-T cells, we also generated the sdCAR-T cell line against cognate tumor cells expressing human mesothelin (MSLN) and integrin avβ3.  Finally, the activity of sdCAR-T cell and FHBM is verified via in vitro and in vivo expts.  In the presence of FHBM, the designed sdCAR-T cells exerted high activity including activation and proliferation and had specific cytotoxicity in a time- and dose-dependent manner in vitro.  Furthermore, using a combination of FHBM in nude mice, sdCAR-T cells significantly inhibited the growth of MSLN+ K562 cells and released lower levels of the cytokines (e.g., interleukin-2, interferon a, interleukin-6, and tumor necrosis factor a) relative to conventional CAR-T cells, obtaining specific, controllable, and enhanced cytotoxicity.  Our data indicate that FHBM can accurately control timing and dose of injected CAR-T cells, and sdCAR-T cells exert significant antitumor activity while releasing lower levels of cytokines for the cognate tumor cells expressing both MSLN and integrin avβ3.  Therefore, combination therapies using sdCAR-T cells and the switch mol. FHBM have significant potential to treat malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSoIovesVPirVg90H21EOLACvtfcHk0liBhybAhjYGqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVyqtbo%253D&md5=09aed161fbdf1af7a7448d0d7bf557e3</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1186%2Fs13045-018-0591-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-018-0591-7%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DXue%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DSetrerrahmane%26aufirst%3DS.%26aulast%3DChi%26aufirst%3DX.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DH.%26atitle%3DAccurate%2520control%2520of%2520dual-receptor-engineered%2520T%2520cell%2520activity%2520through%2520a%2520bifunctional%2520anti-angiogenic%2520peptide%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D44%26doi%3D10.1186%2Fs13045-018-0591-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span> <span> </span><span class="NLM_article-title">Folate-targeted therapies for cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">6811</span>– <span class="NLM_lpage">6824</span>, <span class="refDoi"> DOI: 10.1021/jm100509v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100509v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6811-6824&issue=19&author=W.+Xiaauthor=P.+S.+Low&title=Folate-targeted+therapies+for+cancer&doi=10.1021%2Fjm100509v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Folate-Targeted Therapies for Cancer</span></div><div class="casAuthors">Xia, Wei; Low, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6811-6824</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This article discusses the use of folic acid as a ligand to target therapeutic cargos of many sizes, shapes, mechanisms of action to tumor cells both in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpihPD6hMJ_77Vg90H21EOLACvtfcHk0lgteNZgmzQzyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCit7w%253D&md5=8d302235e47b742beed54f482c637c49</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm100509v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100509v%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DW.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DFolate-targeted%2520therapies%2520for%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D19%26spage%3D6811%26epage%3D6824%26doi%3D10.1021%2Fjm100509v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kularatne, S. A.</span></span> <span> </span><span class="NLM_article-title">Folate-targeted therapeutic and imaging agents for cancer</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2009.03.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.cbpa.2009.03.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=19419901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVWltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=256-262&issue=3&author=P.+S.+Lowauthor=S.+A.+Kularatne&title=Folate-targeted+therapeutic+and+imaging+agents+for+cancer&doi=10.1016%2Fj.cbpa.2009.03.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Folate-targeted therapeutic and imaging agents for cancer</span></div><div class="casAuthors">Low, Philip Stewart; Kularatne, Sumith Anurasiri</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">256-262</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Cancer therapies that exploit targeting ligands to deliver attached cytotoxic drugs selectively to malignant cells are currently receiving significant attention.  While antibody-targeted drugs have been the first to enter the clinic, recent studies demonstrate that the vitamin folic acid can also be used to deliver attached imaging and therapeutic agents selectively to malignant cells in both animal tumor models and human cancer patients.  Thus, folate conjugates bind to folate receptors that are overexpressed on ∼40% of human cancers and mediate internalization of their attached drugs by receptor-mediated endocytosis.  With the use of proper linkers, folate-targeted drugs can be released inside their target cells where they can perform their desired cytotoxic functions.  Based on this strategy, six folate-targeted drugs are currently in human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp_l-sdKEElbVg90H21EOLACvtfcHk0lgteNZgmzQzyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVWltbY%253D&md5=c6b6b07b0df9d1355e99da7c471a2a4b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2009.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2009.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DLow%26aufirst%3DP.%2BS.%26aulast%3DKularatne%26aufirst%3DS.%2BA.%26atitle%3DFolate-targeted%2520therapeutic%2520and%2520imaging%2520agents%2520for%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D13%26issue%3D3%26spage%3D256%26epage%3D262%26doi%3D10.1016%2Fj.cbpa.2009.03.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putt, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visscher, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span> <span> </span><span class="NLM_article-title">Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4485</span>– <span class="NLM_lpage">4495</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.23321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.18632%2Foncotarget.23321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29435118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BC1Mrgsl2gsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=4485-4495&author=J.+Shenauthor=Y.+Huauthor=K.+S.+Puttauthor=S.+Singhalauthor=H.+Hanauthor=D.+W.+Visscherauthor=L.+M.+Murphyauthor=P.+S.+Low&title=Assessment+of+folate+receptor+alpha+and+beta+expression+in+selection+of+lung+and+pancreatic+cancer+patients+for+receptor+targeted+therapies&doi=10.18632%2Foncotarget.23321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies</span></div><div class="casAuthors">Shen Jiayin; Hu Yingwen; Low Philip S; Hu Yingwen; Putt Karson S; Low Philip S; Singhal Sunil; Han Haiyong; Visscher Daniel W; Murphy Linda M</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">4485-4495</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A number of folate receptor (FR) targeted small molecular drugs and monoclonal antibodies have been introduced into clinical trials to treat FR positive cancers.  Because the therapeutic efficacy of these drugs depends prominently on the level of FR-α expression on the cancer cells, patients have been commonly selected for FR-targeted therapies based on the intensity of a folate-targeted radioimaging agent.  Unfortunately, uptake of such imaging agents can be mediated by both major isoforms of the folate receptor, FR-α and FR-β.  Logically, if the FR positive cell population in a tumor mass is dominated by FR-β positive macrophages, patients could be selected for therapy that have few FR-expressing cancer cells.  Although several IHC studies have examined expression of either FR-α or FR-β, no study to date has investigated expression of both FR-α and FR-β in the same tumor mass.  Herein, we utilize monoclonal antibodies specific for FR-α (mAb343) and FR-β (m909) to query each isoform's expression in a range of cancers.  We show that lung and pancreatic adenocarcinomas express the full spectrum of FR-α and FR-β combinations with ~76% of lung adenocarcinomas expressing both FR-α and FR-β while pancreatic cancers express primarily FR-β.  Thus, while folate-targeted imaging of lung cancer patients might accurately reflect the expression of FR-α on lung cancer cells, imaging of pancreatic cancer patients could mislead a physician into treating a nonresponding patient.  Overall, these data suggest that an independent analysis of both FR-α and FR-β should be obtained to predict the potential efficacy of a folate-targeted drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhwKE-wGzFGHRxY89Cm6SyfW6udTcc2ebbAdBjxW8o5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mrgsl2gsg%253D%253D&md5=fd2db81c8dd8af772b2c9963d0b49edf</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.23321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.23321%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DPutt%26aufirst%3DK.%2BS.%26aulast%3DSinghal%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DH.%26aulast%3DVisscher%26aufirst%3DD.%2BW.%26aulast%3DMurphy%26aufirst%3DL.%2BM.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DAssessment%2520of%2520folate%2520receptor%2520alpha%2520and%2520beta%2520expression%2520in%2520selection%2520of%2520lung%2520and%2520pancreatic%2520cancer%2520patients%2520for%2520receptor%2520targeted%2520therapies%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D4485%26epage%3D4495%26doi%3D10.18632%2Foncotarget.23321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shannessy, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiel, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somers, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vachani, A.</span></span> <span> </span><span class="NLM_article-title">Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.18632%2Foncotarget.519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=22547449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BC38rptlymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=414-425&issue=4&author=D.+J.+O%E2%80%99Shannessyauthor=G.+Yuauthor=R.+Smaleauthor=Y.+S.+Fuauthor=S.+Singhalauthor=R.+P.+Thielauthor=E.+B.+Somersauthor=A.+Vachani&title=Folate+receptor+alpha+expression+in+lung+cancer%3A+diagnostic+and+prognostic+significance&doi=10.18632%2Foncotarget.519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance</span></div><div class="casAuthors">O'Shannessy Daniel J; Yu Gordon; Smale Robert; Fu Yao-Shi; Singhal Sunil; Thiel Robert P; Somers Elizabeth B; Vachani Anil</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">414-25</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">With the advent of targeted therapies directed towards folate receptor alpha, with several such agents in late stage clinical development, the sensitive and robust detection of folate receptor alpha in tissues is of importance relative to patient selection and perhaps prognosis and prediction of response.  The goal of the present study was to evaluate the expression of folate receptor alpha in non-small cell lung cancer specimens to determine its frequency of expression and its potential for prognosis.  The distribution of folate receptor alpha expression in normal tissues as well as its expression and relationship to non-small cell lung cancer subtypes was assessed by immunohistochemistry using tissue microarrays and fine needle aspirates and an optimized manual staining method using the recently developed monoclonal antibody 26B3.  The association between folate receptor alpha expression and clinical outcome was also evaluated on a tissue microarray created from formalin fixed paraffin embedded specimens from patients with surgically resected lung adenocarcinoma.  Folate receptor alpha expression was shown to have a high discriminatory capacity for lung adenocarcinomas versus squamous cell carcinomas.  While 74% of adenocarcinomas were positive for folate receptor alpha expression, our results found that only 13% of squamous cell carcinomas were FRA positive (p<0.0001).  In patients with adenocarcinoma that underwent surgical resection, increased folate receptor alpha expression was associated with improved overall survival (Hazard Ratio 0.39, 95% CI 0.18-0.85).  These data demonstrate the diagnostic relevance of folate receptor alpha expression in non-small cell lung cancer as determined by immunohistochemistry and suggest that determination of folate receptor alpha expression provides prognostic information in patients with lung adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcbyMocnYSbRBrI9DTGjC0fW6udTcc2eajwri1IQ7Xq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rptlymtA%253D%253D&md5=833c984bd0b4ef2ee55c2a89589509d2</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.519%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shannessy%26aufirst%3DD.%2BJ.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DSmale%26aufirst%3DR.%26aulast%3DFu%26aufirst%3DY.%2BS.%26aulast%3DSinghal%26aufirst%3DS.%26aulast%3DThiel%26aufirst%3DR.%2BP.%26aulast%3DSomers%26aufirst%3DE.%2BB.%26aulast%3DVachani%26aufirst%3DA.%26atitle%3DFolate%2520receptor%2520alpha%2520expression%2520in%2520lung%2520cancer%253A%2520diagnostic%2520and%2520prognostic%2520significance%26jtitle%3DOncotarget%26date%3D2012%26volume%3D3%26issue%3D4%26spage%3D414%26epage%3D425%26doi%3D10.18632%2Foncotarget.519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boogerd, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boonstra, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charehbili, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoogstins, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prevoo, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Velde, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahrmeijer, A. L.</span></span> <span> </span><span class="NLM_article-title">Concordance of folate receptor-α expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">17442</span>– <span class="NLM_lpage">17454</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.7856</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.18632%2Foncotarget.7856" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=26943581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BC28jmvFWnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=17442-17454&author=L.+S.+Boogerdauthor=M.+C.+Boonstraauthor=A.+J.+Beckauthor=A.+Charehbiliauthor=C.+E.+Hoogstinsauthor=H.+A.+Prevooauthor=S.+Singhalauthor=P.+S.+Lowauthor=C.+J.+van+de+Veldeauthor=A.+L.+Vahrmeijer&title=Concordance+of+folate+receptor-%CE%B1+expression+between+biopsy%2C+primary+tumor+and+metastasis+in+breast+cancer+and+lung+cancer+patients&doi=10.18632%2Foncotarget.7856"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Concordance of folate receptor-α expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients</span></div><div class="casAuthors">Boogerd Leonora S F; Boonstra Martin C; Beck Ann-Jean; Charehbili Ayoub; Hoogstins Charlotte E S; Prevoo Hendrica A J M; van de Velde Cornelis J H; Vahrmeijer Alexander L; Singhal Sunil; Low Philip S</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">17442-54</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Folate receptor alpha (FRα) is known to be upregulated in a variety of cancers, including non-small cell lung cancer (NSCLC) and breast cancer.  To ensure reliable implementation of diagnostic- and therapeutic agents, concordance of FRα expression between biopsy, primary tumor and metastases is important.  Using immunohistochemistry (Mab 26B3.F2) these concordances were investigated in 60 NSCLC and 40 breast cancer patients.  False positivity of FRα expression on breast and lung cancer biopsies was limited to less than 5%.  In NSCLC, FRα expression was shown in 21/34 adenocarcinomas and 4/26 squamous cell carcinomas (SCC).  Concordance of FRα expression between biopsy and primary tumor was achieved in respectively 83% and 91% of adenocarcinomas and SCCs.  Approximately 80% of all local and distant metastases of NSCLC patients showed concordant FRα expression as their corresponding primary tumor.  In breast cancer, FRα positivity was shown in 12/40 biopsies, 20/40 lumpectomies and 6/20 LN metastases, with concordance of 68% between biopsy and primary tumor and 60% between primary tumor and LN metastases.  In conclusion, this study shows high concordance rates of FRα expression between biopsies and metastases compared to primary NSCLC and breast cancers, underscoring the applicability of FRα-targeted agents in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHa1U3EVaFUOR_TJajKxJDfW6udTcc2eajwri1IQ7Xq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jmvFWnsA%253D%253D&md5=46664ddc0987d902cff937348efa156d</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.7856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.7856%26sid%3Dliteratum%253Aachs%26aulast%3DBoogerd%26aufirst%3DL.%2BS.%26aulast%3DBoonstra%26aufirst%3DM.%2BC.%26aulast%3DBeck%26aufirst%3DA.%2BJ.%26aulast%3DCharehbili%26aufirst%3DA.%26aulast%3DHoogstins%26aufirst%3DC.%2BE.%26aulast%3DPrevoo%26aufirst%3DH.%2BA.%26aulast%3DSinghal%26aufirst%3DS.%26aulast%3DLow%26aufirst%3DP.%2BS.%26aulast%3Dvan%2Bde%2BVelde%26aufirst%3DC.%2BJ.%26aulast%3DVahrmeijer%26aufirst%3DA.%2BL.%26atitle%3DConcordance%2520of%2520folate%2520receptor-%25CE%25B1%2520expression%2520between%2520biopsy%252C%2520primary%2520tumor%2520and%2520metastasis%2520in%2520breast%2520cancer%2520and%2520lung%2520cancer%2520patients%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D17442%26epage%3D17454%26doi%3D10.18632%2Foncotarget.7856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rader, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabat, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbas, C. F.</span></span> <span> </span><span class="NLM_article-title">A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>332</i></span>,  <span class="NLM_fpage">889</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1016/S0022-2836(03)00992-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2FS0022-2836%2803%2900992-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=12972259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntVGltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=2003&pages=889-899&author=C.+Raderauthor=J.+M.+Turnerauthor=A.+Heineauthor=D.+Shabatauthor=S.+C.+Sinhaauthor=I.+A.+Wilsonauthor=R.+A.+Lernerauthor=C.+F.+Barbas&title=A+humanized+aldolase+antibody+for+selective+chemotherapy+and+adaptor+immunotherapy&doi=10.1016%2FS0022-2836%2803%2900992-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">A Humanized Aldolase Antibody for Selective Chemotherapy and Adaptor Immunotherapy</span></div><div class="casAuthors">Rader, Christoph; Turner, James M.; Heine, Andreas; Shabat, Doron; Sinha, Subhash C.; Wilson, Ian A.; Lerner, Richard A.; Barbas, Carlos F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">889-899</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Mouse monoclonal antibody 38C2 is the prototype of a new class of catalytic antibodies that were generated by reactive immunization.  Through a reactive lysine, 38C2 catalyzes aldol and retro-aldol reactions using the enamine mechanism of natural aldolases.  In addn. to its remarkable versatility and efficacy in synthetic org. chem., 38C2 has been used for the selective activation of prodrugs in vitro and in vivo and thereby emerged as a promising tool for selective chemotherapy.  Adding another application with relevance for cancer therapy, designated adaptor immunotherapy, we have recently shown that 38C2 can be chem. programmed to target tumors by formation of a covalent bond of defined stoichiometry with a β-diketone deriv. of an integrin αvβ3 targeting RGD peptidomimetic.  However, a major limitation for the transition from preclin. to clin. evaluation is the human anti-mouse antibody immune response that mouse 38C2 is likely to elicit in a majority of patients after single administration.  Here, we report the humanization of mouse 38C2 based on rational design guided by mol. modeling.  In essence, the catalytic center of mouse 38C2, which encompasses a deep hydrophobic pocket with a reactive lysine residue at the bottom, was grafted into a human antibody framework.  Humanized 38C2 IgG1 was found to bind to β-diketone haptens with conserved affinities and revealed strong catalytic activity with identical kcat and slightly higher KM values compared to the parental mouse antibody.  Furthermore, humanized 38C2 IgG1 revealed efficiency in prodrug activation and chem. programming comparable to the parental mouse antibody.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr47I_eNKtJArVg90H21EOLACvtfcHk0ljHgayVj1dVEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntVGltLY%253D&md5=3e245f887a81643e18e48f1a24065283</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2FS0022-2836%2803%2900992-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-2836%252803%252900992-6%26sid%3Dliteratum%253Aachs%26aulast%3DRader%26aufirst%3DC.%26aulast%3DTurner%26aufirst%3DJ.%2BM.%26aulast%3DHeine%26aufirst%3DA.%26aulast%3DShabat%26aufirst%3DD.%26aulast%3DSinha%26aufirst%3DS.%2BC.%26aulast%3DWilson%26aufirst%3DI.%2BA.%26aulast%3DLerner%26aufirst%3DR.%2BA.%26aulast%3DBarbas%26aufirst%3DC.%2BF.%26atitle%3DA%2520humanized%2520aldolase%2520antibody%2520for%2520selective%2520chemotherapy%2520and%2520adaptor%2520immunotherapy%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2003%26volume%3D332%26spage%3D889%26epage%3D899%26doi%3D10.1016%2FS0022-2836%2803%2900992-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, T. R.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudecek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rader, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, H.</span></span> <span> </span><span class="NLM_article-title">Chemically programmable and switchable CAR-T therapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">12178</span>– <span class="NLM_lpage">12185</span>, <span class="refDoi"> DOI: 10.1002/anie.202005432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1002%2Fanie.202005432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BB3cXps1OrsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=12178-12185&author=J.+Qiauthor=K.+Tsujiauthor=D.+Hymelauthor=T.+R.+Burkeauthor=M.+Hudecekauthor=C.+Raderauthor=H.+Peng&title=Chemically+programmable+and+switchable+CAR-T+therapy&doi=10.1002%2Fanie.202005432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically Programmable and Switchable CAR-T Therapy</span></div><div class="casAuthors">Qi, Junpeng; Tsuji, Kohei; Hymel, David; Burke, Terrence R., Jr.; Hudecek, Michael; Rader, Christoph; Peng, Haiyong</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">12178-12185</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Although macromols. on cell surfaces are predominantly targeted and drugged with antibodies, they harbor pockets that are only accessible to small mols. and constitutes a rich subset of binding sites with immense potential diagnostic and therapeutic utility.  Compared to antibodies, however, small mols. are disadvantaged by a less confined biodistribution, shorter circulatory half-life, and inability to communicate with the immune system.  Presented herein is a method that endows small mols. with the ability to recruit and activate chimeric antigen receptor T cells (CAR-Ts).  It is based on a CAR-T platform that uses a chem. programmed antibody fragment (cp-Fab) as on/off switch.  In proof-of-concept studies, this cp-Fab/CAR-T system targeting folate binding proteins on the cell surface mediated potent and specific eradication of folate-receptor-expressing cancer cells in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonmTVFQWotJLVg90H21EOLACvtfcHk0ljHgayVj1dVEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXps1OrsLY%253D&md5=967b58cdf6a886e34693ac40e306a583</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Fanie.202005432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.202005432%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DTsuji%26aufirst%3DK.%26aulast%3DHymel%26aufirst%3DD.%26aulast%3DBurke%26aufirst%3DT.%2BR.%26aulast%3DHudecek%26aufirst%3DM.%26aulast%3DRader%26aufirst%3DC.%26aulast%3DPeng%26aufirst%3DH.%26atitle%3DChemically%2520programmable%2520and%2520switchable%2520CAR-T%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2020%26volume%3D59%26spage%3D12178%26epage%3D12185%26doi%3D10.1002%2Fanie.202005432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherwood, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caballero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. H.</span></span> <span> </span><span class="NLM_article-title">Redirection of genetically engineered CAR-T cells using bifunctional small molecules</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">2832</span>– <span class="NLM_lpage">2835</span>, <span class="refDoi"> DOI: 10.1021/jacs.5b00106</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b00106" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVSjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=2832-2835&author=M.+S.+Kimauthor=J.+S.+Maauthor=H.+Yunauthor=Y.+Caoauthor=J.+Y.+Kimauthor=V.+Chiauthor=D.+Wangauthor=A.+Woodsauthor=L.+Sherwoodauthor=D.+Caballeroauthor=J.+Gonzalezauthor=P.+G.+Schultzauthor=T.+S.+Youngauthor=C.+H.+Kim&title=Redirection+of+genetically+engineered+CAR-T+cells+using+bifunctional+small+molecules&doi=10.1021%2Fjacs.5b00106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Redirection of genetically engineered CAR-T cells using bifunctional small molecules</span></div><div class="casAuthors">Kim, Min Soo; Ma, Jennifer S. Y.; Yun, Hwayoung; Cao, Yu; Kim, Ji Young; Chi, Victor; Wang, Danling; Woods, Ashley; Sherwood, Lance; Caballero, Dawna; Gonzalez, Jose; Schultz, Peter G.; Young, Travis S.; Kim, Chan Hyuk</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2832-2835</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chimeric antigen receptor (CAR)-engineered T cells (CAR-Ts) provide a potent antitumor response and have become a promising treatment option for cancer.  However, despite their efficacy, CAR-T cells are assocd. with significant safety challenges related to the inability to control their activation and expansion and terminate their response.  Herein, we demonstrate that a bifunctional small mol. "switch" consisting of folate conjugated to fluorescein isothiocyanate (folate-FITC) can redirect and regulate FITC-specific CAR-T cell activity toward folate receptor (FR)-overexpressing tumor cells.  This system was shown to be highly cytotoxic to FR-pos. cells with no activity against FR-neg. cells, demonstrating the specificity of redirection by folate-FITC.  Anti-FITC-CAR-T cell activation and proliferation was strictly dependent on the presence of both folate-FITC and FR-pos. cells and was dose titratable with folate-FITC switch.  This novel treatment paradigm may ultimately lead to increased safety for CAR-T cell immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP7R0iuovQ5LVg90H21EOLACvtfcHk0ljHgayVj1dVEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVSjtrw%253D&md5=0222add2bdb0309ecd01ee062308aac3</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b00106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b00106%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BS.%26aulast%3DMa%26aufirst%3DJ.%2BS.%26aulast%3DYun%26aufirst%3DH.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DChi%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWoods%26aufirst%3DA.%26aulast%3DSherwood%26aufirst%3DL.%26aulast%3DCaballero%26aufirst%3DD.%26aulast%3DGonzalez%26aufirst%3DJ.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DYoung%26aufirst%3DT.%2BS.%26aulast%3DKim%26aufirst%3DC.%2BH.%26atitle%3DRedirection%2520of%2520genetically%2520engineered%2520CAR-T%2520cells%2520using%2520bifunctional%2520small%2520molecules%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D2832%26epage%3D2835%26doi%3D10.1021%2Fjacs.5b00106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwakiri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonobe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyahara, R.</span></span> <span> </span><span class="NLM_article-title">Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers</span>. <i>Ann. Surg. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">889</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1245/s10434-007-9755-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1245%2Fs10434-007-9755-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=18181001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FpvFOjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=889-899&author=S.+Iwakiriauthor=M.+Sonobeauthor=S.+Nagaiauthor=T.+Hirataauthor=H.+Wadaauthor=R.+Miyahara&title=Expression+status+of+folate+receptor+alpha+is+significantly+correlated+with+prognosis+in+non-small-cell+lung+cancers&doi=10.1245%2Fs10434-007-9755-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers</span></div><div class="casAuthors">Iwakiri Shotaro; Sonobe Makoto; Nagai Shinjiro; Hirata Toshiki; Wada Hiromi; Miyahara Ryo</div><div class="citationInfo"><span class="NLM_cas:title">Annals of surgical oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">889-99</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  To evaluate the prognostic value of folate receptor alpha (FOLR1) and/or reduced folate carrier (RFC1) expression, which are well-characterized folate transporters, in completely resected non-small-cell lung cancer (NSCLC).  METHODS:  We quantitatively examined gene expression of FOLR1 and RFC1 in surgical specimens resected from NSCLC patients.  A total of 119 consecutive patients from January 2003 to June 2004 were included.  RESULTS:  In adenocarcinoma, the FOLR1 gene expression was downregulated in smokers and male patients (P = 0.006 and P < 0.001, respectively).  In addition, FOLR1 expression values in patients with well-differentiated, early p-stage, pT1, pN0, EGFR mutant, and p53 wild-type cancers were significantly higher than those for poorly differentiated, advanced p-stage, pT2-4, pN1-3, EGFR wild-type, and p53 mutant (P < 0.001, P < 0.001, P < 0.001, P = 0.002, P < 0.001 and P = 0.023, respectively).  In squamous cell carcinoma, FOLR1 expression values in patients with pN1-3 was significantly higher than those with pN0 (P = 0.037).  Moreover, the 3-year survival rate and disease-free survival rate of high-FOLR1-expressing patients (94.7% and 75.4%) were significantly higher than those of low-FOLR1-expressing patients (80.9% and 60.8%) (P = 0.008 and P = 0.038).  A multivariate analysis confirmed that high FOLR1 expression was an independent and significant factor predicting a favorable prognosis (P = 0.043).  CONCLUSIONS:  Higher levels of FOLR1 appear to be associated with better prognoses for patients with lung adenocarcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvmLb-OofhPLJzI8owOhpDfW6udTcc2ebbGOvmAVpCPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FpvFOjtw%253D%253D&md5=c1e90d286c7f256d6e08759ca604cc38</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1245%2Fs10434-007-9755-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1245%252Fs10434-007-9755-3%26sid%3Dliteratum%253Aachs%26aulast%3DIwakiri%26aufirst%3DS.%26aulast%3DSonobe%26aufirst%3DM.%26aulast%3DNagai%26aufirst%3DS.%26aulast%3DHirata%26aufirst%3DT.%26aulast%3DWada%26aufirst%3DH.%26aulast%3DMiyahara%26aufirst%3DR.%26atitle%3DExpression%2520status%2520of%2520folate%2520receptor%2520alpha%2520is%2520significantly%2520correlated%2520with%2520prognosis%2520in%2520non-small-cell%2520lung%2520cancers%26jtitle%3DAnn.%2520Surg.%2520Oncol.%26date%3D2008%26volume%3D15%26spage%3D889%26epage%3D899%26doi%3D10.1245%2Fs10434-007-9755-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span> <span> </span><span class="NLM_article-title">Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer</span>. <i>BioSci. Trends</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">298</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.5582/bst.2018.01048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.5582%2Fbst.2018.01048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29899195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFygur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=298-308&author=W.+Chuauthor=Y.+Zhouauthor=Q.+Tangauthor=M.+Wangauthor=Y.+Jiauthor=J.+Yanauthor=D.+Yinauthor=S.+Zhangauthor=H.+Luauthor=J.+Shen&title=Bi-specific+ligand-controlled+chimeric+antigen+receptor+T-cell+therapy+for+non-small+cell+lung+cancer&doi=10.5582%2Fbst.2018.01048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer</span></div><div class="casAuthors">Chu, Wenqi; Zhou, Yixiong; Tang, Qi; Wang, Min; Ji, Yongjia; Yan, Jingjing; Yin, Dan; Zhang, Shuye; Lu, Hongzhou; Shen, Jiayin</div><div class="citationInfo"><span class="NLM_cas:title">BioScience Trends</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">298-308</span>CODEN:
                <span class="NLM_cas:coden">BTIRCZ</span>;
        ISSN:<span class="NLM_cas:issn">1881-7815</span>.
    
            (<span class="NLM_cas:orgname">International Research and Cooperation Association for Bio & Socio-Sciences Advancement</span>)
        </div><div class="casAbstract">Our goal is to develop a switch-controlled approach to enable better control of reactivity and safety of chimeric antigen receptor (CAR)-T therapy for non-small-cell lung cancer (NSCLC).  Lentiviral transduction was performed to generate anti-FITC CAR-T cells and target cells stably expressing either isoform of the folate receptor.  Colorimetric-based cytotoxic assay, ELISA, and multiparametric flow cytometry anal. were used to evaluate the specificity and activity of CAR-T cells in vitro.  Human primary T cells stably expressing the fully human anti-FITC CAR were generated.  Anti- FITC CAR-T cells displayed antigen-specific and folate-FTIC dependent reactivity against engineered A549-FRa and THP-1-FRss.  The selective activation and proliferation of anti- FITC CAR-T cells in vitro stringently relied on the co-existence of folate-FITC and FRexpressing target cells and was dose-titratable with the folate-FITC switch.  The excellent in vitro efficacy and specificity of an adaptor-controlled CAR-T therapy to target both tumor cells and tumor-assocd. macrophages in NSCLCs were validated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQadyBRXI45bVg90H21EOLACvtfcHk0lj0s64ZZVkl_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFygur3L&md5=77493173fbfa57ef67a79fed5a11577f</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.5582%2Fbst.2018.01048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5582%252Fbst.2018.01048%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DJ.%26atitle%3DBi-specific%2520ligand-controlled%2520chimeric%2520antigen%2520receptor%2520T-cell%2520therapy%2520for%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DBioSci.%2520Trends%26date%3D2018%26volume%3D12%26spage%3D298%26epage%3D308%26doi%3D10.5582%2Fbst.2018.01048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrentino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Pace, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nappo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercogliano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, M. F.</span></span> <span> </span><span class="NLM_article-title">The emerging role of large immunophilin FK506 binding protein 51 in cancer</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5424</span>– <span class="NLM_lpage">5429</span>, <span class="refDoi"> DOI: 10.2174/092986711798194333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.2174%2F092986711798194333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=22087835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs12ntbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=5424-5429&author=S.+Romanoauthor=A.+Sorrentinoauthor=A.+L.+Di+Paceauthor=G.+Nappoauthor=C.+Mercoglianoauthor=M.+F.+Romano&title=The+emerging+role+of+large+immunophilin+FK506+binding+protein+51+in+cancer&doi=10.2174%2F092986711798194333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging role of large immunophilin FK506 binding protein 51 in cancer</span></div><div class="casAuthors">Romano, S.; Sorrentino, A.; Di Pace, A. L.; Nappo, G.; Mercogliano, C.; Romano, M. F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">5424-5429</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  FK506 binding protein 51 (FKBP51) is an immunophilin physiol. expressed in lymphocytes.  Very recently, aberrant expression of this protein was found in melanoma; FKBP51 expression correlates with melanoma aggressiveness and is maximal in metastatic lesions.  FKBP51 promotes NF-κB activation and is involved in the resistance to genotoxic agents, including anthracyclines and ionizing radiation.  FKBP51 is a cochaperone with peptidyl-prolyl isomerase activity that regulates several biol. processes through protein-protein interaction.  There is increasing evidence that FKBP51 hyperexpression is assocd. with cancer and this protein has a relevant role in sustaining cell growth, malignancy, and resistance to therapy.  There is also evidence that FKBP ligands are potent anticancer agents, in addn. to their immunosuppressant activity.  In particular, rapamycin and its analogs have shown antitumor activity across a variety of human cancers in clin. trials.  Although, classically, rapamycin actions are ascribed to inhibition of mTOR, recent studies indicate FKBP51 is also an important mol. determinant of the drug's anticancer activity.  The aim of this article is to review the functions of FKBP51, esp. in view of the recent findings that this protein is a potential oncogene when deregulated and a candidate target for signaling therapies against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNMBg5WKfsjbVg90H21EOLACvtfcHk0liXyWC3OImL7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs12ntbnE&md5=ddaaee6c24d6bbf74a4082e82cb3d6d1</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.2174%2F092986711798194333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711798194333%26sid%3Dliteratum%253Aachs%26aulast%3DRomano%26aufirst%3DS.%26aulast%3DSorrentino%26aufirst%3DA.%26aulast%3DDi%2BPace%26aufirst%3DA.%2BL.%26aulast%3DNappo%26aufirst%3DG.%26aulast%3DMercogliano%26aufirst%3DC.%26aulast%3DRomano%26aufirst%3DM.%2BF.%26atitle%3DThe%2520emerging%2520role%2520of%2520large%2520immunophilin%2520FK506%2520binding%2520protein%252051%2520in%2520cancer%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D5424%26epage%3D5429%26doi%3D10.2174%2F092986711798194333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Magid, A. F.</span></span> <span> </span><span class="NLM_article-title">Rapalogs potential as practical alternatives to rapamycin</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">845</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00215</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00215" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVais7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=843-845&issue=6&author=A.+F.+Abdel-Magid&title=Rapalogs+potential+as+practical+alternatives+to+rapamycin&doi=10.1021%2Facsmedchemlett.9b00215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Rapalogs Potential as Practical Alternatives to Rapamycin</span></div><div class="casAuthors">Abdel-Magid, Ahmed F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">843-845</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZKY61vhMwz7Vg90H21EOLACvtfcHk0liXyWC3OImL7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVais7zL&md5=f40133ceb19c14c0da072d06275b8437</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00215%26sid%3Dliteratum%253Aachs%26aulast%3DAbdel-Magid%26aufirst%3DA.%2BF.%26atitle%3DRapalogs%2520potential%2520as%2520practical%2520alternatives%2520to%2520rapamycin%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D6%26spage%3D843%26epage%3D845%26doi%3D10.1021%2Facsmedchemlett.9b00215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayle, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimley, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stankunas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gestwicki, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wandless, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabtree, G. R.</span></span> <span> </span><span class="NLM_article-title">Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2005.10.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.chembiol.2005.10.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=16426976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsV2qug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=99-107&issue=1&author=J.+H.+Bayleauthor=J.+S.+Grimleyauthor=K.+Stankunasauthor=J.+E.+Gestwickiauthor=T.+J.+Wandlessauthor=G.+R.+Crabtree&title=Rapamycin+analogs+with+differential+binding+specificity+permit+orthogonal+control+of+protein+activity&doi=10.1016%2Fj.chembiol.2005.10.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity</span></div><div class="casAuthors">Bayle, J. Henri; Grimley, Joshua S.; Stankunas, Kryn; Gestwicki, Jason E.; Wandless, Thomas J.; Crabtree, Gerald R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-107</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Controlling protein dimerization with small mols. has broad application to the study of protein function.  Rapamycin has 2 binding surfaces: 1 that binds to FKBP12 and the other to the Frb domain of mTor/FRAP, directing their dimerization.  Rapamycin is a potent cell growth inhibitor, but chem. modification of the surface contacting Frb alleviates this effect.  Productive interactions with Frb-fused proteins can be restored by mutation of Frb to accommodate the rapamycin analog (a rapalog).  We have quant. assessed the interaction between rapalogs functionalized at C16 and C20 and a panel of Frb mutants.  Several drug-Frb mutant combinations have different and nonoverlapping specificities.  These Frb-rapalog partners permit the selective control of different Frb fusion proteins without cross-reaction.  The orthogonal control of multiple target proteins broadens the capabilities of chem. induction of dimerization to regulate biol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp_k8iNRbma7Vg90H21EOLACvtfcHk0ljmcuCggnl_fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsV2qug%253D%253D&md5=35cc7ca0060d404c9e6e448c9e0d51c9</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2005.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2005.10.017%26sid%3Dliteratum%253Aachs%26aulast%3DBayle%26aufirst%3DJ.%2BH.%26aulast%3DGrimley%26aufirst%3DJ.%2BS.%26aulast%3DStankunas%26aufirst%3DK.%26aulast%3DGestwicki%26aufirst%3DJ.%2BE.%26aulast%3DWandless%26aufirst%3DT.%2BJ.%26aulast%3DCrabtree%26aufirst%3DG.%2BR.%26atitle%3DRapamycin%2520analogs%2520with%2520differential%2520binding%2520specificity%2520permit%2520orthogonal%2520control%2520of%2520protein%2520activity%26jtitle%3DChem.%2520Biol.%26date%3D2006%26volume%3D13%26issue%3D1%26spage%3D99%26epage%3D107%26doi%3D10.1016%2Fj.chembiol.2005.10.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J.</span></span> <span> </span><span class="NLM_article-title">Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>273</i></span> (<span class="NLM_issue">5272</span>),  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1126/science.273.5272.239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1126%2Fscience.273.5272.239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=8662507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1Crs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1996&pages=239-242&issue=5272&author=J.+Choiauthor=J.+Chenauthor=S.+L.+Schreiberauthor=J.+Clardy&title=Structure+of+the+FKBP12-rapamycin+complex+interacting+with+the+binding+domain+of+human+FRAP&doi=10.1126%2Fscience.273.5272.239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP</span></div><div class="casAuthors">Choi, Jungwon; Chen, Jie; Schreiber, Stuart L.; Clardy, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">5272</span>),
    <span class="NLM_cas:pages">239-242</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Rapamycin, a potent immunosuppressive agent, binds two proteins: the FK506-binding protein (FKBP12) and the FKBP-rapamycin-assocd. protein (FRAP).  A crystal structure of the ternary complex of human FKBP12, rapamycin, and the FKBP12-rapamycin-binding (FRB) domain of human FRAP at a resoln. of 2.7 angstroms revealed the two proteins bound together as a result of the ability of rapamycin to occupy two different hydrophobic binding pockets simultaneously.  The structure shows extensive interactions between rapamycin and both proteins, but fewer interactions between the proteins.  The structure of the FRB domain of FRAP clarifies both rapamycin-independent and -dependent effects obsd. for mutants of FRAP and its homologs in the family of proteins related to the ataxia-telangiectasis mutant gene product, and it illustrates how a small cell-permeable mol. can mediate protein dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwBLM2PsItYLVg90H21EOLACvtfcHk0ljmcuCggnl_fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1Crs7k%253D&md5=c72a82e14c09d9a705215b4ac0525336</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1126%2Fscience.273.5272.239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.273.5272.239%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DClardy%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520the%2520FKBP12-rapamycin%2520complex%2520interacting%2520with%2520the%2520binding%2520domain%2520of%2520human%2520FRAP%26jtitle%3DScience%26date%3D1996%26volume%3D273%26issue%3D5272%26spage%3D239%26epage%3D242%26doi%3D10.1126%2Fscience.273.5272.239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roybal, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puchner, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onuffer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, W. A.</span></span> <span> </span><span class="NLM_article-title">Remote control of therapeutic T cells through a small molecule-gated chimeric receptor</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>350</i></span>, <span class="NLM_elocation-id">aab4077</span> <span class="refDoi"> DOI: 10.1126/science.aab4077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1126%2Fscience.aab4077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=26405231" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2015&author=C.+Y.+Wuauthor=K.+T.+Roybalauthor=E.+M.+Puchnerauthor=J.+Onufferauthor=W.+A.+Lim&title=Remote+control+of+therapeutic+T+cells+through+a+small+molecule-gated+chimeric+receptor&doi=10.1126%2Fscience.aab4077"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1126%2Fscience.aab4077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aab4077%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BY.%26aulast%3DRoybal%26aufirst%3DK.%2BT.%26aulast%3DPuchner%26aufirst%3DE.%2BM.%26aulast%3DOnuffer%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DW.%2BA.%26atitle%3DRemote%2520control%2520of%2520therapeutic%2520T%2520cells%2520through%2520a%2520small%2520molecule-gated%2520chimeric%2520receptor%26jtitle%3DScience%26date%3D2015%26volume%3D350%26doi%3D10.1126%2Fscience.aab4077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Certo, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazar, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarjour, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astrakhan, A.</span></span> <span> </span><span class="NLM_article-title">Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e124430</span> <span class="refDoi"> DOI: 10.1172/jci.insight.124430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1172%2Fjci.insight.124430" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&author=W.+H.+Leungauthor=J.+Gayauthor=U.+Martinauthor=T.+E.+Garrettauthor=H.+M.+Hortonauthor=M.+T.+Certoauthor=B.+R.+Blazarauthor=R.+A.+Morganauthor=P.+D.+Gregoryauthor=J.+Jarjourauthor=A.+Astrakhan&title=Sensitive+and+adaptable+pharmacological+control+of+CAR+T+cells+through+extracellular+receptor+dimerization&doi=10.1172%2Fjci.insight.124430"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.124430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.124430%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DW.%2BH.%26aulast%3DGay%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DU.%26aulast%3DGarrett%26aufirst%3DT.%2BE.%26aulast%3DHorton%26aufirst%3DH.%2BM.%26aulast%3DCerto%26aufirst%3DM.%2BT.%26aulast%3DBlazar%26aufirst%3DB.%2BR.%26aulast%3DMorgan%26aufirst%3DR.%2BA.%26aulast%3DGregory%26aufirst%3DP.%2BD.%26aulast%3DJarjour%26aufirst%3DJ.%26aulast%3DAstrakhan%26aufirst%3DA.%26atitle%3DSensitive%2520and%2520adaptable%2520pharmacological%2520control%2520of%2520CAR%2520T%2520cells%2520through%2520extracellular%2520receptor%2520dimerization%26jtitle%3DJCI%2520Insight%26date%3D2019%26volume%3D4%26doi%3D10.1172%2Fjci.insight.124430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marechal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filhol, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirot, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchateau, P.</span></span> <span> </span><span class="NLM_article-title">Design of chimeric antigen receptors with integrated controllable transient functions</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">18950</span>, <span class="refDoi"> DOI: 10.1038/srep18950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fsrep18950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=26750734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsFKrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=18950&author=A.+Juilleratauthor=A.+Marechalauthor=J.+M.+Filholauthor=J.+Valtonauthor=A.+Duclertauthor=L.+Poirotauthor=P.+Duchateau&title=Design+of+chimeric+antigen+receptors+with+integrated+controllable+transient+functions&doi=10.1038%2Fsrep18950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Design of chimeric antigen receptors with integrated controllable transient functions</span></div><div class="casAuthors">Juillerat, Alexandre; Marechal, Alan; Filhol, Jean-Marie; Valton, Julien; Duclert, Aymeric; Poirot, Laurent; Duchateau, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18950</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The ability to control T cells engineered to permanently express chimeric antigen receptors (CARs) is a key feature to improve safety.  Here, we describe the development of a new CAR architecture with an integrated switch-on system that permits to control the CAR T-cell function.  This system offers the advantage of a transient CAR T-cell for safety while letting open the possibility of multiple cytotoxicity cycles using a small mol. drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox5cnpgu9OyLVg90H21EOLACvtfcHk0lhnfGrG1QhX0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsFKrsQ%253D%253D&md5=ede9d7144175cc0d1410b7397bd724a8</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fsrep18950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep18950%26sid%3Dliteratum%253Aachs%26aulast%3DJuillerat%26aufirst%3DA.%26aulast%3DMarechal%26aufirst%3DA.%26aulast%3DFilhol%26aufirst%3DJ.%2BM.%26aulast%3DValton%26aufirst%3DJ.%26aulast%3DDuclert%26aufirst%3DA.%26aulast%3DPoirot%26aufirst%3DL.%26aulast%3DDuchateau%26aufirst%3DP.%26atitle%3DDesign%2520of%2520chimeric%2520antigen%2520receptors%2520with%2520integrated%2520controllable%2520transient%2520functions%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D18950%26doi%3D10.1038%2Fsrep18950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duong, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collinson-Pautz, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szymanski, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toler, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slawin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayle, J. H.</span></span> <span> </span><span class="NLM_article-title">Two-dimensional regulation of CAR-T cell therapy with orthogonal switches</span>. <i>Mol. Ther. Oncolytics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1016/j.omto.2018.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.omto.2018.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=30740516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BB3cfhtFSquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=124-137&author=M.+T.+Duongauthor=M.+R.+Collinson-Pautzauthor=E.+Morschlauthor=A.+Luauthor=S.+P.+Szymanskiauthor=M.+Zhangauthor=M.+E.+Brandtauthor=W.+C.+Changauthor=K.+L.+Sharpauthor=S.+M.+Tolerauthor=K.+M.+Slawinauthor=A.+E.+Fosterauthor=D.+M.+Spencerauthor=J.+H.+Bayle&title=Two-dimensional+regulation+of+CAR-T+cell+therapy+with+orthogonal+switches&doi=10.1016%2Fj.omto.2018.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches</span></div><div class="casAuthors">Duong MyLinh T; Collinson-Pautz Matthew R; Morschl Eva; Lu An; Szymanski Slawomir P; Zhang Ming; Brandt Mary E; Chang Wei-Chun; Sharp Kelly L; Toler Steven M; Slawin Kevin M; Foster Aaron E; Spencer David M; Bayle J Henri</div><div class="citationInfo"><span class="NLM_cas:title">Molecular therapy oncolytics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">124-137</span>
        ISSN:<span class="NLM_cas:issn">2372-7705</span>.
    </div><div class="casAbstract">Use of chimeric antigen receptors (CARs) as the basis of targeted adoptive T cell therapies has enabled dramatic efficacy against multiple hematopoietic malignancies, but potency against bulky and solid tumors has lagged, potentially due to insufficient CAR-T cell expansion and persistence.  To improve CAR-T cell efficacy, we utilized a potent activation switch based on rimiducid-inducible MyD88 and CD40 (iMC)-signaling elements.  To offset potential toxicity risks by this enhanced CAR, an orthogonally regulated, rapamycin-induced, caspase-9-based safety switch (iRC9) was developed to allow in vivo elimination of CAR-T cells. iMC costimulation induced by systemic rimiducid administration enhanced CAR-T cell proliferation, cytokine secretion, and antitumor efficacy in both in vitro assays and xenograft tumor models.  Conversely, rapamycin-mediated iRC9 dimerization rapidly induced apoptosis in a dose-dependent fashion as an approach to mitigate therapy-related toxicity.  This novel, regulatable dual-switch system may promote greater CAR-T cell expansion and prolonged persistence in a drug-dependent manner while providing a safety switch to mitigate toxicity concerns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRa2AZtp5SCeFf1XRtfYM0dfW6udTcc2eYgwVVmO35AT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfhtFSquw%253D%253D&md5=ba1c554bfc65ad6e718180f97d2bac86</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.omto.2018.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.omto.2018.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DDuong%26aufirst%3DM.%2BT.%26aulast%3DCollinson-Pautz%26aufirst%3DM.%2BR.%26aulast%3DMorschl%26aufirst%3DE.%26aulast%3DLu%26aufirst%3DA.%26aulast%3DSzymanski%26aufirst%3DS.%2BP.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DBrandt%26aufirst%3DM.%2BE.%26aulast%3DChang%26aufirst%3DW.%2BC.%26aulast%3DSharp%26aufirst%3DK.%2BL.%26aulast%3DToler%26aufirst%3DS.%2BM.%26aulast%3DSlawin%26aufirst%3DK.%2BM.%26aulast%3DFoster%26aufirst%3DA.%2BE.%26aulast%3DSpencer%26aufirst%3DD.%2BM.%26aulast%3DBayle%26aufirst%3DJ.%2BH.%26atitle%3DTwo-dimensional%2520regulation%2520of%2520CAR-T%2520cell%2520therapy%2520with%2520orthogonal%2520switches%26jtitle%3DMol.%2520Ther.%2520Oncolytics%26date%3D2019%26volume%3D12%26spage%3D124%26epage%3D137%26doi%3D10.1016%2Fj.omto.2018.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Philip, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokalaki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekkaoui, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straathof, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flutter, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marafioti, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraverty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quezada, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peggs, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pule, M.</span></span> <span> </span><span class="NLM_article-title">A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">1277</span>– <span class="NLM_lpage">1287</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-01-545020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1182%2Fblood-2014-01-545020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=24970931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFaks7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=1277-1287&author=B.+Philipauthor=E.+Kokalakiauthor=L.+Mekkaouiauthor=S.+Thomasauthor=K.+Straathofauthor=B.+Flutterauthor=V.+Marinauthor=T.+Marafiotiauthor=R.+Chakravertyauthor=D.+Linchauthor=S.+A.+Quezadaauthor=K.+S.+Peggsauthor=M.+Pule&title=A+highly+compact+epitope-based+marker%2Fsuicide+gene+for+easier+and+safer+T-cell+therapy&doi=10.1182%2Fblood-2014-01-545020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy</span></div><div class="casAuthors">Philip, Brian; Kokalaki, Evangelia; Mekkaoui, Leila; Thomas, Simon; Straathof, Karin; Flutter, Barry; Marin, Virna; Marafioti, Teresa; Chakraverty, Ronjon; Linch, David; Quezada, Sergio A.; Peggs, Karl S.; Pule, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1277-1287</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A compact marker/suicide gene that utilizes established clin.-grade reagents and pharmaceuticals would be of considerable practical utility to T-cell cancer gene therapy.  Marker genes enable measurement of transduction and allow selection of transduced cells, whereas suicide genes allow selective deletion of administered T cells in the face of toxicity.  We have created a highly compact marker/suicide gene for T cells combining target epitopes from both CD34 and CD20 antigens (RQR8).  This construct allows selection with the clin. approved CliniMACS CD34 system (Miltenyi).  Further, the construct binds the widely used pharmaceutical antibody rituximab, resulting in selective deletion of transgene-expressing cells.  We have tested the functionality of RQR8 in vitro and in vivo as well as in combination with T-cell engineering components.  We predict that RQR8 will make T-cell gene therapy both safer and cheaper.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcy054S65i37Vg90H21EOLACvtfcHk0lhnfGrG1QhX0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFaks7jK&md5=b8aed6b107c297f5654c5bc6df4ca952</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-01-545020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-01-545020%26sid%3Dliteratum%253Aachs%26aulast%3DPhilip%26aufirst%3DB.%26aulast%3DKokalaki%26aufirst%3DE.%26aulast%3DMekkaoui%26aufirst%3DL.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DStraathof%26aufirst%3DK.%26aulast%3DFlutter%26aufirst%3DB.%26aulast%3DMarin%26aufirst%3DV.%26aulast%3DMarafioti%26aufirst%3DT.%26aulast%3DChakraverty%26aufirst%3DR.%26aulast%3DLinch%26aufirst%3DD.%26aulast%3DQuezada%26aufirst%3DS.%2BA.%26aulast%3DPeggs%26aufirst%3DK.%2BS.%26aulast%3DPule%26aufirst%3DM.%26atitle%3DA%2520highly%2520compact%2520epitope-based%2520marker%252Fsuicide%2520gene%2520for%2520easier%2520and%2520safer%2520T-cell%2520therapy%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D1277%26epage%3D1287%26doi%3D10.1182%2Fblood-2014-01-545020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanghellini, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondanza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traversari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomoni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turchetto, L.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">500</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(09)70074-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2FS1470-2045%2809%2970074-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=19345145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BD1Mzhs1WksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=489-500&author=F.+Ciceriauthor=C.+Boniniauthor=M.+T.+Stanghelliniauthor=A.+Bondanzaauthor=C.+Traversariauthor=M.+Salomoniauthor=L.+Turchetto&title=Infusion+of+suicide-gene-engineered+donor+lymphocytes+after+family+haploidentical+haemopoietic+stem-cell+transplantation+for+leukaemia+%28the+TK007+trial%29%3A+a+non-randomised+phase+I-II+study&doi=10.1016%2FS1470-2045%2809%2970074-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study</span></div><div class="casAuthors">Ciceri Fabio; Bonini Chiara; Stanghellini Maria Teresa Lupo; Bondanza Attilio; Traversari Catia; Salomoni Monica; Turchetto Lucia; Colombi Scialini; Bernardi Massimo; Peccatori Jacopo; Pescarollo Alessandra; Servida Paolo; Magnani Zulma; Perna Serena K; Valtolina Veronica; Crippa Fulvio; Callegaro Luciano; Spoldi Elena; Crocchiolo Roberto; Fleischhauer Katharina; Ponzoni Maurilio; Vago Luca; Rossini Silvano; Santoro Armando; Todisco Elisabetta; Apperley Jane; Olavarria Eduardo; Slavin Shimon; Weissinger Eva M; Ganser Arnold; Stadler Michael; Yannaki Evangelia; Fassas Athanasios; Anagnostopoulos Achilles; Bregni Marco; Stampino Corrado Gallo; Bruzzi Paolo; Bordignon Claudio</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">489-500</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Procedures to prevent severe graft-versus-host disease (GVHD) delay immune reconstitution secondary to transplants of haploidentical haemopoietic stem cells for the treatment of leukaemia, leading to high rates of late infectious mortality.  We aimed to systematically add back genetically engineered donor lymphocytes to facilitate immune reconstitution and prevent late mortality.  METHODS:  In a phase I-II, multicentre, non-randomised trial of haploidentical stem-cell transplantation, we infused donor lymphocytes expressing herpes-simplex thymidine kinase suicide gene (TK-cells) after transplantation.  The primary study endpoint was immune reconstitution defined as circulating CD3+ count of 100 cells per muL or more for two consecutive observations.  Analysis was by intention to treat.  This trial is registered with ClinicalTrials.gov, number NCT00423124.  FINDINGS:  From Aug 13, 2002, to March 26, 2008, 50 patients (median age 51 years, range 17-66) received haploidentical stem-cell transplants for high-risk leukaemia.  Immune reconstitution was not recorded before infusion of TK-cells. 28 patients received TK-cells starting 28 days after transplantation; 22 patients obtained immune reconstitution at median 75 days (range 34-127) from transplantation and 23 days (13-42) from infusion.  Ten patients developed acute GVHD (grade I-IV) and one developed chronic GVHD, which were controlled by induction of the suicide gene.  Overall survival at 3 years was 49% (95% CI 25-73) for 19 patients who were in remission from primary leukaemia at the time of stem-cell transplantation.  After TK-cell infusion, the last death due to infection was at 166 days, this was the only infectious death at more than 100 days.  No acute or chronic adverse events were related to the gene-transfer procedure.  INTERPRETATION:  Infusion of TK-cells might be effective in accelerating immune reconstitution, while controlling GVHD and protecting patients from late mortality in those who are candidates for haploidentical stem-cell transplantation.  FUNDING:  MolMed SpA, Italian Association for Cancer Research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRI4Hc6QPHd8N1QT_1O5WBYfW6udTcc2eaUcOaepa8F8bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mzhs1WksQ%253D%253D&md5=1437304bd92cb65c824640edb1872e85</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2809%2970074-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252809%252970074-9%26sid%3Dliteratum%253Aachs%26aulast%3DCiceri%26aufirst%3DF.%26aulast%3DBonini%26aufirst%3DC.%26aulast%3DStanghellini%26aufirst%3DM.%2BT.%26aulast%3DBondanza%26aufirst%3DA.%26aulast%3DTraversari%26aufirst%3DC.%26aulast%3DSalomoni%26aufirst%3DM.%26aulast%3DTurchetto%26aufirst%3DL.%26atitle%3DInfusion%2520of%2520suicide-gene-engineered%2520donor%2520lymphocytes%2520after%2520family%2520haploidentical%2520haemopoietic%2520stem-cell%2520transplantation%2520for%2520leukaemia%2520%2528the%2520TK007%2520trial%2529%253A%2520a%2520non-randomised%2520phase%2520I-II%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2009%26volume%3D10%26spage%3D489%26epage%3D500%26doi%3D10.1016%2FS1470-2045%2809%2970074-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flowers, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, S. R.</span></span> <span> </span><span class="NLM_article-title">Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">2294</span>– <span class="NLM_lpage">2302</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-08-3503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1182%2Fblood-2005-08-3503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=16282341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFOjtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=2294-2302&author=C.+Bergerauthor=M.+E.+Flowersauthor=E.+H.+Warrenauthor=S.+R.+Riddell&title=Analysis+of+transgene-specific+immune+responses+that+limit+the+in+vivo+persistence+of+adoptively+transferred+HSV-TK-modified+donor+T+cells+after+allogeneic+hematopoietic+cell+transplantation&doi=10.1182%2Fblood-2005-08-3503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation</span></div><div class="casAuthors">Berger, Carolina; Flowers, Mary E.; Warren, Edus H.; Riddell, Stanley R.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2294-2302</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The introduction of an inducible suicide gene such as the herpes simplex virus thymidine kinase (HSV-TK) might allow exploitation of the antitumor activity of donor T cells after allogeneic hematopoietic cell transplantation (HCT) without graft vs. host disease.  However, HSV-TK is foreign, and immune responses to gene-modified T cells could lead to their premature elimination.  The authors show that after the infusion of HSV-TK-modified donor T cells to HCT recipients, CD8+ and CD4+ T-cell responses to HSV-TK are rapidly induced and coincide with the disappearance of transferred cells.  Cytokine flow cytometry using an overlapping panel of HSV-TK peptides allowed rapid detection and quantitation of HSV-TK-specific T cells in the blood and identified multiple immunogenic epitopes.  Repeated infusion of modified T cells boosted the induced HSV-TK-specific T cells, which persisted as memory cells.  These studies demonstrate the need for non-immunogenic suicide genes and identify a strategy for detection of CD4+ and CD8+ T-cell responses to transgene products that should be generally applicable to monitoring patients on gene therapy trials.  The potency of gene-modified T cells to elicit robust and durable immune responses imply this approach might be used for vaccination to elicit T-cell responses to viral or tumor antigens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiZVv9YToL27Vg90H21EOLACvtfcHk0ljvBJ137LKD2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFOjtL0%253D&md5=5b4e8fffde18fa836a58304125428f5d</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-08-3503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-08-3503%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DC.%26aulast%3DFlowers%26aufirst%3DM.%2BE.%26aulast%3DWarren%26aufirst%3DE.%2BH.%26aulast%3DRiddell%26aufirst%3DS.%2BR.%26atitle%3DAnalysis%2520of%2520transgene-specific%2520immune%2520responses%2520that%2520limit%2520the%2520in%2520vivo%2520persistence%2520of%2520adoptively%2520transferred%2520HSV-TK-modified%2520donor%2520T%2520cells%2520after%2520allogeneic%2520hematopoietic%2520cell%2520transplantation%26jtitle%3DBlood%26date%3D2006%26volume%3D107%26spage%3D2294%26epage%3D2302%26doi%3D10.1182%2Fblood-2005-08-3503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cribioli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philip, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tettamanti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzitola, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biagi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pule, M.</span></span> <span> </span><span class="NLM_article-title">Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells</span>. <i>Hum. Gene Ther: Methods.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1089/hgtb.2012.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1089%2Fhgtb.2012.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=23186165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVOnur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=376-386&author=V.+Marinauthor=E.+Cribioliauthor=B.+Philipauthor=S.+Tettamantiauthor=I.+Pizzitolaauthor=A.+Biondiauthor=E.+Biagiauthor=M.+Pule&title=Comparison+of+different+suicide-gene+strategies+for+the+safety+improvement+of+genetically+manipulated+T+cells&doi=10.1089%2Fhgtb.2012.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of Different Suicide-Gene Strategies for the Safety Improvement of Genetically Manipulated T Cells</span></div><div class="casAuthors">Marin, Virna; Cribioli, Elisabetta; Philip, Brian; Tettamanti, Sarah; Pizzitola, Irene; Biondi, Andrea; Biagi, Ettore; Pule, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Human Gene Therapy: Methods</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">376-386</span>CODEN:
                <span class="NLM_cas:coden">HGTPAN</span>;
        ISSN:<span class="NLM_cas:issn">1946-6544</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Use of adoptive T-cell therapy (ACT) is increasing; however, T-cell therapy can result in severe toxicity.  Consequently, several suicide-gene strategies that allow selective destruction of the infused T cells have been described.  We compared effectiveness of four such strategies in vitro in Epstein Barr virus (EBV)-cytotoxic T lymphocytes (CTLs).  Herpes simplex virus thymidine kinase (HSV-TK), human inducible caspase 9 (iCasp9), mutant human thymidylate kinase (mTMPK), and human CD20 codon optimized genes were cloned in frame with 2A-truncated codon optimized CD34 (dCD34) in a retroviral vector.  Codon-optimization considerably improved CD20 expression.  EBV-CTLs could be efficiently transduced in all constructs, with transgene expression similar to the control vector contg. dCD34 alone.  Expression was maintained for prolonged cultures.  Expression of the suicide genes was not assocd. with alterations in immunophenotype, proliferation, or function of CTLs.  Activation of HSV-TK, iCasp9, and CD20 ultimately resulted in equally effective destruction of transduced T cells.  However, while iCasp9 and CD20 effected immediate cell-death induction, HSV-TK-expressing T cells required 3 days of exposure to ganciclovir to reach full effect. mTMPK-transduced cells showed lower T-cell killing all time points.  Our results suggest that the faster activity of iCasp9 might be advantageous in treating certain types of acutely life-threatening toxicity.  Codon-optimized CD20 has potential as a suicide gene.  Marin and colleagues compare the effectiveness of four suicide-gene strategies in a model in vitro T-cell system.  Herpes simplex virus thymidine kinase (HSV-TK), human inducible caspase 9 (iCasp9), mutant human thymidylate kinase (mTMPK), and human CD20 codon-optimized genes were cloned in frame with 2A-truncated codon optimized CD34 in a retroviral vector.  Suicide-gene activation ultimately resulted in equally effective destruction of transduced T cells, with iCasp9 and CD20 displaying the most immediate induction of cell death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrm4H0Lf5ODrVg90H21EOLACvtfcHk0ljvBJ137LKD2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVOnur8%253D&md5=1c00332b8b412d3760a2bc49d9669566</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1089%2Fhgtb.2012.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fhgtb.2012.050%26sid%3Dliteratum%253Aachs%26aulast%3DMarin%26aufirst%3DV.%26aulast%3DCribioli%26aufirst%3DE.%26aulast%3DPhilip%26aufirst%3DB.%26aulast%3DTettamanti%26aufirst%3DS.%26aulast%3DPizzitola%26aufirst%3DI.%26aulast%3DBiondi%26aufirst%3DA.%26aulast%3DBiagi%26aufirst%3DE.%26aulast%3DPule%26aufirst%3DM.%26atitle%3DComparison%2520of%2520different%2520suicide-gene%2520strategies%2520for%2520the%2520safety%2520improvement%2520of%2520genetically%2520manipulated%2520T%2520cells%26jtitle%3DHum.%2520Gene%2520Ther%253A%2520Methods.%26date%3D2012%26volume%3D23%26spage%3D376%26epage%3D386%26doi%3D10.1089%2Fhgtb.2012.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Stasi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tey, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy-Nasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straathof, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durett, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grilley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoldo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krance, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heslop, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, M. K.</span></span> <span> </span><span class="NLM_article-title">Inducible apoptosis as a safety switch for adoptive cell therapy</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">1673</span>– <span class="NLM_lpage">1683</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1106152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1056%2FNEJMoa1106152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=22047558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWqtbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=1673-1683&author=A.+Di%0AStasiauthor=S.+K.+Teyauthor=G.+Dottiauthor=Y.+Fujitaauthor=A.+Kennedy-Nasserauthor=C.+Martinezauthor=K.+Straathofauthor=E.+Liuauthor=A.+G.+Durettauthor=B.+Grilleyauthor=H.+Liuauthor=C.+R.+Cruzauthor=B.+Savoldoauthor=A.+P.+Geeauthor=J.+Schindlerauthor=R.+A.+Kranceauthor=H.+E.+Heslopauthor=D.+M.+Spencerauthor=C.+M.+Rooneyauthor=M.+K.+Brenner&title=Inducible+apoptosis+as+a+safety+switch+for+adoptive+cell+therapy&doi=10.1056%2FNEJMoa1106152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Inducible apoptosis as a safety switch for adoptive cell therapy</span></div><div class="casAuthors">Di Stasi, Antonio; Tey, Siok-Keen; Dotti, Gianpietro; Fujita, Yuriko; Kennedy-Nasser, Alana; Martinez, Caridad; Straathof, Karin; Liu, Enli; Durett, April G.; Grilley, Bambi; Liu, Hao; Cruz, Conrad R.; Savoldo, Barbara; Gee, Adrian P.; Schindler, John; Krance, Robert A.; Heslop, Helen E.; Spencer, David M.; Rooney, Cliona M.; Brenner, Malcolm K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1673-1683</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  BACKGROUND Cellular therapies could play a role in cancer treatment and regenerative medicine if it were possible to quickly eliminate the infused cells in case of adverse events.  We devised an inducible T-cell safety switch that is based on the fusion of human caspase 9 to a modified human FK-binding protein, allowing conditional dimerization.  When exposed to a synthetic dimerizing drug, the inducible caspase 9 (iCasp9) becomes activated and leads to the rapid death of cells expressing this construct.  METHODS We tested the activity of our safety switch by introducing the gene into donor T cells given to enhance immune reconstitution in recipients of haploidentical stem-cell transplants.  Patients received AP1903, an otherwise bioinert small-mol. dimerizing drug, if graft-vs.-host disease (GVHD) developed.  We measured the effects of AP1903 on GVHD and on the function and persistence of the cells contg. the iCasp9 safety switch.  RESULTS Five patients between the ages of 3 and 17 years who had undergone stem-cell transplantation for relapsed acute leukemia were treated with the genetically modified T cells.  The cells were detected in peripheral blood from all five patients and increased in no. over time, despite their constitutive transgene expression.  A single dose of dimerizing drug, given to four patients in whom GVHD developed, eliminated more than 90% of the modified T cells within 30 min after administration and ended the GVHD without recurrence.  CONCLUSIONS The iCasp9 cell-suicide system may increase the safety of cellular therapies and expand their clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtaxH1EJFljLVg90H21EOLACvtfcHk0lgWGDEPI8CQqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWqtbbF&md5=5adcc0e5acc341b06e4e9472959961f0</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1106152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1106152%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BStasi%26aufirst%3DA.%26aulast%3DTey%26aufirst%3DS.%2BK.%26aulast%3DDotti%26aufirst%3DG.%26aulast%3DFujita%26aufirst%3DY.%26aulast%3DKennedy-Nasser%26aufirst%3DA.%26aulast%3DMartinez%26aufirst%3DC.%26aulast%3DStraathof%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DE.%26aulast%3DDurett%26aufirst%3DA.%2BG.%26aulast%3DGrilley%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DCruz%26aufirst%3DC.%2BR.%26aulast%3DSavoldo%26aufirst%3DB.%26aulast%3DGee%26aufirst%3DA.%2BP.%26aulast%3DSchindler%26aufirst%3DJ.%26aulast%3DKrance%26aufirst%3DR.%2BA.%26aulast%3DHeslop%26aufirst%3DH.%2BE.%26aulast%3DSpencer%26aufirst%3DD.%2BM.%26aulast%3DRooney%26aufirst%3DC.%2BM.%26aulast%3DBrenner%26aufirst%3DM.%2BK.%26atitle%3DInducible%2520apoptosis%2520as%2520a%2520safety%2520switch%2520for%2520adoptive%2520cell%2520therapy%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D1673%26epage%3D1683%26doi%3D10.1056%2FNEJMoa1106152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diaconu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoldo, B.</span></span> <span> </span><span class="NLM_article-title">Inducible Caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">580</span>– <span class="NLM_lpage">592</span>, <span class="refDoi"> DOI: 10.1016/j.ymthe.2017.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.ymthe.2017.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=28187946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFCltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=580-592&author=I.+Diaconuauthor=B.+Ballardauthor=M.+Zhangauthor=Y.+Chenauthor=J.+Westauthor=G.+Dottiauthor=B.+Savoldo&title=Inducible+Caspase-9+selectively+modulates+the+toxicities+of+CD19-specific+chimeric+antigen+receptor-modified+T+cells&doi=10.1016%2Fj.ymthe.2017.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells</span></div><div class="casAuthors">Diaconu, Iulia; Ballard, Brandon; Zhang, Ming; Chen, Yuhui; West, John; Dotti, Gianpietro; Savoldo, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">580-592</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0024</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Immunotherapy with T cells expressing the chimeric antigen receptor (CAR) specific for the CD19 antigen (CD19.CAR-Ts) is a very effective treatment in B cell lymphoid malignancies.  However, B cell aplasia and cytokine release syndrome (CRS) secondary to the infusion of CD19.  CAR-Ts remain significant drawbacks.  The inclusion of safety switches into the vector encoding the CAR is seen as the safest method to terminate the effects of CD19.  CAR-Ts in case of severe toxicities or after achieving long-term sustained remissions.  By contrast, the complete elimination of CD19.  CAR-Ts when CRS occurs may jeopardize clin. responses as CRS and antitumor activity seem to concur.  We have demonstrated, in a humanized mouse model, that the inducible caspase-9 (iC9) safety switch can eliminate CD19.  CAR-Ts in a dose-dependent manner, allowing either a selective containment of CD19.  CAR-T expansion in case of CRS or complete deletion on demand granting normal B cell reconstitution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb8U_LN9JImrVg90H21EOLACvtfcHk0lhsjYJazCf2rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFCltrk%253D&md5=bf490b4d7d31fdb86669d5d4242a77bb</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.ymthe.2017.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymthe.2017.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DDiaconu%26aufirst%3DI.%26aulast%3DBallard%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWest%26aufirst%3DJ.%26aulast%3DDotti%26aufirst%3DG.%26aulast%3DSavoldo%26aufirst%3DB.%26atitle%3DInducible%2520Caspase-9%2520selectively%2520modulates%2520the%2520toxicities%2520of%2520CD19-specific%2520chimeric%2520antigen%2520receptor-modified%2520T%2520cells%26jtitle%3DMol.%2520Ther.%26date%3D2017%26volume%3D25%26spage%3D580%26epage%3D592%26doi%3D10.1016%2Fj.ymthe.2017.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoyos, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoldo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintarelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendravada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heslop, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotti, G.</span></span> <span> </span><span class="NLM_article-title">Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1160</span>– <span class="NLM_lpage">1170</span>, <span class="refDoi"> DOI: 10.1038/leu.2010.75</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fleu.2010.75" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=20428207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFShs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=1160-1170&author=V.+Hoyosauthor=B.+Savoldoauthor=C.+Quintarelliauthor=A.+Mahendravadaauthor=M.+Zhangauthor=J.+Veraauthor=H.+E.+Heslopauthor=C.+M.+Rooneyauthor=M.+K.+Brennerauthor=G.+Dotti&title=Engineering+CD19-specific+T+lymphocytes+with+interleukin-15+and+a+suicide+gene+to+enhance+their+anti-lymphoma%2Fleukemia+effects+and+safety&doi=10.1038%2Fleu.2010.75"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety</span></div><div class="casAuthors">Hoyos, V.; Savoldo, B.; Quintarelli, C.; Mahendravada, A.; Zhang, M.; Vera, J.; Heslop, H. E.; Rooney, C. M.; Brenner, M. K.; Dotti, G.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1160-1170</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">T lymphocytes expressing a chimeric antigen receptor (CAR) targeting the CD19 antigen (CAR.19) may be of value for the therapy of B-cell malignancies.  Because the in vivo survival, expansion and anti-lymphoma activity of CAR.19+ T cells remain suboptimal even when the CAR contains a CD28 costimulatory endodomain, we generated a novel construct that also incorporates the interleukin-15 (IL-15) gene and an inducible caspase-9-based suicide gene (iC9/CAR.19/IL-15).  We found that compared with CAR.19+ T cells, iC9/CAR.19/IL-15+ T cells had: (1) greater numeric expansion upon antigen stimulation (10-fold greater expansion in vitro, and 3- to 15-fold greater expansion in vivo) and reduced cell death rate (Annexin-V+/7-AAD+ cells 10±6% for iC9/CAR.19/IL-15+ T cells and 32±19% for CAR.19+ T cells); (2) reduced expression of the programmed death 1 (PD-1) receptor upon antigen stimulation (PD-1+ cells <15% for iC9/CAR.19/IL-15+ T cells vs. >40% for CAR.19+ T cells); and (3) improved antitumor effects in vivo (from 4.7- to 5.4-fold reduced tumor growth).  In addn., iC9/CAR.19/IL-15+ T cells were efficiently eliminated upon pharmacol. activation of the suicide gene.  In summary, this strategy safely increases the anti-lymphoma/leukemia effects of CAR.19-redirected T lymphocytes and may be a useful approach for treatment of patients with B-cell malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgBL73xQZmE7Vg90H21EOLACvtfcHk0lhsjYJazCf2rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFShs74%253D&md5=387f9927dd7154744dea7cd9294ce721</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1038%2Fleu.2010.75&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2010.75%26sid%3Dliteratum%253Aachs%26aulast%3DHoyos%26aufirst%3DV.%26aulast%3DSavoldo%26aufirst%3DB.%26aulast%3DQuintarelli%26aufirst%3DC.%26aulast%3DMahendravada%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DVera%26aufirst%3DJ.%26aulast%3DHeslop%26aufirst%3DH.%2BE.%26aulast%3DRooney%26aufirst%3DC.%2BM.%26aulast%3DBrenner%26aufirst%3DM.%2BK.%26aulast%3DDotti%26aufirst%3DG.%26atitle%3DEngineering%2520CD19-specific%2520T%2520lymphocytes%2520with%2520interleukin-15%2520and%2520a%2520suicide%2520gene%2520to%2520enhance%2520their%2520anti-lymphoma%252Fleukemia%2520effects%2520and%2520safety%26jtitle%3DLeukemia%26date%3D2010%26volume%3D24%26spage%3D1160%26epage%3D1170%26doi%3D10.1038%2Fleu.2010.75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Budde, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frayo, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouns, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Till, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Press, O. W.</span></span> <span> </span><span class="NLM_article-title">Combining a CD20 chimeric antigen receptor and an inducible Caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e82742</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0082742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1371%2Fjournal.pone.0082742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=24358223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKnsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=L.+E.+Buddeauthor=C.+Bergerauthor=Y.+Linauthor=J.+Wangauthor=X.+Linauthor=S.+E.+Frayoauthor=S.+A.+Brounsauthor=D.+M.+Spencerauthor=B.+G.+Tillauthor=M.+C.+Jensenauthor=S.+R.+Riddellauthor=O.+W.+Press&title=Combining+a+CD20+chimeric+antigen+receptor+and+an+inducible+Caspase+9+suicide+switch+to+improve+the+efficacy+and+safety+of+T+cell+adoptive+immunotherapy+for+lymphoma&doi=10.1371%2Fjournal.pone.0082742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma</span></div><div class="casAuthors">Budde, Lihua E.; Berger, Carolina; Lin, Yukang; Wang, Jinjuan; Lin, Xubin; Frayo, Shani E.; Brouns, Shaunda A.; Spencer, David M.; Till, Brian G.; Jensen, Michael C.; Riddell, Stanley R.; Press, Oliver W.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e82742/1-e82742/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Modification of T cells with chimeric antigen receptors (CAR) has emerged as a promising treatment modality for human malignancies.  Integration of co-stimulatory domains into CARs can augment the activation and function of genetically targeted T cells against tumors.  However, the potential for insertional mutagenesis and toxicities due to the infused cells have made development of safe methods for removing transferred cells an important consideration.  We have genetically modified human T cells with a lentiviral vector to express a CD20-CAR contg. both CD28 and CD137 co-stimulatory domains, a "suicide gene" relying on inducible activation of caspase 9 (iC9), and a truncated CD19 selectable marker.  Rapid expansion (2000 fold) of the transduced T cells was achieved in 28 days after stimulation with artificial antigen presenting cells.  Transduced T cells exhibited effective CD20-specific cytotoxic activity in vitro and in a mouse xenograft tumor model.  Activation of the iC9 suicide switch resulted in efficient removal of transduced T cells both in vitro and in vivo.  Our work demonstrates the feasibility and promise of this approach for treating CD20+ malignancies in a safe and more efficient manner.  A phase I clin. trial using this approach in patients with relapsed indolent B-NHL is planned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrctGCj_X1de7Vg90H21EOLACvtfcHk0lhsjYJazCf2rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKnsrw%253D&md5=bfde2750cf44fbcc030be0b937be9c3c</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0082742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0082742%26sid%3Dliteratum%253Aachs%26aulast%3DBudde%26aufirst%3DL.%2BE.%26aulast%3DBerger%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DFrayo%26aufirst%3DS.%2BE.%26aulast%3DBrouns%26aufirst%3DS.%2BA.%26aulast%3DSpencer%26aufirst%3DD.%2BM.%26aulast%3DTill%26aufirst%3DB.%2BG.%26aulast%3DJensen%26aufirst%3DM.%2BC.%26aulast%3DRiddell%26aufirst%3DS.%2BR.%26aulast%3DPress%26aufirst%3DO.%2BW.%26atitle%3DCombining%2520a%2520CD20%2520chimeric%2520antigen%2520receptor%2520and%2520an%2520inducible%2520Caspase%25209%2520suicide%2520switch%2520to%2520improve%2520the%2520efficacy%2520and%2520safety%2520of%2520T%2520cell%2520adoptive%2520immunotherapy%2520for%2520lymphoma%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0082742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krance, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamble, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durett, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakhova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoldo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Stasi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grilley, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heslop, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, M. K.</span></span> <span> </span><span class="NLM_article-title">Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">4103</span>– <span class="NLM_lpage">4113</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-02-628354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1182%2Fblood-2015-02-628354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=25977584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlersrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=4103-4113&author=X.+Zhouauthor=G.+Dottiauthor=R.+A.+Kranceauthor=C.+A.+Martinezauthor=S.+Naikauthor=R.+T.+Kambleauthor=A.+G.+Durettauthor=O.+Dakhovaauthor=B.+Savoldoauthor=A.+Di+Stasiauthor=D.+M.+Spencerauthor=Y.+F.+Linauthor=H.+Liuauthor=B.+J.+Grilleyauthor=A.+P.+Geeauthor=C.+M.+Rooneyauthor=H.+E.+Heslopauthor=M.+K.+Brenner&title=Inducible+caspase-9+suicide+gene+controls+adverse+effects+from+alloreplete+T+cells+after+haploidentical+stem+cell+transplantation&doi=10.1182%2Fblood-2015-02-628354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation</span></div><div class="casAuthors">Zhou, Xiaoou; Dotti, Gianpietro; Krance, Robert A.; Martinez, Caridad A.; Naik, Swati; Kamble, Rammurti T.; Durett, April G.; Dakhova, Olga; Savoldo, Barbara; Di Stasi, Antonio; Spencer, David M.; Lin, Yu-Feng; Liu, Hao; Grilley, Bambi J.; Gee, Adrian P.; Rooney, Cliona M.; Heslop, Helen E.; Brenner, Malcolm K.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">4103-4113</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">To test the feasibility of a single T-cell manipulation to eliminate alloreactivity while sparing antiviral and antitumor T cells, we infused 12 haploidentical hematopoietic stem cell transplant patients with increasing nos. of alloreplete haploidentical T cells expressing the inducible caspase 9 suicide gene (iC9-T cells).  We detd. whether the iC9-T cells produced immune reconstitution and if any resultant graft-vs.-host disease (GVHD) could be controlled by administration of a chem. inducer of dimerization (CID; AP1903/Rimiducid).  All patients receiving >104 alloreplete iC9-T lymphocytes per kg achieved rapid reconstitution of immune responses toward 5 major pathogenic viruses and concomitant control of active infections.  Four patients received a single AP1903 dose.  CID infusion eliminated 85% to 95% of circulating CD3+CD19+ T cells within 30 min, with no recurrence of GVHD within 90 days.  In one patient, symptoms and signs of GVHD-assocd. cytokine release syndrome (CRS-hyperpyrexia, high levels of proinflammatory cytokines, and rash) resolved within 2 h of AP1903 infusion.  One patient with varicella zoster virus meningitis and acute GVHD had iC9-T cells present in the cerebrospinal fluid, which were reduced by >90% after CID.  Notably, virus-specific T cells recovered even after AP1903 administration and continued to protect against infection.  Hence, alloreplete iC9-T cells can reconstitute immunity posttransplant and administration of CID can eliminate them from both peripheral blood and the central nervous system (CNS), leading to rapid resoln. of GVHD and CRS.  The approach may therefore be useful for the rapid and effective treatment of toxicities assocd. with infusion of engineered T lymphocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4Vmr9e0JVl7Vg90H21EOLACvtfcHk0lgePcxAdElYdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlersrzK&md5=96cc02907194c066252fec9f44308598</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-02-628354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-02-628354%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DDotti%26aufirst%3DG.%26aulast%3DKrance%26aufirst%3DR.%2BA.%26aulast%3DMartinez%26aufirst%3DC.%2BA.%26aulast%3DNaik%26aufirst%3DS.%26aulast%3DKamble%26aufirst%3DR.%2BT.%26aulast%3DDurett%26aufirst%3DA.%2BG.%26aulast%3DDakhova%26aufirst%3DO.%26aulast%3DSavoldo%26aufirst%3DB.%26aulast%3DDi%2BStasi%26aufirst%3DA.%26aulast%3DSpencer%26aufirst%3DD.%2BM.%26aulast%3DLin%26aufirst%3DY.%2BF.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DGrilley%26aufirst%3DB.%2BJ.%26aulast%3DGee%26aufirst%3DA.%2BP.%26aulast%3DRooney%26aufirst%3DC.%2BM.%26aulast%3DHeslop%26aufirst%3DH.%2BE.%26aulast%3DBrenner%26aufirst%3DM.%2BK.%26atitle%3DInducible%2520caspase-9%2520suicide%2520gene%2520controls%2520adverse%2520effects%2520from%2520alloreplete%2520T%2520cells%2520after%2520haploidentical%2520stem%2520cell%2520transplantation%26jtitle%3DBlood%26date%3D2015%26volume%3D125%26spage%3D4103%26epage%3D4113%26doi%3D10.1182%2Fblood-2015-02-628354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendravada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinners, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crisostomo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collinson-Pautz, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pentcheva-Hoang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayle, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slawin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, D. M.</span></span> <span> </span><span class="NLM_article-title">Regulated expansion and survival of chimeric antigen receptor-modified T cells using small molecule-dependent inducible MyD88/CD40</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2176</span>– <span class="NLM_lpage">2188</span>, <span class="refDoi"> DOI: 10.1016/j.ymthe.2017.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.ymthe.2017.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=28697888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKlsbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=2176-2188&author=A.+E.+Fosterauthor=A.+Mahendravadaauthor=N.+P.+Shinnersauthor=W.+C.+Changauthor=J.+Crisostomoauthor=A.+Luauthor=M.+Khalilauthor=E.+Morschlauthor=J.+L.+Shawauthor=S.+Sahaauthor=M.+T.+Duongauthor=M.+R.+Collinson-Pautzauthor=D.+L.+Torresauthor=T.+Rodriguezauthor=T.+Pentcheva-Hoangauthor=J.+H.+Bayleauthor=K.+M.+Slawinauthor=D.+M.+Spencer&title=Regulated+expansion+and+survival+of+chimeric+antigen+receptor-modified+T+cells+using+small+molecule-dependent+inducible+MyD88%2FCD40&doi=10.1016%2Fj.ymthe.2017.06.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40</span></div><div class="casAuthors">Foster, Aaron E.; Mahendravada, Aruna; Shinners, Nicholas P.; Chang, Wei-Chun; Crisostomo, Jeannette; Lu, An; Khalil, Mariam; Morschl, Eva; Shaw, Joanne L.; Saha, Sunandan; Duong, My Linh T.; Collinson-Pautz, Matthew R.; Torres, David L.; Rodriguez, Tania; Pentcheva-Hoang, Tsvetelina; Bayle, J. Henri; Slawin, Kevin M.; Spencer, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2176-2188</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0024</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Anti-tumor efficacy of T cells engineered to express chimeric antigen receptors (CARs) is dependent on their specificity, survival, and in vivo expansion following adoptive transfer.  Toll-like receptor (TLR) and CD40 signaling in T cells can improve persistence and drive proliferation of antigen-specific CD4+ and CD8+ T cells following pathogen challenge or in graft-vs.-host disease (GvHD) settings, suggesting that these costimulatory pathways may be co-opted to improve CAR-T cell persistence and function.  Here, we present a novel strategy to activate TLR and CD40 signaling in human T cells using inducible MyD88/CD40 (iMC), which can be triggered in vivo via the synthetic dimerizing ligand, rimiducid, to provide potent costimulation to CAR-modified T cells.  Importantly, the concurrent activation of iMC (with rimiducid) and CAR (by antigen recognition) is required for interleukin (IL)-2 prodn. and robust CAR-T cell expansion and may provide a user-controlled mechanism to amplify CAR-T cell levels in vivo and augment anti-tumor efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8afsIgYOqCLVg90H21EOLACvtfcHk0lgePcxAdElYdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKlsbjI&md5=0c50ee62a00a32ec903b311ae253e9a1</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ymthe.2017.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymthe.2017.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DFoster%26aufirst%3DA.%2BE.%26aulast%3DMahendravada%26aufirst%3DA.%26aulast%3DShinners%26aufirst%3DN.%2BP.%26aulast%3DChang%26aufirst%3DW.%2BC.%26aulast%3DCrisostomo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DA.%26aulast%3DKhalil%26aufirst%3DM.%26aulast%3DMorschl%26aufirst%3DE.%26aulast%3DShaw%26aufirst%3DJ.%2BL.%26aulast%3DSaha%26aufirst%3DS.%26aulast%3DDuong%26aufirst%3DM.%2BT.%26aulast%3DCollinson-Pautz%26aufirst%3DM.%2BR.%26aulast%3DTorres%26aufirst%3DD.%2BL.%26aulast%3DRodriguez%26aufirst%3DT.%26aulast%3DPentcheva-Hoang%26aufirst%3DT.%26aulast%3DBayle%26aufirst%3DJ.%2BH.%26aulast%3DSlawin%26aufirst%3DK.%2BM.%26aulast%3DSpencer%26aufirst%3DD.%2BM.%26atitle%3DRegulated%2520expansion%2520and%2520survival%2520of%2520chimeric%2520antigen%2520receptor-modified%2520T%2520cells%2520using%2520small%2520molecule-dependent%2520inducible%2520MyD88%252FCD40%26jtitle%3DMol.%2520Ther.%26date%3D2017%26volume%3D25%26spage%3D2176%26epage%3D2188%26doi%3D10.1016%2Fj.ymthe.2017.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Stasi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tey, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krance, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durett, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoldo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grilley, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heslop, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotti, G.</span></span> <span> </span><span class="NLM_article-title">Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">3895</span>– <span class="NLM_lpage">3905</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-01-551671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1182%2Fblood-2014-01-551671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=24753538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWhu7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2014&pages=3895-3905&author=X.+Zhouauthor=A.+Di+Stasiauthor=S.+K.+Teyauthor=R.+A.+Kranceauthor=C.+Martinezauthor=K.+S.+Leungauthor=A.+G.+Durettauthor=M.+F.+Wuauthor=H.+Liuauthor=A.+M.+Leenauthor=B.+Savoldoauthor=Y.+F.+Linauthor=B.+J.+Grilleyauthor=A.+P.+Geeauthor=D.+M.+Spencerauthor=C.+M.+Rooneyauthor=H.+E.+Heslopauthor=M.+K.+Brennerauthor=G.+Dotti&title=Long-term+outcome+after+haploidentical+stem+cell+transplant+and+infusion+of+T+cells+expressing+the+inducible+caspase+9+safety+transgene&doi=10.1182%2Fblood-2014-01-551671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene</span></div><div class="casAuthors">Zhou, Xiaoou; Di Stasi, Antonio; Tey, Siok-Keen; Krance, Robert A.; Martinez, Caridad; Leung, Kathryn S.; Durett, April G.; Wu, Meng-Fen; Liu, Hao; Leen, Ann M.; Savoldo, Barbara; Lin, Yu-Feng; Grilley, Bambi J.; Gee, Adrian P.; Spencer, David M.; Rooney, Cliona M.; Heslop, Helen E.; Brenner, Malcolm K.; Dotti, Gianpietro</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">3895-3905</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Adoptive transfer of donor-derived T lymphocytes expressing a safety switch may promote immune reconstitution in patients undergoing haploidentical hematopoietic stem cell transplant (haplo-HSCT) without the risk for uncontrolled graft vs. host disease (GvHD).  Thus, patients who develop GvHD after infusion of allodepleted donor-derived T cells expressing an inducible human caspase 9 (iC9) had their disease effectively controlled by a single administration of a small-mol. drug (AP1903) that dimerizes and activates the iC9 transgene.  We now report the long-term follow-up of 10 patients infused with such safety switch-modified T cells.  We find long-term persistence of iC9-modified (iC9-T) T cells in vivo in the absence of emerging oligoclonality and a robust immunol. benefit, mediated initially by the infused cells themselves and subsequently by an apparently accelerated reconstitution of endogenous naive T lymphocytes.  As a consequence, these patients have immediate and sustained protection from major pathogens, including cytomegalovirus, adenovirus, BK virus, and Epstein-Barr virus in the absence of acute or chronic GvHD, supporting the beneficial effects of this approach to immune reconstitution after haplo-HSCT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos7VrzIKSizrVg90H21EOLACvtfcHk0lhIHX30OXIWgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWhu7nM&md5=53358083fbcf274c5112b4c0648ca466</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-01-551671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-01-551671%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DDi%2BStasi%26aufirst%3DA.%26aulast%3DTey%26aufirst%3DS.%2BK.%26aulast%3DKrance%26aufirst%3DR.%2BA.%26aulast%3DMartinez%26aufirst%3DC.%26aulast%3DLeung%26aufirst%3DK.%2BS.%26aulast%3DDurett%26aufirst%3DA.%2BG.%26aulast%3DWu%26aufirst%3DM.%2BF.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLeen%26aufirst%3DA.%2BM.%26aulast%3DSavoldo%26aufirst%3DB.%26aulast%3DLin%26aufirst%3DY.%2BF.%26aulast%3DGrilley%26aufirst%3DB.%2BJ.%26aulast%3DGee%26aufirst%3DA.%2BP.%26aulast%3DSpencer%26aufirst%3DD.%2BM.%26aulast%3DRooney%26aufirst%3DC.%2BM.%26aulast%3DHeslop%26aufirst%3DH.%2BE.%26aulast%3DBrenner%26aufirst%3DM.%2BK.%26aulast%3DDotti%26aufirst%3DG.%26atitle%3DLong-term%2520outcome%2520after%2520haploidentical%2520stem%2520cell%2520transplant%2520and%2520infusion%2520of%2520T%2520cells%2520expressing%2520the%2520inducible%2520caspase%25209%2520safety%2520transgene%26jtitle%3DBlood%26date%3D2014%26volume%3D123%26spage%3D3895%26epage%3D3905%26doi%3D10.1182%2Fblood-2014-01-551671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span> <span> </span><span class="NLM_article-title">A Chemical Switch System to Modulate Chimeric Antigen Receptor T Cell Activity through Proteolysis-Targeting Chimaera Technology</span>. <i>ACS Synth. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">987</span>– <span class="NLM_lpage">992</span>, <span class="refDoi"> DOI: 10.1021/acssynbio.9b00476</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acssynbio.9b00476" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotFCkt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=987-992&issue=5&author=S.+M.+Leeauthor=C.+H.+Kangauthor=S.+U.+Choiauthor=Y.+Kimauthor=J.+Y.+Hwangauthor=H.+G.+Jeongauthor=C.+H.+Park&title=A+Chemical+Switch+System+to+Modulate+Chimeric+Antigen+Receptor+T+Cell+Activity+through+Proteolysis-Targeting+Chimaera+Technology&doi=10.1021%2Facssynbio.9b00476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">A Chemical Switch System to Modulate Chimeric Antigen Receptor T Cell Activity through Proteolysis-Targeting Chimaera Technology</span></div><div class="casAuthors">Lee, So Myoung; Kang, Chung Hyo; Choi, Sang Un; Kim, Yeongrin; Hwang, Jong Yeon; Jeong, Hye Gwang; Park, Chi Hoon</div><div class="citationInfo"><span class="NLM_cas:title">ACS Synthetic Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">987-992</span>CODEN:
                <span class="NLM_cas:coden">ASBCD6</span>;
        ISSN:<span class="NLM_cas:issn">2161-5063</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite the excellent efficacy of chimeric antigen receptor (CAR T) cell therapy, concerns about its safety have been constantly raised.  The side effects of CAR T cells result from an aberrantly upregulation of CAR T cell activity.  Therefore, it is crucial to control the CAR T cell activity whenever the patient is at risk.  For this purpose, the iCas9 system, which induces apoptosis in CAR T cell through caspase-9 dimerization by compd., has been invented and is currently going under clin. trial.  However, the iCas9 system is irreversible, as the entire CAR T cell population is removed from the patient.  Thus, CAR T cells, which are very expensive, should be reinfused to the patients after they recovered from the side-effect.  Here, we propose a new CAR T cell safety strategy, which targets CAR "protein", not CAR "T cell".  In this system, the CAR construct is modified to bear a bromodomain (BD).  The addn. of a BD in the CAR protein did not interfere with the original CAR functions, such as cytokine secretion and target cell lysis.  Our data showed that the use of a proteolysis-targeting chimaera (PROTAC) compd. against BD successfully degraded the BD-contg. CAR protein.  Moreover, the CAR expression is recovered when the PROTAC compd. is removed from the cell, demonstrating that our system is reversible.  In a target cell lysis assay, the PROTAC compd. successfully suppressed the lytic activity of CAR T cells by degrading the CAR protein.  In conclusion, we developed a new safety system in which CAR T cells can be "reversibly" controlled by a compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcEdqIGfaX97Vg90H21EOLACvtfcHk0lhIHX30OXIWgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotFCkt7c%253D&md5=13fb6d56c3d4dbc74d6954f48e3c48ce</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facssynbio.9b00476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facssynbio.9b00476%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BM.%26aulast%3DKang%26aufirst%3DC.%2BH.%26aulast%3DChoi%26aufirst%3DS.%2BU.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DHwang%26aufirst%3DJ.%2BY.%26aulast%3DJeong%26aufirst%3DH.%2BG.%26aulast%3DPark%26aufirst%3DC.%2BH.%26atitle%3DA%2520Chemical%2520Switch%2520System%2520to%2520Modulate%2520Chimeric%2520Antigen%2520Receptor%2520T%2520Cell%2520Activity%2520through%2520Proteolysis-Targeting%2520Chimaera%2520Technology%26jtitle%3DACS%2520Synth.%2520Biol.%26date%3D2020%26volume%3D9%26issue%3D5%26spage%3D987%26epage%3D992%26doi%3D10.1021%2Facssynbio.9b00476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nandakumar, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.</span></span> <span> </span><span class="NLM_article-title">Design and pharmaceutical applications of proteolysis-targeting chimeric molecules</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">114211</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2020.114211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.bcp.2020.114211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=32866456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVSmsLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2020&pages=114211&author=Y.+Liangauthor=K.+S.+Nandakumarauthor=K.+Cheng&title=Design+and+pharmaceutical+applications+of+proteolysis-targeting+chimeric+molecules&doi=10.1016%2Fj.bcp.2020.114211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Design and pharmaceutical applications of proteolysis-targeting chimeric molecules</span></div><div class="casAuthors">Liang, Yuqing; Nandakumar, Kutty Selva; Cheng, Kui</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">114211</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Proteolysis-targeting chimeras (PROTACs), the hetero-bifunctional compds. contg. a specific ligand to bind the target protein, a suitable linker, and an E3 ubiquitin ligase substrate, are being developed for therapeutic applications.  PROTACs hijack the catalytic activity of ubiquitin E3 ligases to mediate proteasome dependent degrdn. of selected protein of interest (POI), by bringing the ligase and POI into close spatial proximity and initiating the poly-ubiquitination process.  Compared to the traditional small-mol. drugs, PROTACs reduce the problems of dosage, drug resistance, side effects and undruggable targets that could not be targeted pharmacol.  In this review, all the POIs, and peptide to small-mol. based PROTACs developed during the past two decades are summarized and directions for future development are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolWEaC4ysC07Vg90H21EOLACvtfcHk0lhIHX30OXIWgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVSmsLvI&md5=1c3c88f438675db747b36683e511d242</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2020.114211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2020.114211%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DNandakumar%26aufirst%3DK.%2BS.%26aulast%3DCheng%26aufirst%3DK.%26atitle%3DDesign%2520and%2520pharmaceutical%2520applications%2520of%2520proteolysis-targeting%2520chimeric%2520molecules%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2020%26volume%3D182%26spage%3D114211%26doi%3D10.1016%2Fj.bcp.2020.114211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varshavsky, A.</span></span> <span> </span><span class="NLM_article-title">N-degron and C-degron pathways of protein degradation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">366</span>, <span class="refDoi"> DOI: 10.1073/pnas.1816596116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1073%2Fpnas.1816596116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=30622213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVKgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=358-366&author=A.+Varshavsky&title=N-degron+and+C-degron+pathways+of+protein+degradation&doi=10.1073%2Fpnas.1816596116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">N-degron and C-degron pathways of protein degradation</span></div><div class="casAuthors">Varshavsky, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">358-366</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A review.  This perspective is partly review and partly proposal.  N-degrons and C-degrons are degrdn. signals whose main determinants are, resp., the N-terminal and C-terminal residues of cellular proteins.  N-degrons and C-degrons include, to varying extents, adjoining sequence motifs, and also internal lysine residues that function as polyubiquitylation sites.  Discovered in 1986, N-degrons were the first degrdn. signals in short-lived proteins.  A particularly large set of C-degrons was discovered in 2018.  We describe multifunctional proteolytic systems that target N-degrons and C-degrons.  We also propose to denote these systems as "N-degron pathways" and "C-degron pathways.".  The former notation replaces the earlier name "N-end rule pathways.".  The term "N-end rule" was introduced 33 years ago, when only some N-terminal residues were thought to be destabilizing.  However, studies over the last three decades have shown that all 20 amino acids of the genetic code can act, in cognate sequence contexts, as destabilizing N-terminal residues.  Advantages of the proposed terms include their brevity and semantic uniformity for N-degrons and C-degrons.  In addn. to being topol. analogous, N-degrons and C-degrons are related functionally.  A proteolytic cleavage of a subunit in a multisubunit complex can create, at the same time, an N-degron (in a C-terminal fragment) and a spatially adjacent C-degron (in an N-terminal fragment).  Consequently, both fragments of a subunit can be selectively destroyed through attacks by the N-degron and C-degron pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr80d0bxpecnLVg90H21EOLACvtfcHk0ljVWw17IvrZcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVKgtQ%253D%253D&md5=c9a7b5260caf96d886af0376e0d92a26</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1816596116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1816596116%26sid%3Dliteratum%253Aachs%26aulast%3DVarshavsky%26aufirst%3DA.%26atitle%3DN-degron%2520and%2520C-degron%2520pathways%2520of%2520protein%2520degradation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26volume%3D116%26spage%3D358%26epage%3D366%26doi%3D10.1073%2Fpnas.1816596116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouchnak, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Wijk, K. J.</span></span> <span> </span><span class="NLM_article-title">N-Degron Pathways in Plastids</span>. <i>Trends Plant Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.1016/j.tplants.2019.06.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.tplants.2019.06.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=31300194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlWnsLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=917-926&author=I.+Bouchnakauthor=K.+J.+van+Wijk&title=N-Degron+Pathways+in+Plastids&doi=10.1016%2Fj.tplants.2019.06.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">N-Degron Pathways in Plastids</span></div><div class="casAuthors">Bouchnak, Imen; van Wijk, Klaas J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Plant Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">917-926</span>CODEN:
                <span class="NLM_cas:coden">TPSCF9</span>;
        ISSN:<span class="NLM_cas:issn">1360-1385</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein amino (N) termini are major determinants of protein stability in the cytosol of eukaryotes and prokaryotes, conceptualized in the N-end rule pathway, lately referred to as N-degron pathways.  Here we argue for the existence of N-degron pathways in plastids of apicomplexa, algae, and plants.  The prokaryotic N-degron pathway depends on a caseinolytic protease (CLP) S recognin (adaptor) for the recognition and delivery of N-degron-bearing substrates to CLP chaperone-protease systems.  Diversified CLP systems are found in chloroplasts and nonphotosynthetic plastids, including CLPS homologs that specifically interact with a subset of N-terminal residues and stromal proteins.  Chloroplast N-terminome data show enrichment of classic stabilizing residues [Ala (A), Ser (S), Val (V), Thr (T)] and avoidance of charged and large hydrophobic residues.  We outline exptl. test strategies for plastid N-degron pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqWt_-Ft_KmrVg90H21EOLACvtfcHk0ljVWw17IvrZcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlWnsLbM&md5=b43b80eedbf2cf6c28789f585687202c</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.tplants.2019.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tplants.2019.06.013%26sid%3Dliteratum%253Aachs%26aulast%3DBouchnak%26aufirst%3DI.%26aulast%3Dvan%2BWijk%26aufirst%3DK.%2BJ.%26atitle%3DN-Degron%2520Pathways%2520in%2520Plastids%26jtitle%3DTrends%2520Plant%2520Sci.%26date%3D2019%26volume%3D24%26spage%3D917%26epage%3D926%26doi%3D10.1016%2Fj.tplants.2019.06.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabek, N.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin ligases: structure, function, and regulation</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1146/annurev-biochem-060815-014922</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1146%2Fannurev-biochem-060815-014922" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=28375744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsFShsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2017&pages=129-157&author=N.+Zhengauthor=N.+Shabek&title=Ubiquitin+ligases%3A+structure%2C+function%2C+and+regulation&doi=10.1146%2Fannurev-biochem-060815-014922"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin Ligases: Structure, Function, and Regulation</span></div><div class="casAuthors">Zheng, Ning; Shabek, Nitzan</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">129-157</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  Ubiquitin E3 ligases control every aspect of eukaryotic biol. by promoting protein ubiquitination and degrdn.  At the end of a three-enzyme cascade, ubiquitin ligases mediate the transfer of ubiquitin from an E2 ubiquitin-conjugating enzyme to specific substrate proteins.  Early investigations of E3s of the RING (really interesting new gene) and HECT (homologous to the E6AP carboxyl terminus) types shed light on their enzymic activities, general architectures, and substrate degron-binding modes.  Recent studies have provided deeper mechanistic insights into their catalysis, activation, and regulation.  In this review, we summarize the current progress in structure-function studies of ubiquitin ligases as well as exciting new discoveries of novel classes of E3s and diverse substrate recognition mechanisms.  Our increased understanding of ubiquitin ligase function and regulation has provided the rationale for developing E3-targeting therapeutics for the treatment of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq6AYlt-T3-bVg90H21EOLACvtfcHk0lg7ERL658ZfuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsFShsb0%253D&md5=3e9fde71ba7871385290f118fc4a768a</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1146%2Fannurev-biochem-060815-014922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-biochem-060815-014922%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DN.%26aulast%3DShabek%26aufirst%3DN.%26atitle%3DUbiquitin%2520ligases%253A%2520structure%252C%2520function%252C%2520and%2520regulation%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2017%26volume%3D86%26spage%3D129%26epage%3D157%26doi%3D10.1146%2Fannurev-biochem-060815-014922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yesbolatova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tominari, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanemaki, M. T.</span></span> <span> </span><span class="NLM_article-title">Ligand-induced genetic degradation as a tool for target validation</span>. <i>Drug Discovery Today: Technol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1016/j.ddtec.2018.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.ddtec.2018.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=31200864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BB3M3mvFWrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2019&pages=91-98&author=A.+Yesbolatovaauthor=Y.+Tominariauthor=M.+T.+Kanemaki&title=Ligand-induced+genetic+degradation+as+a+tool+for+target+validation&doi=10.1016%2Fj.ddtec.2018.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-induced genetic degradation as a tool for target validation</span></div><div class="casAuthors">Yesbolatova Aisha; Tominari Yusuke; Kanemaki Masato T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today. Technologies</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">91-98</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Targeted protein degraders, known as proteolysis targeting chimeras (PROTACs), are drawing more attention as next-generation drugs to target currently undruggable proteins.  As drug discovery of functional degraders involves time- and cost-consuming laborious processes, we propose employing a ligand-induced genetic degradation system to validate candidate proteins before degrader development.  Genetic degradation mimics degrader treatment by depleting a degron-fused protein in the presence of a defined ligand.  All genetic systems use a combination of a degron and defined ligand that enables a protein of interest fused with the degron to be recruited to an E3 ubiquitin ligase for ubiquitylation and subsequent degradation by the proteasome.  However, these events are based on different principles and have different features.  We review the dTAG, HaloTag-based, auxin-inducible degron (AID), and destabilizing domain (DD) systems and discuss a strategy for degrader discovery against novel target proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQCRHissLLXoXy-c-E1v-fmfW6udTcc2ebdJwbqkQQA5bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3mvFWrug%253D%253D&md5=5ef6a19eda7b6714683b019ac7a0e521</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2018.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2018.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DYesbolatova%26aufirst%3DA.%26aulast%3DTominari%26aufirst%3DY.%26aulast%3DKanemaki%26aufirst%3DM.%2BT.%26atitle%3DLigand-induced%2520genetic%2520degradation%2520as%2520a%2520tool%2520for%2520target%2520validation%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2019%26volume%3D31%26spage%3D91%26epage%3D98%26doi%3D10.1016%2Fj.ddtec.2018.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busser, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temburni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirot, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchateau, P.</span></span> <span> </span><span class="NLM_article-title">Modulation of chimeric antigen receptor surface expression by a small molecule switch</span>. <i>BMC Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">44</span>, <span class="refDoi"> DOI: 10.1186/s12896-019-0537-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1186%2Fs12896-019-0537-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=31269942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BB3MzjvVSgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=44&author=A.+Juilleratauthor=D.+Tkachauthor=B.+W.+Busserauthor=S.+Temburniauthor=J.+Valtonauthor=A.+Duclertauthor=L.+Poirotauthor=S.+Depilauthor=P.+Duchateau&title=Modulation+of+chimeric+antigen+receptor+surface+expression+by+a+small+molecule+switch&doi=10.1186%2Fs12896-019-0537-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of chimeric antigen receptor surface expression by a small molecule switch</span></div><div class="casAuthors">Juillerat Alexandre; Tkach Diane; Busser Brian W; Temburni Sonal; Valton Julien; Duclert Aymeric; Poirot Laurent; Depil Stephane; Duchateau Philippe</div><div class="citationInfo"><span class="NLM_cas:title">BMC biotechnology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Engineered therapeutic cells have attracted a great deal of interest due to their potential applications in treating a wide range of diseases, including cancer and autoimmunity.  Chimeric antigen receptor (CAR) T-cells are designed to detect and kill tumor cells that present a specific, predefined antigen.  The rapid expansion of targeted antigen beyond CD19, has highlighted new challenges, such as autoactivation and T-cell fratricide, that could impact the capacity to manufacture engineered CAR T-cells.  Therefore, the development of strategies to control CAR expression at the surface of T-cells and their functions is under intense investigations.  RESULTS:  Here, we report the development and evaluation of an off-switch directly embedded within a CAR construct (SWIFF-CAR).  The incorporation of a self-cleaving degradation moiety controlled by a protease/protease inhibitor pair allowed the ex vivo tight and reversible control of the CAR surface presentation and the subsequent CAR-induced signaling and cytolytic functions of the engineered T-cells using the cell permeable Asunaprevir (ASN) small molecule.  CONCLUSIONS:  The strategy described in this study could, in principle, be broadly adapted to CAR T-cells development to circumvent some of the possible hurdle of CAR T-cell manufacturing.  This system essentially creates a CAR T-cell with an integrated functional rheostat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR1CKVhGP9EQmyYR5VtavbzfW6udTcc2eZQFkfAKtU-g7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzjvVSgug%253D%253D&md5=f6bbb44e0e41a0b470027b61c8f480d6</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1186%2Fs12896-019-0537-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12896-019-0537-3%26sid%3Dliteratum%253Aachs%26aulast%3DJuillerat%26aufirst%3DA.%26aulast%3DTkach%26aufirst%3DD.%26aulast%3DBusser%26aufirst%3DB.%2BW.%26aulast%3DTemburni%26aufirst%3DS.%26aulast%3DValton%26aufirst%3DJ.%26aulast%3DDuclert%26aufirst%3DA.%26aulast%3DPoirot%26aufirst%3DL.%26aulast%3DDepil%26aufirst%3DS.%26aulast%3DDuchateau%26aufirst%3DP.%26atitle%3DModulation%2520of%2520chimeric%2520antigen%2520receptor%2520surface%2520expression%2520by%2520a%2520small%2520molecule%2520switch%26jtitle%3DBMC%2520Biotechnol.%26date%3D2019%26volume%3D19%26spage%3D44%26doi%3D10.1186%2Fs12896-019-0537-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, K. G.</span></span> <span> </span><span class="NLM_article-title">PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">7124</span>– <span class="NLM_lpage">7129</span>, <span class="refDoi"> DOI: 10.1073/pnas.1521738113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1073%2Fpnas.1521738113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=27274052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC28Xptlyqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=7124-7129&issue=26&author=K.+Rainaauthor=J.+Luauthor=Y.+Qianauthor=M.+Altieriauthor=D.+Gordonauthor=A.+M.+Rossiauthor=J.+Wangauthor=X.+Chenauthor=H.+Dongauthor=K.+Siuauthor=J.+D.+Winklerauthor=A.+P.+Crewauthor=C.+M.+Crewsauthor=K.+G.+Coleman&title=PROTAC-induced+BET+protein+degradation+as+a+therapy+for+castration-resistant+prostate+cancer&doi=10.1073%2Fpnas.1521738113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer</span></div><div class="casAuthors">Raina, Kanak; Lu, Jing; Qian, Yimin; Altieri, Martha; Gordon, Deborah; Rossi, Ann Marie K.; Wang, Jing; Chen, Xin; Dong, Hanqing; Siu, Kam; Winkler, James D.; Crew, Andrew P.; Crews, Craig M.; Coleman, Kevin G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7124-7129</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Prostate cancer has the second highest incidence among cancers in men worldwide and is the second leading cause of cancer deaths of men in the United States.  Although androgen deprivation can initially lead to remission, the disease often progresses to castration-resistant prostate cancer (CRPC), which is still reliant on androgen receptor (AR) signaling and is assocd. with a poor prognosis.  Some success against CRPC has been achieved by drugs that target AR signaling, but secondary resistance invariably emerges, and new therapies are urgently needed.  Recently, inhibitors of bromodomain and extra-terminal (BET) family proteins have shown growth-inhibitory activity in preclin. models of CRPC.  Here, we demonstrate that ARV-771, a small-mol. pan-BET degrader based on proteolysis-targeting chimera (PROTAC) technol., demonstrates dramatically improved efficacy in cellular models of CRPC as compared with BET inhibition.  Unlike BET inhibitors, ARV-771 results in suppression of both AR signaling and AR levels and leads to tumor regression in a CRPC mouse xenograft model.  This study is, to our knowledge, the first to demonstrate efficacy with a small-mol. BET degrader in a solid-tumor malignancy and potentially represents an important therapeutic advance in the treatment of CRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD7QtYgZVig7Vg90H21EOLACvtfcHk0lh6QWqd1rtapA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xptlyqs7s%253D&md5=34218e685ad72950f3eb85586110c43d</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1521738113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1521738113%26sid%3Dliteratum%253Aachs%26aulast%3DRaina%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DAltieri%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DD.%26aulast%3DRossi%26aufirst%3DA.%2BM.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DSiu%26aufirst%3DK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26aulast%3DColeman%26aufirst%3DK.%2BG.%26atitle%3DPROTAC-induced%2520BET%2520protein%2520degradation%2520as%2520a%2520therapy%2520for%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26issue%3D26%26spage%3D7124%26epage%3D7129%26doi%3D10.1073%2Fpnas.1521738113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">755</span>– <span class="NLM_lpage">763</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2015.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.chembiol.2015.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=26051217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWrtbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=755-763&issue=6&author=J.+Luauthor=Y.+Qianauthor=M.+Altieriauthor=H.+Dongauthor=J.+Wangauthor=K.+Rainaauthor=J.+Hinesauthor=J.+D.+Winklerauthor=A.+P.+Crewauthor=K.+Colemanauthor=C.+M.+Crews&title=Hijacking+the+E3+ubiquitin+ligase+cereblon+to+efficiently+target+BRD4&doi=10.1016%2Fj.chembiol.2015.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4</span></div><div class="casAuthors">Lu, Jing; Qian, Yimin; Altieri, Martha; Dong, Hanqing; Wang, Jing; Raina, Kanak; Hines, John; Winkler, James D.; Crew, Andrew P.; Coleman, Kevin; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">755-763</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">BRD4, a bromodomain and extraterminal domain (BET) family member, is an attractive target in multiple pathol. settings, particularly cancer.  While BRD4 inhibitors have shown some promise in MYC-driven malignancies such as Burkitt's lymphoma (BL), we show that BRD4 inhibitors lead to robust BRD4 protein accumulation, which may account for their limited suppression of MYC expression, modest antiproliferative activity, and lack of apoptotic induction.  To address these limitations we designed ARV-825, a hetero-bifunctional PROTAC (Proteolysis Targeting Chimera) that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degrdn. of BRD4 in all BL cell lines tested.  Consequently, ARV-825 more effectively suppresses c-MYC levels and downstream signaling than small-mol. BRD4 inhibitors, resulting in more effective cell proliferation inhibition and apoptosis induction in BL.  Our findings provide strong evidence that cereblon-based PROTACs provide a better and more efficient strategy in targeting BRD4 than traditional small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Ol4grCG2RbVg90H21EOLACvtfcHk0lh6QWqd1rtapA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWrtbrM&md5=a64675e7a0cd006a8737be9730f447e3</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2015.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2015.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DAltieri%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DRaina%26aufirst%3DK.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DColeman%26aufirst%3DK.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DHijacking%2520the%2520E3%2520ubiquitin%2520ligase%2520cereblon%2520to%2520efficiently%2520target%2520BRD4%26jtitle%3DChem.%2520Biol.%26date%3D2015%26volume%3D22%26issue%3D6%26spage%3D755%26epage%3D763%26doi%3D10.1016%2Fj.chembiol.2015.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khire, U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albelda, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milone, M. C.</span></span> <span> </span><span class="NLM_article-title">Ligand-induced degradation of a CAR permits reversible remote control of CAR T cell activity in vitro and in vivo</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1600</span>– <span class="NLM_lpage">1613</span>, <span class="refDoi"> DOI: 10.1016/j.ymthe.2020.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.ymthe.2020.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=32559430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlKktrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=1600-1613&author=S.+A.+Richmanauthor=L.-C.+Wangauthor=E.+K.+Moonauthor=U.+R.+Khireauthor=S.+M.+Albeldaauthor=M.+C.+Milone&title=Ligand-induced+degradation+of+a+CAR+permits+reversible+remote+control+of+CAR+T+cell+activity+in+vitro+and+in+vivo&doi=10.1016%2Fj.ymthe.2020.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity In Vitro and In Vivo</span></div><div class="casAuthors">Richman, Sarah A.; Wang, Liang-Chuan; Khire, Uday R.; Albelda, Steven M.; Milone, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1600-1613</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0024</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Chimeric antigen receptor (CAR)-modified T cells are endowed with novel antigen specificity and are most often administered to patients without an engineered mechanism to control the CAR T cells once infused.  "Suicide switches" such as the small mol.-controlled, inducible caspase-9 (iCas9) system afford the ability to selectively eliminate engineered T cells; however, these approaches are designed for all-or-none, irreversible termination of an ongoing immune response.  In order to permit reversible and adjustable modulation, we have created a CAR that is capable of on-demand downregulation by fusing the CAR to a previously developed ligand-induced degrdn. (LID) domain.  Addn. of a small mol. ligand triggers exposure of a cryptic degron within the LID domain, resulting in proteasomal degrdn. of the CAR-LID fusion protein and loss of CAR on the surface of T cells.  This fusion construct allowed for reversible and "tunable" inhibition of CAR T cell activity in vitro.  Delivery of the triggering mol. in CAR-LID-treated tumor-bearing mice temporarily reduced CAR activity through modulation of CAR surface expression.  The ability to more flexibly modulate CAR T cell expression through a small mol. provides a platform for controlling possible adverse side effects, as well as preclin. investigations of CAR T cell biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh1TTSO6Te2rVg90H21EOLACvtfcHk0ljEztYZbsh0Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlKktrjE&md5=a88451f909e111847690b616a0c52862</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.ymthe.2020.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymthe.2020.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DRichman%26aufirst%3DS.%2BA.%26aulast%3DWang%26aufirst%3DL.-C.%26aulast%3DMoon%26aufirst%3DE.%2BK.%26aulast%3DKhire%26aufirst%3DU.%2BR.%26aulast%3DAlbelda%26aufirst%3DS.%2BM.%26aulast%3DMilone%26aufirst%3DM.%2BC.%26atitle%3DLigand-induced%2520degradation%2520of%2520a%2520CAR%2520permits%2520reversible%2520remote%2520control%2520of%2520CAR%2520T%2520cell%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Ther.%26date%3D2020%26volume%3D28%26spage%3D1600%26epage%3D1613%26doi%3D10.1016%2Fj.ymthe.2020.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weichsel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wooldridge, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenton-May, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewell, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zezula, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gostick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einsele, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seggewiss, R.</span></span> <span> </span><span class="NLM_article-title">Profound inhibition of antigen-specific T-cell effector functions by dasatinib</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2484</span>– <span class="NLM_lpage">2491</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-4393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1158%2F1078-0432.CCR-07-4393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=18413841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvFGmur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=2484-2491&issue=8&author=R.+Weichselauthor=C.+Dixauthor=L.+Wooldridgeauthor=M.+Clementauthor=A.+Fenton-Mayauthor=A.+K.+Sewellauthor=J.+Zezulaauthor=E.+Greinerauthor=E.+Gostickauthor=D.+A.+Priceauthor=H.+Einseleauthor=R.+Seggewiss&title=Profound+inhibition+of+antigen-specific+T-cell+effector+functions+by+dasatinib&doi=10.1158%2F1078-0432.CCR-07-4393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib</span></div><div class="casAuthors">Weichsel, Ralf; Dix, Carolin; Wooldridge, Linda; Clement, Matthew; Fenton-May, Angharad; Sewell, Andrew K.; Zezula, Josef; Greiner, Elisabeth; Gostick, Emma; Price, David A.; Einsele, Hermann; Seggewiss, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2484-2491</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The dual BCR-ABL/SRC kinase inhibitor dasatinib entered the clinic for the treatment of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia.  Because SRC kinases are known to play an important role in physiol. T-cell activation, we analyzed the immunobiol. effects of dasatinib on T-cell function.  The effect of dasatinib on multiple T-cell effector functions was examd. at clin. relevant doses (1-100 nmol/L); the promiscuous tyrosine kinase inhibitor staurosporine was used as a comparator.  Purified human CD3+ cells and virus-specific CD8+ T cells from healthy blood donors were studied directly ex vivo; antigen-specific effects were confirmed in defined T-cell clones.  Functional outcomes included cytokine prodn. (interleukin-2, IFNγ, and tumor necrosis factor α), degranulation (CD107a/b mobilization), activation (CD69 up-regulation), proliferation (carboxyfluorescein diacetate succinimidyl ester diln.), apoptosis/necrosis induction, and signal transduction.  Both dasatinib and staurosporine inhibited T-cell activation, proliferation, cytokine prodn., and degranulation in a dose-dependent manner.  Mechanistically, this was mediated by the blockade of early signal transduction events and was not due to loss of T-cell viability.  Overall, CD4+ T cells seemed to be more sensitive to these effects than CD8+ T cells, and naive T cells more sensitive than memory T-cell subsets.  The inhibitory effects of dasatinib were so profound that all T-cell effector functions were shut down at therapeutically relevant concns.  These findings indicate that caution is warranted with use of this drug in the clin. setting and provide a rationale to explore the potential of dasatinib as an immunosuppressant in the fields of transplantation and T-cell-driven autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLsnjesiG2xrVg90H21EOLACvtfcHk0ljEztYZbsh0Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvFGmur0%253D&md5=9260418b1ccea3b8d3a99caab450c762</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-4393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-4393%26sid%3Dliteratum%253Aachs%26aulast%3DWeichsel%26aufirst%3DR.%26aulast%3DDix%26aufirst%3DC.%26aulast%3DWooldridge%26aufirst%3DL.%26aulast%3DClement%26aufirst%3DM.%26aulast%3DFenton-May%26aufirst%3DA.%26aulast%3DSewell%26aufirst%3DA.%2BK.%26aulast%3DZezula%26aufirst%3DJ.%26aulast%3DGreiner%26aufirst%3DE.%26aulast%3DGostick%26aufirst%3DE.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DEinsele%26aufirst%3DH.%26aulast%3DSeggewiss%26aufirst%3DR.%26atitle%3DProfound%2520inhibition%2520of%2520antigen-specific%2520T-cell%2520effector%2520functions%2520by%2520dasatinib%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26issue%3D8%26spage%3D2484%26epage%3D2491%26doi%3D10.1158%2F1078-0432.CCR-07-4393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riesenberg, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Development of molecular and pharmacological switches for chimeric antigen receptor T cells</span>. <i>Exp. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">27</span>, <span class="refDoi"> DOI: 10.1186/s40164-019-0151-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1186%2Fs40164-019-0151-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=31709128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BB3Mjntl2isA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=27&author=B.+X.+Wuauthor=N.+J.+Songauthor=B.+P.+Riesenbergauthor=Z.+Li&title=Development+of+molecular+and+pharmacological+switches+for+chimeric+antigen+receptor+T+cells&doi=10.1186%2Fs40164-019-0151-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Development of molecular and pharmacological switches for chimeric antigen receptor T cells</span></div><div class="casAuthors">Wu Bill X; Song No-Joon; Riesenberg Brian P; Li Zihai</div><div class="citationInfo"><span class="NLM_cas:title">Experimental hematology & oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27</span>
        ISSN:<span class="NLM_cas:issn">2162-3619</span>.
    </div><div class="casAbstract">The use of chimeric antigen receptor (CAR) T cell technology as a therapeutic strategy for the treatment blood-born human cancers has delivered outstanding clinical efficacy.  However, this treatment modality can also be associated with serious adverse events in the form of cytokine release syndrome.  While several avenues are being pursued to limit the off-target effects, it is critically important that any intervention strategy has minimal consequences on long term efficacy.  A recent study published in Science Translational Medicine by Dr.  Hudecek's group proved that dasatinib, a tyrosine kinase inhibitor, can serve as an on/off switch for CD19-CAR-T cells in preclinical models by limiting toxicities while maintaining therapeutic efficacy.  In this editorial, we discuss the recent strategies for generating safer CAR-T cells, and also important questions surrounding the use of dasatinib for emergency intervention of CAR-T cell mediated cytokine release syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeAtUkKoWv1wwxfk_AGB-EfW6udTcc2ebe873G9W318bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mjntl2isA%253D%253D&md5=6997da39a387268a330c523e8796a837</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1186%2Fs40164-019-0151-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40164-019-0151-z%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%2BX.%26aulast%3DSong%26aufirst%3DN.%2BJ.%26aulast%3DRiesenberg%26aufirst%3DB.%2BP.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DDevelopment%2520of%2520molecular%2520and%2520pharmacological%2520switches%2520for%2520chimeric%2520antigen%2520receptor%2520T%2520cells%26jtitle%3DExp.%2520Hematol.%2520Oncol.%26date%3D2019%26volume%3D8%26spage%3D27%26doi%3D10.1186%2Fs40164-019-0151-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mestermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giavridis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rydzek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nerreter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mades, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadelain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einsele, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudecek, M.</span></span> <span> </span><span class="NLM_article-title">The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">eaau5907</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aau5907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1126%2Fscitranslmed.aau5907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=31270272" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&author=K.+Mestermannauthor=T.+Giavridisauthor=J.+Weberauthor=J.+Rydzekauthor=S.+Frenzauthor=T.+Nerreterauthor=A.+Madesauthor=M.+Sadelainauthor=H.+Einseleauthor=M.+Hudecek&title=The+tyrosine+kinase+inhibitor+dasatinib+acts+as+a+pharmacologic+on%2Foff+switch+for+CAR+T+cells&doi=10.1126%2Fscitranslmed.aau5907"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aau5907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aau5907%26sid%3Dliteratum%253Aachs%26aulast%3DMestermann%26aufirst%3DK.%26aulast%3DGiavridis%26aufirst%3DT.%26aulast%3DWeber%26aufirst%3DJ.%26aulast%3DRydzek%26aufirst%3DJ.%26aulast%3DFrenz%26aufirst%3DS.%26aulast%3DNerreter%26aufirst%3DT.%26aulast%3DMades%26aufirst%3DA.%26aulast%3DSadelain%26aufirst%3DM.%26aulast%3DEinsele%26aufirst%3DH.%26aulast%3DHudecek%26aufirst%3DM.%26atitle%3DThe%2520tyrosine%2520kinase%2520inhibitor%2520dasatinib%2520acts%2520as%2520a%2520pharmacologic%2520on%252Foff%2520switch%2520for%2520CAR%2520T%2520cells%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26doi%3D10.1126%2Fscitranslmed.aau5907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynn, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotillo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lattin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackall, C. L.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic control of CAR-T cell function using dasatinib</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">717</span>, <span class="refDoi"> DOI: 10.1182/bloodadvances.2018028720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1182%2Fbloodadvances.2018028720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=30814055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslyhtrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&pages=711-717&author=E.+W.+Weberauthor=R.+C.+Lynnauthor=E.+Sotilloauthor=J.+Lattinauthor=P.+Xuauthor=C.+L.+Mackall&title=Pharmacologic+control+of+CAR-T+cell+function+using+dasatinib&doi=10.1182%2Fbloodadvances.2018028720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic control of CAR-T cell function using dasatinib</span></div><div class="casAuthors">Weber, Evan W.; Lynn, Rachel C.; Sotillo, Elena; Lattin, John; Xu, Peng; Mackall, Crystal L.</div><div class="citationInfo"><span class="NLM_cas:title">Blood Advances</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">711-717</span>CODEN:
                <span class="NLM_cas:coden">BALDBA</span>;
        ISSN:<span class="NLM_cas:issn">2473-9537</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Chimeric antigen receptor (CAR) T-cell therapy mediates high response rates in relapsed/refractory B-cell malignancies.  Given the similarities in the manner in which TCRs and CARs transduce intracellular signals, the author hypothesized that dasatinib would suppress CAR-T cell activation and function.  To assess the effects of dasatinib on human CAR-T cell activation, CD19.28ζ or CD19.BBζ CAR-T cells with CD19+ Nalm6-GL target cells was cocultured with escalating concns. of dasatinib.  The results provide a compelling basis for testing dasatinib in the treatment of CAR-assocd. neurotoxicity (CRES).  In summary, the novel observation that a com. available, well-tolerated oral agent directly and reversibly modulating CAR-T cell functionality has been reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprc5E8M13uR7Vg90H21EOLACvtfcHk0ljja6LS2WvsmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslyhtrfP&md5=27226fdcf4b1394c890a1449bc2fc1a7</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2018028720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2018028720%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DE.%2BW.%26aulast%3DLynn%26aufirst%3DR.%2BC.%26aulast%3DSotillo%26aufirst%3DE.%26aulast%3DLattin%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DMackall%26aufirst%3DC.%2BL.%26atitle%3DPharmacologic%2520control%2520of%2520CAR-T%2520cell%2520function%2520using%2520dasatinib%26jtitle%3DBlood%2520Adv.%26date%3D2019%26volume%3D3%26spage%3D711%26epage%3D717%26doi%3D10.1182%2Fbloodadvances.2018028720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blake, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayrhofer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, A. B.</span></span> <span> </span><span class="NLM_article-title">The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro</span>. <i>Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>127</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">330</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1016/j.clim.2008.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.clim.2008.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=18395492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmt12ru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2008&pages=330-339&issue=3&author=S.+Blakeauthor=T.+P.+Hughesauthor=G.+Mayrhoferauthor=A.+B.+Lyons&title=The+Src%2FABL+kinase+inhibitor+dasatinib+%28BMS-354825%29+inhibits+function+of+normal+human+T-lymphocytes+in+vitro&doi=10.1016%2Fj.clim.2008.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro</span></div><div class="casAuthors">Blake, Stephen; Hughes, Timothy P.; Mayrhofer, Graham; Lyons, A. Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">330-339</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Dasatinib (BMS-354825) is a Src/ABL tyrosine kinase inhibitor currently approved for the treatment of chronic myeloid leukemia.  Dasatinib has increased potency against ABL compared to the current therapy imatinib, and is effective in many cases where disease is resistant to imatinib.  Dasatinib also inhibits many Src-family tyrosine kinases.  We have demonstrated in this study that dasatinib is able to block the function of normal human T-lymphocytes in vitro at clin. relevant concns.  T-cell functions including proliferation, activation and cytokine prodn. were all uniformly inhibited in the presence of dasatinib.  We also demonstrated inhibition of TCR signaling through Src-family kinase LCK, and predicted that inhibition of LCK and other kinases involved in T-cell signaling by dasatinib is responsible for the suppression of T-cell function.  These findings raise the concern about potential T-cell inhibition in patients taking dasatinib, and suggest a possible application for the treatment of T-cell mediated immune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon59yxL66SFLVg90H21EOLACvtfcHk0ljja6LS2WvsmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmt12ru7c%253D&md5=59574b5a4a2bf4e774a152e74d57850e</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2008.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2008.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DT.%2BP.%26aulast%3DMayrhofer%26aufirst%3DG.%26aulast%3DLyons%26aufirst%3DA.%2BB.%26atitle%3DThe%2520Src%252FABL%2520kinase%2520inhibitor%2520dasatinib%2520%2528BMS-354825%2529%2520inhibits%2520function%2520of%2520normal%2520human%2520T-lymphocytes%2520in%2520vitro%26jtitle%3DClin.%2520Immunol.%26date%3D2008%26volume%3D127%26issue%3D3%26spage%3D330%26epage%3D339%26doi%3D10.1016%2Fj.clim.2008.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/medium/jm0c02054_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02054&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/medium/jm0c02054_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of the differences between conventional CD8<sup>+</sup> T cells and CD8<sup>+</sup> CAR-T cells in killing tumor cells and the architectural evolution of CARs. Conventional CD8<sup>+</sup> T cells specifically recognize the peptide–MHC class I (pMHC-I) complex on the surface of APCs through the TCR, which transduces activation signals into the intracellular compartment through CD3, enabling the initial activation of T cells. By recognizing tumor cells through an artificially introduced single-chain fragment variant (scFv), CD3ζ domain, and costimulatory domain, CAR-T cells are activated and kill tumor cells independent of MHC restriction. The structural differences of several generations of CARs are mainly located in the transmembrane and intracellular domains. The intracellular domain of the first-generation CAR lacked the costimulatory signal domain and contained only the CD3 domain. The second-generation CARs were equipped with only one of the CD28 or 4-1BB costimulatory domains to provide the second signal for the activation of CAR-T cells. The third-generation CAR structures had two costimulatory domains. The fourth-generation CAR structure may be designed to express separate cytokine transgenes (<i>e.g.</i>, IL-12). The fifth-generation CAR is yet to be developed; it is not yet clear whether it specifically refers to the approach incorporating a truncated cytoplasmic domain of IL-2 receptor β and the transcription factor STAT3-binding motif. Abbreviations: APC, antigen-presenting cell; Costim, costimulatory domain; IL-2Rβ, IL-2 receptor β; TAA, tumor-associated antigen.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02054&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/medium/jm0c02054_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic diagram of the FITC/folate-based safety switch. (A) The formation of pseudoimmunological synapses between tumors and CAR-T cells is mediated by safety switches. CAR-T cells are not activated to eliminate tumors without a FITC/folate-based safety switch, even in the presence of tumor-associated antigens. FITC/folate-based safety switches are anticipated to effectively regulate the activities of CAR-T cells to manage severe CRS. (B) The FITC/folate-based safety switch mediates the formation of pseudoimmunological synapses <i>via</i> two components of binding sites. These two components can combine with predesigned antigen receptors present on the surface of CAR-T cells as well as the abnormally expressed receptors or epitopes present on the surface of tumor cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02054&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/medium/jm0c02054_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0013.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of the FITC/Folate-Based Safety Switch: (A) General Scheme for the Synthesis of Site-Specific FITC–Antibody Conjugates <i>via</i> Click Chemistry; (B) Synthesis of FITC–Folate Conjugates</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02054&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/medium/jm0c02054_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Comparison of the anticancer and cytotoxic effects of switchable and conventional CAR-T cells. (A) Comparison of <i>in vitro</i> cytotoxicities and <i>in vivo</i> radiance quantifications in the region of interest (ROI) of conventional CAR-T cells and anti-FITC CAR-T cells with an optimized anti-CD19 AB-FITC switch. Reproduced from ref <a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a>. Published by the National Academy of Sciences. (B) Comparison of <i>in vivo</i> antitumor efficacies and <i>in vitro</i> cytotoxicities of conventional anti-Her2 CAR-T and sCAR-T cells. Reproduced with permission from ref <a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a>. Copyright 2016 Wiley-VCH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02054&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/medium/jm0c02054_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Schematic representation of rapamycin as a molecular switch. Comparisons of the cytotoxicities and anticancer effects of modified CD19-DARIC T cells and conventional CAR-T cells are shown. (A) In the absence of rapamycin, the antigen recognition domain is separated from the signal transduction domain of the CAR structure. The formation of the tripartite complex bridges the antigen recognition and signal transduction domains, restoring the CAR structure as a whole molecule. Thus, rapamycin can be used to regulate the activities of CAR-T cells remotely to avoid potentially fatal toxic effects. (B) (left) The cytotoxicity of CD19-DARIC T cells was comparable to that of conventional CD19-CAR-T cells. (right) Bioluminescence data showing superior <i>in vivo</i> activity of CD19-DARIC T cells with non-immunosuppressive rapamycin concentrations compared with conventional CD19-CAR-T cells. Reproduced with permission from ref <a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a>. Copyright 2019 American Society for Clinical Investigation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02054&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/medium/jm0c02054_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Schematic diagram of the iCas9 system and the <i>in vivo</i> antitumor activity. (A) Schematic diagram of the iCas9 system inducing apoptosis of CAR-T cells. Rimiducid and iCas9 are part of a potent suicide gene system that efficiently induces apoptosis of CAR-T cells in the case of CRS. iCas9 is a fusion protein composed of FKBP12-F36V (an F36V mutant of FK506-binding protein) and ΔCaspase9. Rimiducid is a small-molecule dimerizing agent that can bind to FKBP12-F36V with high affinity. Once rimiducid induces homodimerization of iCas9, the caspase cascade is triggered to activate caspase 3, 6, and 7, leading to apoptosis of CAR-T cells. (B) Summary of the bioluminescence signal in severe combined immunodeficient (SCID) mice engrafted either ip or sc with 3 × 10<sup>6</sup> Daudi cells labeled with FFLuc. Reproduced with permission from ref <a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a>. Copyright 2010 Springer Nature.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02054&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/medium/jm0c02054_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Schematic diagram of PROTAC technology controlling CAR degradation through the ubiquitin–proteasome system. (A) Asunaprevir, known as an HCV NS3 protease inhibitor, inhibits HCV NS3 protease from cleaving the degron from CAR. Thus, the degron together with CAR is degraded by the proteasome. (B) Administration of ARV771 or ARV825 induces CAR degradation by the E3 ligase–proteasome pathway. (C) Shield-1 displaces and exposes the degron to the proteasome by competitively binding to FKBP12-F36V. Abbreviations: Costim, costimulatory; BD, bromodomain; E2, E2 ligase; E3, E3 ligase; Ub, ubiquitin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02054&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/medium/jm0c02054_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Schematic diagram depicting distinct mechanisms of small-molecule compounds applied in safety switches. FITC–folate conjugates act as safety switches that induce the formation of pseudoimmunological synapses between tumors and CAR-T cells. Rapamycin mediates assembly of the FKBP12–rapamycin–FRB tripartite complex that bridges the extracellular antigen recognition domain with costimulatory and CD3ζ domains. Rimiducid binds to FKBP12-F36V and induces caspase-9 dimerization with consequent apoptosis of CAR-T cells. PROTAC compounds in conjunction with degrons control the surface expression levels of CARs by inducing degradation of CARs. Dasatinib prevents the activation of CAR-T cells by inhibiting the phosphorylation of Lck, CD3ζ, and ZAP70 molecules. Costim, costimulatory domain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02054/20210716/images/large/jm0c02054_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02054&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i20">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53118" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53118" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 91 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, V.</span></span> <span> </span><span class="NLM_article-title">Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2017.156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fnrclinonc.2017.156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=28975930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FltV2ksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=11-12&issue=1&author=V.+Prasad&title=Immunotherapy%3A+Tisagenlecleucel+-+the+first+approved+CAR-T-cell+therapy%3A+implications+for+payers+and+policy+makers&doi=10.1038%2Fnrclinonc.2017.156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers</span></div><div class="casAuthors">Prasad Vinay</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Clinical oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRQ-hrFX0bM7nRxY89Cm6SyfW6udTcc2ebJ0T_7eZlVebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FltV2ksg%253D%253D&md5=92bc7bd66ed2ce17917f8aec564c41ea</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2017.156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2017.156%26sid%3Dliteratum%253Aachs%26aulast%3DPrasad%26aufirst%3DV.%26atitle%3DImmunotherapy%253A%2520Tisagenlecleucel%2520-%2520the%2520first%2520approved%2520CAR-T-cell%2520therapy%253A%2520implications%2520for%2520payers%2520and%2520policy%2520makers%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D15%26issue%3D1%26spage%3D11%26epage%3D12%26doi%3D10.1038%2Fnrclinonc.2017.156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yip, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, R.</span></span> <span> </span><span class="NLM_article-title">The market for chimeric antigen receptor T cell therapies</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fnrd.2017.266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29375140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVeqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=161-162&author=A.+Yipauthor=R.+Webster&title=The+market+for+chimeric+antigen+receptor+T+cell+therapies&doi=10.1038%2Fnrd.2017.266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The market for chimeric antigen receptor T cell therapies</span></div><div class="casAuthors">Yip, Amy; Webster, Rachel M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-162</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">This article discusses the market for chimeric antigen receptor (CAR) T cell therapies, focusing on haematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCffdVEf0fN7Vg90H21EOLACvtfcHk0ljCFsFda1WfRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVeqtL0%253D&md5=d3f333b2d8a340be05f621ae355c25fa</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.266%26sid%3Dliteratum%253Aachs%26aulast%3DYip%26aufirst%3DA.%26aulast%3DWebster%26aufirst%3DR.%26atitle%3DThe%2520market%2520for%2520chimeric%2520antigen%2520receptor%2520T%2520cell%2520therapies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D161%26epage%3D162%26doi%3D10.1038%2Fnrd.2017.266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrusciel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban-Wojciuk, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcimowicz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurkowiak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gliwinski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marjanski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rzyman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biernat, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadziuszko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montesano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marek-Trzonkowska, N.</span></span> <span> </span><span class="NLM_article-title">Adoptive Cell Therapy-harnessing antigen-specific T cells to target solid tumours</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">683</span>, <span class="refDoi"> DOI: 10.3390/cancers12030683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.3390%2Fcancers12030683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVShtrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=683&author=E.+Chruscielauthor=Z.+Urban-Wojciukauthor=L.+Arcimowiczauthor=M.+Kurkowiakauthor=J.+Kowalskiauthor=M.+Gliwinskiauthor=T.+Marjanskiauthor=W.+Rzymanauthor=W.+Biernatauthor=R.+Dziadziuszkoauthor=C.+Montesanoauthor=R.+Bernardiniauthor=N.+Marek-Trzonkowska&title=Adoptive+Cell+Therapy-harnessing+antigen-specific+T+cells+to+target+solid+tumours&doi=10.3390%2Fcancers12030683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Adoptive cell therapy-harnessing antigen-specific T cells to target solid tumours</span></div><div class="casAuthors">Chrusciel, Elzbieta; Urban-Wojciuk, Zuzanna; Arcimowicz, Lukasz; Kurkowiak, Malgorzata; Kowalski, Jacek; Gliwinski, Mateusz; Marjanski, Tomasz; Rzyman, Witold; Biernat, Wojciech; Dziadziuszko, Rafal; Montesano, Carla; Bernardini, Roberta; Marek-Trzonkowska, Natalia</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">683</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">In recent years, much research has been focused on the field of adoptive cell therapies (ACT) that use native or genetically modified T cells as therapeutic tools.  Immunotherapy with T cells expressing chimeric antigen receptors (CARs) demonstrated great success in the treatment of haematol. malignancies, whereas adoptive transfer of autologous tumor infiltrating lymphocytes (TILs) proved to be highly effective in metastatic melanoma.  These encouraging results initiated many studies where ACT was tested as a treatment for various solid tumors.  In this review, we provide an overview of the challenges of T cell-based immunotherapies of solid tumors.  We describe alternative approaches for choosing the most efficient T cells for cancer treatment in terms of their tumor-specificity and phenotype.  Finally, we present strategies for improvement of anti-tumor potential of T cells, including combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhn1-ZN5FDW7Vg90H21EOLACvtfcHk0ljCFsFda1WfRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVShtrjM&md5=8593ca5d44dddfe51069aafd9310e706</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3390%2Fcancers12030683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12030683%26sid%3Dliteratum%253Aachs%26aulast%3DChrusciel%26aufirst%3DE.%26aulast%3DUrban-Wojciuk%26aufirst%3DZ.%26aulast%3DArcimowicz%26aufirst%3DL.%26aulast%3DKurkowiak%26aufirst%3DM.%26aulast%3DKowalski%26aufirst%3DJ.%26aulast%3DGliwinski%26aufirst%3DM.%26aulast%3DMarjanski%26aufirst%3DT.%26aulast%3DRzyman%26aufirst%3DW.%26aulast%3DBiernat%26aufirst%3DW.%26aulast%3DDziadziuszko%26aufirst%3DR.%26aulast%3DMontesano%26aufirst%3DC.%26aulast%3DBernardini%26aufirst%3DR.%26aulast%3DMarek-Trzonkowska%26aufirst%3DN.%26atitle%3DAdoptive%2520Cell%2520Therapy-harnessing%2520antigen-specific%2520T%2520cells%2520to%2520target%2520solid%2520tumours%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26spage%3D683%26doi%3D10.3390%2Fcancers12030683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maude, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aplenc, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacey, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahnke, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melenhorst, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rheingold, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teachey, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grupp, S. A.</span></span> <span> </span><span class="NLM_article-title">Chimeric antigen receptor T cells for sustained remissions in leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">1507</span>– <span class="NLM_lpage">1517</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1407222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1056%2FNEJMoa1407222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=25317870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVSls73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=1507-1517&author=S.+L.+Maudeauthor=N.+Freyauthor=P.+A.+Shawauthor=R.+Aplencauthor=D.+M.+Barrettauthor=N.+J.+Buninauthor=A.+Chewauthor=V.+E.+Gonzalezauthor=Z.+Zhengauthor=S.+F.+Laceyauthor=Y.+D.+Mahnkeauthor=J.+J.+Melenhorstauthor=S.+R.+Rheingoldauthor=A.+Shenauthor=D.+T.+Teacheyauthor=B.+L.+Levineauthor=C.+H.+Juneauthor=D.+L.+Porterauthor=S.+A.+Grupp&title=Chimeric+antigen+receptor+T+cells+for+sustained+remissions+in+leukemia&doi=10.1056%2FNEJMoa1407222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric antigen receptor T cells for sustained remissions in leukemia</span></div><div class="casAuthors">Maude, Shannon L.; Frey, Noelle; Shaw, Pamela A.; Aplenc, Richard; Barrett, David M.; Bunin, Nancy J.; Chew, Anne; Gonzalez, Vanessa E.; Zheng, Zhaohui; Lacey, Simon F.; Mahnke, Yolanda D.; Melenhorst, Jan J.; Rheingold, Susan R.; Shen, Angela; Teachey, David T.; Levine, Bruce L.; June, Carl H.; Porter, David L.; Grupp, Stephan A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1507-1517, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies.  Chimeric antigen receptor-modified T cells targeting CD19 may overcome many limitations of conventional therapies and induce remission in patients with refractory disease.  Methods: We infused autologous T cells transduced with a CD19-directed chimeric antigen receptor (CTL019) lentiviral vector in patients with relapsed or refractory ALL at doses of 0.76 × 106 to 20.6 × 106 CTL019 cells per kg of body wt.  Patients were monitored for a response, toxic effects, and the expansion and persistence of circulating CTL019 T cells.  Results: A total of 30 children and adults received CTL019.  Complete remission was achieved in 27 patients (90%), including 2 patients with blinatumomab-refractory disease and 15 who had undergone stem-cell transplantation.  CTL019 cells proliferated in vivo and were detectable in the blood, bone marrow, and cerebrospinal fluid of patients who had a response.  Sustained remission was achieved with a 6-mo event-free survival rate of 67% (95% confidence interval [CI], 51 to 88) and an overall survival rate of 78% (95% CI, 65 to 95).  At 6 mo, the probability that a patient would have persistence of CTL019 was 68% (95% CI, 50 to 92) and the probability that a patient would have relapse-free B-cell aplasia was 73% (95% CI, 57 to 94).  All the patients had the cytokine-release syndrome.  Severe cytokine-release syndrome, which developed in 27% of the patients, was assocd. with a higher disease burden before infusion and was effectively treated with the anti-interleukin-6 receptor antibody tocilizumab.  Conclusions: Chimeric antigen receptor-modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL.  CTL019 was assocd. with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 mo were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMldO024V5VrVg90H21EOLACvtfcHk0lh3Jy7R3nVWDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVSls73K&md5=7f13aaa25ae118901d3bec614b07cc3a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1407222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1407222%26sid%3Dliteratum%253Aachs%26aulast%3DMaude%26aufirst%3DS.%2BL.%26aulast%3DFrey%26aufirst%3DN.%26aulast%3DShaw%26aufirst%3DP.%2BA.%26aulast%3DAplenc%26aufirst%3DR.%26aulast%3DBarrett%26aufirst%3DD.%2BM.%26aulast%3DBunin%26aufirst%3DN.%2BJ.%26aulast%3DChew%26aufirst%3DA.%26aulast%3DGonzalez%26aufirst%3DV.%2BE.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DLacey%26aufirst%3DS.%2BF.%26aulast%3DMahnke%26aufirst%3DY.%2BD.%26aulast%3DMelenhorst%26aufirst%3DJ.%2BJ.%26aulast%3DRheingold%26aufirst%3DS.%2BR.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DTeachey%26aufirst%3DD.%2BT.%26aulast%3DLevine%26aufirst%3DB.%2BL.%26aulast%3DJune%26aufirst%3DC.%2BH.%26aulast%3DPorter%26aufirst%3DD.%2BL.%26aulast%3DGrupp%26aufirst%3DS.%2BA.%26atitle%3DChimeric%2520antigen%2520receptor%2520T%2520cells%2520for%2520sustained%2520remissions%2520in%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D1507%26epage%3D1517%26doi%3D10.1056%2FNEJMoa1407222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svoboda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasta, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mato, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anak, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogdon, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruteanu-Malinici, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhoj, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landsburg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacey, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melenhorst, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, C. H.</span></span> <span> </span><span class="NLM_article-title">Chimeric antigen receptor T cells in refractory B-Cell lymphomas</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">2545</span>– <span class="NLM_lpage">2554</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1708566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1056%2FNEJMoa1708566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29226764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=2545-2554&author=S.+J.+Schusterauthor=J.+Svobodaauthor=E.+A.+Chongauthor=S.+D.+Nastaauthor=A.+R.+Matoauthor=O.+Anakauthor=J.+L.+Brogdonauthor=I.+Pruteanu-Maliniciauthor=V.+Bhojauthor=D.+Landsburgauthor=M.+Wasikauthor=B.+L.+Levineauthor=S.+F.+Laceyauthor=J.+J.+Melenhorstauthor=D.+L.+Porterauthor=C.+H.+June&title=Chimeric+antigen+receptor+T+cells+in+refractory+B-Cell+lymphomas&doi=10.1056%2FNEJMoa1708566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric antigen receptor T cells in refractory B-cell lymphomas</span></div><div class="casAuthors">Schuster, Stephen J.; Svoboda, Jakub; Chong, Elise A.; Nasta, Sunita D.; Mato, Anthony R.; Anak, Ozlem; Brogdon, Jennifer L.; Pruteanu-Malinici, Iulian; Bhoj, Vijay; Landsburg, Daniel; Wasik, Mariusz; Levine, Bruce L.; Lacey, Simon F.; Melenhorst, Jan J.; Porter, David L.; June, Carl H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2545-2554</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Patients with diffuse large B-cell lymphoma or follicular lymphoma that is refractory to or that relapses after immunochemotherapy and transplantation have a poor prognosis.  High response rates have been reported with the use of T cells modified by chimeric antigen receptor (CAR) that target CD19 in B-cell cancers, although data regarding B-cell lymphomas are limited. methods We used autologous T cells that express a CD19-directed CAR (CTL019) to treat patients with diffuse large B-cell lymphoma or follicular lymphoma that had relapsed or was refractory to previous treatments.  Patients were monitored for response to treatment, toxic effects, the expansion and persistence of CTL019 cells in vivo, and immune recovery. results A total of 28 adult patients with lymphoma received CTL019 cells, and 18 of 28 had a response (64%; 95% confidence interval [CI], 44 to 81).  Complete remission occurred in 6 of 14 patients with diffuse large B-cell lymphoma (43%; 95% CI, 18 to 71) and 10 of 14 patients with follicular lymphoma (71%; 95% CI, 42 to 92).  CTL019 cells proliferated in vivo and were detectable in the blood and bone marrow of patients who had a response and patients who did not have a response.  Sustained remissions were achieved, and at a median follow-up of 28.6 mo, 86% of patients with diffuse large B-cell lymphoma who had a response (95% CI, 33 to 98) and 89% of patients with follicular lymphoma who had a response (95% CI, 43 to 98) had maintained the response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZL6YpNA3zJbVg90H21EOLACvtfcHk0lh3Jy7R3nVWDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGjtbs%253D&md5=ccaf409a1f47453d2b95ba8376fcf035</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1708566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1708566%26sid%3Dliteratum%253Aachs%26aulast%3DSchuster%26aufirst%3DS.%2BJ.%26aulast%3DSvoboda%26aufirst%3DJ.%26aulast%3DChong%26aufirst%3DE.%2BA.%26aulast%3DNasta%26aufirst%3DS.%2BD.%26aulast%3DMato%26aufirst%3DA.%2BR.%26aulast%3DAnak%26aufirst%3DO.%26aulast%3DBrogdon%26aufirst%3DJ.%2BL.%26aulast%3DPruteanu-Malinici%26aufirst%3DI.%26aulast%3DBhoj%26aufirst%3DV.%26aulast%3DLandsburg%26aufirst%3DD.%26aulast%3DWasik%26aufirst%3DM.%26aulast%3DLevine%26aufirst%3DB.%2BL.%26aulast%3DLacey%26aufirst%3DS.%2BF.%26aulast%3DMelenhorst%26aufirst%3DJ.%2BJ.%26aulast%3DPorter%26aufirst%3DD.%2BL.%26aulast%3DJune%26aufirst%3DC.%2BH.%26atitle%3DChimeric%2520antigen%2520receptor%2520T%2520cells%2520in%2520refractory%2520B-Cell%2520lymphomas%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D2545%26epage%3D2554%26doi%3D10.1056%2FNEJMoa1708566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">Engineering CAR-T cells</span>. <i>Biomarker Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">22</span>, <span class="refDoi"> DOI: 10.1186/s40364-017-0102-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1186%2Fs40364-017-0102-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=28652918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BC1cjitFSgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=22&author=C.+Zhangauthor=J.+Liuauthor=J.+F.+Zhongauthor=X.+Zhang&title=Engineering+CAR-T+cells&doi=10.1186%2Fs40364-017-0102-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering CAR-T cells</span></div><div class="casAuthors">Zhang Cheng; Liu Jun; Zhang Xi; Zhong Jiang F</div><div class="citationInfo"><span class="NLM_cas:title">Biomarker research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">22</span>
        ISSN:<span class="NLM_cas:issn">2050-7771</span>.
    </div><div class="casAbstract">Chimeric antigen receptor redirected T cells (CAR-T cells) have achieved inspiring outcomes in patients with B cell malignancies, and are now being investigated in other hematologic malignancies and solid tumors.  CAR-T cells are generated by the T cells from patients' or donors' blood.  After the T cells are expanded and genetically modified, they are reinfused into the patients.  However, many challenges still need to be resolved in order for this technology to gain widespread adoption.  In this review, we first discuss the structure and evolution of chimeric antigen receptors.  We then report on the tools used for production of CAR-T cells.  Finally, we address the challenges posed by CAR-T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgIN211pEHHq-9TkgmBqTqfW6udTcc2eYnTZGu2FEOarntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjitFSgtg%253D%253D&md5=1f2973140d40b7b5a2164b40229e874e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1186%2Fs40364-017-0102-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40364-017-0102-y%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhong%26aufirst%3DJ.%2BF.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DEngineering%2520CAR-T%2520cells%26jtitle%3DBiomarker%2520Res.%26date%3D2017%26volume%3D5%26spage%3D22%26doi%3D10.1186%2Fs40364-017-0102-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotti, G.</span></span> <span> </span><span class="NLM_article-title">Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy</span>. <i>Expert Opin. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">873</span>, <span class="refDoi"> DOI: 10.1517/14712598.2011.573476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1517%2F14712598.2011.573476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=21463133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFOnsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=855-873&author=C.+A.+Ramosauthor=G.+Dotti&title=Chimeric+antigen+receptor+%28CAR%29-engineered+lymphocytes+for+cancer+therapy&doi=10.1517%2F14712598.2011.573476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy</span></div><div class="casAuthors">Ramos, Carlos A.; Dotti, Gianpietro</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">855-873</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Chimeric antigen receptors (CARs) usually combine the antigen binding site of a monoclonal antibody with the signal activating machinery of a T cell, freeing antigen recognition from MHC restriction and thus breaking one of the barriers to more widespread application of cellular therapy.  Similar to treatment strategies employing monoclonal antibodies, T cells expressing CARs are highly targeted, but addnl. offer the potential benefits of active trafficking to tumor sites, in vivo expansion and long-term persistence.  Furthermore, gene transfer allows the introduction of countermeasures to tumor immune evasion and of safety mechanisms.Areas covered: The basic structure of so-called first and later generation CARs and their potential advantages over other immune therapy systems.  How these mols. can be grafted into immune cells (including retroviral and non-retroviral transduction methods) and strategies to improve the in vivo persistence and function of immune cells expressing CARs.  Examples of tumor-assocd. antigens that have been targeted in preclin. models and clin. experience with these modified cells.  Safety issues surrounding CAR gene transfer into T cells and potential solns. to them.Expert opinion: Because of recent advances in immunol., genetics and cell processing, CAR-modified T cells will likely play an increasing role in the cellular therapy of cancer, chronic infections and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5rBLFV7PoYLVg90H21EOLACvtfcHk0lh-G_6pAa2lmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFOnsrw%253D&md5=b09ede2a6e2b1d25d532953f2fba5514</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1517%2F14712598.2011.573476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.2011.573476%26sid%3Dliteratum%253Aachs%26aulast%3DRamos%26aufirst%3DC.%2BA.%26aulast%3DDotti%26aufirst%3DG.%26atitle%3DChimeric%2520antigen%2520receptor%2520%2528CAR%2529-engineered%2520lymphocytes%2520for%2520cancer%2520therapy%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2011%26volume%3D11%26spage%3D855%26epage%3D873%26doi%3D10.1517%2F14712598.2011.573476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eshhar, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waks, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, D. G.</span></span> <span> </span><span class="NLM_article-title">Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">720</span>– <span class="NLM_lpage">724</span>, <span class="refDoi"> DOI: 10.1073/pnas.90.2.720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1073%2Fpnas.90.2.720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=8421711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADyaK3sXitVCkurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=720-724&author=Z.+Eshharauthor=T.+Waksauthor=G.+Grossauthor=D.+G.+Schindler&title=Specific+activation+and+targeting+of+cytotoxic+lymphocytes+through+chimeric+single+chains+consisting+of+antibody-binding+domains+and+the+gamma+or+zeta+subunits+of+the+immunoglobulin+and+T-cell+receptors&doi=10.1073%2Fpnas.90.2.720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors</span></div><div class="casAuthors">Eshhar, Zelig; Waks, Tova; Gross, Gideon; Schindler, Daniel G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">720-4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The generation of tumor-specific lymphocytes and their use in adoptive immunotherapy is limited to a few malignancies because most spontaneous tumors are very weak or not at all immunogenic.  On the other hand, many antitumor antibodies have been described which bind tumor-assocd. antigens shared among tumors of the same histol.  Combining the variable regions (Fv) of an antibody with the const. regions of the T-cell receptor (TCR) chains results in chimeric genes endowing T lymphocytes with antibody-type specificity, potentially allowing cellular adoptive immunotherapy against types of tumors not previously possible.  To generalize and extend this approach to addnl. lymphocyte-activating mols., the designed and constructed chimeric genes composed of a single-chain Fv domain (scFv) of an antibody linked with γ or ζ chains, the common signal-transducing subunits of the Ig receptor and the TCR.  Such chimeric genes contg. the Fv region of an anti-trinitophenyl antibody could be expressed as functional surface receptors in a cytolytic T-cell hybridoma.  They triggered interleukin 2 secretion upon encountering antigen and mediated non-major-histocompatibility-complex-restricted hapten-specific target cell lysis.  Such chimeric receptors can be exploited to provide T cells and other effector lymphocytes, such as natural killer cells, with antibody-type recognition directly coupled to cellular activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYNQLwO2EOMrVg90H21EOLACvtfcHk0lh-G_6pAa2lmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXitVCkurY%253D&md5=224226a20d25ffc9cf4ce40257d14c53</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.90.2.720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.90.2.720%26sid%3Dliteratum%253Aachs%26aulast%3DEshhar%26aufirst%3DZ.%26aulast%3DWaks%26aufirst%3DT.%26aulast%3DGross%26aufirst%3DG.%26aulast%3DSchindler%26aufirst%3DD.%2BG.%26atitle%3DSpecific%2520activation%2520and%2520targeting%2520of%2520cytotoxic%2520lymphocytes%2520through%2520chimeric%2520single%2520chains%2520consisting%2520of%2520antibody-binding%2520domains%2520and%2520the%2520gamma%2520or%2520zeta%2520subunits%2520of%2520the%2520immunoglobulin%2520and%2520T-cell%2520receptors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1993%26volume%3D90%26spage%3D720%26epage%3D724%26doi%3D10.1073%2Fpnas.90.2.720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadelain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brentjens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riviere, I.</span></span> <span> </span><span class="NLM_article-title">The promise and potential pitfalls of chimeric antigen receptors</span>. <i>Curr. Opin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1016/j.coi.2009.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.coi.2009.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=19327974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVCgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=215-223&author=M.+Sadelainauthor=R.+Brentjensauthor=I.+Riviere&title=The+promise+and+potential+pitfalls+of+chimeric+antigen+receptors&doi=10.1016%2Fj.coi.2009.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The promise and potential pitfalls of chimeric antigen receptors</span></div><div class="casAuthors">Sadelain, Michel; Brentjens, Renier; Riviere, Isabelle</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">215-223</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  One important purpose of T cell engineering is to generate tumor-targeted T cells through the genetic transfer of antigen-specific receptors, which consist of either physiol., MHC-restricted T cell receptors (TCRs) or non MHC-restricted chimeric antigen receptors (CARs).  CARs combine antigen-specificity and T cell activating properties in a single fusion mol.  First generation CARs, which included as their signaling domain the cytoplasmic region of the CD3ζ or Fc receptor γ chain, effectively redirected T cell cytotoxicity but failed to enable T cell proliferation and survival upon repeated antigen exposure.  Receptors encompassing both CD28 and CD3ζ are the prototypes for second generation CARs, which are now rapidly expanding to a diverse array of receptors with different functional properties.  First generation CARs have been tested in phase I clin. studies in patients with ovarian cancer, renal cancer, lymphoma, and neuroblastoma, where they have induced modest responses.  Second generation CARs, which are just now entering the clin. arena in the B cell malignancies and other cancers, will provide a more significant test for this approach.  If the immunogenicity of CARs can be averted, the versatility of their design and HLA-independent antigen recognition will make CARs tools of choice for T cell engineering for the development of targeted cancer immunotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-UZMlP4fPebVg90H21EOLACvtfcHk0lh-G_6pAa2lmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVCgtLc%253D&md5=ab5443309173bbde22c679dc2f5090e8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.coi.2009.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coi.2009.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DSadelain%26aufirst%3DM.%26aulast%3DBrentjens%26aufirst%3DR.%26aulast%3DRiviere%26aufirst%3DI.%26atitle%3DThe%2520promise%2520and%2520potential%2520pitfalls%2520of%2520chimeric%2520antigen%2520receptors%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2009%26volume%3D21%26spage%3D215%26epage%3D223%26doi%3D10.1016%2Fj.coi.2009.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savoldo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mims, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrum, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamble, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollard, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grilley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heslop, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotti, G.</span></span> <span> </span><span class="NLM_article-title">CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">1822</span>– <span class="NLM_lpage">1826</span>, <span class="refDoi"> DOI: 10.1172/JCI46110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1172%2FJCI46110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=21540550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvFKnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=1822-1826&author=B.+Savoldoauthor=C.+A.+Ramosauthor=E.+Liuauthor=M.+P.+Mimsauthor=M.+J.+Keatingauthor=G.+Carrumauthor=R.+T.+Kambleauthor=C.+M.+Bollardauthor=A.+P.+Geeauthor=Z.+Meiauthor=H.+Liuauthor=B.+Grilleyauthor=C.+M.+Rooneyauthor=H.+E.+Heslopauthor=M.+K.+Brennerauthor=G.+Dotti&title=CD28+costimulation+improves+expansion+and+persistence+of+chimeric+antigen+receptor-modified+T+cells+in+lymphoma+patients&doi=10.1172%2FJCI46110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients</span></div><div class="casAuthors">Savoldo, Barbara; Ramos, Carlos Almeida; Liu, Enli; Mims, Martha P.; Keating, Michael J.; Carrum, George; Kamble, Rammurti T.; Bollard, Catherine M.; Gee, Adrian P.; Mei, Zhuyong; Liu, Hao; Grilley, Bambi; Rooney, Cliona M.; Heslop, Helen E.; Brenner, Malcolm K.; Dotti, Gianpietro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1822-1826</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Targeted T cell immunotherapies using engineered T lymphocytes expressing tumor-directed chimeric antigen receptors (CARs) are designed to benefit patients with cancer.  Although incorporation of costimulatory endodomains within these CARs increases the proliferation of CAR-redirected T lymphocytes, it has proven difficult to draw definitive conclusions about the specific effects of costimulatory endodomains on the expansion, persistence, and antitumor effectiveness of CAR-redirected T cells in human subjects, owing to the lack of side-by-side comparisons with T cells bearing only a single signaling domain.  We therefore designed a study that allowed us to directly measure the consequences of adding a costimulatory endodomain to CAR-redirected T cells.  Patients with B cell lymphomas were simultaneously infused with 2 autologous T cell products expressing CARs with the same specificity for the CD19 antigen, present on most B cell malignancies.  One CAR encoded both the costimulatory CD28 and the ζ-endodomains, while the other encoded only the ζ-endodomain.  CAR+ T cells contg. the CD28 endodomain showed strikingly enhanced expansion and persistence compared with CAR+ T cells lacking this endodomain.  These results demonstrate the superiority of CARs with dual signal domains and confirm a method of comparing CAR-modified T cells within individual patients, thereby avoiding patient-to-patient variability and accelerating the development of optimal T cell immunotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK9WGbnfmoGrVg90H21EOLACvtfcHk0lhfN4SqvXI8tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvFKnt7o%253D&md5=7ec0c6af57071880831b0a7fa17caa7b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1172%2FJCI46110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI46110%26sid%3Dliteratum%253Aachs%26aulast%3DSavoldo%26aufirst%3DB.%26aulast%3DRamos%26aufirst%3DC.%2BA.%26aulast%3DLiu%26aufirst%3DE.%26aulast%3DMims%26aufirst%3DM.%2BP.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DCarrum%26aufirst%3DG.%26aulast%3DKamble%26aufirst%3DR.%2BT.%26aulast%3DBollard%26aufirst%3DC.%2BM.%26aulast%3DGee%26aufirst%3DA.%2BP.%26aulast%3DMei%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DGrilley%26aufirst%3DB.%26aulast%3DRooney%26aufirst%3DC.%2BM.%26aulast%3DHeslop%26aufirst%3DH.%2BE.%26aulast%3DBrenner%26aufirst%3DM.%2BK.%26aulast%3DDotti%26aufirst%3DG.%26atitle%3DCD28%2520costimulation%2520improves%2520expansion%2520and%2520persistence%2520of%2520chimeric%2520antigen%2520receptor-modified%2520T%2520cells%2520in%2520lymphoma%2520patients%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26spage%3D1822%26epage%3D1826%26doi%3D10.1172%2FJCI46110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milone, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binder, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teachey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samanta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakhal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloss, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danet-Desnoyers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campana, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grupp, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, C. H.</span></span> <span> </span><span class="NLM_article-title">Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1453</span>– <span class="NLM_lpage">1464</span>, <span class="refDoi"> DOI: 10.1038/mt.2009.83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fmt.2009.83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=19384291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=1453-1464&author=M.+C.+Miloneauthor=J.+D.+Fishauthor=C.+Carpenitoauthor=R.+G.+Carrollauthor=G.+K.+Binderauthor=D.+Teacheyauthor=M.+Samantaauthor=M.+Lakhalauthor=B.+Glossauthor=G.+Danet-Desnoyersauthor=D.+Campanaauthor=J.+L.+Rileyauthor=S.+A.+Gruppauthor=C.+H.+June&title=Chimeric+receptors+containing+CD137+signal+transduction+domains+mediate+enhanced+survival+of+T+cells+and+increased+antileukemic+efficacy+in+vivo&doi=10.1038%2Fmt.2009.83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo</span></div><div class="casAuthors">Milone, Michael C.; Fish, Jonathan D.; Carpenito, Carmine; Carroll, Richard G.; Binder, Gwendolyn K.; Teachey, David; Samanta, Minu; Lakhal, Mehdi; Gloss, Brian; Danet-Desnoyers, Gwenn; Campana, Dario; Riley, James L.; Grupp, Stephan A.; June, Carl H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1453-1464</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Persistence of T cells engineered with chimeric antigen receptors (CARs) has been a major barrier to use of these cells for molecularly targeted adoptive immunotherapy.  To address this issue, we created a series of CARs that contain the T cell receptor-ζ (TCR-ζ) signal transduction domain with the CD28 and/or CD137 (4-1BB) intracellular domains in tandem.  After short-term expansion, primary human T cells were subjected to lentiviral gene transfer, resulting in large nos. of cells with >85% CAR expression.  In an immunodeficient mouse xenograft model of primary human pre-B-cell acute lymphoblastic leukemia, human T cells expressing anti-CD19 CARs contg. CD137 exhibited the greatest antileukemic efficacy and prolonged (>6 mo) survival in vivo, and were significantly more effective than cells expressing CARs contg. TCR-ζ alone or CD28-ζ signaling receptors.  We uncovered a previously unrecognized, antigen-independent effect of CARs expressing the CD137 cytoplasmic domain that likely contributes to the enhanced antileukemic efficacy and survival in tumor bearing mice.  Furthermore, our studies revealed significant discrepancies between in vitro and in vivo surrogate measures of CAR efficacy.  Together these results suggest that incorporation of the CD137 signaling domain in CARs should improve the persistence of CARs in the hematol. malignancies and hence maximize their antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOdpTM_J3qa7Vg90H21EOLACvtfcHk0lhfN4SqvXI8tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVWqsLk%253D&md5=29d09c68851cdfd2953ac10dfcfb8be9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fmt.2009.83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2009.83%26sid%3Dliteratum%253Aachs%26aulast%3DMilone%26aufirst%3DM.%2BC.%26aulast%3DFish%26aufirst%3DJ.%2BD.%26aulast%3DCarpenito%26aufirst%3DC.%26aulast%3DCarroll%26aufirst%3DR.%2BG.%26aulast%3DBinder%26aufirst%3DG.%2BK.%26aulast%3DTeachey%26aufirst%3DD.%26aulast%3DSamanta%26aufirst%3DM.%26aulast%3DLakhal%26aufirst%3DM.%26aulast%3DGloss%26aufirst%3DB.%26aulast%3DDanet-Desnoyers%26aufirst%3DG.%26aulast%3DCampana%26aufirst%3DD.%26aulast%3DRiley%26aufirst%3DJ.%2BL.%26aulast%3DGrupp%26aufirst%3DS.%2BA.%26aulast%3DJune%26aufirst%3DC.%2BH.%26atitle%3DChimeric%2520receptors%2520containing%2520CD137%2520signal%2520transduction%2520domains%2520mediate%2520enhanced%2520survival%2520of%2520T%2520cells%2520and%2520increased%2520antileukemic%2520efficacy%2520in%2520vivo%26jtitle%3DMol.%2520Ther.%26date%3D2009%26volume%3D17%26spage%3D1453%26epage%3D1464%26doi%3D10.1038%2Fmt.2009.83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Govers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebestyen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roszik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Brakel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrevoets, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szoor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panoutsopoulou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broertjes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vereb, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szollosi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debets, R.</span></span> <span> </span><span class="NLM_article-title">TCRs genetically linked to CD28 and CD3epsilon do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>193</i></span>,  <span class="NLM_fpage">5315</span>– <span class="NLM_lpage">5326</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1302074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.4049%2Fjimmunol.1302074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=25320284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyjtbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2014&pages=5315-5326&author=C.+Goversauthor=Z.+Sebestyenauthor=J.+Roszikauthor=M.+van+Brakelauthor=C.+Berrevoetsauthor=A.+Szoorauthor=K.+Panoutsopoulouauthor=M.+Broertjesauthor=T.+Vanauthor=G.+Verebauthor=J.+Szollosiauthor=R.+Debets&title=TCRs+genetically+linked+to+CD28+and+CD3epsilon+do+not+mispair+with+endogenous+TCR+chains+and+mediate+enhanced+T+cell+persistence+and+anti-melanoma+activity&doi=10.4049%2Fjimmunol.1302074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">TCRs Genetically Linked to CD28 and CD3ε Do Not Mispair with Endogenous TCR Chains and Mediate Enhanced T Cell Persistence and Anti-Melanoma Activity</span></div><div class="casAuthors">Govers, Coen; Sebestyen, Zsolt; Roszik, Janos; van Brakel, Mandy; Berrevoets, Cor; Szoeor, Arpad; Panoutsopoulou, Konstantina; Broertjes, Marieke; Van, Tan; Vereb, Gyoergy; Szoellosi, Janos; Debets, Reno</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5315-5326</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Adoptive transfer of T cells that are gene engineered to express a defined TCR represents a feasible and promising therapy for patients with tumors.  However, TCR gene therapy is hindered by the transient presence and effectiveness of transferred T cells, which are anticipated to be improved by adequate T cell costimulation.  In this article, we report the identification and characterization of a novel two-chain TCR linked to CD28 and CD3ε (i.e., TCR:28ε).  This modified TCR demonstrates enhanced binding of peptide-MHC and mediates enhanced T cell function following stimulation with peptide compared with wild-type TCR.  Surface expression of TCR:28ε depends on the transmembrane domain of CD28, whereas T cell functions depend on the intracellular domains of both CD28 and CD3ε, with IL-2 prodn. showing dependency on CD28:LCK binding.  TCR:28ε, but not wild-type TCR, induces detectable immune synapses in primary human T cells, and such immune synapses show significantly enhanced accumulation of TCR transgenes and markers of early TCR signaling, such as phosphorylated LCK and ERK.  Importantly, TCR:28ε does not show signs of off-target recognition, as evidenced by lack of TCR mispairing, as well as preserved specificity.  Notably, when testing TCR:28ε in immune-competent mice, we obsd. a drastic increase in T cell survival, which was accompanied by regression of large melanomas with limited recurrence.  Our data argue that TCR transgenes that contain CD28, and, thereby, may provide T cell costimulation in an immune-suppressive environment, represent candidate receptors to treat patients with tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQAd2X83-fFrVg90H21EOLACvtfcHk0lgq2BEiJZF_lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyjtbrO&md5=b71212b64adedea30d15ffdb7df605e6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1302074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1302074%26sid%3Dliteratum%253Aachs%26aulast%3DGovers%26aufirst%3DC.%26aulast%3DSebestyen%26aufirst%3DZ.%26aulast%3DRoszik%26aufirst%3DJ.%26aulast%3Dvan%2BBrakel%26aufirst%3DM.%26aulast%3DBerrevoets%26aufirst%3DC.%26aulast%3DSzoor%26aufirst%3DA.%26aulast%3DPanoutsopoulou%26aufirst%3DK.%26aulast%3DBroertjes%26aufirst%3DM.%26aulast%3DVan%26aufirst%3DT.%26aulast%3DVereb%26aufirst%3DG.%26aulast%3DSzollosi%26aufirst%3DJ.%26aulast%3DDebets%26aufirst%3DR.%26atitle%3DTCRs%2520genetically%2520linked%2520to%2520CD28%2520and%2520CD3epsilon%2520do%2520not%2520mispair%2520with%2520endogenous%2520TCR%2520chains%2520and%2520mediate%2520enhanced%2520T%2520cell%2520persistence%2520and%2520anti-melanoma%2520activity%26jtitle%3DJ.%2520Immunol.%26date%3D2014%26volume%3D193%26spage%3D5315%26epage%3D5326%26doi%3D10.4049%2Fjimmunol.1302074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carpenito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milone, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonet, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakhal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suhoski, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varela-Rohena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haines, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitjan, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albelda, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, C. H.</span></span> <span> </span><span class="NLM_article-title">Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">3360</span>– <span class="NLM_lpage">3365</span>, <span class="refDoi"> DOI: 10.1073/pnas.0813101106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1073%2Fpnas.0813101106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=19211796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivF2jsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=3360-3365&author=C.+Carpenitoauthor=M.+C.+Miloneauthor=R.+Hassanauthor=J.+C.+Simonetauthor=M.+Lakhalauthor=M.+M.+Suhoskiauthor=A.+Varela-Rohenaauthor=K.+M.+Hainesauthor=D.+F.+Heitjanauthor=S.+M.+Albeldaauthor=R.+G.+Carrollauthor=J.+L.+Rileyauthor=I.+Pastanauthor=C.+H.+June&title=Control+of+large%2C+established+tumor+xenografts+with+genetically+retargeted+human+T+cells+containing+CD28+and+CD137+domains&doi=10.1073%2Fpnas.0813101106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains</span></div><div class="casAuthors">Carpenito, Carmine; Milone, Michael C.; Hassan, Raffit; Simonet, Jacqueline C.; Lakhal, Mehdi; Suhoski, Megan M.; Varela-Rohena, Angel; Haines, Kathleen M.; Heitjan, Daniel F.; Albelda, Steven M.; Carroll, Richard G.; Riley, James L.; Pastan, Ira; June, Carl H.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3360-3365</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Mesothelin is a cell-surface mol. over-expressed on a large fraction of carcinomas, and thus is an attractive target of immunotherapy.  A molecularly targeted therapy for these cancers was created by engineering T cells to express a chimeric receptor with high affinity for human mesothelin.  Lentiviral vectors were used to express a single-chain variable fragment that binds mesothelin and that is fused to signaling domains derived from T-cell receptor zeta, CD28, and CD137 (4-1BB).  When stimulated by mesothelin, lentivirally transduced T cells were induced to proliferate, express the antiapoptotic gene Bcl-XL, and secrete multiple cytokines, all features characteristic of central memory T cells.  When transferred intratumorally or i.v. into NOD/scid/IL2rγ-/- mice engrafted with large pre-established tumors, the engineered T cells reduced the tumor burden, and in some cases resulted in complete eradication of the tumors at low effector-to-target ratios.  Incorporation of the CD137 signaling domain specifically reprogrammed cells for multifunctional cytokine secretion and enhanced persistence of T cells.  These findings have important implications for adoptive immunotherapy of cancer, esp. in the context of poorly immunogenic tumors.  Genetically redirected T cells have promise of targeting T lymphocytes to tumor antigens, confer resistance to the tumor microenvironment, and providing immunosurveillance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1x8gxtesA8rVg90H21EOLACvtfcHk0lgq2BEiJZF_lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivF2jsbw%253D&md5=9c2e1243ffc503022d04ed1fa465fa82</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0813101106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0813101106%26sid%3Dliteratum%253Aachs%26aulast%3DCarpenito%26aufirst%3DC.%26aulast%3DMilone%26aufirst%3DM.%2BC.%26aulast%3DHassan%26aufirst%3DR.%26aulast%3DSimonet%26aufirst%3DJ.%2BC.%26aulast%3DLakhal%26aufirst%3DM.%26aulast%3DSuhoski%26aufirst%3DM.%2BM.%26aulast%3DVarela-Rohena%26aufirst%3DA.%26aulast%3DHaines%26aufirst%3DK.%2BM.%26aulast%3DHeitjan%26aufirst%3DD.%2BF.%26aulast%3DAlbelda%26aufirst%3DS.%2BM.%26aulast%3DCarroll%26aufirst%3DR.%2BG.%26aulast%3DRiley%26aufirst%3DJ.%2BL.%26aulast%3DPastan%26aufirst%3DI.%26aulast%3DJune%26aufirst%3DC.%2BH.%26atitle%3DControl%2520of%2520large%252C%2520established%2520tumor%2520xenografts%2520with%2520genetically%2520retargeted%2520human%2520T%2520cells%2520containing%2520CD28%2520and%2520CD137%2520domains%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D3360%26epage%3D3365%26doi%3D10.1073%2Fpnas.0813101106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hombach, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abken, H.</span></span> <span> </span><span class="NLM_article-title">Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation</span>. <i>Hum. Gene Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.1089/hum.2012.247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1089%2Fhum.2012.247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=23350854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktleltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=259-269&author=A.+A.+Hombachauthor=M.+Chmielewskiauthor=G.+Rapplauthor=H.+Abken&title=Adoptive+immunotherapy+with+redirected+T+cells+produces+CCR7-+cells+that+are+trapped+in+the+periphery+and+benefit+from+combined+CD28-OX40+costimulation&doi=10.1089%2Fhum.2012.247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Adoptive Immunotherapy with Redirected T Cells Produces CCR7- Cells That Are Trapped in the Periphery and Benefit from Combined CD28-OX40 Costimulation</span></div><div class="casAuthors">Hombach, Andreas A.; Chmielewski, Markus; Rappl, Gunter; Abken, Hinrich</div><div class="citationInfo"><span class="NLM_cas:title">Human Gene Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">259-269</span>CODEN:
                <span class="NLM_cas:coden">HGTHE3</span>;
        ISSN:<span class="NLM_cas:issn">1043-0342</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Adoptive therapy of cancer with genetically redirected T cells showed spectacular efficacy in recent trials.  A body of preclin. and clin. data indicate that young effector and central memory T cells perform superior in a primary antitumor response; repetitive antigen engagement, however, drives T-cell maturation to terminally differentiated cells assocd. with the loss of CCR7, which enables T cells to persist in peripheral tissues.  In this work, we explored the antitumor efficacy of CCR7- T cells when redirected in an antigen-dependent fashion by a chimeric antigen receptor (CAR) toward tumors in the periphery.  CAR-engineered CCR7- T cells more efficiently accumulated at the tumor site, secreted more IFN-γ, expressed higher amts. of cytotoxic mols., and showed superior tumor cell lysis compared to the younger CCR7+ cells.  CCR7- T cells, however, were more prone to spontaneous and activation-induced cell death, which could be counteracted by simultaneous CD28 and OX40 (CD134) costimulation.  Consequently, the combined CD28-ζ-OX40 signaling CAR rescued CCR7- T cells from apoptosis, which then produced more efficient antitumor efficacy than CCR7+ T cells redirected by the same CAR.  Data suggest that T-cell therapy will benefit from combined CD28-ζ-OX40 stimulation in the long-term by rescuing continuously generated CCR7- T cells for an antitumor attack.  Hombach and colleagues explore the antitumor efficacy of T cells lacking chemokine receptor CCR7 (CCR7- T cells) redirected by a chimeric antigen receptor (CAR) toward peripheral tumors.  Although antigen-specific CAR-engineered CCR7- T cells were more prone to spontaneous and activation-induced cell death, they accumulated more efficiently at tumor sites, secreted more interferon-γ, expressed higher amts. of cytotoxic mols., and showed superior tumor cell lysis.  CCR7- T cell activation-induced cell death was counteracted when cells were instead redirected by a combined CD28 and OX40 costimulatory CAR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ7M6v2CO6VrVg90H21EOLACvtfcHk0lgq2BEiJZF_lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktleltbk%253D&md5=fbb4d165116b00036bf9c7861f9fa70c</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1089%2Fhum.2012.247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fhum.2012.247%26sid%3Dliteratum%253Aachs%26aulast%3DHombach%26aufirst%3DA.%2BA.%26aulast%3DChmielewski%26aufirst%3DM.%26aulast%3DRappl%26aufirst%3DG.%26aulast%3DAbken%26aufirst%3DH.%26atitle%3DAdoptive%2520immunotherapy%2520with%2520redirected%2520T%2520cells%2520produces%2520CCR7-%2520cells%2520that%2520are%2520trapped%2520in%2520the%2520periphery%2520and%2520benefit%2520from%2520combined%2520CD28-OX40%2520costimulation%26jtitle%3DHum.%2520Gene%2520Ther.%26date%3D2013%26volume%3D24%26spage%3D259%26epage%3D269%26doi%3D10.1089%2Fhum.2012.247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abate-Daga, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagisetty, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gattinoni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miermont, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teper, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudloff, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Restifo, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, R. A.</span></span> <span> </span><span class="NLM_article-title">A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer</span>. <i>Hum. Gene Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1003</span>– <span class="NLM_lpage">1012</span>, <span class="refDoi"> DOI: 10.1089/hum.2013.209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1089%2Fhum.2013.209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=24694017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitV2ntrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=1003-1012&issue=12&author=D.+Abate-Dagaauthor=K.+H.+Lagisettyauthor=E.+Tranauthor=Z.+Zhengauthor=L.+Gattinoniauthor=Z.+Yuauthor=W.+R.+Burnsauthor=A.+M.+Miermontauthor=Y.+Teperauthor=U.+Rudloffauthor=N.+P.+Restifoauthor=S.+A.+Feldmanauthor=S.+A.+Rosenbergauthor=R.+A.+Morgan&title=A+novel+chimeric+antigen+receptor+against+prostate+stem+cell+antigen+mediates+tumor+destruction+in+a+humanized+mouse+model+of+pancreatic+cancer&doi=10.1089%2Fhum.2013.209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Chimeric Antigen Receptor Against Prostate Stem Cell Antigen Mediates Tumor Destruction in a Humanized Mouse Model of Pancreatic Cancer</span></div><div class="casAuthors">Abate-Daga, Daniel; Lagisetty, Kiran H.; Tran, Eric; Zheng, Zhili; Gattinoni, Luca; Yu, Zhiya; Burns, William R.; Miermont, Anne M.; Teper, Yaroslav; Rudloff, Udo; Restifo, Nicholas P.; Feldman, Steven A.; Rosenberg, Steven A.; Morgan, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Human Gene Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1003-1012</span>CODEN:
                <span class="NLM_cas:coden">HGTHE3</span>;
        ISSN:<span class="NLM_cas:issn">1043-0342</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Despite advances in the understanding of its mol. pathophysiol., pancreatic cancer remains largely incurable, highlighting the need for novel therapies.  We developed a chimeric antigen receptor (CAR) specific for prostate stem cell antigen (PSCA), a glycoprotein that is overexpressed in pancreatic cancer starting at early stages of malignant transformation.  To optimize the CAR design, we used antigen-recognition domains derived from mouse or human antibodies, and intracellular signaling domains contg. one or two T cell costimulatory elements, in addn. to CD3zeta.  Comparing multiple constructs established that the CAR based on human monoclonal antibody Ha1-4.117 had the greatest reactivity in vitro.  To further analyze this CAR, we developed a human pancreatic cancer xenograft model and adoptively transferred CAR-engineered T cells into animals with established tumors.  CAR-engineered human lymphocytes induced significant antitumor activity, and unlike what has been described for other CARs, a second-generation CAR (contg. CD28 cosignaling domain) induced a more potent antitumor effect than a third-generation CAR (contg. CD28 and 41BB cosignaling domains).  While our results provide evidence to support PSCA as a target antigen for CAR-based immunotherapy of pancreatic cancer, the expression of PSCA on selected normal tissues could be a source of limiting toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouotN47Usys7Vg90H21EOLACvtfcHk0ljOgLjvHCk1SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitV2ntrnI&md5=5ea2fc25cee4a24f71109e115920c847</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1089%2Fhum.2013.209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fhum.2013.209%26sid%3Dliteratum%253Aachs%26aulast%3DAbate-Daga%26aufirst%3DD.%26aulast%3DLagisetty%26aufirst%3DK.%2BH.%26aulast%3DTran%26aufirst%3DE.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DGattinoni%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DBurns%26aufirst%3DW.%2BR.%26aulast%3DMiermont%26aufirst%3DA.%2BM.%26aulast%3DTeper%26aufirst%3DY.%26aulast%3DRudloff%26aufirst%3DU.%26aulast%3DRestifo%26aufirst%3DN.%2BP.%26aulast%3DFeldman%26aufirst%3DS.%2BA.%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26aulast%3DMorgan%26aufirst%3DR.%2BA.%26atitle%3DA%2520novel%2520chimeric%2520antigen%2520receptor%2520against%2520prostate%2520stem%2520cell%2520antigen%2520mediates%2520tumor%2520destruction%2520in%2520a%2520humanized%2520mouse%2520model%2520of%2520pancreatic%2520cancer%26jtitle%3DHum.%2520Gene%2520Ther.%26date%3D2014%26volume%3D25%26issue%3D12%26spage%3D1003%26epage%3D1012%26doi%3D10.1089%2Fhum.2013.209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chmielewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abken, H.</span></span> <span> </span><span class="NLM_article-title">TRUCKs: the fourth generation of CARs</span>. <i>Expert Opin. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1145</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1517/14712598.2015.1046430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1517%2F14712598.2015.1046430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=25985798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFyqsrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=1145-1154&author=M.+Chmielewskiauthor=H.+Abken&title=TRUCKs%3A+the+fourth+generation+of+CARs&doi=10.1517%2F14712598.2015.1046430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">TRUCKs: the fourth generation of CARs</span></div><div class="casAuthors">Chmielewski, Markus; Abken, Hinrich</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1145-1154</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: Adoptive cell therapy of malignant diseases takes advantage of the cellular immune system to recognize and destroy cancer cells.  This is impressively demonstrated by redirecting T cells with a chimeric antigen receptor (CAR) towards CD19, inducing complete and lasting remission of leukemia in more than two-thirds of patients in early phase trials.  Areas covered: We outline how the CAR strategy is highly specific in redirecting T cells towards pre-defined target cells, however, reaches its limits when targeting solid tumors with a tremendous phenotypic heterogeneity.  After initial tumor redn. by CAR T cells, antigen-neg. cancer cells not recognized by CAR may give rise to tumor relapse.  The situation may be overcome by CAR-mediated activation of T cells in the tumor, releasing inducible IL-12 which augments T-cell activation and attracts and activates innate immune cells to eliminate antigen-neg. cancer cells in the targeted lesion.  Expert opinion: CAR T cells with a transgenic 'payload', so-called TRUCK T cells or the 'fourth-generation' CAR T cells, are worthwhile to explore to shape the tumor environment by the inducible release of transgenic immune modifiers.  Such TRUCK T cells are moreover envisioned to be applied in fields beyond cancer therapy including the therapy of virus infections, auto-immune diseases or metabolic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ_GDRaZwN1LVg90H21EOLACvtfcHk0ljOgLjvHCk1SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFyqsrvN&md5=159cc23be6bbcf0b17c107ca08e3c9a0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1517%2F14712598.2015.1046430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.2015.1046430%26sid%3Dliteratum%253Aachs%26aulast%3DChmielewski%26aufirst%3DM.%26aulast%3DAbken%26aufirst%3DH.%26atitle%3DTRUCKs%253A%2520the%2520fourth%2520generation%2520of%2520CARs%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2015%26volume%3D15%26spage%3D1145%26epage%3D1154%26doi%3D10.1517%2F14712598.2015.1046430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alizadeh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecoraro, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ann, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C. E.</span></span> <span> </span><span class="NLM_article-title">IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-18-0466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1158%2F2326-6066.CIR-18-0466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=30890531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVyjurnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=759-772&issue=5&author=D.+Alizadehauthor=R.+A.+Wongauthor=X.+Yangauthor=D.+Wangauthor=J.+R.+Pecoraroauthor=C.+F.+Kuoauthor=B.+Aguilarauthor=Y.+Qiauthor=D.+K.+Annauthor=R.+Starrauthor=R.+Urakauthor=X.+Wangauthor=S.+J.+Formanauthor=C.+E.+Brown&title=IL15+enhances+CAR-T+cell+antitumor+activity+by+reducing+mTORC1+activity+and+preserving+their+stem+cell+memory+phenotype&doi=10.1158%2F2326-6066.CIR-18-0466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype</span></div><div class="casAuthors">Alizadeh, Darya; Wong, Robyn A.; Yang, Xin; Wang, Dongrui; Pecoraro, Joseph R.; Kuo, Cheng-Fu; Aguilar, Brenda; Qi, Yue; Ann, David K.; Starr, Renate; Urak, Ryan; Wang, Xiuli; Forman, Stephen J.; Brown, Christine E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">759-772</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Improvements in the quality and fitness of chimeric antigen receptor (CAR)-engineered T cells, through CAR design or manufg. optimizations, could enhance the therapeutic potential of CAR-T cells.  One parameter influencing the effectiveness of CAR-T cell therapy is the differentiation status of the final product: CAR-T cells that are less-differentiated and less exhausted are more therapeutically effective.  In the current study, we demonstrate that CAR-T cells expanded in IL15 (CAR-T/IL15) preserve a less-differentiated stem cell memory (Tscm) phenotype, defined by expression of CD62L+CD45RA+ CCR7+, as compared with cells cultured in IL2 (CAR-T/IL2).  CAR-T/IL15 cells exhibited reduced expression of exhaustion markers, higher antiapoptotic properties, and increased proliferative capacity upon antigen challenge.  Furthermore, CAR-T/IL15 cells exhibited decreased mTORC1 activity, reduced expression of glycolytic enzymes and improved mitochondrial fitness.  CAR-T/IL2 cells cultured in rapamycin (mTORC1 inhibitor) shared phenotypic features with CAR-T/IL15 cells, suggesting that IL15-mediated redn. of mTORC1 activity is responsible for preserving the Tscm phenotype.  CAR-T/IL15 cells promoted superior antitumor responses in vivo in comparison with CAR-T/IL2 cells.  Inclusion of cytokines IL7 and/or IL21 in addn. to IL15 reduced the beneficial effects of IL15 on CAR-T phenotype and antitumor potency.  Our findings show that IL15 preserves the CAR-T cell Tscm phenotype and improves their metabolic fitness, which results in superior in vivo antitumor activity, thus opening an avenue that may improve future adoptive T-cell therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-D-xwBOvnrrVg90H21EOLACvtfcHk0li8mbvq5m2wxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVyjurnK&md5=f8aa1f5d992abbcac9fbc8c6826afabc</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-18-0466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-18-0466%26sid%3Dliteratum%253Aachs%26aulast%3DAlizadeh%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DR.%2BA.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DPecoraro%26aufirst%3DJ.%2BR.%26aulast%3DKuo%26aufirst%3DC.%2BF.%26aulast%3DAguilar%26aufirst%3DB.%26aulast%3DQi%26aufirst%3DY.%26aulast%3DAnn%26aufirst%3DD.%2BK.%26aulast%3DStarr%26aufirst%3DR.%26aulast%3DUrak%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DForman%26aufirst%3DS.%2BJ.%26aulast%3DBrown%26aufirst%3DC.%2BE.%26atitle%3DIL15%2520enhances%2520CAR-T%2520cell%2520antitumor%2520activity%2520by%2520reducing%2520mTORC1%2520activity%2520and%2520preserving%2520their%2520stem%2520cell%2520memory%2520phenotype%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2019%26volume%3D7%26issue%3D5%26spage%3D759%26epage%3D772%26doi%3D10.1158%2F2326-6066.CIR-18-0466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeku, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijewarnasuriya, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Leeuwen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purdon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniyan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brentjens, R. J.</span></span> <span> </span><span class="NLM_article-title">Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2130</span>– <span class="NLM_lpage">2141</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2018.04.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.celrep.2018.04.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29768210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsFygt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=2130-2141&issue=7&author=M.+P.+Avanziauthor=O.+Yekuauthor=X.+Liauthor=D.+P.+Wijewarnasuriyaauthor=D.+G.+van+Leeuwenauthor=K.+Cheungauthor=H.+Parkauthor=T.+J.+Purdonauthor=A.+F.+Daniyanauthor=M.+H.+Spitzerauthor=R.+J.+Brentjens&title=Engineered+tumor-targeted+T+cells+mediate+enhanced+anti-tumor+efficacy+both+directly+and+through+activation+of+the+endogenous+immune+system&doi=10.1016%2Fj.celrep.2018.04.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System</span></div><div class="casAuthors">Avanzi, Mauro P.; Yeku, Oladapo; Li, Xinghuo; Wijewarnasuriya, Dinali P.; van Leeuwen, Dayenne G.; Cheung, Kenneth; Park, Hyebin; Purdon, Terence J.; Daniyan, Anthony F.; Spitzer, Matthew H.; Brentjens, Renier J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2130-2141</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Chimeric antigen receptor (CAR) T cell therapy has proven clin. beneficial against B cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma.  However, suboptimal clin. outcomes have been assocd. with decreased expansion and persistence of adoptively transferred CAR T cells, antigen-neg. relapses, and impairment by an immunosuppressive tumor microenvironment.  Improvements in CAR T cell design are required to enhance clin. efficacy, as well as broaden the applicability of this technol.  Here, we demonstrate that interleukin-18 (IL-18)-secreting CAR T cells exhibit enhanced in vivo expansion and persistence and significantly increase long-term survival in syngeneic mouse models of both hematol. and solid malignancies.  In addn., we demonstrate that IL-18-secreting CAR T cells are capable of modulating the tumor microenvironment, as well as enhancing an effective endogenous anti-tumor immune response.  IL-18-secreting CAR T cells represent a promising strategy to enhance the clin. outcomes of adoptive T cell therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqscfnTMdvtA7Vg90H21EOLACvtfcHk0li8mbvq5m2wxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsFygt7o%253D&md5=0b3d391a36296cb5c86ef66d7d7f31ba</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2018.04.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2018.04.051%26sid%3Dliteratum%253Aachs%26aulast%3DAvanzi%26aufirst%3DM.%2BP.%26aulast%3DYeku%26aufirst%3DO.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWijewarnasuriya%26aufirst%3DD.%2BP.%26aulast%3Dvan%2BLeeuwen%26aufirst%3DD.%2BG.%26aulast%3DCheung%26aufirst%3DK.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DPurdon%26aufirst%3DT.%2BJ.%26aulast%3DDaniyan%26aufirst%3DA.%2BF.%26aulast%3DSpitzer%26aufirst%3DM.%2BH.%26aulast%3DBrentjens%26aufirst%3DR.%2BJ.%26atitle%3DEngineered%2520tumor-targeted%2520T%2520cells%2520mediate%2520enhanced%2520anti-tumor%2520efficacy%2520both%2520directly%2520and%2520through%2520activation%2520of%2520the%2520endogenous%2520immune%2520system%26jtitle%3DCell%2520Rep.%26date%3D2018%26volume%3D23%26issue%3D7%26spage%3D2130%26epage%3D2141%26doi%3D10.1016%2Fj.celrep.2018.04.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamada, K.</span></span> <span> </span><span class="NLM_article-title">IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">346</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1038/nbt.4086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fnbt.4086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29505028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVOlu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=346-351&issue=4&author=K.+Adachiauthor=Y.+Kanoauthor=T.+Nagaiauthor=N.+Okuyamaauthor=Y.+Sakodaauthor=K.+Tamada&title=IL-7+and+CCL19+expression+in+CAR-T+cells+improves+immune+cell+infiltration+and+CAR-T+cell+survival+in+the+tumor&doi=10.1038%2Fnbt.4086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor</span></div><div class="casAuthors">Adachi, Keishi; Kano, Yosuke; Nagai, Tomohiko; Okuyama, Namiko; Sakoda, Yukimi; Tamada, Koji</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">346-351</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Infiltration, accumulation, and survival of chimeric antigen receptor T (CAR-T) cells in solid tumors is crucial for tumor clearance.  We engineered CAR-T cells to express interleukin (IL)-7 and CCL19 (7 × 19 CAR-T cells), as these factors are essential for the maintenance of T-cell zones in lymphoid organs.  In mice, 7 × 19 CAR-T cells achieved complete regression of pre-established solid tumors and prolonged mouse survival, with superior anti-tumor activity compared to conventional CAR-T cells.  Histopathol. analyses showed increased infiltration of dendritic cells (DC) and T cells into tumor tissues following 7 × 19 CAR-T cell therapy.  Depletion of recipient T cells before 7 × 19 CAR-T cell administration dampened the therapeutic effects of 7 × 19 CAR-T cell treatment, suggesting that CAR-T cells and recipient immune cells collaborated to exert anti-tumor activity.  Following treatment of mice with 7 × 19 CAR-T cells, both recipient conventional T cells and administered CAR-T cells generated memory responses against tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYltatjh4Ir7Vg90H21EOLACvtfcHk0li8mbvq5m2wxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVOlu74%253D&md5=86ffd1f1dd5fbbbc7a64d346d4e6080f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnbt.4086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.4086%26sid%3Dliteratum%253Aachs%26aulast%3DAdachi%26aufirst%3DK.%26aulast%3DKano%26aufirst%3DY.%26aulast%3DNagai%26aufirst%3DT.%26aulast%3DOkuyama%26aufirst%3DN.%26aulast%3DSakoda%26aufirst%3DY.%26aulast%3DTamada%26aufirst%3DK.%26atitle%3DIL-7%2520and%2520CCL19%2520expression%2520in%2520CAR-T%2520cells%2520improves%2520immune%2520cell%2520infiltration%2520and%2520CAR-T%2520cell%2520survival%2520in%2520the%2520tumor%26jtitle%3DNat.%2520Biotechnol.%26date%3D2018%26volume%3D36%26issue%3D4%26spage%3D346%26epage%3D351%26doi%3D10.1038%2Fnbt.4086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kagoya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anczurowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saso, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minden, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, N.</span></span> <span> </span><span class="NLM_article-title">A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">352</span>– <span class="NLM_lpage">359</span>, <span class="refDoi"> DOI: 10.1038/nm.4478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fnm.4478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29400710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=352-359&author=Y.+Kagoyaauthor=S.+Tanakaauthor=T.+Guoauthor=M.+Anczurowskiauthor=C.+H.+Wangauthor=K.+Sasoauthor=M.+O.+Butlerauthor=M.+D.+Mindenauthor=N.+Hirano&title=A+novel+chimeric+antigen+receptor+containing+a+JAK-STAT+signaling+domain+mediates+superior+antitumor+effects&doi=10.1038%2Fnm.4478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects</span></div><div class="casAuthors">Kagoya, Yuki; Tanaka, Shinya; Guo, Tingxi; Anczurowski, Mark; Wang, Chung-Hsi; Saso, Kayoko; Butler, Marcus O.; Minden, Mark D.; Hirano, Naoto</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">352-359</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The adoptive transfer of T cells engineered with a chimeric antigen receptor (CAR) (hereafter referred to as CAR-T cells) specific for the B lymphocyte antigen CD19 has shown impressive clin. responses in patients with refractory B cell malignancies.  However, the therapeutic effects of CAR-T cells that target other malignancies have not yet resulted in significant clin. benefit.  Although inefficient tumor trafficking and various immunosuppressive mechanisms can impede CAR-T cell effector responses, the signals delivered by the current CAR constructs may still be insufficient to fully activate antitumor T cell functions.  Optimal T cell activation and proliferation requires multiple signals, including T cell receptor (TCR) engagement (signal 1), co-stimulation (signal 2) and cytokine engagement (signal 3).  However, CAR constructs currently being tested in the clinic contain a CD3z (TCR signaling) domain and co-stimulatory domain(s) but not a domain that transmits signal 3 (refs. 13, 14, 15, 16, 17, 18).  Here we have developed a novel CAR construct capable of inducing cytokine signaling after antigen stimulation.  This new-generation CD19 CAR encodes a truncated cytoplasmic domain from the interleukin (IL)-2 receptor β-chain (IL-2Rβ) and a STAT3-binding tyrosine-X-X-glutamine (YXXQ) motif, together with the TCR signaling (CD3z) and co-stimulatory (CD28) domains (hereafter referred to as 28-ΔIL2RB-z(YXXQ)).  The 28-ΔIL2RB-z(YXXQ) CAR-T cells showed antigen-dependent activation of the JAK kinase and of the STAT3 and STAT5 transcription factors signaling pathways, which promoted their proliferation and prevented terminal differentiation in vitro.  The 28-ΔIL2RB-z(YXXQ) CAR-T cells demonstrated superior in vivo persistence and antitumor effects in models of liq. and solid tumors as compared with CAR-T cells expressing a CD28 or 4-1BB co-stimulatory domain alone.  Taken together, these results suggest that our new-generation CAR has the potential to demonstrate superior antitumor effects with minimal toxicity in the clinic and that clin. translation of this novel CAR is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNT3m_IKkclrVg90H21EOLACvtfcHk0lj2DgYquEocaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCiu7o%253D&md5=21137ad18d890e713d4a329350995cf3</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnm.4478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4478%26sid%3Dliteratum%253Aachs%26aulast%3DKagoya%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DAnczurowski%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DC.%2BH.%26aulast%3DSaso%26aufirst%3DK.%26aulast%3DButler%26aufirst%3DM.%2BO.%26aulast%3DMinden%26aufirst%3DM.%2BD.%26aulast%3DHirano%26aufirst%3DN.%26atitle%3DA%2520novel%2520chimeric%2520antigen%2520receptor%2520containing%2520a%2520JAK-STAT%2520signaling%2520domain%2520mediates%2520superior%2520antitumor%2520effects%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D352%26epage%3D359%26doi%3D10.1038%2Fnm.4478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tokarew, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogonek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endres, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Bergwelt-Baildon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobold, S.</span></span> <span> </span><span class="NLM_article-title">Teaching an old dog new tricks: next-generation CAR T cells</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1038/s41416-018-0325-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fs41416-018-0325-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=30413825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFOjt7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2019&pages=26-37&author=N.+Tokarewauthor=J.+Ogonekauthor=S.+Endresauthor=M.+von+Bergwelt-Baildonauthor=S.+Kobold&title=Teaching+an+old+dog+new+tricks%3A+next-generation+CAR+T+cells&doi=10.1038%2Fs41416-018-0325-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Teaching an old dog new tricks: next-generation CAR T cells</span></div><div class="casAuthors">Tokarew, Nicholas; Ogonek, Justyna; Endres, Stefan; von Bergwelt-Baildon, Michael; Kobold, Sebastian</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-37</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Adoptive T cell therapy (ACT) refers to the therapeutic use of T cells.  T cells genetically engineered to express chimeric antigen receptors (CAR) constitute the most clin. advanced form of ACT approved to date for the treatment of CD19-pos. leukemias and lymphomas.  CARs are synthetic receptors that are able to confer antigen-binding and activating functions on T cells with the aim of therapeutically targeting cancer cells.  Several factors are essential for CAR T cell therapy to be effective, such as recruitment, activation, expansion and persistence of bioengineered T cells at the tumor site.  Despite the advances made in CAR T cell therapy, however, most tumor entities still escape immune detection and elimination.  A no. of strategies counteracting these problems will need to be addressed in order to render T cell therapy effective in more situations than currently possible.  Non-haematol. tumors are also the subject of active investigation, but ACT has so far shown only marginal success rates in these cases.  New approaches are needed to enhance the ability of ACT to target solid tumors without increasing toxicity, by improving recognition, infiltration, and persistence within tumors, as well as an enhanced resistance to the suppressive tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr56iJiHa1nxbVg90H21EOLACvtfcHk0lj2DgYquEocaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFOjt7fL&md5=d0ac6d54dbe5511e3e75245f935517ea</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fs41416-018-0325-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41416-018-0325-1%26sid%3Dliteratum%253Aachs%26aulast%3DTokarew%26aufirst%3DN.%26aulast%3DOgonek%26aufirst%3DJ.%26aulast%3DEndres%26aufirst%3DS.%26aulast%3Dvon%2BBergwelt-Baildon%26aufirst%3DM.%26aulast%3DKobold%26aufirst%3DS.%26atitle%3DTeaching%2520an%2520old%2520dog%2520new%2520tricks%253A%2520next-generation%2520CAR%2520T%2520cells%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2019%26volume%3D120%26spage%3D26%26epage%3D37%26doi%3D10.1038%2Fs41416-018-0325-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waller, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borchmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuirk, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jäger, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaglowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreadis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westin, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleury, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachanova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mielke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magenau, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holte, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacaud, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anak, Ö.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salles, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maziarz, R. T.</span></span> <span> </span><span class="NLM_article-title">Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1804980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1056%2FNEJMoa1804980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=30501490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=45-56&issue=1&author=S.+J.+Schusterauthor=M.+R.+Bishopauthor=C.+S.+Tamauthor=E.+K.+Wallerauthor=P.+Borchmannauthor=J.+P.+McGuirkauthor=U.+J%C3%A4gerauthor=S.+Jaglowskiauthor=C.+Andreadisauthor=J.+R.+Westinauthor=I.+Fleuryauthor=V.+Bachanovaauthor=S.+R.+Foleyauthor=P.+J.+Hoauthor=S.+Mielkeauthor=J.+M.+Magenauauthor=H.+Holteauthor=S.+Pantanoauthor=L.+B.+Pacaudauthor=R.+Awasthiauthor=J.+Chuauthor=%C3%96.+Anakauthor=G.+Sallesauthor=R.+T.+Maziarz&title=Tisagenlecleucel+in+adult+relapsed+or+refractory+diffuse+large+B-cell+lymphoma&doi=10.1056%2FNEJMoa1804980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma</span></div><div class="casAuthors">Schuster, Stephen J.; Bishop, Michael R.; Tam, Constantine S.; Waller, Edmund K.; Borchmann, Peter; McGuirk, Joseph P.; Jager, Ulrich; Jaglowski, Samantha; Andreadis, Charalambos; Westin, Jason R.; Fleury, Isabelle; Bachanova, Veronika; Foley, S. Ronan; Ho, P. Joy; Mielke, Stephan; Magenau, John M.; Holte, Harald; Pantano, Serafino; Pacaud, Lida B.; Awasthi, Rakesh; Chu, Jufen; Anak, Ozlem; Salles, Gilles; Maziarz, Richard T.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-56</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis.  The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, phase 2a study.  We conducted an international, phase 2, pivotal study of centrally manufd. tisagenlecleucel involving adult patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for or had disease progression after autologous hematopoietic stem-cell transplantation.  The primary end point was the best overall response rate (i.e., the percentage of patients who had a complete or partial response), as judged by an independent review committee.  A total of 93 patients received an infusion and were included in the evaluation of efficacy.  The median time from infusion to data cutoff was 14 mo (range, 0.1 to 26).  The best overall response rate was 52% (95% confidence interval, 41 to 62); 40% of the patients had complete responses, and 12% had partial responses.  Response rates were consistent across prognostic subgroups.  At 12 mo after the initial response, the rate of relapse-free survival was estd. to be 65% (79% among patients with a complete response).  The most common grade 3 or 4 adverse events of special interest included cytokine release syndrome (22%), neurol. events (12%), cytopenias lasting more than 28 days (32%), infections (20%), and febrile neutropenia (14%).  Three patients died from disease progression within 30 days after infusion.  No deaths were attributed to tisagenlecleucel, cytokine release syndrome, or cerebral edema.  No differences between response groups in tumor expression of CD19 or immune checkpoint-related proteins were found.  In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYUl7vblDrEbVg90H21EOLACvtfcHk0lj2DgYquEocaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtbc%253D&md5=b8ead75d6b00fbb05cbe0416763d9314</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1804980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1804980%26sid%3Dliteratum%253Aachs%26aulast%3DSchuster%26aufirst%3DS.%2BJ.%26aulast%3DBishop%26aufirst%3DM.%2BR.%26aulast%3DTam%26aufirst%3DC.%2BS.%26aulast%3DWaller%26aufirst%3DE.%2BK.%26aulast%3DBorchmann%26aufirst%3DP.%26aulast%3DMcGuirk%26aufirst%3DJ.%2BP.%26aulast%3DJ%25C3%25A4ger%26aufirst%3DU.%26aulast%3DJaglowski%26aufirst%3DS.%26aulast%3DAndreadis%26aufirst%3DC.%26aulast%3DWestin%26aufirst%3DJ.%2BR.%26aulast%3DFleury%26aufirst%3DI.%26aulast%3DBachanova%26aufirst%3DV.%26aulast%3DFoley%26aufirst%3DS.%2BR.%26aulast%3DHo%26aufirst%3DP.%2BJ.%26aulast%3DMielke%26aufirst%3DS.%26aulast%3DMagenau%26aufirst%3DJ.%2BM.%26aulast%3DHolte%26aufirst%3DH.%26aulast%3DPantano%26aufirst%3DS.%26aulast%3DPacaud%26aufirst%3DL.%2BB.%26aulast%3DAwasthi%26aufirst%3DR.%26aulast%3DChu%26aufirst%3DJ.%26aulast%3DAnak%26aufirst%3D%25C3%2596.%26aulast%3DSalles%26aufirst%3DG.%26aulast%3DMaziarz%26aufirst%3DR.%2BT.%26atitle%3DTisagenlecleucel%2520in%2520adult%2520relapsed%2520or%2520refractory%2520diffuse%2520large%2520B-cell%2520lymphoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26issue%3D1%26spage%3D45%26epage%3D56%26doi%3D10.1056%2FNEJMoa1804980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neelapu, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locke, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lekakis, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miklos, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braunschweig, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oluwole, O. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmerman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiff, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedberg, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deol, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farooq, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McSweeney, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avivi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westin, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghobadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komanduri, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witzig, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reagan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navale, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aycock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elias, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiezorek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, W. Y.</span></span> <span> </span><span class="NLM_article-title">Axicabtagene Ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">2531</span>– <span class="NLM_lpage">2544</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1707447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1056%2FNEJMoa1707447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29226797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=2531-2544&issue=26&author=S.+S.+Neelapuauthor=F.+L.+Lockeauthor=N.+L.+Bartlettauthor=L.+J.+Lekakisauthor=D.+B.+Miklosauthor=C.+A.+Jacobsonauthor=I.+Braunschweigauthor=O.+O.+Oluwoleauthor=T.+Siddiqiauthor=Y.+Linauthor=J.+M.+Timmermanauthor=P.+J.+Stiffauthor=J.+W.+Friedbergauthor=I.+W.+Flinnauthor=A.+Goyauthor=B.+T.+Hillauthor=M.+R.+Smithauthor=A.+Deolauthor=U.+Farooqauthor=P.+McSweeneyauthor=J.+Munozauthor=I.+Aviviauthor=J.+E.+Castroauthor=J.+R.+Westinauthor=J.+C.+Chavezauthor=A.+Ghobadiauthor=K.+V.+Komanduriauthor=R.+Levyauthor=E.+D.+Jacobsenauthor=T.+E.+Witzigauthor=P.+Reaganauthor=A.+Botauthor=J.+Rossiauthor=L.+Navaleauthor=Y.+Jiangauthor=J.+Aycockauthor=M.+Eliasauthor=D.+Changauthor=J.+Wiezorekauthor=W.+Y.+Go&title=Axicabtagene+Ciloleucel+CAR+T-Cell+therapy+in+refractory+large+B-cell+lymphoma&doi=10.1056%2FNEJMoa1707447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma</span></div><div class="casAuthors">Neelapu, S. S.; Locke, F. L.; Bartlett, N. L.; Lekakis, L. J.; Miklos, D. B.; Jacobson, C. A.; Braunschweig, I.; Oluwole, O. O.; Siddiqi, T.; Lin, Y.; Timmerman, J. M.; Stiff, P. J.; Friedberg, J. W.; Flinn, I. W.; Goy, A.; Hill, B. T.; Smith, M. R.; Deol, A.; Farooq, U.; McSweeney, P.; Munoz, J.; Avivi, I.; Castro, J. E.; Westin, J. R.; Chavez, J. C.; Ghobadi, A.; Komanduri, K. V.; Levy, R.; Jacobsen, E. D.; Witzig, T. E.; Reagan, P.; Bot, A.; Rossi, J.; Navale, L.; Jiang, Y.; Aycock, J.; Elias, M.; Chang, D.; Wiezorek, J.; Go, W. Y.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2531-2544</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after the failure of conventional therapy.  In this multicenter, phase 2 trial, we enrolled 111 patients with diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, or transformed follicular lymphoma who had refractory disease despite undergoing recommended prior therapy.  Patients received a target dose of 2 x106 anti-CD19 CAR T cells per kg of body wt. after receiving a conditioning regimen of low-dose cyclophosphamide and fludarabine.  The primary end point was the rate of objective response (calcd. as the combined rates of complete response and partial response).  Secondary end points included overall survival, safety, and biomarker assessments. results Among the 111 patients who were enrolled, axi-cel was successfully manufd. for 110 (99%) and administered to 101 (91%).  The objective response rate was 82%, and the complete response rate was 54%.  With a median follow-up of 15.4 mo, 42% of the patients continued to have a response, with 40% continuing to have a complete response.  The overall rate of survival at 18 mo was 52%.  The most common adverse events of grade 3 or higher during treatment were neutropenia (in 78% of the patients), anemia (in 43%), and thrombocytopenia (in 38%).  Grade 3 or higher cytokine release syndrome and neurol. events occurred in 13% and 28% of the patients, resp.  Three of the patients died during treatment.  Higher CAR T-cell levels in blood were assocd. with response. conclusions In this multicenter study, patients with refractory large B-cell lymphoma who received CAR T-cell therapy with axi-cel had high levels of durable response, with a safety profile that included myelosuppression, the cytokine release syndrome, and neurol. events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPvC_XgxwBMbVg90H21EOLACvtfcHk0liQnMD3TxdCYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGjtbw%253D&md5=fb9e690e5a97b82f7438a57560eae470</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1707447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1707447%26sid%3Dliteratum%253Aachs%26aulast%3DNeelapu%26aufirst%3DS.%2BS.%26aulast%3DLocke%26aufirst%3DF.%2BL.%26aulast%3DBartlett%26aufirst%3DN.%2BL.%26aulast%3DLekakis%26aufirst%3DL.%2BJ.%26aulast%3DMiklos%26aufirst%3DD.%2BB.%26aulast%3DJacobson%26aufirst%3DC.%2BA.%26aulast%3DBraunschweig%26aufirst%3DI.%26aulast%3DOluwole%26aufirst%3DO.%2BO.%26aulast%3DSiddiqi%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DTimmerman%26aufirst%3DJ.%2BM.%26aulast%3DStiff%26aufirst%3DP.%2BJ.%26aulast%3DFriedberg%26aufirst%3DJ.%2BW.%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DHill%26aufirst%3DB.%2BT.%26aulast%3DSmith%26aufirst%3DM.%2BR.%26aulast%3DDeol%26aufirst%3DA.%26aulast%3DFarooq%26aufirst%3DU.%26aulast%3DMcSweeney%26aufirst%3DP.%26aulast%3DMunoz%26aufirst%3DJ.%26aulast%3DAvivi%26aufirst%3DI.%26aulast%3DCastro%26aufirst%3DJ.%2BE.%26aulast%3DWestin%26aufirst%3DJ.%2BR.%26aulast%3DChavez%26aufirst%3DJ.%2BC.%26aulast%3DGhobadi%26aufirst%3DA.%26aulast%3DKomanduri%26aufirst%3DK.%2BV.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DJacobsen%26aufirst%3DE.%2BD.%26aulast%3DWitzig%26aufirst%3DT.%2BE.%26aulast%3DReagan%26aufirst%3DP.%26aulast%3DBot%26aufirst%3DA.%26aulast%3DRossi%26aufirst%3DJ.%26aulast%3DNavale%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DAycock%26aufirst%3DJ.%26aulast%3DElias%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DD.%26aulast%3DWiezorek%26aufirst%3DJ.%26aulast%3DGo%26aufirst%3DW.%2BY.%26atitle%3DAxicabtagene%2520Ciloleucel%2520CAR%2520T-Cell%2520therapy%2520in%2520refractory%2520large%2520B-cell%2520lymphoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26issue%3D26%26spage%3D2531%26epage%3D2544%26doi%3D10.1056%2FNEJMoa1707447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brudno, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochenderfer, J. N.</span></span> <span> </span><span class="NLM_article-title">Toxicities of chimeric antigen receptor T cells: recognition and management</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">3321</span>– <span class="NLM_lpage">3330</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-04-703751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1182%2Fblood-2016-04-703751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=27207799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1entL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=3321-3330&author=J.+N.+Brudnoauthor=J.+N.+Kochenderfer&title=Toxicities+of+chimeric+antigen+receptor+T+cells%3A+recognition+and+management&doi=10.1182%2Fblood-2016-04-703751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Toxicities of chimeric antigen receptor T cells: recognition and management</span></div><div class="casAuthors">Brudno, Jennifer N.; Kochenderfer, James N.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3321-3330</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Chimeric antigen receptor (CAR) T cells can produce durable remissions in hematol. malignancies that are not responsive to std. therapies.  Yet the use of CAR T cells is limited by potentially severe toxicities.  Early case reports of unexpected organ damage and deaths following CAR T-cell therapy first highlighted the possible dangers of this new treatment.  CAR T cells can potentially damage normal tissues by specifically targeting a tumor-assocd. antigen that is also expressed on those tissues.  Cytokine release syndrome (CRS), a systemic inflammatory response caused by cytokines released by infused CAR T cells can lead to widespread reversible organ dysfunction.  CRS is the most common type of toxicity caused by CAR T cells.  Neurol. toxicity due to CAR T cells might in some cases have a different pathophysiol. than CRS and requires different management.  Aggressive supportive care is necessary for all patients experiencing CAR T-cell toxicities, with early intervention for hypotension and treatment of concurrent infections being essential.  Interleukin-6 receptor blockade with tocilizumab remains the mainstay pharmacol. therapy for CRS, though indications for administration vary among centers.  Corticosteroids should be reserved for neurol. toxicities and CRS not responsive to tocilizumab.  Pharmacol. management is complicated by the risk of immunosuppressive therapy abrogating the antimalignancy activity of the CAR T cells.  This review describes the toxicities caused by CAR T cells and reviews the published approaches used to manage toxicities.  We present guidelines for treating patients experiencing CRS and other adverse events following CAR T-cell therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDOudIS6qIB7Vg90H21EOLACvtfcHk0liQnMD3TxdCYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1entL%252FE&md5=ddb69cbba2280cf8cb0bc406296f496e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-04-703751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-04-703751%26sid%3Dliteratum%253Aachs%26aulast%3DBrudno%26aufirst%3DJ.%2BN.%26aulast%3DKochenderfer%26aufirst%3DJ.%2BN.%26atitle%3DToxicities%2520of%2520chimeric%2520antigen%2520receptor%2520T%2520cells%253A%2520recognition%2520and%2520management%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D3321%26epage%3D3330%26doi%3D10.1182%2Fblood-2016-04-703751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kochenderfer, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spaner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maric, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetler-Stevenson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherry, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kammula, U. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devillier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurencot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. A.</span></span> <span> </span><span class="NLM_article-title">B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">2709</span>– <span class="NLM_lpage">2720</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-10-384388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1182%2Fblood-2011-10-384388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=22160384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFalt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=2709-2720&author=J.+N.+Kochenderferauthor=M.+E.+Dudleyauthor=S.+A.+Feldmanauthor=W.+H.+Wilsonauthor=D.+E.+Spanerauthor=I.+Maricauthor=M.+Stetler-Stevensonauthor=G.+Q.+Phanauthor=M.+S.+Hughesauthor=R.+M.+Sherryauthor=J.+C.+Yangauthor=U.+S.+Kammulaauthor=L.+Devillierauthor=R.+Carpenterauthor=D.+A.+Nathanauthor=R.+A.+Morganauthor=C.+Laurencotauthor=S.+A.+Rosenberg&title=B-cell+depletion+and+remissions+of+malignancy+along+with+cytokine-associated+toxicity+in+a+clinical+trial+of+anti-CD19+chimeric-antigen-receptor-transduced+T+cells&doi=10.1182%2Fblood-2011-10-384388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells</span></div><div class="casAuthors">Kochenderfer, James N.; Dudley, Mark E.; Feldman, Steven A.; Wilson, Wyndham H.; Spaner, David E.; Maric, Irina; Stetler-Stevenson, Maryalice; Phan, Giao Q.; Hughes, Marybeth S.; Sherry, Richard M.; Yang, James C.; Kammula, Udai S.; Devillier, Laura; Carpenter, Robert; Nathan, Debbie-Ann N.; Morgan, Richard A.; Laurencot, Carolyn; Rosenberg, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2709-2720</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">We conducted a clin. trial to assess adoptive transfer of T cells genetically modified to express an anti-CD19 chimeric Ag receptor (CAR).  Our clin. protocol consisted of chemotherapy followed by an infusion of anti-CD19-CAR-transduced T cells and a course of IL-2.  Six of the 8 patients treated on our protocol obtained remissions of their advanced, progressive B-cell malignancies.  Four of the 8 patients treated on the protocol had long-term depletion of normal polyclonal CD19+ B-lineage cells.  Cells contg. the anti-CD19 CAR gene were detected in the blood of all patients.  Four of the 8 treated patients had prominent elevations in serum levels of the inflammatory cytokines IFNγ and TNF.  The severity of acute toxicities experienced by the patients correlated with serum IFNγ and TNF levels.  The infused anti-CD19-CAR-transduced T cells were a possible source of these inflammatory cytokines because we demonstrated peripheral blood T cells that produced TNF and IFNγ ex vivo in a CD19-specific manner after anti-CD19-CAR-transduced T-cell infusions.  Anti-CD19-CAR-transduced T cells have great promise to improve the treatment of B-cell malignancies because of a potent ability to eradicate CD19+ cells in vivo; however, reversible cytokine-assocd. toxicities occurred after CAR-transduced T-cell infusions.  This.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmC2cqDf7ufrVg90H21EOLACvtfcHk0ljz3a5lenj3KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFalt7o%253D&md5=30012c2bbd452b6846353eac1ae2e691</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-10-384388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-10-384388%26sid%3Dliteratum%253Aachs%26aulast%3DKochenderfer%26aufirst%3DJ.%2BN.%26aulast%3DDudley%26aufirst%3DM.%2BE.%26aulast%3DFeldman%26aufirst%3DS.%2BA.%26aulast%3DWilson%26aufirst%3DW.%2BH.%26aulast%3DSpaner%26aufirst%3DD.%2BE.%26aulast%3DMaric%26aufirst%3DI.%26aulast%3DStetler-Stevenson%26aufirst%3DM.%26aulast%3DPhan%26aufirst%3DG.%2BQ.%26aulast%3DHughes%26aufirst%3DM.%2BS.%26aulast%3DSherry%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DKammula%26aufirst%3DU.%2BS.%26aulast%3DDevillier%26aufirst%3DL.%26aulast%3DCarpenter%26aufirst%3DR.%26aulast%3DNathan%26aufirst%3DD.%2BA.%26aulast%3DMorgan%26aufirst%3DR.%2BA.%26aulast%3DLaurencot%26aufirst%3DC.%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26atitle%3DB-cell%2520depletion%2520and%2520remissions%2520of%2520malignancy%2520along%2520with%2520cytokine-associated%2520toxicity%2520in%2520a%2520clinical%2520trial%2520of%2520anti-CD19%2520chimeric-antigen-receptor-transduced%2520T%2520cells%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D2709%26epage%3D2720%26doi%3D10.1182%2Fblood-2011-10-384388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grupp, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackall, C. L.</span></span> <span> </span><span class="NLM_article-title">Current concepts in the diagnosis and management of cytokine release syndrome</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">195</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-05-552729</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1182%2Fblood-2014-05-552729" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=24876563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1WktbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=188-195&author=D.+W.+Leeauthor=R.+Gardnerauthor=D.+L.+Porterauthor=C.+U.+Louisauthor=N.+Ahmedauthor=M.+Jensenauthor=S.+A.+Gruppauthor=C.+L.+Mackall&title=Current+concepts+in+the+diagnosis+and+management+of+cytokine+release+syndrome&doi=10.1182%2Fblood-2014-05-552729"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Current concepts in the diagnosis and management of cytokine release syndrome</span></div><div class="casAuthors">Lee, Daniel W.; Gardner, Rebecca; Porter, David L.; Louis, Chrystal U.; Ahmed, Nabil; Jensen, Michael; Grupp, Stephan A.; Mackall, Crystal L.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">188-195</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  As immune-based therapies for cancer become potent, more effective, and more widely available, optimal management of their unique toxicities becomes increasingly important.  Cytokine release syndrome (CRS) is a potentially life-threatening toxicity that has been obsd. following administration of natural and bispecific antibodies and, more recently, following adoptive T-cell therapies for cancer.  CRS is assocd. with elevated circulating levels of several cytokines including interleukin (IL)-6 and interferon γ, and uncontrolled studies demonstrate that immunosuppression using tocilizumab, an anti-IL-6 receptor antibody, with or without corticosteroids, can reverse the syndrome.  However, because early and aggressive immunosuppression could limit the efficacy of the immunotherapy, current approaches seek to limit administration of immunosuppressive therapy to patients at risk for life-threatening consequences of the syndrome.  This report presents a novel system to grade the severity of CRS in individual patients and a treatment algorithm for management of CRS based on severity.  The goal of our approach is to maximize the chance for therapeutic benefit from the immunotherapy while minimizing the risk for life threatening complications of CRS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG59RbNPGZCrVg90H21EOLACvtfcHk0ljz3a5lenj3KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1WktbrM&md5=2eec294eaa6681177a18221634e3edda</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-05-552729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-05-552729%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DD.%2BW.%26aulast%3DGardner%26aufirst%3DR.%26aulast%3DPorter%26aufirst%3DD.%2BL.%26aulast%3DLouis%26aufirst%3DC.%2BU.%26aulast%3DAhmed%26aufirst%3DN.%26aulast%3DJensen%26aufirst%3DM.%26aulast%3DGrupp%26aufirst%3DS.%2BA.%26aulast%3DMackall%26aufirst%3DC.%2BL.%26atitle%3DCurrent%2520concepts%2520in%2520the%2520diagnosis%2520and%2520management%2520of%2520cytokine%2520release%2520syndrome%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D188%26epage%3D195%26doi%3D10.1182%2Fblood-2014-05-552729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santomasso, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locke, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghobadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turtle, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brudno, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maus, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mead, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eldjerou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peggs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPersio, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Brink, M. R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komanduri, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grupp, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neelapu, S. S.</span></span> <span> </span><span class="NLM_article-title">ASBMT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells</span>. <i>Biol. Blood Marrow Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">625</span>– <span class="NLM_lpage">638</span>, <span class="refDoi"> DOI: 10.1016/j.bbmt.2018.12.758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.bbmt.2018.12.758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=30592986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1aksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=625-638&issue=4&author=D.+W.+Leeauthor=B.+D.+Santomassoauthor=F.+L.+Lockeauthor=A.+Ghobadiauthor=C.+J.+Turtleauthor=J.+N.+Brudnoauthor=M.+V.+Mausauthor=J.+H.+Parkauthor=E.+Meadauthor=S.+Pavleticauthor=W.+Y.+Goauthor=L.+Eldjerouauthor=R.+A.+Gardnerauthor=N.+Freyauthor=K.+J.+Curranauthor=K.+Peggsauthor=M.+Pasquiniauthor=J.+F.+DiPersioauthor=M.+R.+M.+van+den+Brinkauthor=K.+V.+Komanduriauthor=S.+A.+Gruppauthor=S.+S.+Neelapu&title=ASBMT+consensus+grading+for+cytokine+release+syndrome+and+neurologic+toxicity+associated+with+immune+effector+cells&doi=10.1016%2Fj.bbmt.2018.12.758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">ASBMT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells</span></div><div class="casAuthors">Lee, Daniel W.; Santomasso, Bianca D.; Locke, Frederick L.; Ghobadi, Armin; Turtle, Cameron J.; Brudno, Jennifer N.; Maus, Marcela V.; Park, Jae H.; Mead, Elena; Pavletic, Steven; Go, William Y.; Eldjerou, Lamis; Gardner, Rebecca A.; Frey, Noelle; Curran, Kevin J.; Peggs, Karl; Pasquini, Marcelo; Di Persio, John F.; van den Brink, Marcel R. M.; Komanduri, Krishna V.; Grupp, Stephan A.; Neelapu, Sattva S.</div><div class="citationInfo"><span class="NLM_cas:title">Biology of Blood and Marrow Transplantation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">625-638</span>CODEN:
                <span class="NLM_cas:coden">BBMTF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-8791</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Chimeric antigen receptor (CAR) T cell therapy is rapidly emerging as one of the most promising therapies for hematol. malignancies.  Two CAR T products were recently approved in the United States and Europe for the treatment of patients up to age 25 years with relapsed or refractory B cell acute lymphoblastic leukemia and/or adults with large B cell lymphoma.  These therapies are assocd. with unique toxicities of cytokine release syndrome (CRS) and neurol. toxicity.  The assessment and grading of these toxicities vary considerably across clin. trials and across institutions, making it difficult to compare the safety of different products and hindering the ability to develop optimal strategies for management of these toxicities.  Therefore, in an effort to harmonize the definitions and grading systems for CRS and neurotoxicity, experts from all aspects of the field met on June 20 and 21, 2018, at a meeting supported by the American Society for Blood and Marrow Transplantation (ASBMT) in Arlington, VA.  Here we report the consensus recommendations of that group and propose new definitions and grading for CRS and neurotoxicity that are objective, easy to apply, and ultimately more accurately categorize the severity of these toxicities.  The goal is to provide a uniform consensus grading system for CRS and neurotoxicity assocd. with immune effector cell therapies, for use across clin. trials and in the postapproval clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHSdFF-1LsELVg90H21EOLACvtfcHk0ljz3a5lenj3KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1aksbw%253D&md5=3dfa0271be9d48f99a8bee88c50686cb</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bbmt.2018.12.758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbmt.2018.12.758%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DD.%2BW.%26aulast%3DSantomasso%26aufirst%3DB.%2BD.%26aulast%3DLocke%26aufirst%3DF.%2BL.%26aulast%3DGhobadi%26aufirst%3DA.%26aulast%3DTurtle%26aufirst%3DC.%2BJ.%26aulast%3DBrudno%26aufirst%3DJ.%2BN.%26aulast%3DMaus%26aufirst%3DM.%2BV.%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DMead%26aufirst%3DE.%26aulast%3DPavletic%26aufirst%3DS.%26aulast%3DGo%26aufirst%3DW.%2BY.%26aulast%3DEldjerou%26aufirst%3DL.%26aulast%3DGardner%26aufirst%3DR.%2BA.%26aulast%3DFrey%26aufirst%3DN.%26aulast%3DCurran%26aufirst%3DK.%2BJ.%26aulast%3DPeggs%26aufirst%3DK.%26aulast%3DPasquini%26aufirst%3DM.%26aulast%3DDiPersio%26aufirst%3DJ.%2BF.%26aulast%3Dvan%2Bden%2BBrink%26aufirst%3DM.%2BR.%2BM.%26aulast%3DKomanduri%26aufirst%3DK.%2BV.%26aulast%3DGrupp%26aufirst%3DS.%2BA.%26aulast%3DNeelapu%26aufirst%3DS.%2BS.%26atitle%3DASBMT%2520consensus%2520grading%2520for%2520cytokine%2520release%2520syndrome%2520and%2520neurologic%2520toxicity%2520associated%2520with%2520immune%2520effector%2520cells%26jtitle%3DBiol.%2520Blood%2520Marrow%2520Transplant.%26date%3D2019%26volume%3D25%26issue%3D4%26spage%3D625%26epage%3D638%26doi%3D10.1016%2Fj.bbmt.2018.12.758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davila, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riviere, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartido, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borquez-Ojeda, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olszewska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasielewska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinglot, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youssif, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintanilla, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernal, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhassira, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roboz, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maslak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frattini, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giralt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadelain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brentjens, R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">224</span>),  <span class="NLM_fpage">224ra25</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3008226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1126%2Fscitranslmed.3008226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=24553386" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=224ra25&issue=224&author=M.+L.+Davilaauthor=I.+Riviereauthor=X.+Wangauthor=S.+Bartidoauthor=J.+Parkauthor=K.+Curranauthor=S.+S.+Chungauthor=J.+Stefanskiauthor=O.+Borquez-Ojedaauthor=M.+Olszewskaauthor=J.+Quauthor=T.+Wasielewskaauthor=Q.+Heauthor=M.+Finkauthor=H.+Shinglotauthor=M.+Youssifauthor=M.+Satterauthor=Y.+Wangauthor=J.+Hoseyauthor=H.+Quintanillaauthor=E.+Haltonauthor=Y.+Bernalauthor=D.+C.+Bouhassiraauthor=M.+E.+Arcilaauthor=M.+Gonenauthor=G.+J.+Robozauthor=P.+Maslakauthor=D.+Douerauthor=M.+G.+Frattiniauthor=S.+Giraltauthor=M.+Sadelainauthor=R.+Brentjens&title=Efficacy+and+toxicity+management+of+19%E2%80%9328z+CAR+T+cell+therapy+in+B+cell+acute+lymphoblastic+leukemia&doi=10.1126%2Fscitranslmed.3008226"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3008226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3008226%26sid%3Dliteratum%253Aachs%26aulast%3DDavila%26aufirst%3DM.%2BL.%26aulast%3DRiviere%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DBartido%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DChung%26aufirst%3DS.%2BS.%26aulast%3DStefanski%26aufirst%3DJ.%26aulast%3DBorquez-Ojeda%26aufirst%3DO.%26aulast%3DOlszewska%26aufirst%3DM.%26aulast%3DQu%26aufirst%3DJ.%26aulast%3DWasielewska%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DFink%26aufirst%3DM.%26aulast%3DShinglot%26aufirst%3DH.%26aulast%3DYoussif%26aufirst%3DM.%26aulast%3DSatter%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHosey%26aufirst%3DJ.%26aulast%3DQuintanilla%26aufirst%3DH.%26aulast%3DHalton%26aufirst%3DE.%26aulast%3DBernal%26aufirst%3DY.%26aulast%3DBouhassira%26aufirst%3DD.%2BC.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DGonen%26aufirst%3DM.%26aulast%3DRoboz%26aufirst%3DG.%2BJ.%26aulast%3DMaslak%26aufirst%3DP.%26aulast%3DDouer%26aufirst%3DD.%26aulast%3DFrattini%26aufirst%3DM.%2BG.%26aulast%3DGiralt%26aufirst%3DS.%26aulast%3DSadelain%26aufirst%3DM.%26aulast%3DBrentjens%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520toxicity%2520management%2520of%252019%25E2%2580%259328z%2520CAR%2520T%2520cell%2520therapy%2520in%2520B%2520cell%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2014%26volume%3D6%26issue%3D224%26spage%3D224ra25%26doi%3D10.1126%2Fscitranslmed.3008226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camisa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbiera, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purevdorj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genua, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanvito, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponzoni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doglioni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristofori, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traversari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordignon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostuni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casucci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondanza, A.</span></span> <span> </span><span class="NLM_article-title">Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">739</span>– <span class="NLM_lpage">748</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0036-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fs41591-018-0036-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29808007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=739-748&issue=6&author=M.+Norelliauthor=B.+Camisaauthor=G.+Barbieraauthor=L.+Falconeauthor=A.+Purevdorjauthor=M.+Genuaauthor=F.+Sanvitoauthor=M.+Ponzoniauthor=C.+Doglioniauthor=P.+Cristoforiauthor=C.+Traversariauthor=C.+Bordignonauthor=F.+Ciceriauthor=R.+Ostuniauthor=C.+Boniniauthor=M.+Casucciauthor=A.+Bondanza&title=Monocyte-derived+IL-1+and+IL-6+are+differentially+required+for+cytokine-release+syndrome+and+neurotoxicity+due+to+CAR+T+cells&doi=10.1038%2Fs41591-018-0036-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells</span></div><div class="casAuthors">Norelli, Margherita; Camisa, Barbara; Barbiera, Giulia; Falcone, Laura; Purevdorj, Ayurzana; Genua, Marco; Sanvito, Francesca; Ponzoni, Maurilio; Doglioni, Claudio; Cristofori, Patrizia; Traversari, Catia; Bordignon, Claudio; Ciceri, Fabio; Ostuni, Renato; Bonini, Chiara; Casucci, Monica; Bondanza, Attilio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">739-748</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">In the clinic, chimeric antigen receptor-modified T (CAR T) cell therapy is frequently assocd. with life-threatening cytokine-release syndrome (CRS) and neurotoxicity.  Understanding the nature of these pathologies and developing treatments for them are hampered by the lack of appropriate animal models.  Herein, we describe a mouse model recapitulating key features of CRS and neurotoxicity.  In humanized mice with high leukemia burden, CAR T cell-mediated clearance of cancer triggered high fever and elevated IL-6 levels, which are hallmarks of CRS.  Human monocytes were the major source of IL-1 and IL-6 during CRS.  Accordingly, the syndrome was prevented by monocyte depletion or by blocking IL-6 receptor with tocilizumab.  Nonetheless, tocilizumab failed to protect mice from delayed lethal neurotoxicity, characterized by meningeal inflammation.  Instead, the IL-1 receptor antagonist anakinra abolished both CRS and neurotoxicity, resulting in substantially extended leukemia-free survival.  These findings offer a therapeutic strategy to tackle neurotoxicity and open new avenues to safer CAR T cell therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq700n-_pyK5rVg90H21EOLACvtfcHk0lj--sikVEl5nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVelsbjN&md5=6ee5e872943b103cbe0bcf56ef3d5efb</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0036-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0036-4%26sid%3Dliteratum%253Aachs%26aulast%3DNorelli%26aufirst%3DM.%26aulast%3DCamisa%26aufirst%3DB.%26aulast%3DBarbiera%26aufirst%3DG.%26aulast%3DFalcone%26aufirst%3DL.%26aulast%3DPurevdorj%26aufirst%3DA.%26aulast%3DGenua%26aufirst%3DM.%26aulast%3DSanvito%26aufirst%3DF.%26aulast%3DPonzoni%26aufirst%3DM.%26aulast%3DDoglioni%26aufirst%3DC.%26aulast%3DCristofori%26aufirst%3DP.%26aulast%3DTraversari%26aufirst%3DC.%26aulast%3DBordignon%26aufirst%3DC.%26aulast%3DCiceri%26aufirst%3DF.%26aulast%3DOstuni%26aufirst%3DR.%26aulast%3DBonini%26aufirst%3DC.%26aulast%3DCasucci%26aufirst%3DM.%26aulast%3DBondanza%26aufirst%3DA.%26atitle%3DMonocyte-derived%2520IL-1%2520and%2520IL-6%2520are%2520differentially%2520required%2520for%2520cytokine-release%2520syndrome%2520and%2520neurotoxicity%2520due%2520to%2520CAR%2520T%2520cells%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26issue%3D6%26spage%3D739%26epage%3D748%26doi%3D10.1038%2Fs41591-018-0036-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span> <span> </span><span class="NLM_article-title">Gasdermin E-mediated Target Cell Pyroptosis by CAR T Cells Triggers Cytokine Release Syndrome</span>. <i>Sci. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">43</span>), <span class="NLM_elocation-id">eaax7969</span> <span class="refDoi"> DOI: 10.1126/sciimmunol.aax7969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1126%2Fsciimmunol.aax7969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=31953257" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&issue=43&author=Y.+Liuauthor=Y.+Fangauthor=X.+Chenauthor=Z.+Wangauthor=X.+Liangauthor=T.+Zhangauthor=M.+Liuauthor=N.+Zhouauthor=J.+Lvauthor=K.+Tangauthor=J.+Xieauthor=Y.+Gaoauthor=F.+Chengauthor=Y.+Zhouauthor=Z.+Zhangauthor=Y.+Huauthor=X.+Zhangauthor=Q.+Gaoauthor=Y.+Zhangauthor=B.+Huang&title=Gasdermin+E-mediated+Target+Cell+Pyroptosis+by+CAR+T+Cells+Triggers+Cytokine+Release+Syndrome&doi=10.1126%2Fsciimmunol.aax7969"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1126%2Fsciimmunol.aax7969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciimmunol.aax7969%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DLv%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DK.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DB.%26atitle%3DGasdermin%2520E-mediated%2520Target%2520Cell%2520Pyroptosis%2520by%2520CAR%2520T%2520Cells%2520Triggers%2520Cytokine%2520Release%2520Syndrome%26jtitle%3DSci.%2520Immunol.%26date%3D2020%26volume%3D5%26issue%3D43%26doi%3D10.1126%2Fsciimmunol.aax7969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maude, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teachey, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grupp, S. A.</span></span> <span> </span><span class="NLM_article-title">Managing cytokine release syndrome associated with novel T cell-engaging therapies</span>. <i>Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1097/PPO.0000000000000035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1097%2FPPO.0000000000000035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=24667956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=119-122&issue=2&author=S.+L.+Maudeauthor=D.+Barrettauthor=D.+T.+Teacheyauthor=S.+A.+Grupp&title=Managing+cytokine+release+syndrome+associated+with+novel+T+cell-engaging+therapies&doi=10.1097%2FPPO.0000000000000035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies</span></div><div class="casAuthors">Maude, Shannon L.; Barrett, David; Teachey, David T.; Grupp, Stephan A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Journal (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-122</span>CODEN:
                <span class="NLM_cas:coden">CAJOCB</span>;
        ISSN:<span class="NLM_cas:issn">1528-9117</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Chimeric antigen receptor (CAR)-modified T cells and bispecific T cell-engaging antibodies have demonstrated dramatic clin. responses in recent clin. trials.  The hallmark of these novel highly active immunotherapies is nonphysiol. T cell activation, which has correlated not only with greatly increased efficacy but also with notable toxicity in some cases.  We and others have obsd. a cytokine release syndrome (CRS), which correlates with both toxicity and efficacy in patients receiving T cell-engaging therapies.  In addn. to elevations in effector cytokines, such as interferon-γ, cytokines assocd. with hemophagocytic lymphohistiocytosis or macrophage activation syndrome, such as interleukin (IL)-10 and IL-6, may also be markedly elevated.  Whereas corticosteroids may control some of these toxicities, their potential to block T cell activation and abrogate clin. benefit is a concern.  Detailed studies of T cell proliferation and the resultant immune activation produced by these novel therapies have led to more targeted approaches that have the potential to provide superior toxicity control without compromising efficacy.  One approach we have developed targets IL-6, a prominent cytokine in CRS, using the IL-6R antagonist tocilizumab.  We will review the pathophysiol. and management options for CRS assocd. with T cell-engaging therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokoUPADluSbrVg90H21EOLACvtfcHk0lgfeRhu2GhtHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOqtro%253D&md5=b7707b5d7f22159b72a233f2bf380ddd</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1097%2FPPO.0000000000000035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPPO.0000000000000035%26sid%3Dliteratum%253Aachs%26aulast%3DMaude%26aufirst%3DS.%2BL.%26aulast%3DBarrett%26aufirst%3DD.%26aulast%3DTeachey%26aufirst%3DD.%2BT.%26aulast%3DGrupp%26aufirst%3DS.%2BA.%26atitle%3DManaging%2520cytokine%2520release%2520syndrome%2520associated%2520with%2520novel%2520T%2520cell-engaging%2520therapies%26jtitle%3DCancer%2520J.%26date%3D2014%26volume%3D20%26issue%3D2%26spage%3D119%26epage%3D122%26doi%3D10.1097%2FPPO.0000000000000035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez-Cruz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moghimi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershenson, Z. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mourelatos, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grupp, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milone, M. C.</span></span> <span> </span><span class="NLM_article-title">High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-17-0211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1158%2F2326-6066.CIR-17-0211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29180536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVSltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=36-46&issue=1&author=S.+A.+Richmanauthor=S.+Nunez-Cruzauthor=B.+Moghimiauthor=L.+Z.+Liauthor=Z.+T.+Gershensonauthor=Z.+Mourelatosauthor=D.+M.+Barrettauthor=S.+A.+Gruppauthor=M.+C.+Milone&title=High-affinity+GD2-specific+CAR+T+cells+induce+fatal+encephalitis+in+a+preclinical+neuroblastoma+model&doi=10.1158%2F2326-6066.CIR-17-0211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model</span></div><div class="casAuthors">Richman, Sarah A.; Nunez-Cruz, Selene; Moghimi, Babak; Li, Lucy Z.; Gershenson, Zachary T.; Mourelatos, Zissimos; Barrett, David M.; Grupp, Stephan A.; Milone, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-46</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The GD2 ganglioside, which is abundant on the surface of neuroblastoma cells, is targeted by an FDA-approved therapeutic monoclonal antibody and is an attractive tumor-assocd. antigen for cellular immunotherapy.  Chimeric antigen receptor (CAR)-modified T cells can have potent antitumor activity in B-cell malignancies, and trials to harness this cytolytic activity toward GD2 in neuroblastoma are under way.  In an effort to enhance the antitumor activity of CAR T cells that target GD2, we generated variant CAR constructs predicted to improve the stability and the affinity of the GD2-binding, 14G2a-based, single-chain variable fragment (scFv) of the CAR and compared their properties in vivo.  We included the E101K mutation of GD2 scFv (GD2-E101K) that has enhanced antitumor activity against a GD2+ human neuroblastoma xenograft in vivo.  However, this enhanced antitumor efficacy in vivo was concomitantly assocd. with lethal central nervous system (CNS) toxicity comprised of extensive CAR T-cell infiltration and proliferation within the brain and neuronal destruction.  The encephalitis was localized to the cerebellum and basal regions of the brain that display low amts. of GD2.  Our results highlight the challenges assocd. with target antigens that exhibit shared expression on crit. normal tissues.  Despite the success of GD2-specific antibody therapies in the treatment of neuroblastoma, the fatal neurotoxicity of GD2-specific CAR T-cell therapy obsd. in our studies suggests that GD2 may be a difficult target antigen for CAR T-cell therapy without addnl. strategies that can control CAR T-cell function within the CNS.  Cancer Immunol Res; 6(1); 36-46. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ_8y4apr5j7Vg90H21EOLACvtfcHk0lgfeRhu2GhtHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVSltA%253D%253D&md5=2fc2a027a315681db5e608e421c005f8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-17-0211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-17-0211%26sid%3Dliteratum%253Aachs%26aulast%3DRichman%26aufirst%3DS.%2BA.%26aulast%3DNunez-Cruz%26aufirst%3DS.%26aulast%3DMoghimi%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DL.%2BZ.%26aulast%3DGershenson%26aufirst%3DZ.%2BT.%26aulast%3DMourelatos%26aufirst%3DZ.%26aulast%3DBarrett%26aufirst%3DD.%2BM.%26aulast%3DGrupp%26aufirst%3DS.%2BA.%26aulast%3DMilone%26aufirst%3DM.%2BC.%26atitle%3DHigh-affinity%2520GD2-specific%2520CAR%2520T%2520cells%2520induce%2520fatal%2520encephalitis%2520in%2520a%2520preclinical%2520neuroblastoma%2520model%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2018%26volume%3D6%26issue%3D1%26spage%3D36%26epage%3D46%26doi%3D10.1158%2F2326-6066.CIR-17-0211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neelapu, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kebriaei, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locke, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komanduri, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulbis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loghin, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Groot, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezvani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shpall, E. J.</span></span> <span> </span><span class="NLM_article-title">Chimeric antigen receptor T-cell therapy - assessment and management of toxicities</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2017.148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fnrclinonc.2017.148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=28925994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWnur%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=47-62&issue=1&author=S.+S.+Neelapuauthor=S.+Tummalaauthor=P.+Kebriaeiauthor=W.+Wierdaauthor=C.+Gutierrezauthor=F.+L.+Lockeauthor=K.+V.+Komanduriauthor=Y.+Linauthor=N.+Jainauthor=N.+Daverauthor=J.+Westinauthor=A.+M.+Gulbisauthor=M.+E.+Loghinauthor=J.+F.+de+Grootauthor=S.+Adkinsauthor=S.+E.+Davisauthor=K.+Rezvaniauthor=P.+Hwuauthor=E.+J.+Shpall&title=Chimeric+antigen+receptor+T-cell+therapy+-+assessment+and+management+of+toxicities&doi=10.1038%2Fnrclinonc.2017.148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric antigen receptor T-cell therapy - assessment and management of toxicities</span></div><div class="casAuthors">Neelapu, Sattva S.; Tummala, Sudhakar; Kebriaei, Partow; Wierda, William; Gutierrez, Cristina; Locke, Frederick L.; Komanduri, Krishna V.; Lin, Yi; Jain, Nitin; Daver, Naval; Westin, Jason; Gulbis, Alison M.; Loghin, Monica E.; de Groot, John F.; Adkins, Sherry; Davis, Suzanne E.; Rezvani, Katayoun; Hwu, Patrick; Shpall, Elizabeth J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-62</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Immunotherapy using T cells genetically engineered to express a chimeric antigen receptor (CAR) is rapidly emerging as a promising new treatment for haematol. and non-haematol. malignancies.  CAR-T-cell therapy can induce rapid and durable clin. responses, but is assocd. with unique acute toxicities, which can be severe or even fatal.  Cytokine-release syndrome (CRS), the most commonly obsd. toxicity, can range in severity from low-grade constitutional symptoms to a high-grade syndrome assocd. with life-threatening multiorgan dysfunction; rarely, severe CRS can evolve into fulminant haemophagocytic lymphohistiocytosis (HLH).  Neurotoxicity, termed CAR-T-cell-related encephalopathy syndrome (CRES), is the second most-common adverse event, and can occur concurrently with or after CRS.  Intensive monitoring and prompt management of toxicities is essential to minimize the morbidity and mortality assocd. with this potentially curative therapeutic approach; however, algorithms for accurate and consistent grading and management of the toxicities are lacking.  To address this unmet need, we formed a CAR-T-cell-therapy-assocd. TOXicity (CARTOX) Working Group, comprising investigators from multiple institutions and medical disciplines who have experience in treating patients with various CAR-T-cell therapy products.  Herein, we describe the multidisciplinary approach adopted at our institutions, and provide recommendations for monitoring, grading, and managing the acute toxicities that can occur in patients treated with CAR-T-cell therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8WOainkYsd7Vg90H21EOLACvtfcHk0ljjus14ONNwdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWnur%252FN&md5=846c1202a25d0103715504274fe91ec4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2017.148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2017.148%26sid%3Dliteratum%253Aachs%26aulast%3DNeelapu%26aufirst%3DS.%2BS.%26aulast%3DTummala%26aufirst%3DS.%26aulast%3DKebriaei%26aufirst%3DP.%26aulast%3DWierda%26aufirst%3DW.%26aulast%3DGutierrez%26aufirst%3DC.%26aulast%3DLocke%26aufirst%3DF.%2BL.%26aulast%3DKomanduri%26aufirst%3DK.%2BV.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DJain%26aufirst%3DN.%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DWestin%26aufirst%3DJ.%26aulast%3DGulbis%26aufirst%3DA.%2BM.%26aulast%3DLoghin%26aufirst%3DM.%2BE.%26aulast%3Dde%2BGroot%26aufirst%3DJ.%2BF.%26aulast%3DAdkins%26aufirst%3DS.%26aulast%3DDavis%26aufirst%3DS.%2BE.%26aulast%3DRezvani%26aufirst%3DK.%26aulast%3DHwu%26aufirst%3DP.%26aulast%3DShpall%26aufirst%3DE.%2BJ.%26atitle%3DChimeric%2520antigen%2520receptor%2520T-cell%2520therapy%2520-%2520assessment%2520and%2520management%2520of%2520toxicities%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D15%26issue%3D1%26spage%3D47%26epage%3D62%26doi%3D10.1038%2Fnrclinonc.2017.148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gust, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taraseviciute, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turtle, C. J.</span></span> <span> </span><span class="NLM_article-title">Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1091</span>– <span class="NLM_lpage">1101</span>, <span class="refDoi"> DOI: 10.1007/s40263-018-0582-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1007%2Fs40263-018-0582-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=30387077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BB3cvlvFSjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=1091-1101&issue=12&author=J.+Gustauthor=A.+Taraseviciuteauthor=C.+J.+Turtle&title=Neurotoxicity+Associated+with+CD19-Targeted+CAR-T+Cell+Therapies&doi=10.1007%2Fs40263-018-0582-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies</span></div><div class="casAuthors">Gust Juliane; Gust Juliane; Taraseviciute Agne; Turtle Cameron J; Turtle Cameron J</div><div class="citationInfo"><span class="NLM_cas:title">CNS drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1091-1101</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Neurotoxicity is an important and common complication of chimeric antigen receptor-T cell therapies.  Acute neurologic signs and/or symptoms occur in a significant proportion of patients treated with CD19-directed chimeric antigen receptor-T cells for B-cell malignancies.  Clinical manifestations include headache, confusion, delirium, language disturbance, seizures and rarely, acute cerebral edema.  Neurotoxicity is associated with cytokine release syndrome, which occurs in the setting of in-vivo chimeric antigen receptor-T cell activation and proliferation.  The mechanisms that lead to neurotoxicity remain unknown, but data from patients and animal models suggest there is compromise of the blood-brain barrier, associated with high levels of cytokines in the blood and cerebrospinal fluid, as well as endothelial activation.  Corticosteroids, interleukin-6-targeted therapies, and supportive care are frequently used to manage patients with neurotoxicity, but high-quality evidence of their efficacy is lacking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvASt5-xt-3iXXDYhVZBdlfW6udTcc2eZH_gNbPHsVgbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvlvFSjsw%253D%253D&md5=29d8f967df80e956b2be7adb3ddb4905</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs40263-018-0582-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-018-0582-9%26sid%3Dliteratum%253Aachs%26aulast%3DGust%26aufirst%3DJ.%26aulast%3DTaraseviciute%26aufirst%3DA.%26aulast%3DTurtle%26aufirst%3DC.%2BJ.%26atitle%3DNeurotoxicity%2520Associated%2520with%2520CD19-Targeted%2520CAR-T%2520Cell%2520Therapies%26jtitle%3DCNS%2520Drugs%26date%3D2018%26volume%3D32%26issue%3D12%26spage%3D1091%26epage%3D1101%26doi%3D10.1007%2Fs40263-018-0582-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. J.</span></span> <span> </span><span class="NLM_article-title">EGF receptor variant III as a target antigen for tumor immunotherapy</span>. <i>Expert Rev. Vaccines</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">977</span>– <span class="NLM_lpage">985</span>, <span class="refDoi"> DOI: 10.1586/14760584.7.7.977</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1586%2F14760584.7.7.977" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=18767947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOiur7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=977-985&author=G.+Liauthor=A.+J.+Wong&title=EGF+receptor+variant+III+as+a+target+antigen+for+tumor+immunotherapy&doi=10.1586%2F14760584.7.7.977"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">EGF receptor variant III as a target antigen for tumor immunotherapy</span></div><div class="casAuthors">Li, Gordon; Wong, Albert J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Vaccines</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">977-985</span>CODEN:
                <span class="NLM_cas:coden">ERVXAX</span>;
        ISSN:<span class="NLM_cas:issn">1476-0584</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  The EGF receptor (EGFR) is the first tyrosine kinase receptor ever cloned and remains at the forefront of targeted therapies against cancer.  Currently, there are four US FDA-approved drugs and several more in Phase III studies that target the EGFR.  These drugs, while resulting in some dramatic remissions, have not resulted in strong nor consistent improvements in survival.  EGFR variant III (EGFRvIII) is the most common variant of the EGFR and is present in many different cancer types but not in normal tissue.  It results from the fusion of exon 1 to exon 8 of the EGFR gene, which results in a novel glycine at the junction.  This mutant receptor is constitutively active in these tumors and can lead directly to cancer phenotypes due to its oncogenic properties.  EGFRvIII is an attractive target antigen for cancer immunotherapy because it is not expressed in normal tissue and because cells producing EGFRvIII have an enhanced capacity for dysregulated growth, survival, invasion and angiogenesis.  In this review, we will discuss preclin. and clin. data from studies using EGFRvIII as the target antigen for immunotherapy, with a focus on the potential for greatly improved survival for patients diagnosed with glioblastoma multiforme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoylRB6S3onALVg90H21EOLACvtfcHk0ljjus14ONNwdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOiur7L&md5=6c5f467642becb388707ce1354a78cac</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1586%2F14760584.7.7.977&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14760584.7.7.977%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DG.%26aulast%3DWong%26aufirst%3DA.%2BJ.%26atitle%3DEGF%2520receptor%2520variant%2520III%2520as%2520a%2520target%2520antigen%2520for%2520tumor%2520immunotherapy%26jtitle%3DExpert%2520Rev.%2520Vaccines%26date%3D2008%26volume%3D7%26spage%3D977%26epage%3D985%26doi%3D10.1586%2F14760584.7.7.977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfeiffer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thalheimer, F. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danisch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wels, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modlich, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stripecke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoeyen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchholz, C. J.</span></span> <span> </span><span class="NLM_article-title">In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e9158</span>, <span class="refDoi"> DOI: 10.15252/emmm.201809158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.15252%2Femmm.201809158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=30224381" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=e9158&author=A.+Pfeifferauthor=F.+B.+Thalheimerauthor=S.+Hartmannauthor=A.+M.+Frankauthor=R.+R.+Benderauthor=S.+Danischauthor=C.+Costaauthor=W.+S.+Welsauthor=U.+Modlichauthor=R.+Stripeckeauthor=E.+Verhoeyenauthor=C.+J.+Buchholz&title=In+vivo+generation+of+human+CD19-CAR+T+cells+results+in+B-cell+depletion+and+signs+of+cytokine+release+syndrome&doi=10.15252%2Femmm.201809158"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.15252%2Femmm.201809158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Femmm.201809158%26sid%3Dliteratum%253Aachs%26aulast%3DPfeiffer%26aufirst%3DA.%26aulast%3DThalheimer%26aufirst%3DF.%2BB.%26aulast%3DHartmann%26aufirst%3DS.%26aulast%3DFrank%26aufirst%3DA.%2BM.%26aulast%3DBender%26aufirst%3DR.%2BR.%26aulast%3DDanisch%26aufirst%3DS.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DWels%26aufirst%3DW.%2BS.%26aulast%3DModlich%26aufirst%3DU.%26aulast%3DStripecke%26aufirst%3DR.%26aulast%3DVerhoeyen%26aufirst%3DE.%26aulast%3DBuchholz%26aufirst%3DC.%2BJ.%26atitle%3DIn%2520vivo%2520generation%2520of%2520human%2520CD19-CAR%2520T%2520cells%2520results%2520in%2520B-cell%2520depletion%2520and%2520signs%2520of%2520cytokine%2520release%2520syndrome%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2018%26volume%3D10%26spage%3De9158%26doi%3D10.15252%2Femmm.201809158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurencot, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. A.</span></span> <span> </span><span class="NLM_article-title">Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">851</span>, <span class="refDoi"> DOI: 10.1038/mt.2010.24</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fmt.2010.24" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=20179677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitlaitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=843-851&author=R.+A.+Morganauthor=J.+C.+Yangauthor=M.+Kitanoauthor=M.+E.+Dudleyauthor=C.+M.+Laurencotauthor=S.+A.+Rosenberg&title=Case+report+of+a+serious+adverse+event+following+the+administration+of+T+cells+transduced+with+a+chimeric+antigen+receptor+recognizing+ERBB2&doi=10.1038%2Fmt.2010.24"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2</span></div><div class="casAuthors">Morgan, Richard A.; Yang, James C.; Kitano, Mio; Dudley, Mark E.; Laurencot, Carolyn M.; Rosenberg, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">843-851</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In an attempt to treat cancer patients with ERBB2 overexpressing tumors, we developed a chimeric antigen receptor (CAR) based on the widely used humanized monoclonal antibody (mAb) Trastuzumab (Herceptin).  An optimized CAR vector contg. CD28, 4-1BB, and CD3ζ signaling moieties was assembled in a γ-retroviral vector and used to transduce autologous peripheral blood lymphocytes (PBLs) from a patient with colon cancer metastatic to the lungs and liver, refractory to multiple std. treatments.  The gene transfer efficiency into autologous T cells was 79% CAR+ in CD3+ cells and these cells demonstrated high-specific reactivity in in vitro coculture assays.  Following completion of nonmyeloablative conditioning, the patient received 1010 cells i.v.  Within 15 min after cell infusion the patient experienced respiratory distress, and displayed a dramatic pulmonary infiltrate on chest X-ray.  She was intubated and despite intensive medical intervention the patient died 5 days after treatment.  Serum samples after cell infusion showed marked increases in interferon-γ (IFN-γ), granulocyte macrophage-colony stimulating factor (GM-CSF), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and IL-10, consistent with a cytokine storm.  We speculate that the large no. of administered cells localized to the lung immediately following infusion and were triggered to release cytokine by the recognition of low levels of ERBB2 on lung epithelial cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9wVmmJ9_IVLVg90H21EOLACvtfcHk0lgSMthsHOR5Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitlaitb4%253D&md5=fdf1fd771d8ce6bb9c83f46e58d89db6</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fmt.2010.24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2010.24%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DR.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DKitano%26aufirst%3DM.%26aulast%3DDudley%26aufirst%3DM.%2BE.%26aulast%3DLaurencot%26aufirst%3DC.%2BM.%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26atitle%3DCase%2520report%2520of%2520a%2520serious%2520adverse%2520event%2520following%2520the%2520administration%2520of%2520T%2520cells%2520transduced%2520with%2520a%2520chimeric%2520antigen%2520receptor%2520recognizing%2520ERBB2%26jtitle%3DMol.%2520Ther.%26date%3D2010%26volume%3D18%26spage%3D843%26epage%3D851%26doi%3D10.1038%2Fmt.2010.24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anwer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaukat, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahid, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husnain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PerskY, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riaz, I. B.</span></span> <span> </span><span class="NLM_article-title">Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review</span>. <i>Immunotherapy</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.2217/imt-2016-0127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.2217%2Fimt-2016-0127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=28128714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslWgtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=123-130&author=F.+Anwerauthor=A.+A.+Shaukatauthor=U.+Zahidauthor=M.+Husnainauthor=A.+McBrideauthor=D.+PerskYauthor=M.+Limauthor=N.+Hasanauthor=I.+B.+Riaz&title=Donor+origin+CAR+T+cells%3A+graft+versus+malignancy+effect+without+GVHD%2C+a+systematic+review&doi=10.2217%2Fimt-2016-0127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review</span></div><div class="casAuthors">Anwer, Faiz; Shaukat, Al-Aman; Zahid, Umar; Husnain, Muhammad; McBride, Ali; Persky, Daniel; Lim, Melissa; Hasan, Nida; Bin Riaz, Irbaz</div><div class="citationInfo"><span class="NLM_cas:title">Immunotherapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-130</span>CODEN:
                <span class="NLM_cas:coden">IMMUCO</span>;
        ISSN:<span class="NLM_cas:issn">1750-743X</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  CD19, CD20 chimeric antigen receptor T (CAR T) cell therapy has shown promising results for the treatment of relapsed or refractory hematol. malignancies.  Best results have been reported in acute lymphoblastic leukemia patients with a complete response rate above 80%.  Patients who received donor-derived CAR T cells for the relapsed malignancy after stem cell transplantation (allogenic hematopoietic stem cell transplant) were identified from the published trials.  A total of 72 patients from seven studies were treated with donor-derived CAR T cells.  Only five out of 72 patients (6.9%) developed graft vs. host disease.  Use of donor-derived CAR T cell for relapse prophylaxis, minimal residual disease clearance or salvage from relapse is therefore highly effective, and risk of graft vs. host disease flare is very low.  Side effects include cytokine release syndrome, tumor lysis syndrome, B-cell aplasia along with CNS toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpTdR0lWIk7LVg90H21EOLACvtfcHk0lgSMthsHOR5Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslWgtbw%253D&md5=fc7ea4bfcd96a72aa1834c1bce65cc25</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.2217%2Fimt-2016-0127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fimt-2016-0127%26sid%3Dliteratum%253Aachs%26aulast%3DAnwer%26aufirst%3DF.%26aulast%3DShaukat%26aufirst%3DA.%2BA.%26aulast%3DZahid%26aufirst%3DU.%26aulast%3DHusnain%26aufirst%3DM.%26aulast%3DMcBride%26aufirst%3DA.%26aulast%3DPerskY%26aufirst%3DD.%26aulast%3DLim%26aufirst%3DM.%26aulast%3DHasan%26aufirst%3DN.%26aulast%3DRiaz%26aufirst%3DI.%2BB.%26atitle%3DDonor%2520origin%2520CAR%2520T%2520cells%253A%2520graft%2520versus%2520malignancy%2520effect%2520without%2520GVHD%252C%2520a%2520systematic%2520review%26jtitle%3DImmunotherapy%26date%3D2017%26volume%3D9%26spage%3D123%26epage%3D130%26doi%3D10.2217%2Fimt-2016-0127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tey, S. K.</span></span> <span> </span><span class="NLM_article-title">Adoptive T-cell therapy: adverse events and safety switches</span>. <i>Clin. Transl. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">e17</span> <span class="refDoi"> DOI: 10.1038/cti.2014.11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fcti.2014.11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=25505965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12msb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&author=S.+K.+Tey&title=Adoptive+T-cell+therapy%3A+adverse+events+and+safety+switches&doi=10.1038%2Fcti.2014.11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Adoptive T-cell therapy: adverse events and safety switches</span></div><div class="casAuthors">Tey, Siok-Keen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e17/1-e17/7</span>CODEN:
                <span class="NLM_cas:coden">CTILBR</span>;
        ISSN:<span class="NLM_cas:issn">2050-0068</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">A review.  The potential of adoptive T-cell therapy in effecting complete and durable responses has been demonstrated in a no. of malignant and infectious diseases.  Ongoing progress in T-cell engineering has given cause for optimism in the broader clin. applicability of this approach.  However, the development of more potent T cells is checked by safety concerns, highlighted by the occurrence of on-target and off-target toxicities that, although uncommon, have been fatal on occasions.  Timely pharmacol. intervention is effective in the management of a majority of adverse events but adoptively transferred T cells can persist long term, along with any unwanted effects.  A recently validated cellular safety switch, inducible caspase 9 (iCasp9), has the potential to mitigate the risks of T-cell therapy by enabling the elimination of transferred T cells if required.  In hematopoietic stem cell transplantation, iCasp9-modified donor T cells can be rapidly eliminated in the event of graft-vs.-host disease.  This review presents an overview of the risks assocd. with modern T-cell therapy and the development, clin. results and potential future application of the iCasp9 safety switch.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVezTfqwEFGLVg90H21EOLACvtfcHk0lgPQV106-YYhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12msb7P&md5=e6373d986ab7d355a99583f6088ee581</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fcti.2014.11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcti.2014.11%26sid%3Dliteratum%253Aachs%26aulast%3DTey%26aufirst%3DS.%2BK.%26atitle%3DAdoptive%2520T-cell%2520therapy%253A%2520adverse%2520events%2520and%2520safety%2520switches%26jtitle%3DClin.%2520Transl.%2520Immunol.%26date%3D2014%26volume%3D3%26doi%3D10.1038%2Fcti.2014.11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Acerbi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broggi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anghileri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eoli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiariti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broggi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferroli, P.</span></span> <span> </span><span class="NLM_article-title">Fluorescein-guided surgery for malignant gliomas: a review</span>. <i>Neurosurg. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">547</span>– <span class="NLM_lpage">557</span>, <span class="refDoi"> DOI: 10.1007/s10143-014-0546-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1007%2Fs10143-014-0546-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=24756415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BC2cnlvVektQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2014&pages=547-557&author=F.+Acerbiauthor=C.+Cavalloauthor=M.+Broggiauthor=R.+Cordellaauthor=E.+Anghileriauthor=M.+Eoliauthor=M.+Schiaritiauthor=G.+Broggiauthor=P.+Ferroli&title=Fluorescein-guided+surgery+for+malignant+gliomas%3A+a+review&doi=10.1007%2Fs10143-014-0546-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorescein-guided surgery for malignant gliomas: a review</span></div><div class="casAuthors">Acerbi Francesco; Cavallo Claudio; Broggi Morgan; Cordella Roberto; Anghileri Elena; Eoli Marica; Schiariti Marco; Broggi Giovanni; Ferroli Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Neurosurgical review</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">547-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fluorescein is widely used as a fluorescent tracer for many applications.  Its capacity to accumulate in cerebral areas where there has been blood-brain barrier damage makes it particularly suitable as a dye for the intraoperative visualization of malignant gliomas (MGs).  In this report, we describe the results of a comprehensive review on the use of fluorescein in the surgical treatment of MGs.  A comprehensive literature search and review for English-written articles concerning the use of fluorescein in the resection of MGs has been conducted.  The search was executed through a PubMed literature search using the following keywords: malignant gliomas, glioblastomas, high-grade gliomas, YELLOW 560, total removal, dedicated filter, neurosurgery, brain tumors, intracranial tumors, and confocal microscopy.  The literature search resulted in the retrieval of 412 evidence-based articles.  Of these, 17 were found to be strictly related to the resection of MG with the aid of fluorescein.  In addition to these 17, we have included 2 articles derived from a personal database of the corresponding author (FA).  The analysis of the articles reviewed revealed three major applications of fluorescein during surgery for MGs that was documented: Fluorescein-guided resection of MGs with white-light illumination, fluorescein-guided resection of MGs with a surgical microscope equipped with a dedicated filter for fluorescein, and confocal microscopy for intraoperative histopathological analysis on MGs.  The systemic review conducted on the use of fluorescein in MGs explored the applications and the different modalities in which fluorescein has been used.  The data we have gathered indicates that fluorescein-guided surgery is a safe, effective, and convenient technique to achieve a high rate of total removal in MGs.  Further prospective comparative trials, however, are still necessary to prove the impact of fluorescein-guided surgery on both progression-free survival and overall survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSzK17LlH9Teftos8R3JUhXfW6udTcc2eYA-xmZ1npmkrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnlvVektQ%253D%253D&md5=cb312c8caa694ae28d80aa28b770395f</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs10143-014-0546-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10143-014-0546-6%26sid%3Dliteratum%253Aachs%26aulast%3DAcerbi%26aufirst%3DF.%26aulast%3DCavallo%26aufirst%3DC.%26aulast%3DBroggi%26aufirst%3DM.%26aulast%3DCordella%26aufirst%3DR.%26aulast%3DAnghileri%26aufirst%3DE.%26aulast%3DEoli%26aufirst%3DM.%26aulast%3DSchiariti%26aufirst%3DM.%26aulast%3DBroggi%26aufirst%3DG.%26aulast%3DFerroli%26aufirst%3DP.%26atitle%3DFluorescein-guided%2520surgery%2520for%2520malignant%2520gliomas%253A%2520a%2520review%26jtitle%3DNeurosurg.%2520Rev.%26date%3D2014%26volume%3D37%26spage%3D547%26epage%3D557%26doi%3D10.1007%2Fs10143-014-0546-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Dam, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Themelis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crane, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harlaar, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleijhuis, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelder, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarantopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arts, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Zee, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ntziachristos, V.</span></span> <span> </span><span class="NLM_article-title">Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1315</span>– <span class="NLM_lpage">1319</span>, <span class="refDoi"> DOI: 10.1038/nm.2472</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fnm.2472" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=21926976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFylsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=1315-1319&author=G.+M.+van%0ADamauthor=G.+Themelisauthor=L.+M.+Craneauthor=N.+J.+Harlaarauthor=R.+G.+Pleijhuisauthor=W.+Kelderauthor=A.+Sarantopoulosauthor=J.+S.+de+Jongauthor=H.+J.+Artsauthor=A.+G.+van+der+Zeeauthor=J.+Bartauthor=P.+S.+Lowauthor=V.+Ntziachristos&title=Intraoperative+tumor-specific+fluorescence+imaging+in+ovarian+cancer+by+folate+receptor-alpha+targeting%3A+first+in-human+results&doi=10.1038%2Fnm.2472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results</span></div><div class="casAuthors">van Dam, Gooitzen M.; Themelis, George; Crane, Lucia M. A.; Harlaar, Niels J.; Pleijhuis, Rick G.; Kelder, Wendy; Sarantopoulos, Athanasios; de Jong, Johannes S.; Arts, Henriette J. G.; van der Zee, Ate G. J.; Bart, Joost; Low, Philip S.; Ntziachristos, Vasilis</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1315-1319</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The prognosis in advanced-stage ovarian cancer remains poor.  Tumor-specific intraoperative fluorescence imaging may improve staging and debulking efforts in cytoreductive surgery and thereby improve prognosis.  The overexpression of folate receptor-α (FR-α) in 90-95% of epithelial ovarian cancers prompted the investigation of intraoperative tumor-specific fluorescence imaging in ovarian cancer surgery using an FR-α-targeted fluorescent agent.  In patients with ovarian cancer, intraoperative tumor-specific fluorescence imaging with an FR-α-targeted fluorescent agent showcased the potential applications in patients with ovarian cancer for improved intraoperative staging and more radical cytoreductive surgery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJtb6YYXRHBrVg90H21EOLACvtfcHk0lgPQV106-YYhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFylsrfN&md5=04402cfbf8b9b08a2596b76d9be26ff9</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fnm.2472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2472%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BDam%26aufirst%3DG.%2BM.%26aulast%3DThemelis%26aufirst%3DG.%26aulast%3DCrane%26aufirst%3DL.%2BM.%26aulast%3DHarlaar%26aufirst%3DN.%2BJ.%26aulast%3DPleijhuis%26aufirst%3DR.%2BG.%26aulast%3DKelder%26aufirst%3DW.%26aulast%3DSarantopoulos%26aufirst%3DA.%26aulast%3Dde%2BJong%26aufirst%3DJ.%2BS.%26aulast%3DArts%26aufirst%3DH.%2BJ.%26aulast%3Dvan%2Bder%2BZee%26aufirst%3DA.%2BG.%26aulast%3DBart%26aufirst%3DJ.%26aulast%3DLow%26aufirst%3DP.%2BS.%26aulast%3DNtziachristos%26aufirst%3DV.%26atitle%3DIntraoperative%2520tumor-specific%2520fluorescence%2520imaging%2520in%2520ovarian%2520cancer%2520by%2520folate%2520receptor-alpha%2520targeting%253A%2520first%2520in-human%2520results%26jtitle%3DNat.%2520Med.%26date%3D2011%26volume%3D17%26spage%3D1315%26epage%3D1319%26doi%3D10.1038%2Fnm.2472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacivita, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span> <span> </span><span class="NLM_article-title">Developments in fluorescent probes for receptor research</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">706</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2009.03.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.drudis.2009.03.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=19573791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFyktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=706-712&author=M.+Leopoldoauthor=E.+Lacivitaauthor=F.+Berardiauthor=R.+Perrone&title=Developments+in+fluorescent+probes+for+receptor+research&doi=10.1016%2Fj.drudis.2009.03.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Developments in fluorescent probes for receptor research</span></div><div class="casAuthors">Leopoldo, Marcello; Lacivita, Enza; Berardi, Francesco; Perrone, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">13/14</span>),
    <span class="NLM_cas:pages">706-712</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Early reports on the identification of fluorescent probes for receptors date back to mid-1970s.  Fluorescent probes were initially used to visualize mol. targets in an analogous way to the use of fluorescent antibodies but with the same resoln. as isotopically labeled ligands.  In parallel to the rapid development of techniques, such as fluorescence correlation spectroscopy, multi-photon excitation fluorescence microscopy, fluorescence polarization and in vivo fluorescence imaging, fluorescent probes are becoming multifaceted tools in life science.  The present review will focus on how the design of fluorescent ligands for receptors has evolved to meet the needs of most recent fluorescence applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqOP-3fq6YUrVg90H21EOLACvtfcHk0ljqB1oVtAtYeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFyktLc%253D&md5=3de8004e2782a83b6bb503e6dc6496c9</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.03.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.03.015%26sid%3Dliteratum%253Aachs%26aulast%3DLeopoldo%26aufirst%3DM.%26aulast%3DLacivita%26aufirst%3DE.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DPerrone%26aufirst%3DR.%26atitle%3DDevelopments%2520in%2520fluorescent%2520probes%2520for%2520receptor%2520research%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D706%26epage%3D712%26doi%3D10.1016%2Fj.drudis.2009.03.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazane, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugh, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonslow, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochenderfer, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span> <span> </span><span class="NLM_article-title">Versatile strategy for controlling the specificity and activity of engineered T cells</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">E450</span>– <span class="NLM_lpage">E458</span>, <span class="refDoi"> DOI: 10.1073/pnas.1524193113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1073%2Fpnas.1524193113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=26759368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC28Xns1antA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=E450-E458&author=J.+S.+Maauthor=J.+Y.+Kimauthor=S.+A.+Kazaneauthor=S.+H.+Choiauthor=H.+Y.+Yunauthor=M.+S.+Kimauthor=D.+T.+Rodgersauthor=H.+M.+Pughauthor=O.+Singerauthor=S.+B.+Sunauthor=B.+R.+Fonslowauthor=J.+N.+Kochenderferauthor=T.+M.+Wrightauthor=P.+G.+Schultzauthor=T.+S.+Youngauthor=C.+H.+Kimauthor=Y.+Cao&title=Versatile+strategy+for+controlling+the+specificity+and+activity+of+engineered+T+cells&doi=10.1073%2Fpnas.1524193113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Versatile strategy for controlling the specificity and activity of engineered T cells</span></div><div class="casAuthors">Ma, Jennifer S. Y.; Kim, Ji Young; Kazane, Stephanie A.; Choi, Sei-hyun; Yun, Hwa Young; Kim, Min Soo; Rodgers, David T.; Pugh, Holly M.; Singer, Oded; Sun, Sophie B.; Fonslow, Bryan R.; Kochenderfer, James N.; Wright, Timothy M.; Schultz, Peter G.; Young, Travis S.; Kim, Chan Hyuk; Cao, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">E450-E458</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The adoptive transfer of autologous T cells engineered to express a chimeric antigen receptor (CAR) has emerged as a promising cancer therapy.  Despite impressive clin. efficacy, the general application of current CAR-T-cell therapy is limited by serious treatment-related toxicities.  One approach to improve the safety of CAR-T cells involves making their activation and proliferation dependent upon adaptor mols. that mediate formation of the immunol. synapse between the target cancer cell and T-cell.  Here, the authors describe the design and synthesis of structurally defined semisynthetic adaptors the authors refer to as "switch" mols., in which anti-CD19 and anti-CD22 antibody fragments are site-specifically modified with FITC using genetically encoded noncanonical amino acids.  This approach allows the precise control over the geometry and stoichiometry of complex formation between CD19- or CD22-expressing cancer cells and a "universal" anti-FITC-directed CAR-T cell.  Optimization of this CAR-switch combination results in potent, dose-dependent in vivo antitumor activity in xenograft models.  The advantage of being able to titrate CAR-T-cell in vivo activity was further evidenced by reduced in vivo toxicity and the elimination of persistent B-cell aplasia in immune-competent mice.  The ability to control CAR-T cell and cancer cell interactions using intermediate switch mols. may expand the scope of engineered T-cell therapy to solid tumors, as well as indications beyond cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpyqnoedhMJbVg90H21EOLACvtfcHk0ljqB1oVtAtYeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xns1antA%253D%253D&md5=8a3ca3ccfac0d66d05ec4be93323a970</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1524193113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1524193113%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DKazane%26aufirst%3DS.%2BA.%26aulast%3DChoi%26aufirst%3DS.%2BH.%26aulast%3DYun%26aufirst%3DH.%2BY.%26aulast%3DKim%26aufirst%3DM.%2BS.%26aulast%3DRodgers%26aufirst%3DD.%2BT.%26aulast%3DPugh%26aufirst%3DH.%2BM.%26aulast%3DSinger%26aufirst%3DO.%26aulast%3DSun%26aufirst%3DS.%2BB.%26aulast%3DFonslow%26aufirst%3DB.%2BR.%26aulast%3DKochenderfer%26aufirst%3DJ.%2BN.%26aulast%3DWright%26aufirst%3DT.%2BM.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DYoung%26aufirst%3DT.%2BS.%26aulast%3DKim%26aufirst%3DC.%2BH.%26aulast%3DCao%26aufirst%3DY.%26atitle%3DVersatile%2520strategy%2520for%2520controlling%2520the%2520specificity%2520and%2520activity%2520of%2520engineered%2520T%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3DE450%26epage%3DE458%26doi%3D10.1073%2Fpnas.1524193113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampton, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazagova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugh, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazane, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T. S.</span></span> <span> </span><span class="NLM_article-title">Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7520</span>– <span class="NLM_lpage">7524</span>, <span class="refDoi"> DOI: 10.1002/anie.201601902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1002%2Fanie.201601902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC28XntFGhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=7520-7524&author=Y.+Caoauthor=D.+T.+Rodgersauthor=J.+Duauthor=I.+Ahmadauthor=E.+N.+Hamptonauthor=J.+S.+Maauthor=M.+Mazagovaauthor=S.+H.+Choiauthor=H.+Y.+Yunauthor=H.+Xiaoauthor=P.+Yangauthor=X.+Luoauthor=R.+K.+Limauthor=H.+M.+Pughauthor=F.+Wangauthor=S.+A.+Kazaneauthor=T.+M.+Wrightauthor=C.+H.+Kimauthor=P.+G.+Schultzauthor=T.+S.+Young&title=Design+of+Switchable+Chimeric+Antigen+Receptor+T+Cells+Targeting+Breast+Cancer&doi=10.1002%2Fanie.201601902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer</span></div><div class="casAuthors">Cao, Yu; Rodgers, David T.; Du, Juanjuan; Ahmad, Insha; Hampton, Eric N.; Ma, Jennifer S. Y.; Mazagova, Magdalena; Choi, Sei-hyun; Yun, Hwa Young; Xiao, Han; Yang, Pengyu; Luo, Xiaozhou; Lim, Reyna K. V.; Pugh, Holly M.; Wang, Feng; Kazane, Stephanie A.; Wright, Timothy M.; Kim, Chan Hyuk; Schultz, Peter G.; Young, Travis S.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7520-7524</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Chimeric antigen receptor T (CAR-T) cells have demonstrated promising results against hematol. malignancies, but have encountered significant challenges in translation to solid tumors.  To overcome these hurdles, the authors have developed a switchable CAR-T cell platform in which the activity of the engineered cell is controlled by dosage of an antibody-based switch.  Herein, the authors apply this approach to Her2-expressing breast cancers by engineering switch mols. through site-specific incorporation of FITC or grafting of a peptide neo-epitope (PNE) into the anti-Her2 antibody trastuzumab (clone 4D5).  The authors demonstrate that both switch formats can be readily optimized to redirect CAR-T cells (specific for the corresponding FITC or PNE) to Her2-expressing tumor cells, and afford dose-titratable activation of CAR-T cells ex vivo and complete clearance of the tumor in rodent xenograft models.  This strategy may facilitate the application of immunotherapy to solid tumors by affording comparable efficacy with improved safety owing to switch-based control of the CAR-T response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptJTcWT8ddcbVg90H21EOLACvtfcHk0ljqB1oVtAtYeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntFGhsLs%253D&md5=8a7805a2b6a4a66979a029671f36cf16</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fanie.201601902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201601902%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DY.%26aulast%3DRodgers%26aufirst%3DD.%2BT.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DAhmad%26aufirst%3DI.%26aulast%3DHampton%26aufirst%3DE.%2BN.%26aulast%3DMa%26aufirst%3DJ.%2BS.%26aulast%3DMazagova%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DS.%2BH.%26aulast%3DYun%26aufirst%3DH.%2BY.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DLim%26aufirst%3DR.%2BK.%26aulast%3DPugh%26aufirst%3DH.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKazane%26aufirst%3DS.%2BA.%26aulast%3DWright%26aufirst%3DT.%2BM.%26aulast%3DKim%26aufirst%3DC.%2BH.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DYoung%26aufirst%3DT.%2BS.%26atitle%3DDesign%2520of%2520Switchable%2520Chimeric%2520Antigen%2520Receptor%2520T%2520Cells%2520Targeting%2520Breast%2520Cancer%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D7520%26epage%3D7524%26doi%3D10.1002%2Fanie.201601902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasarao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanduluru, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span> <span> </span><span class="NLM_article-title">Use of a single CAR T cell and several bispecific adapters facilitates eradication of multiple antigenically different solid tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-18-1834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1158%2F0008-5472.CAN-18-1834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=30482775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos1aiu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=387-396&issue=2&author=Y.+G.+Leeauthor=I.+Marksauthor=M.+Srinivasaraoauthor=A.+K.+Kanduluruauthor=S.+M.+Mahalingamauthor=X.+Liuauthor=H.+Chuauthor=P.+S.+Low&title=Use+of+a+single+CAR+T+cell+and+several+bispecific+adapters+facilitates+eradication+of+multiple+antigenically+different+solid+tumors&doi=10.1158%2F0008-5472.CAN-18-1834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Use of a single CAR T cell and several bispecific adapters facilitates eradication of multiple antigenically different solid tumors</span></div><div class="casAuthors">Lee, Yong Gu; Marks, Isaac; Srinivasarao, Madduri; Kanduluru, Ananda Kumar; Mahalingam, Sakkarapalayam M.; Liu, Xin; Chu, Haiyan; Low, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">387-396</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Most solid tumors are comprised of multiple clones that express orthogonal antigens, suggesting that novel strategies must be developed in order to adapt chimeric antigen receptor (CAR) T-cell therapies to treat heterogeneous solid tumors.  Here, we utilized a cocktail of low-mol.-wt.bispecific adapters, each comprised of fluorescein linked to a different tumor-specific ligand, to bridge between an antifluorescein CAR on the engineered T cell and a unique antigen on the cancer cell.  This formation of an immunol. synapse between the CAR T cell and cancer cell enabled use of a single antifluorescein CAR T cell to eradicate a diversity of antigenically different solid tumors implanted concurrently in NSG mice.  Based on these data, we suggest that a carefully designed cocktail of bispecific adapters in combination with antifluorescein CAR T cells can overcome tumor antigen escape mechanisms that lead to disease recurrence following many CAR T-cell therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTEYUbvxURY7Vg90H21EOLACvtfcHk0lhBDadioyIBFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos1aiu70%253D&md5=4fbae4398604a2cc0a83e07e04ad7228</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-1834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-1834%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%2BG.%26aulast%3DMarks%26aufirst%3DI.%26aulast%3DSrinivasarao%26aufirst%3DM.%26aulast%3DKanduluru%26aufirst%3DA.%2BK.%26aulast%3DMahalingam%26aufirst%3DS.%2BM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DChu%26aufirst%3DH.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DUse%2520of%2520a%2520single%2520CAR%2520T%2520cell%2520and%2520several%2520bispecific%2520adapters%2520facilitates%2520eradication%2520of%2520multiple%2520antigenically%2520different%2520solid%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26issue%3D2%26spage%3D387%26epage%3D396%26doi%3D10.1158%2F0008-5472.CAN-18-1834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favalli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandholzer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millul, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzamalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matasci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myburgh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manz, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neri, D.</span></span> <span> </span><span class="NLM_article-title">Impact of ligand size and conjugation chemistry on the performance of universal chimeric antigen receptor T-cells for tumor killing</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1775</span>– <span class="NLM_lpage">1783</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.0c00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.0c00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFWmtrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2020&pages=1775-1783&issue=7&author=C.+Pellegrinoauthor=N.+Favalliauthor=M.+Sandholzerauthor=L.+Voltaauthor=G.+Bassiauthor=J.+Millulauthor=S.+Cazzamalliauthor=M.+Matasciauthor=A.+Villaauthor=R.+Myburghauthor=M.+G.+Manzauthor=D.+Neri&title=Impact+of+ligand+size+and+conjugation+chemistry+on+the+performance+of+universal+chimeric+antigen+receptor+T-cells+for+tumor+killing&doi=10.1021%2Facs.bioconjchem.0c00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Ligand Size and Conjugation Chemistry on the Performance of Universal Chimeric Antigen Receptor T-Cells for Tumor Killing</span></div><div class="casAuthors">Pellegrino, Christian; Favalli, Nicholas; Sandholzer, Michael; Volta, Laura; Bassi, Gabriele; Millul, Jacopo; Cazzamalli, Samuele; Matasci, Mattia; Villa, Alessandra; Myburgh, Renier; Manz, Markus G.; Neri, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1775-1783</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">All Universal Chimeric Antigen Receptor T-cells (UniCAR T-cells) are T-cells which have been engineered to recognize a haptenated ligand.  Due to this feature, UniCAR T-cells have the potential to mediate a potent and selective tumor killing only in the presence of a haptenated tumor ligand, thus avoiding the long-lasting biocidal effects of conventional CAR T-cells.  We have used fluorescein-labeled versions of small org. ligands and different antibody formats specific to carbonic anhydrase IX (a tumor-assocd. antigen) in order to assess whether the killing potential of UniCAR T-cells depended on the mol. features of the haptenated mol.  Both small mol. ligands and larger antibody fragments were potent in mediating tumor cell killing over a broad concn. range.  Antibodies could be conveniently used both in IgG format and as smaller diabody fragments.  Importantly, the use of site-specific chem. modification strategies for the antibody coupling to fluorescein led to a substantial improvement of tumor cell killing performance, compared to the random modification of primary amino groups on the antibody surface.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp1I2YW_nSMrVg90H21EOLACvtfcHk0lhBDadioyIBFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFWmtrjK&md5=c4b673d38b1d6c00b1e14d49da3c2d49</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.0c00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.0c00258%26sid%3Dliteratum%253Aachs%26aulast%3DPellegrino%26aufirst%3DC.%26aulast%3DFavalli%26aufirst%3DN.%26aulast%3DSandholzer%26aufirst%3DM.%26aulast%3DVolta%26aufirst%3DL.%26aulast%3DBassi%26aufirst%3DG.%26aulast%3DMillul%26aufirst%3DJ.%26aulast%3DCazzamalli%26aufirst%3DS.%26aulast%3DMatasci%26aufirst%3DM.%26aulast%3DVilla%26aufirst%3DA.%26aulast%3DMyburgh%26aufirst%3DR.%26aulast%3DManz%26aufirst%3DM.%2BG.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DImpact%2520of%2520ligand%2520size%2520and%2520conjugation%2520chemistry%2520on%2520the%2520performance%2520of%2520universal%2520chimeric%2520antigen%2520receptor%2520T-cells%2520for%2520tumor%2520killing%26jtitle%3DBioconjugate%2520Chem.%26date%3D2020%26volume%3D31%26issue%3D7%26spage%3D1775%26epage%3D1783%26doi%3D10.1021%2Facs.bioconjchem.0c00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setrerrahmane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span> <span> </span><span class="NLM_article-title">Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">44</span>, <span class="refDoi"> DOI: 10.1186/s13045-018-0591-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1186%2Fs13045-018-0591-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29558951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVyqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=44&author=E.+Zhangauthor=J.+Guauthor=J.+Xueauthor=C.+Linauthor=C.+Liuauthor=M.+Liauthor=J.+Haoauthor=S.+Setrerrahmaneauthor=X.+Chiauthor=W.+Qiauthor=J.+Huauthor=H.+Xu&title=Accurate+control+of+dual-receptor-engineered+T+cell+activity+through+a+bifunctional+anti-angiogenic+peptide&doi=10.1186%2Fs13045-018-0591-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide</span></div><div class="casAuthors">Zhang, Erhao; Gu, Jieyi; Xue, Jianpeng; Lin, Chenyu; Liu, Chen; Li, Mengwei; Hao, Jingchao; Setrerrahmane, Sarra; Chi, Xiaowei; Qi, Weiyan; Hu, Jialiang; Xu, Hanmei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">44/1-44/14</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Chimeric antigen receptors (CARs) presented on T cell surfaces enable redirection of T cell specificity, which has enormous promise in antitumor therapy.  However, excessive activity and poor control over such engineered T cells cause significant safety challenges, such as cytokine release syndrome and organ toxicities.  To enhance the specificity and controllable activity of CAR-T cells, we report a novel switchable dual-receptor CAR-engineered T (sdCAR-T) cell and a new switch mol. of FITC-HM-3 bifunctional mol. (FHBM) in this study.  We designed a fusion mol. comprising FITC and HM-3.  HM-3, an antitumor peptide including an Arg-Gly-Asp sequence, can specifically target integrin avβ3 that is presented on some tumor cells.  Moreover, to improve the specificity of CAR-T cells, we also generated the sdCAR-T cell line against cognate tumor cells expressing human mesothelin (MSLN) and integrin avβ3.  Finally, the activity of sdCAR-T cell and FHBM is verified via in vitro and in vivo expts.  In the presence of FHBM, the designed sdCAR-T cells exerted high activity including activation and proliferation and had specific cytotoxicity in a time- and dose-dependent manner in vitro.  Furthermore, using a combination of FHBM in nude mice, sdCAR-T cells significantly inhibited the growth of MSLN+ K562 cells and released lower levels of the cytokines (e.g., interleukin-2, interferon a, interleukin-6, and tumor necrosis factor a) relative to conventional CAR-T cells, obtaining specific, controllable, and enhanced cytotoxicity.  Our data indicate that FHBM can accurately control timing and dose of injected CAR-T cells, and sdCAR-T cells exert significant antitumor activity while releasing lower levels of cytokines for the cognate tumor cells expressing both MSLN and integrin avβ3.  Therefore, combination therapies using sdCAR-T cells and the switch mol. FHBM have significant potential to treat malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSoIovesVPirVg90H21EOLACvtfcHk0lhBDadioyIBFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVyqtbo%253D&md5=09aed161fbdf1af7a7448d0d7bf557e3</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1186%2Fs13045-018-0591-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-018-0591-7%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DXue%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DSetrerrahmane%26aufirst%3DS.%26aulast%3DChi%26aufirst%3DX.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DH.%26atitle%3DAccurate%2520control%2520of%2520dual-receptor-engineered%2520T%2520cell%2520activity%2520through%2520a%2520bifunctional%2520anti-angiogenic%2520peptide%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D44%26doi%3D10.1186%2Fs13045-018-0591-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span> <span> </span><span class="NLM_article-title">Folate-targeted therapies for cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">6811</span>– <span class="NLM_lpage">6824</span>, <span class="refDoi"> DOI: 10.1021/jm100509v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100509v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6811-6824&issue=19&author=W.+Xiaauthor=P.+S.+Low&title=Folate-targeted+therapies+for+cancer&doi=10.1021%2Fjm100509v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Folate-Targeted Therapies for Cancer</span></div><div class="casAuthors">Xia, Wei; Low, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6811-6824</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This article discusses the use of folic acid as a ligand to target therapeutic cargos of many sizes, shapes, mechanisms of action to tumor cells both in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpihPD6hMJ_77Vg90H21EOLACvtfcHk0lg56va4_xp-7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCit7w%253D&md5=8d302235e47b742beed54f482c637c49</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm100509v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100509v%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DW.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DFolate-targeted%2520therapies%2520for%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D19%26spage%3D6811%26epage%3D6824%26doi%3D10.1021%2Fjm100509v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kularatne, S. A.</span></span> <span> </span><span class="NLM_article-title">Folate-targeted therapeutic and imaging agents for cancer</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2009.03.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.cbpa.2009.03.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=19419901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVWltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=256-262&issue=3&author=P.+S.+Lowauthor=S.+A.+Kularatne&title=Folate-targeted+therapeutic+and+imaging+agents+for+cancer&doi=10.1016%2Fj.cbpa.2009.03.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Folate-targeted therapeutic and imaging agents for cancer</span></div><div class="casAuthors">Low, Philip Stewart; Kularatne, Sumith Anurasiri</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">256-262</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Cancer therapies that exploit targeting ligands to deliver attached cytotoxic drugs selectively to malignant cells are currently receiving significant attention.  While antibody-targeted drugs have been the first to enter the clinic, recent studies demonstrate that the vitamin folic acid can also be used to deliver attached imaging and therapeutic agents selectively to malignant cells in both animal tumor models and human cancer patients.  Thus, folate conjugates bind to folate receptors that are overexpressed on ∼40% of human cancers and mediate internalization of their attached drugs by receptor-mediated endocytosis.  With the use of proper linkers, folate-targeted drugs can be released inside their target cells where they can perform their desired cytotoxic functions.  Based on this strategy, six folate-targeted drugs are currently in human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp_l-sdKEElbVg90H21EOLACvtfcHk0lg56va4_xp-7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVWltbY%253D&md5=c6b6b07b0df9d1355e99da7c471a2a4b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2009.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2009.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DLow%26aufirst%3DP.%2BS.%26aulast%3DKularatne%26aufirst%3DS.%2BA.%26atitle%3DFolate-targeted%2520therapeutic%2520and%2520imaging%2520agents%2520for%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D13%26issue%3D3%26spage%3D256%26epage%3D262%26doi%3D10.1016%2Fj.cbpa.2009.03.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putt, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visscher, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span> <span> </span><span class="NLM_article-title">Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4485</span>– <span class="NLM_lpage">4495</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.23321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.18632%2Foncotarget.23321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29435118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BC1Mrgsl2gsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=4485-4495&author=J.+Shenauthor=Y.+Huauthor=K.+S.+Puttauthor=S.+Singhalauthor=H.+Hanauthor=D.+W.+Visscherauthor=L.+M.+Murphyauthor=P.+S.+Low&title=Assessment+of+folate+receptor+alpha+and+beta+expression+in+selection+of+lung+and+pancreatic+cancer+patients+for+receptor+targeted+therapies&doi=10.18632%2Foncotarget.23321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies</span></div><div class="casAuthors">Shen Jiayin; Hu Yingwen; Low Philip S; Hu Yingwen; Putt Karson S; Low Philip S; Singhal Sunil; Han Haiyong; Visscher Daniel W; Murphy Linda M</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">4485-4495</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A number of folate receptor (FR) targeted small molecular drugs and monoclonal antibodies have been introduced into clinical trials to treat FR positive cancers.  Because the therapeutic efficacy of these drugs depends prominently on the level of FR-α expression on the cancer cells, patients have been commonly selected for FR-targeted therapies based on the intensity of a folate-targeted radioimaging agent.  Unfortunately, uptake of such imaging agents can be mediated by both major isoforms of the folate receptor, FR-α and FR-β.  Logically, if the FR positive cell population in a tumor mass is dominated by FR-β positive macrophages, patients could be selected for therapy that have few FR-expressing cancer cells.  Although several IHC studies have examined expression of either FR-α or FR-β, no study to date has investigated expression of both FR-α and FR-β in the same tumor mass.  Herein, we utilize monoclonal antibodies specific for FR-α (mAb343) and FR-β (m909) to query each isoform's expression in a range of cancers.  We show that lung and pancreatic adenocarcinomas express the full spectrum of FR-α and FR-β combinations with ~76% of lung adenocarcinomas expressing both FR-α and FR-β while pancreatic cancers express primarily FR-β.  Thus, while folate-targeted imaging of lung cancer patients might accurately reflect the expression of FR-α on lung cancer cells, imaging of pancreatic cancer patients could mislead a physician into treating a nonresponding patient.  Overall, these data suggest that an independent analysis of both FR-α and FR-β should be obtained to predict the potential efficacy of a folate-targeted drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhwKE-wGzFGHRxY89Cm6SyfW6udTcc2eZr24mGQsaDOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mrgsl2gsg%253D%253D&md5=fd2db81c8dd8af772b2c9963d0b49edf</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.23321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.23321%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DPutt%26aufirst%3DK.%2BS.%26aulast%3DSinghal%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DH.%26aulast%3DVisscher%26aufirst%3DD.%2BW.%26aulast%3DMurphy%26aufirst%3DL.%2BM.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DAssessment%2520of%2520folate%2520receptor%2520alpha%2520and%2520beta%2520expression%2520in%2520selection%2520of%2520lung%2520and%2520pancreatic%2520cancer%2520patients%2520for%2520receptor%2520targeted%2520therapies%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D4485%26epage%3D4495%26doi%3D10.18632%2Foncotarget.23321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shannessy, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiel, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somers, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vachani, A.</span></span> <span> </span><span class="NLM_article-title">Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.18632%2Foncotarget.519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=22547449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BC38rptlymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=414-425&issue=4&author=D.+J.+O%E2%80%99Shannessyauthor=G.+Yuauthor=R.+Smaleauthor=Y.+S.+Fuauthor=S.+Singhalauthor=R.+P.+Thielauthor=E.+B.+Somersauthor=A.+Vachani&title=Folate+receptor+alpha+expression+in+lung+cancer%3A+diagnostic+and+prognostic+significance&doi=10.18632%2Foncotarget.519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance</span></div><div class="casAuthors">O'Shannessy Daniel J; Yu Gordon; Smale Robert; Fu Yao-Shi; Singhal Sunil; Thiel Robert P; Somers Elizabeth B; Vachani Anil</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">414-25</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">With the advent of targeted therapies directed towards folate receptor alpha, with several such agents in late stage clinical development, the sensitive and robust detection of folate receptor alpha in tissues is of importance relative to patient selection and perhaps prognosis and prediction of response.  The goal of the present study was to evaluate the expression of folate receptor alpha in non-small cell lung cancer specimens to determine its frequency of expression and its potential for prognosis.  The distribution of folate receptor alpha expression in normal tissues as well as its expression and relationship to non-small cell lung cancer subtypes was assessed by immunohistochemistry using tissue microarrays and fine needle aspirates and an optimized manual staining method using the recently developed monoclonal antibody 26B3.  The association between folate receptor alpha expression and clinical outcome was also evaluated on a tissue microarray created from formalin fixed paraffin embedded specimens from patients with surgically resected lung adenocarcinoma.  Folate receptor alpha expression was shown to have a high discriminatory capacity for lung adenocarcinomas versus squamous cell carcinomas.  While 74% of adenocarcinomas were positive for folate receptor alpha expression, our results found that only 13% of squamous cell carcinomas were FRA positive (p<0.0001).  In patients with adenocarcinoma that underwent surgical resection, increased folate receptor alpha expression was associated with improved overall survival (Hazard Ratio 0.39, 95% CI 0.18-0.85).  These data demonstrate the diagnostic relevance of folate receptor alpha expression in non-small cell lung cancer as determined by immunohistochemistry and suggest that determination of folate receptor alpha expression provides prognostic information in patients with lung adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcbyMocnYSbRBrI9DTGjC0fW6udTcc2ea-ZmuQBmd2_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rptlymtA%253D%253D&md5=833c984bd0b4ef2ee55c2a89589509d2</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.519%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shannessy%26aufirst%3DD.%2BJ.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DSmale%26aufirst%3DR.%26aulast%3DFu%26aufirst%3DY.%2BS.%26aulast%3DSinghal%26aufirst%3DS.%26aulast%3DThiel%26aufirst%3DR.%2BP.%26aulast%3DSomers%26aufirst%3DE.%2BB.%26aulast%3DVachani%26aufirst%3DA.%26atitle%3DFolate%2520receptor%2520alpha%2520expression%2520in%2520lung%2520cancer%253A%2520diagnostic%2520and%2520prognostic%2520significance%26jtitle%3DOncotarget%26date%3D2012%26volume%3D3%26issue%3D4%26spage%3D414%26epage%3D425%26doi%3D10.18632%2Foncotarget.519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boogerd, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boonstra, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charehbili, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoogstins, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prevoo, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Velde, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahrmeijer, A. L.</span></span> <span> </span><span class="NLM_article-title">Concordance of folate receptor-α expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">17442</span>– <span class="NLM_lpage">17454</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.7856</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.18632%2Foncotarget.7856" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=26943581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BC28jmvFWnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=17442-17454&author=L.+S.+Boogerdauthor=M.+C.+Boonstraauthor=A.+J.+Beckauthor=A.+Charehbiliauthor=C.+E.+Hoogstinsauthor=H.+A.+Prevooauthor=S.+Singhalauthor=P.+S.+Lowauthor=C.+J.+van+de+Veldeauthor=A.+L.+Vahrmeijer&title=Concordance+of+folate+receptor-%CE%B1+expression+between+biopsy%2C+primary+tumor+and+metastasis+in+breast+cancer+and+lung+cancer+patients&doi=10.18632%2Foncotarget.7856"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Concordance of folate receptor-α expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients</span></div><div class="casAuthors">Boogerd Leonora S F; Boonstra Martin C; Beck Ann-Jean; Charehbili Ayoub; Hoogstins Charlotte E S; Prevoo Hendrica A J M; van de Velde Cornelis J H; Vahrmeijer Alexander L; Singhal Sunil; Low Philip S</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">17442-54</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Folate receptor alpha (FRα) is known to be upregulated in a variety of cancers, including non-small cell lung cancer (NSCLC) and breast cancer.  To ensure reliable implementation of diagnostic- and therapeutic agents, concordance of FRα expression between biopsy, primary tumor and metastases is important.  Using immunohistochemistry (Mab 26B3.F2) these concordances were investigated in 60 NSCLC and 40 breast cancer patients.  False positivity of FRα expression on breast and lung cancer biopsies was limited to less than 5%.  In NSCLC, FRα expression was shown in 21/34 adenocarcinomas and 4/26 squamous cell carcinomas (SCC).  Concordance of FRα expression between biopsy and primary tumor was achieved in respectively 83% and 91% of adenocarcinomas and SCCs.  Approximately 80% of all local and distant metastases of NSCLC patients showed concordant FRα expression as their corresponding primary tumor.  In breast cancer, FRα positivity was shown in 12/40 biopsies, 20/40 lumpectomies and 6/20 LN metastases, with concordance of 68% between biopsy and primary tumor and 60% between primary tumor and LN metastases.  In conclusion, this study shows high concordance rates of FRα expression between biopsies and metastases compared to primary NSCLC and breast cancers, underscoring the applicability of FRα-targeted agents in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHa1U3EVaFUOR_TJajKxJDfW6udTcc2ea-ZmuQBmd2_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jmvFWnsA%253D%253D&md5=46664ddc0987d902cff937348efa156d</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.7856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.7856%26sid%3Dliteratum%253Aachs%26aulast%3DBoogerd%26aufirst%3DL.%2BS.%26aulast%3DBoonstra%26aufirst%3DM.%2BC.%26aulast%3DBeck%26aufirst%3DA.%2BJ.%26aulast%3DCharehbili%26aufirst%3DA.%26aulast%3DHoogstins%26aufirst%3DC.%2BE.%26aulast%3DPrevoo%26aufirst%3DH.%2BA.%26aulast%3DSinghal%26aufirst%3DS.%26aulast%3DLow%26aufirst%3DP.%2BS.%26aulast%3Dvan%2Bde%2BVelde%26aufirst%3DC.%2BJ.%26aulast%3DVahrmeijer%26aufirst%3DA.%2BL.%26atitle%3DConcordance%2520of%2520folate%2520receptor-%25CE%25B1%2520expression%2520between%2520biopsy%252C%2520primary%2520tumor%2520and%2520metastasis%2520in%2520breast%2520cancer%2520and%2520lung%2520cancer%2520patients%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D17442%26epage%3D17454%26doi%3D10.18632%2Foncotarget.7856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rader, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabat, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbas, C. F.</span></span> <span> </span><span class="NLM_article-title">A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>332</i></span>,  <span class="NLM_fpage">889</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1016/S0022-2836(03)00992-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2FS0022-2836%2803%2900992-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=12972259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntVGltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=2003&pages=889-899&author=C.+Raderauthor=J.+M.+Turnerauthor=A.+Heineauthor=D.+Shabatauthor=S.+C.+Sinhaauthor=I.+A.+Wilsonauthor=R.+A.+Lernerauthor=C.+F.+Barbas&title=A+humanized+aldolase+antibody+for+selective+chemotherapy+and+adaptor+immunotherapy&doi=10.1016%2FS0022-2836%2803%2900992-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">A Humanized Aldolase Antibody for Selective Chemotherapy and Adaptor Immunotherapy</span></div><div class="casAuthors">Rader, Christoph; Turner, James M.; Heine, Andreas; Shabat, Doron; Sinha, Subhash C.; Wilson, Ian A.; Lerner, Richard A.; Barbas, Carlos F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">889-899</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Mouse monoclonal antibody 38C2 is the prototype of a new class of catalytic antibodies that were generated by reactive immunization.  Through a reactive lysine, 38C2 catalyzes aldol and retro-aldol reactions using the enamine mechanism of natural aldolases.  In addn. to its remarkable versatility and efficacy in synthetic org. chem., 38C2 has been used for the selective activation of prodrugs in vitro and in vivo and thereby emerged as a promising tool for selective chemotherapy.  Adding another application with relevance for cancer therapy, designated adaptor immunotherapy, we have recently shown that 38C2 can be chem. programmed to target tumors by formation of a covalent bond of defined stoichiometry with a β-diketone deriv. of an integrin αvβ3 targeting RGD peptidomimetic.  However, a major limitation for the transition from preclin. to clin. evaluation is the human anti-mouse antibody immune response that mouse 38C2 is likely to elicit in a majority of patients after single administration.  Here, we report the humanization of mouse 38C2 based on rational design guided by mol. modeling.  In essence, the catalytic center of mouse 38C2, which encompasses a deep hydrophobic pocket with a reactive lysine residue at the bottom, was grafted into a human antibody framework.  Humanized 38C2 IgG1 was found to bind to β-diketone haptens with conserved affinities and revealed strong catalytic activity with identical kcat and slightly higher KM values compared to the parental mouse antibody.  Furthermore, humanized 38C2 IgG1 revealed efficiency in prodrug activation and chem. programming comparable to the parental mouse antibody.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr47I_eNKtJArVg90H21EOLACvtfcHk0lipAp3jdFsMaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntVGltLY%253D&md5=3e245f887a81643e18e48f1a24065283</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2FS0022-2836%2803%2900992-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-2836%252803%252900992-6%26sid%3Dliteratum%253Aachs%26aulast%3DRader%26aufirst%3DC.%26aulast%3DTurner%26aufirst%3DJ.%2BM.%26aulast%3DHeine%26aufirst%3DA.%26aulast%3DShabat%26aufirst%3DD.%26aulast%3DSinha%26aufirst%3DS.%2BC.%26aulast%3DWilson%26aufirst%3DI.%2BA.%26aulast%3DLerner%26aufirst%3DR.%2BA.%26aulast%3DBarbas%26aufirst%3DC.%2BF.%26atitle%3DA%2520humanized%2520aldolase%2520antibody%2520for%2520selective%2520chemotherapy%2520and%2520adaptor%2520immunotherapy%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2003%26volume%3D332%26spage%3D889%26epage%3D899%26doi%3D10.1016%2FS0022-2836%2803%2900992-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, T. R.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudecek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rader, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, H.</span></span> <span> </span><span class="NLM_article-title">Chemically programmable and switchable CAR-T therapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">12178</span>– <span class="NLM_lpage">12185</span>, <span class="refDoi"> DOI: 10.1002/anie.202005432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1002%2Fanie.202005432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BB3cXps1OrsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=12178-12185&author=J.+Qiauthor=K.+Tsujiauthor=D.+Hymelauthor=T.+R.+Burkeauthor=M.+Hudecekauthor=C.+Raderauthor=H.+Peng&title=Chemically+programmable+and+switchable+CAR-T+therapy&doi=10.1002%2Fanie.202005432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically Programmable and Switchable CAR-T Therapy</span></div><div class="casAuthors">Qi, Junpeng; Tsuji, Kohei; Hymel, David; Burke, Terrence R., Jr.; Hudecek, Michael; Rader, Christoph; Peng, Haiyong</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">12178-12185</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Although macromols. on cell surfaces are predominantly targeted and drugged with antibodies, they harbor pockets that are only accessible to small mols. and constitutes a rich subset of binding sites with immense potential diagnostic and therapeutic utility.  Compared to antibodies, however, small mols. are disadvantaged by a less confined biodistribution, shorter circulatory half-life, and inability to communicate with the immune system.  Presented herein is a method that endows small mols. with the ability to recruit and activate chimeric antigen receptor T cells (CAR-Ts).  It is based on a CAR-T platform that uses a chem. programmed antibody fragment (cp-Fab) as on/off switch.  In proof-of-concept studies, this cp-Fab/CAR-T system targeting folate binding proteins on the cell surface mediated potent and specific eradication of folate-receptor-expressing cancer cells in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonmTVFQWotJLVg90H21EOLACvtfcHk0lipAp3jdFsMaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXps1OrsLY%253D&md5=967b58cdf6a886e34693ac40e306a583</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Fanie.202005432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.202005432%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DTsuji%26aufirst%3DK.%26aulast%3DHymel%26aufirst%3DD.%26aulast%3DBurke%26aufirst%3DT.%2BR.%26aulast%3DHudecek%26aufirst%3DM.%26aulast%3DRader%26aufirst%3DC.%26aulast%3DPeng%26aufirst%3DH.%26atitle%3DChemically%2520programmable%2520and%2520switchable%2520CAR-T%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2020%26volume%3D59%26spage%3D12178%26epage%3D12185%26doi%3D10.1002%2Fanie.202005432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherwood, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caballero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. H.</span></span> <span> </span><span class="NLM_article-title">Redirection of genetically engineered CAR-T cells using bifunctional small molecules</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">2832</span>– <span class="NLM_lpage">2835</span>, <span class="refDoi"> DOI: 10.1021/jacs.5b00106</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b00106" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVSjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=2832-2835&author=M.+S.+Kimauthor=J.+S.+Maauthor=H.+Yunauthor=Y.+Caoauthor=J.+Y.+Kimauthor=V.+Chiauthor=D.+Wangauthor=A.+Woodsauthor=L.+Sherwoodauthor=D.+Caballeroauthor=J.+Gonzalezauthor=P.+G.+Schultzauthor=T.+S.+Youngauthor=C.+H.+Kim&title=Redirection+of+genetically+engineered+CAR-T+cells+using+bifunctional+small+molecules&doi=10.1021%2Fjacs.5b00106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Redirection of genetically engineered CAR-T cells using bifunctional small molecules</span></div><div class="casAuthors">Kim, Min Soo; Ma, Jennifer S. Y.; Yun, Hwayoung; Cao, Yu; Kim, Ji Young; Chi, Victor; Wang, Danling; Woods, Ashley; Sherwood, Lance; Caballero, Dawna; Gonzalez, Jose; Schultz, Peter G.; Young, Travis S.; Kim, Chan Hyuk</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2832-2835</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chimeric antigen receptor (CAR)-engineered T cells (CAR-Ts) provide a potent antitumor response and have become a promising treatment option for cancer.  However, despite their efficacy, CAR-T cells are assocd. with significant safety challenges related to the inability to control their activation and expansion and terminate their response.  Herein, we demonstrate that a bifunctional small mol. "switch" consisting of folate conjugated to fluorescein isothiocyanate (folate-FITC) can redirect and regulate FITC-specific CAR-T cell activity toward folate receptor (FR)-overexpressing tumor cells.  This system was shown to be highly cytotoxic to FR-pos. cells with no activity against FR-neg. cells, demonstrating the specificity of redirection by folate-FITC.  Anti-FITC-CAR-T cell activation and proliferation was strictly dependent on the presence of both folate-FITC and FR-pos. cells and was dose titratable with folate-FITC switch.  This novel treatment paradigm may ultimately lead to increased safety for CAR-T cell immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP7R0iuovQ5LVg90H21EOLACvtfcHk0lipAp3jdFsMaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVSjtrw%253D&md5=0222add2bdb0309ecd01ee062308aac3</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b00106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b00106%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BS.%26aulast%3DMa%26aufirst%3DJ.%2BS.%26aulast%3DYun%26aufirst%3DH.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DChi%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWoods%26aufirst%3DA.%26aulast%3DSherwood%26aufirst%3DL.%26aulast%3DCaballero%26aufirst%3DD.%26aulast%3DGonzalez%26aufirst%3DJ.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DYoung%26aufirst%3DT.%2BS.%26aulast%3DKim%26aufirst%3DC.%2BH.%26atitle%3DRedirection%2520of%2520genetically%2520engineered%2520CAR-T%2520cells%2520using%2520bifunctional%2520small%2520molecules%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D2832%26epage%3D2835%26doi%3D10.1021%2Fjacs.5b00106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwakiri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonobe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyahara, R.</span></span> <span> </span><span class="NLM_article-title">Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers</span>. <i>Ann. Surg. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">889</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1245/s10434-007-9755-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1245%2Fs10434-007-9755-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=18181001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FpvFOjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=889-899&author=S.+Iwakiriauthor=M.+Sonobeauthor=S.+Nagaiauthor=T.+Hirataauthor=H.+Wadaauthor=R.+Miyahara&title=Expression+status+of+folate+receptor+alpha+is+significantly+correlated+with+prognosis+in+non-small-cell+lung+cancers&doi=10.1245%2Fs10434-007-9755-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers</span></div><div class="casAuthors">Iwakiri Shotaro; Sonobe Makoto; Nagai Shinjiro; Hirata Toshiki; Wada Hiromi; Miyahara Ryo</div><div class="citationInfo"><span class="NLM_cas:title">Annals of surgical oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">889-99</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  To evaluate the prognostic value of folate receptor alpha (FOLR1) and/or reduced folate carrier (RFC1) expression, which are well-characterized folate transporters, in completely resected non-small-cell lung cancer (NSCLC).  METHODS:  We quantitatively examined gene expression of FOLR1 and RFC1 in surgical specimens resected from NSCLC patients.  A total of 119 consecutive patients from January 2003 to June 2004 were included.  RESULTS:  In adenocarcinoma, the FOLR1 gene expression was downregulated in smokers and male patients (P = 0.006 and P < 0.001, respectively).  In addition, FOLR1 expression values in patients with well-differentiated, early p-stage, pT1, pN0, EGFR mutant, and p53 wild-type cancers were significantly higher than those for poorly differentiated, advanced p-stage, pT2-4, pN1-3, EGFR wild-type, and p53 mutant (P < 0.001, P < 0.001, P < 0.001, P = 0.002, P < 0.001 and P = 0.023, respectively).  In squamous cell carcinoma, FOLR1 expression values in patients with pN1-3 was significantly higher than those with pN0 (P = 0.037).  Moreover, the 3-year survival rate and disease-free survival rate of high-FOLR1-expressing patients (94.7% and 75.4%) were significantly higher than those of low-FOLR1-expressing patients (80.9% and 60.8%) (P = 0.008 and P = 0.038).  A multivariate analysis confirmed that high FOLR1 expression was an independent and significant factor predicting a favorable prognosis (P = 0.043).  CONCLUSIONS:  Higher levels of FOLR1 appear to be associated with better prognoses for patients with lung adenocarcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvmLb-OofhPLJzI8owOhpDfW6udTcc2eZMJHM5ZFYAnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FpvFOjtw%253D%253D&md5=c1e90d286c7f256d6e08759ca604cc38</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1245%2Fs10434-007-9755-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1245%252Fs10434-007-9755-3%26sid%3Dliteratum%253Aachs%26aulast%3DIwakiri%26aufirst%3DS.%26aulast%3DSonobe%26aufirst%3DM.%26aulast%3DNagai%26aufirst%3DS.%26aulast%3DHirata%26aufirst%3DT.%26aulast%3DWada%26aufirst%3DH.%26aulast%3DMiyahara%26aufirst%3DR.%26atitle%3DExpression%2520status%2520of%2520folate%2520receptor%2520alpha%2520is%2520significantly%2520correlated%2520with%2520prognosis%2520in%2520non-small-cell%2520lung%2520cancers%26jtitle%3DAnn.%2520Surg.%2520Oncol.%26date%3D2008%26volume%3D15%26spage%3D889%26epage%3D899%26doi%3D10.1245%2Fs10434-007-9755-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span> <span> </span><span class="NLM_article-title">Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer</span>. <i>BioSci. Trends</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">298</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.5582/bst.2018.01048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.5582%2Fbst.2018.01048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=29899195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFygur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=298-308&author=W.+Chuauthor=Y.+Zhouauthor=Q.+Tangauthor=M.+Wangauthor=Y.+Jiauthor=J.+Yanauthor=D.+Yinauthor=S.+Zhangauthor=H.+Luauthor=J.+Shen&title=Bi-specific+ligand-controlled+chimeric+antigen+receptor+T-cell+therapy+for+non-small+cell+lung+cancer&doi=10.5582%2Fbst.2018.01048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer</span></div><div class="casAuthors">Chu, Wenqi; Zhou, Yixiong; Tang, Qi; Wang, Min; Ji, Yongjia; Yan, Jingjing; Yin, Dan; Zhang, Shuye; Lu, Hongzhou; Shen, Jiayin</div><div class="citationInfo"><span class="NLM_cas:title">BioScience Trends</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">298-308</span>CODEN:
                <span class="NLM_cas:coden">BTIRCZ</span>;
        ISSN:<span class="NLM_cas:issn">1881-7815</span>.
    
            (<span class="NLM_cas:orgname">International Research and Cooperation Association for Bio & Socio-Sciences Advancement</span>)
        </div><div class="casAbstract">Our goal is to develop a switch-controlled approach to enable better control of reactivity and safety of chimeric antigen receptor (CAR)-T therapy for non-small-cell lung cancer (NSCLC).  Lentiviral transduction was performed to generate anti-FITC CAR-T cells and target cells stably expressing either isoform of the folate receptor.  Colorimetric-based cytotoxic assay, ELISA, and multiparametric flow cytometry anal. were used to evaluate the specificity and activity of CAR-T cells in vitro.  Human primary T cells stably expressing the fully human anti-FITC CAR were generated.  Anti- FITC CAR-T cells displayed antigen-specific and folate-FTIC dependent reactivity against engineered A549-FRa and THP-1-FRss.  The selective activation and proliferation of anti- FITC CAR-T cells in vitro stringently relied on the co-existence of folate-FITC and FRexpressing target cells and was dose-titratable with the folate-FITC switch.  The excellent in vitro efficacy and specificity of an adaptor-controlled CAR-T therapy to target both tumor cells and tumor-assocd. macrophages in NSCLCs were validated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQadyBRXI45bVg90H21EOLACvtfcHk0lifM2ApvrzUsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFygur3L&md5=77493173fbfa57ef67a79fed5a11577f</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.5582%2Fbst.2018.01048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5582%252Fbst.2018.01048%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DJ.%26atitle%3DBi-specific%2520ligand-controlled%2520chimeric%2520antigen%2520receptor%2520T-cell%2520therapy%2520for%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DBioSci.%2520Trends%26date%3D2018%26volume%3D12%26spage%3D298%26epage%3D308%26doi%3D10.5582%2Fbst.2018.01048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrentino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Pace, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nappo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercogliano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, M. F.</span></span> <span> </span><span class="NLM_article-title">The emerging role of large immunophilin FK506 binding protein 51 in cancer</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5424</span>– <span class="NLM_lpage">5429</span>, <span class="refDoi"> DOI: 10.2174/092986711798194333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.2174%2F092986711798194333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=22087835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs12ntbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=5424-5429&author=S.+Romanoauthor=A.+Sorrentinoauthor=A.+L.+Di+Paceauthor=G.+Nappoauthor=C.+Mercoglianoauthor=M.+F.+Romano&title=The+emerging+role+of+large+immunophilin+FK506+binding+protein+51+in+cancer&doi=10.2174%2F092986711798194333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging role of large immunophilin FK506 binding protein 51 in cancer</span></div><div class="casAuthors">Romano, S.; Sorrentino, A.; Di Pace, A. L.; Nappo, G.; Mercogliano, C.; Romano, M. F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">5424-5429</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  FK506 binding protein 51 (FKBP51) is an immunophilin physiol. expressed in lymphocytes.  Very recently, aberrant expression of this protein was found in melanoma; FKBP51 expression correlates with melanoma aggressiveness and is maximal in metastatic lesions.  FKBP51 promotes NF-κB activation and is involved in the resistance to genotoxic agents, including anthracyclines and ionizing radiation.  FKBP51 is a cochaperone with peptidyl-prolyl isomerase activity that regulates several biol. processes through protein-protein interaction.  There is increasing evidence that FKBP51 hyperexpression is assocd. with cancer and this protein has a relevant role in sustaining cell growth, malignancy, and resistance to therapy.  There is also evidence that FKBP ligands are potent anticancer agents, in addn. to their immunosuppressant activity.  In particular, rapamycin and its analogs have shown antitumor activity across a variety of human cancers in clin. trials.  Although, classically, rapamycin actions are ascribed to inhibition of mTOR, recent studies indicate FKBP51 is also an important mol. determinant of the drug's anticancer activity.  The aim of this article is to review the functions of FKBP51, esp. in view of the recent findings that this protein is a potential oncogene when deregulated and a candidate target for signaling therapies against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNMBg5WKfsjbVg90H21EOLACvtfcHk0lifM2ApvrzUsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs12ntbnE&md5=ddaaee6c24d6bbf74a4082e82cb3d6d1</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.2174%2F092986711798194333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711798194333%26sid%3Dliteratum%253Aachs%26aulast%3DRomano%26aufirst%3DS.%26aulast%3DSorrentino%26aufirst%3DA.%26aulast%3DDi%2BPace%26aufirst%3DA.%2BL.%26aulast%3DNappo%26aufirst%3DG.%26aulast%3DMercogliano%26aufirst%3DC.%26aulast%3DRomano%26aufirst%3DM.%2BF.%26atitle%3DThe%2520emerging%2520role%2520of%2520large%2520immunophilin%2520FK506%2520binding%2520protein%252051%2520in%2520cancer%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D5424%26epage%3D5429%26doi%3D10.2174%2F092986711798194333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Magid, A. F.</span></span> <span> </span><span class="NLM_article-title">Rapalogs potential as practical alternatives to rapamycin</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">845</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00215</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00215" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVais7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=843-845&issue=6&author=A.+F.+Abdel-Magid&title=Rapalogs+potential+as+practical+alternatives+to+rapamycin&doi=10.1021%2Facsmedchemlett.9b00215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Rapalogs Potential as Practical Alternatives to Rapamycin</span></div><div class="casAuthors">Abdel-Magid, Ahmed F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">843-845</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZKY61vhMwz7Vg90H21EOLACvtfcHk0ljaUqEIiyUrew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVais7zL&md5=f40133ceb19c14c0da072d06275b8437</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00215%26sid%3Dliteratum%253Aachs%26aulast%3DAbdel-Magid%26aufirst%3DA.%2BF.%26atitle%3DRapalogs%2520potential%2520as%2520practical%2520alternatives%2520to%2520rapamycin%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D6%26spage%3D843%26epage%3D845%26doi%3D10.1021%2Facsmedchemlett.9b00215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayle, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimley, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stankunas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gestwicki, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wandless, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabtree, G. R.</span></span> <span> </span><span class="NLM_article-title">Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2005.10.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.chembiol.2005.10.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=16426976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsV2qug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=99-107&issue=1&author=J.+H.+Bayleauthor=J.+S.+Grimleyauthor=K.+Stankunasauthor=J.+E.+Gestwickiauthor=T.+J.+Wandlessauthor=G.+R.+Crabtree&title=Rapamycin+analogs+with+differential+binding+specificity+permit+orthogonal+control+of+protein+activity&doi=10.1016%2Fj.chembiol.2005.10.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity</span></div><div class="casAuthors">Bayle, J. Henri; Grimley, Joshua S.; Stankunas, Kryn; Gestwicki, Jason E.; Wandless, Thomas J.; Crabtree, Gerald R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-107</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Controlling protein dimerization with small mols. has broad application to the study of protein function.  Rapamycin has 2 binding surfaces: 1 that binds to FKBP12 and the other to the Frb domain of mTor/FRAP, directing their dimerization.  Rapamycin is a potent cell growth inhibitor, but chem. modification of the surface contacting Frb alleviates this effect.  Productive interactions with Frb-fused proteins can be restored by mutation of Frb to accommodate the rapamycin analog (a rapalog).  We have quant. assessed the interaction between rapalogs functionalized at C16 and C20 and a panel of Frb mutants.  Several drug-Frb mutant combinations have different and nonoverlapping specificities.  These Frb-rapalog partners permit the selective control of different Frb fusion proteins without cross-reaction.  The orthogonal control of multiple target proteins broadens the capabilities of chem. induction of dimerization to regulate biol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp_k8iNRbma7Vg90H21EOLACvtfcHk0ljaUqEIiyUrew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsV2qug%253D%253D&md5=35cc7ca0060d404c9e6e448c9e0d51c9</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2005.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2005.10.017%26sid%3Dliteratum%253Aachs%26aulast%3DBayle%26aufirst%3DJ.%2BH.%26aulast%3DGrimley%26aufirst%3DJ.%2BS.%26aulast%3DStankunas%26aufirst%3DK.%26aulast%3DGestwicki%26aufirst%3DJ.%2BE.%26aulast%3DWandless%26aufirst%3DT.%2BJ.%26aulast%3DCrabtree%26aufirst%3DG.%2BR.%26atitle%3DRapamycin%2520analogs%2520with%2520differential%2520binding%2520specificity%2520permit%2520orthogonal%2520control%2520of%2520protein%2520activity%26jtitle%3DChem.%2520Biol.%26date%3D2006%26volume%3D13%26issue%3D1%26spage%3D99%26epage%3D107%26doi%3D10.1016%2Fj.chembiol.2005.10.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J.</span></span> <span> </span><span class="NLM_article-title">Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>273</i></span> (<span class="NLM_issue">5272</span>),  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1126/science.273.5272.239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1126%2Fscience.273.5272.239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=8662507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1Crs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1996&pages=239-242&issue=5272&author=J.+Choiauthor=J.+Chenauthor=S.+L.+Schreiberauthor=J.+Clardy&title=Structure+of+the+FKBP12-rapamycin+complex+interacting+with+the+binding+domain+of+human+FRAP&doi=10.1126%2Fscience.273.5272.239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP</span></div><div class="casAuthors">Choi, Jungwon; Chen, Jie; Schreiber, Stuart L.; Clardy, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">5272</span>),
    <span class="NLM_cas:pages">239-242</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Rapamycin, a potent immunosuppressive agent, binds two proteins: the FK506-binding protein (FKBP12) and the FKBP-rapamycin-assocd. protein (FRAP).  A crystal structure of the ternary complex of human FKBP12, rapamycin, and the FKBP12-rapamycin-binding (FRB) domain of human FRAP at a resoln. of 2.7 angstroms revealed the two proteins bound together as a result of the ability of rapamycin to occupy two different hydrophobic binding pockets simultaneously.  The structure shows extensive interactions between rapamycin and both proteins, but fewer interactions between the proteins.  The structure of the FRB domain of FRAP clarifies both rapamycin-independent and -dependent effects obsd. for mutants of FRAP and its homologs in the family of proteins related to the ataxia-telangiectasis mutant gene product, and it illustrates how a small cell-permeable mol. can mediate protein dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwBLM2PsItYLVg90H21EOLACvtfcHk0ljaUqEIiyUrew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1Crs7k%253D&md5=c72a82e14c09d9a705215b4ac0525336</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1126%2Fscience.273.5272.239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.273.5272.239%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DClardy%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520the%2520FKBP12-rapamycin%2520complex%2520interacting%2520with%2520the%2520binding%2520domain%2520of%2520human%2520FRAP%26jtitle%3DScience%26date%3D1996%26volume%3D273%26issue%3D5272%26spage%3D239%26epage%3D242%26doi%3D10.1126%2Fscience.273.5272.239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roybal, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puchner, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onuffer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, W. A.</span></span> <span> </span><span class="NLM_article-title">Remote control of therapeutic T cells through a small molecule-gated chimeric receptor</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>350</i></span>, <span class="NLM_elocation-id">aab4077</span> <span class="refDoi"> DOI: 10.1126/science.aab4077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1126%2Fscience.aab4077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=26405231" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2015&author=C.+Y.+Wuauthor=K.+T.+Roybalauthor=E.+M.+Puchnerauthor=J.+Onufferauthor=W.+A.+Lim&title=Remote+control+of+therapeutic+T+cells+through+a+small+molecule-gated+chimeric+receptor&doi=10.1126%2Fscience.aab4077"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1126%2Fscience.aab4077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aab4077%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BY.%26aulast%3DRoybal%26aufirst%3DK.%2BT.%26aulast%3DPuchner%26aufirst%3DE.%2BM.%26aulast%3DOnuffer%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DW.%2BA.%26atitle%3DRemote%2520control%2520of%2520therapeutic%2520T%2520cells%2520through%2520a%2520small%2520molecule-gated%2520chimeric%2520receptor%26jtitle%3DScience%26date%3D2015%26volume%3D350%26doi%3D10.1126%2Fscience.aab4077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Certo, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazar, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarjour, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astrakhan, A.</span></span> <span> </span><span class="NLM_article-title">Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e124430</span> <span class="refDoi"> DOI: 10.1172/jci.insight.124430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1172%2Fjci.insight.124430" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&author=W.+H.+Leungauthor=J.+Gayauthor=U.+Martinauthor=T.+E.+Garrettauthor=H.+M.+Hortonauthor=M.+T.+Certoauthor=B.+R.+Blazarauthor=R.+A.+Morganauthor=P.+D.+Gregoryauthor=J.+Jarjourauthor=A.+Astrakhan&title=Sensitive+and+adaptable+pharmacological+control+of+CAR+T+cells+through+extracellular+receptor+dimerization&doi=10.1172%2Fjci.insight.124430"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.124430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.124430%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DW.%2BH.%26aulast%3DGay%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DU.%26aulast%3DGarrett%26aufirst%3DT.%2BE.%26aulast%3DHorton%26aufirst%3DH.%2BM.%26aulast%3DCerto%26aufirst%3DM.%2BT.%26aulast%3DBlazar%26aufirst%3DB.%2BR.%26aulast%3DMorgan%26aufirst%3DR.%2BA.%26aulast%3DGregory%26aufirst%3DP.%2BD.%26aulast%3DJarjour%26aufirst%3DJ.%26aulast%3DAstrakhan%26aufirst%3DA.%26atitle%3DSensitive%2520and%2520adaptable%2520pharmacological%2520control%2520of%2520CAR%2520T%2520cells%2520through%2520extracellular%2520receptor%2520dimerization%26jtitle%3DJCI%2520Insight%26date%3D2019%26volume%3D4%26doi%3D10.1172%2Fjci.insight.124430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marechal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filhol, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirot, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchateau, P.</span></span> <span> </span><span class="NLM_article-title">Design of chimeric antigen receptors with integrated controllable transient functions</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">18950</span>, <span class="refDoi"> DOI: 10.1038/srep18950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fsrep18950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=26750734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsFKrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=18950&author=A.+Juilleratauthor=A.+Marechalauthor=J.+M.+Filholauthor=J.+Valtonauthor=A.+Duclertauthor=L.+Poirotauthor=P.+Duchateau&title=Design+of+chimeric+antigen+receptors+with+integrated+controllable+transient+functions&doi=10.1038%2Fsrep18950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Design of chimeric antigen receptors with integrated controllable transient functions</span></div><div class="casAuthors">Juillerat, Alexandre; Marechal, Alan; Filhol, Jean-Marie; Valton, Julien; Duclert, Aymeric; Poirot, Laurent; Duchateau, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18950</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The ability to control T cells engineered to permanently express chimeric antigen receptors (CARs) is a key feature to improve safety.  Here, we describe the development of a new CAR architecture with an integrated switch-on system that permits to control the CAR T-cell function.  This system offers the advantage of a transient CAR T-cell for safety while letting open the possibility of multiple cytotoxicity cycles using a small mol. drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox5cnpgu9OyLVg90H21EOLACvtfcHk0lhcdn8U3oETKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsFKrsQ%253D%253D&md5=ede9d7144175cc0d1410b7397bd724a8</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fsrep18950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep18950%26sid%3Dliteratum%253Aachs%26aulast%3DJuillerat%26aufirst%3DA.%26aulast%3DMarechal%26aufirst%3DA.%26aulast%3DFilhol%26aufirst%3DJ.%2BM.%26aulast%3DValton%26aufirst%3DJ.%26aulast%3DDuclert%26aufirst%3DA.%26aulast%3DPoirot%26aufirst%3DL.%26aulast%3DDuchateau%26aufirst%3DP.%26atitle%3DDesign%2520of%2520chimeric%2520antigen%2520receptors%2520with%2520integrated%2520controllable%2520transient%2520functions%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D18950%26doi%3D10.1038%2Fsrep18950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duong, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collinson-Pautz, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szymanski, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toler, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slawin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayle, J. H.</span></span> <span> </span><span class="NLM_article-title">Two-dimensional regulation of CAR-T cell therapy with orthogonal switches</span>. <i>Mol. Ther. Oncolytics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1016/j.omto.2018.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.omto.2018.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=30740516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BB3cfhtFSquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=124-137&author=M.+T.+Duongauthor=M.+R.+Collinson-Pautzauthor=E.+Morschlauthor=A.+Luauthor=S.+P.+Szymanskiauthor=M.+Zhangauthor=M.+E.+Brandtauthor=W.+C.+Changauthor=K.+L.+Sharpauthor=S.+M.+Tolerauthor=K.+M.+Slawinauthor=A.+E.+Fosterauthor=D.+M.+Spencerauthor=J.+H.+Bayle&title=Two-dimensional+regulation+of+CAR-T+cell+therapy+with+orthogonal+switches&doi=10.1016%2Fj.omto.2018.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches</span></div><div class="casAuthors">Duong MyLinh T; Collinson-Pautz Matthew R; Morschl Eva; Lu An; Szymanski Slawomir P; Zhang Ming; Brandt Mary E; Chang Wei-Chun; Sharp Kelly L; Toler Steven M; Slawin Kevin M; Foster Aaron E; Spencer David M; Bayle J Henri</div><div class="citationInfo"><span class="NLM_cas:title">Molecular therapy oncolytics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">124-137</span>
        ISSN:<span class="NLM_cas:issn">2372-7705</span>.
    </div><div class="casAbstract">Use of chimeric antigen receptors (CARs) as the basis of targeted adoptive T cell therapies has enabled dramatic efficacy against multiple hematopoietic malignancies, but potency against bulky and solid tumors has lagged, potentially due to insufficient CAR-T cell expansion and persistence.  To improve CAR-T cell efficacy, we utilized a potent activation switch based on rimiducid-inducible MyD88 and CD40 (iMC)-signaling elements.  To offset potential toxicity risks by this enhanced CAR, an orthogonally regulated, rapamycin-induced, caspase-9-based safety switch (iRC9) was developed to allow in vivo elimination of CAR-T cells. iMC costimulation induced by systemic rimiducid administration enhanced CAR-T cell proliferation, cytokine secretion, and antitumor efficacy in both in vitro assays and xenograft tumor models.  Conversely, rapamycin-mediated iRC9 dimerization rapidly induced apoptosis in a dose-dependent fashion as an approach to mitigate therapy-related toxicity.  This novel, regulatable dual-switch system may promote greater CAR-T cell expansion and prolonged persistence in a drug-dependent manner while providing a safety switch to mitigate toxicity concerns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRa2AZtp5SCeFf1XRtfYM0dfW6udTcc2eYW89cJ5lH987ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfhtFSquw%253D%253D&md5=ba1c554bfc65ad6e718180f97d2bac86</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.omto.2018.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.omto.2018.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DDuong%26aufirst%3DM.%2BT.%26aulast%3DCollinson-Pautz%26aufirst%3DM.%2BR.%26aulast%3DMorschl%26aufirst%3DE.%26aulast%3DLu%26aufirst%3DA.%26aulast%3DSzymanski%26aufirst%3DS.%2BP.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DBrandt%26aufirst%3DM.%2BE.%26aulast%3DChang%26aufirst%3DW.%2BC.%26aulast%3DSharp%26aufirst%3DK.%2BL.%26aulast%3DToler%26aufirst%3DS.%2BM.%26aulast%3DSlawin%26aufirst%3DK.%2BM.%26aulast%3DFoster%26aufirst%3DA.%2BE.%26aulast%3DSpencer%26aufirst%3DD.%2BM.%26aulast%3DBayle%26aufirst%3DJ.%2BH.%26atitle%3DTwo-dimensional%2520regulation%2520of%2520CAR-T%2520cell%2520therapy%2520with%2520orthogonal%2520switches%26jtitle%3DMol.%2520Ther.%2520Oncolytics%26date%3D2019%26volume%3D12%26spage%3D124%26epage%3D137%26doi%3D10.1016%2Fj.omto.2018.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Philip, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokalaki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekkaoui, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straathof, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flutter, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marafioti, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraverty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quezada, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peggs, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pule, M.</span></span> <span> </span><span class="NLM_article-title">A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">1277</span>– <span class="NLM_lpage">1287</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-01-545020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1182%2Fblood-2014-01-545020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=24970931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFaks7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=1277-1287&author=B.+Philipauthor=E.+Kokalakiauthor=L.+Mekkaouiauthor=S.+Thomasauthor=K.+Straathofauthor=B.+Flutterauthor=V.+Marinauthor=T.+Marafiotiauthor=R.+Chakravertyauthor=D.+Linchauthor=S.+A.+Quezadaauthor=K.+S.+Peggsauthor=M.+Pule&title=A+highly+compact+epitope-based+marker%2Fsuicide+gene+for+easier+and+safer+T-cell+therapy&doi=10.1182%2Fblood-2014-01-545020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy</span></div><div class="casAuthors">Philip, Brian; Kokalaki, Evangelia; Mekkaoui, Leila; Thomas, Simon; Straathof, Karin; Flutter, Barry; Marin, Virna; Marafioti, Teresa; Chakraverty, Ronjon; Linch, David; Quezada, Sergio A.; Peggs, Karl S.; Pule, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1277-1287</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A compact marker/suicide gene that utilizes established clin.-grade reagents and pharmaceuticals would be of considerable practical utility to T-cell cancer gene therapy.  Marker genes enable measurement of transduction and allow selection of transduced cells, whereas suicide genes allow selective deletion of administered T cells in the face of toxicity.  We have created a highly compact marker/suicide gene for T cells combining target epitopes from both CD34 and CD20 antigens (RQR8).  This construct allows selection with the clin. approved CliniMACS CD34 system (Miltenyi).  Further, the construct binds the widely used pharmaceutical antibody rituximab, resulting in selective deletion of transgene-expressing cells.  We have tested the functionality of RQR8 in vitro and in vivo as well as in combination with T-cell engineering components.  We predict that RQR8 will make T-cell gene therapy both safer and cheaper.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcy054S65i37Vg90H21EOLACvtfcHk0ljjG-yd-4Q5zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFaks7jK&md5=b8aed6b107c297f5654c5bc6df4ca952</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-01-545020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-01-545020%26sid%3Dliteratum%253Aachs%26aulast%3DPhilip%26aufirst%3DB.%26aulast%3DKokalaki%26aufirst%3DE.%26aulast%3DMekkaoui%26aufirst%3DL.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DStraathof%26aufirst%3DK.%26aulast%3DFlutter%26aufirst%3DB.%26aulast%3DMarin%26aufirst%3DV.%26aulast%3DMarafioti%26aufirst%3DT.%26aulast%3DChakraverty%26aufirst%3DR.%26aulast%3DLinch%26aufirst%3DD.%26aulast%3DQuezada%26aufirst%3DS.%2BA.%26aulast%3DPeggs%26aufirst%3DK.%2BS.%26aulast%3DPule%26aufirst%3DM.%26atitle%3DA%2520highly%2520compact%2520epitope-based%2520marker%252Fsuicide%2520gene%2520for%2520easier%2520and%2520safer%2520T-cell%2520therapy%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D1277%26epage%3D1287%26doi%3D10.1182%2Fblood-2014-01-545020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanghellini, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondanza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traversari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomoni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turchetto, L.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">500</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(09)70074-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2FS1470-2045%2809%2970074-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=19345145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BD1Mzhs1WksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=489-500&author=F.+Ciceriauthor=C.+Boniniauthor=M.+T.+Stanghelliniauthor=A.+Bondanzaauthor=C.+Traversariauthor=M.+Salomoniauthor=L.+Turchetto&title=Infusion+of+suicide-gene-engineered+donor+lymphocytes+after+family+haploidentical+haemopoietic+stem-cell+transplantation+for+leukaemia+%28the+TK007+trial%29%3A+a+non-randomised+phase+I-II+study&doi=10.1016%2FS1470-2045%2809%2970074-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study</span></div><div class="casAuthors">Ciceri Fabio; Bonini Chiara; Stanghellini Maria Teresa Lupo; Bondanza Attilio; Traversari Catia; Salomoni Monica; Turchetto Lucia; Colombi Scialini; Bernardi Massimo; Peccatori Jacopo; Pescarollo Alessandra; Servida Paolo; Magnani Zulma; Perna Serena K; Valtolina Veronica; Crippa Fulvio; Callegaro Luciano; Spoldi Elena; Crocchiolo Roberto; Fleischhauer Katharina; Ponzoni Maurilio; Vago Luca; Rossini Silvano; Santoro Armando; Todisco Elisabetta; Apperley Jane; Olavarria Eduardo; Slavin Shimon; Weissinger Eva M; Ganser Arnold; Stadler Michael; Yannaki Evangelia; Fassas Athanasios; Anagnostopoulos Achilles; Bregni Marco; Stampino Corrado Gallo; Bruzzi Paolo; Bordignon Claudio</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">489-500</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Procedures to prevent severe graft-versus-host disease (GVHD) delay immune reconstitution secondary to transplants of haploidentical haemopoietic stem cells for the treatment of leukaemia, leading to high rates of late infectious mortality.  We aimed to systematically add back genetically engineered donor lymphocytes to facilitate immune reconstitution and prevent late mortality.  METHODS:  In a phase I-II, multicentre, non-randomised trial of haploidentical stem-cell transplantation, we infused donor lymphocytes expressing herpes-simplex thymidine kinase suicide gene (TK-cells) after transplantation.  The primary study endpoint was immune reconstitution defined as circulating CD3+ count of 100 cells per muL or more for two consecutive observations.  Analysis was by intention to treat.  This trial is registered with ClinicalTrials.gov, number NCT00423124.  FINDINGS:  From Aug 13, 2002, to March 26, 2008, 50 patients (median age 51 years, range 17-66) received haploidentical stem-cell transplants for high-risk leukaemia.  Immune reconstitution was not recorded before infusion of TK-cells. 28 patients received TK-cells starting 28 days after transplantation; 22 patients obtained immune reconstitution at median 75 days (range 34-127) from transplantation and 23 days (13-42) from infusion.  Ten patients developed acute GVHD (grade I-IV) and one developed chronic GVHD, which were controlled by induction of the suicide gene.  Overall survival at 3 years was 49% (95% CI 25-73) for 19 patients who were in remission from primary leukaemia at the time of stem-cell transplantation.  After TK-cell infusion, the last death due to infection was at 166 days, this was the only infectious death at more than 100 days.  No acute or chronic adverse events were related to the gene-transfer procedure.  INTERPRETATION:  Infusion of TK-cells might be effective in accelerating immune reconstitution, while controlling GVHD and protecting patients from late mortality in those who are candidates for haploidentical stem-cell transplantation.  FUNDING:  MolMed SpA, Italian Association for Cancer Research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRI4Hc6QPHd8N1QT_1O5WBYfW6udTcc2eZgpxWs6yw56Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mzhs1WksQ%253D%253D&md5=1437304bd92cb65c824640edb1872e85</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2809%2970074-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252809%252970074-9%26sid%3Dliteratum%253Aachs%26aulast%3DCiceri%26aufirst%3DF.%26aulast%3DBonini%26aufirst%3DC.%26aulast%3DStanghellini%26aufirst%3DM.%2BT.%26aulast%3DBondanza%26aufirst%3DA.%26aulast%3DTraversari%26aufirst%3DC.%26aulast%3DSalomoni%26aufirst%3DM.%26aulast%3DTurchetto%26aufirst%3DL.%26atitle%3DInfusion%2520of%2520suicide-gene-engineered%2520donor%2520lymphocytes%2520after%2520family%2520haploidentical%2520haemopoietic%2520stem-cell%2520transplantation%2520for%2520leukaemia%2520%2528the%2520TK007%2520trial%2529%253A%2520a%2520non-randomised%2520phase%2520I-II%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2009%26volume%3D10%26spage%3D489%26epage%3D500%26doi%3D10.1016%2FS1470-2045%2809%2970074-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flowers, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, S. R.</span></span> <span> </span><span class="NLM_article-title">Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">2294</span>– <span class="NLM_lpage">2302</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-08-3503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1182%2Fblood-2005-08-3503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=16282341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFOjtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=2294-2302&author=C.+Bergerauthor=M.+E.+Flowersauthor=E.+H.+Warrenauthor=S.+R.+Riddell&title=Analysis+of+transgene-specific+immune+responses+that+limit+the+in+vivo+persistence+of+adoptively+transferred+HSV-TK-modified+donor+T+cells+after+allogeneic+hematopoietic+cell+transplantation&doi=10.1182%2Fblood-2005-08-3503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation</span></div><div class="casAuthors">Berger, Carolina; Flowers, Mary E.; Warren, Edus H.; Riddell, Stanley R.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2294-2302</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The introduction of an inducible suicide gene such as the herpes simplex virus thymidine kinase (HSV-TK) might allow exploitation of the antitumor activity of donor T cells after allogeneic hematopoietic cell transplantation (HCT) without graft vs. host disease.  However, HSV-TK is foreign, and immune responses to gene-modified T cells could lead to their premature elimination.  The authors show that after the infusion of HSV-TK-modified donor T cells to HCT recipients, CD8+ and CD4+ T-cell responses to HSV-TK are rapidly induced and coincide with the disappearance of transferred cells.  Cytokine flow cytometry using an overlapping panel of HSV-TK peptides allowed rapid detection and quantitation of HSV-TK-specific T cells in the blood and identified multiple immunogenic epitopes.  Repeated infusion of modified T cells boosted the induced HSV-TK-specific T cells, which persisted as memory cells.  These studies demonstrate the need for non-immunogenic suicide genes and identify a strategy for detection of CD4+ and CD8+ T-cell responses to transgene products that should be generally applicable to monitoring patients on gene therapy trials.  The potency of gene-modified T cells to elicit robust and durable immune responses imply this approach might be used for vaccination to elicit T-cell responses to viral or tumor antigens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiZVv9YToL27Vg90H21EOLACvtfcHk0ljJ5oNWb3UtUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFOjtL0%253D&md5=5b4e8fffde18fa836a58304125428f5d</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-08-3503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-08-3503%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DC.%26aulast%3DFlowers%26aufirst%3DM.%2BE.%26aulast%3DWarren%26aufirst%3DE.%2BH.%26aulast%3DRiddell%26aufirst%3DS.%2BR.%26atitle%3DAnalysis%2520of%2520transgene-specific%2520immune%2520responses%2520that%2520limit%2520the%2520in%2520vivo%2520persistence%2520of%2520adoptively%2520transferred%2520HSV-TK-modified%2520donor%2520T%2520cells%2520after%2520allogeneic%2520hematopoietic%2520cell%2520transplantation%26jtitle%3DBlood%26date%3D2006%26volume%3D107%26spage%3D2294%26epage%3D2302%26doi%3D10.1182%2Fblood-2005-08-3503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cribioli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philip, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tettamanti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzitola, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biagi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pule, M.</span></span> <span> </span><span class="NLM_article-title">Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells</span>. <i>Hum. Gene Ther: Methods.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1089/hgtb.2012.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1089%2Fhgtb.2012.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=23186165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVOnur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=376-386&author=V.+Marinauthor=E.+Cribioliauthor=B.+Philipauthor=S.+Tettamantiauthor=I.+Pizzitolaauthor=A.+Biondiauthor=E.+Biagiauthor=M.+Pule&title=Comparison+of+different+suicide-gene+strategies+for+the+safety+improvement+of+genetically+manipulated+T+cells&doi=10.1089%2Fhgtb.2012.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of Different Suicide-Gene Strategies for the Safety Improvement of Genetically Manipulated T Cells</span></div><div class="casAuthors">Marin, Virna; Cribioli, Elisabetta; Philip, Brian; Tettamanti, Sarah; Pizzitola, Irene; Biondi, Andrea; Biagi, Ettore; Pule, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Human Gene Therapy: Methods</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">376-386</span>CODEN:
                <span class="NLM_cas:coden">HGTPAN</span>;
        ISSN:<span class="NLM_cas:issn">1946-6544</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Use of adoptive T-cell therapy (ACT) is increasing; however, T-cell therapy can result in severe toxicity.  Consequently, several suicide-gene strategies that allow selective destruction of the infused T cells have been described.  We compared effectiveness of four such strategies in vitro in Epstein Barr virus (EBV)-cytotoxic T lymphocytes (CTLs).  Herpes simplex virus thymidine kinase (HSV-TK), human inducible caspase 9 (iCasp9), mutant human thymidylate kinase (mTMPK), and human CD20 codon optimized genes were cloned in frame with 2A-truncated codon optimized CD34 (dCD34) in a retroviral vector.  Codon-optimization considerably improved CD20 expression.  EBV-CTLs could be efficiently transduced in all constructs, with transgene expression similar to the control vector contg. dCD34 alone.  Expression was maintained for prolonged cultures.  Expression of the suicide genes was not assocd. with alterations in immunophenotype, proliferation, or function of CTLs.  Activation of HSV-TK, iCasp9, and CD20 ultimately resulted in equally effective destruction of transduced T cells.  However, while iCasp9 and CD20 effected immediate cell-death induction, HSV-TK-expressing T cells required 3 days of exposure to ganciclovir to reach full effect. mTMPK-transduced cells showed lower T-cell killing all time points.  Our results suggest that the faster activity of iCasp9 might be advantageous in treating certain types of acutely life-threatening toxicity.  Codon-optimized CD20 has potential as a suicide gene.  Marin and colleagues compare the effectiveness of four suicide-gene strategies in a model in vitro T-cell system.  Herpes simplex virus thymidine kinase (HSV-TK), human inducible caspase 9 (iCasp9), mutant human thymidylate kinase (mTMPK), and human CD20 codon-optimized genes were cloned in frame with 2A-truncated codon optimized CD34 in a retroviral vector.  Suicide-gene activation ultimately resulted in equally effective destruction of transduced T cells, with iCasp9 and CD20 displaying the most immediate induction of cell death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrm4H0Lf5ODrVg90H21EOLACvtfcHk0ljxqMIuR3Iarw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVOnur8%253D&md5=1c00332b8b412d3760a2bc49d9669566</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1089%2Fhgtb.2012.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fhgtb.2012.050%26sid%3Dliteratum%253Aachs%26aulast%3DMarin%26aufirst%3DV.%26aulast%3DCribioli%26aufirst%3DE.%26aulast%3DPhilip%26aufirst%3DB.%26aulast%3DTettamanti%26aufirst%3DS.%26aulast%3DPizzitola%26aufirst%3DI.%26aulast%3DBiondi%26aufirst%3DA.%26aulast%3DBiagi%26aufirst%3DE.%26aulast%3DPule%26aufirst%3DM.%26atitle%3DComparison%2520of%2520different%2520suicide-gene%2520strategies%2520for%2520the%2520safety%2520improvement%2520of%2520genetically%2520manipulated%2520T%2520cells%26jtitle%3DHum.%2520Gene%2520Ther%253A%2520Methods.%26date%3D2012%26volume%3D23%26spage%3D376%26epage%3D386%26doi%3D10.1089%2Fhgtb.2012.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Stasi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tey, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy-Nasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straathof, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durett, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grilley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoldo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krance, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heslop, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, M. K.</span></span> <span> </span><span class="NLM_article-title">Inducible apoptosis as a safety switch for adoptive cell therapy</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">1673</span>– <span class="NLM_lpage">1683</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1106152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1056%2FNEJMoa1106152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=22047558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWqtbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=1673-1683&author=A.+Di%0AStasiauthor=S.+K.+Teyauthor=G.+Dottiauthor=Y.+Fujitaauthor=A.+Kennedy-Nasserauthor=C.+Martinezauthor=K.+Straathofauthor=E.+Liuauthor=A.+G.+Durettauthor=B.+Grilleyauthor=H.+Liuauthor=C.+R.+Cruzauthor=B.+Savoldoauthor=A.+P.+Geeauthor=J.+Schindlerauthor=R.+A.+Kranceauthor=H.+E.+Heslopauthor=D.+M.+Spencerauthor=C.+M.+Rooneyauthor=M.+K.+Brenner&title=Inducible+apoptosis+as+a+safety+switch+for+adoptive+cell+therapy&doi=10.1056%2FNEJMoa1106152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Inducible apoptosis as a safety switch for adoptive cell therapy</span></div><div class="casAuthors">Di Stasi, Antonio; Tey, Siok-Keen; Dotti, Gianpietro; Fujita, Yuriko; Kennedy-Nasser, Alana; Martinez, Caridad; Straathof, Karin; Liu, Enli; Durett, April G.; Grilley, Bambi; Liu, Hao; Cruz, Conrad R.; Savoldo, Barbara; Gee, Adrian P.; Schindler, John; Krance, Robert A.; Heslop, Helen E.; Spencer, David M.; Rooney, Cliona M.; Brenner, Malcolm K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1673-1683</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  BACKGROUND Cellular therapies could play a role in cancer treatment and regenerative medicine if it were possible to quickly eliminate the infused cells in case of adverse events.  We devised an inducible T-cell safety switch that is based on the fusion of human caspase 9 to a modified human FK-binding protein, allowing conditional dimerization.  When exposed to a synthetic dimerizing drug, the inducible caspase 9 (iCasp9) becomes activated and leads to the rapid death of cells expressing this construct.  METHODS We tested the activity of our safety switch by introducing the gene into donor T cells given to enhance immune reconstitution in recipients of haploidentical stem-cell transplants.  Patients received AP1903, an otherwise bioinert small-mol. dimerizing drug, if graft-vs.-host disease (GVHD) developed.  We measured the effects of AP1903 on GVHD and on the function and persistence of the cells contg. the iCasp9 safety switch.  RESULTS Five patients between the ages of 3 and 17 years who had undergone stem-cell transplantation for relapsed acute leukemia were treated with the genetically modified T cells.  The cells were detected in peripheral blood from all five patients and increased in no. over time, despite their constitutive transgene expression.  A single dose of dimerizing drug, given to four patients in whom GVHD developed, eliminated more than 90% of the modified T cells within 30 min after administration and ended the GVHD without recurrence.  CONCLUSIONS The iCasp9 cell-suicide system may increase the safety of cellular therapies and expand their clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtaxH1EJFljLVg90H21EOLACvtfcHk0ljxqMIuR3Iarw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWqtbbF&md5=5adcc0e5acc341b06e4e9472959961f0</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1106152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1106152%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BStasi%26aufirst%3DA.%26aulast%3DTey%26aufirst%3DS.%2BK.%26aulast%3DDotti%26aufirst%3DG.%26aulast%3DFujita%26aufirst%3DY.%26aulast%3DKennedy-Nasser%26aufirst%3DA.%26aulast%3DMartinez%26aufirst%3DC.%26aulast%3DStraathof%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DE.%26aulast%3DDurett%26aufirst%3DA.%2BG.%26aulast%3DGrilley%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DCruz%26aufirst%3DC.%2BR.%26aulast%3DSavoldo%26aufirst%3DB.%26aulast%3DGee%26aufirst%3DA.%2BP.%26aulast%3DSchindler%26aufirst%3DJ.%26aulast%3DKrance%26aufirst%3DR.%2BA.%26aulast%3DHeslop%26aufirst%3DH.%2BE.%26aulast%3DSpencer%26aufirst%3DD.%2BM.%26aulast%3DRooney%26aufirst%3DC.%2BM.%26aulast%3DBrenner%26aufirst%3DM.%2BK.%26atitle%3DInducible%2520apoptosis%2520as%2520a%2520safety%2520switch%2520for%2520adoptive%2520cell%2520therapy%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D1673%26epage%3D1683%26doi%3D10.1056%2FNEJMoa1106152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diaconu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoldo, B.</span></span> <span> </span><span class="NLM_article-title">Inducible Caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">580</span>– <span class="NLM_lpage">592</span>, <span class="refDoi"> DOI: 10.1016/j.ymthe.2017.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.ymthe.2017.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=28187946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFCltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=580-592&author=I.+Diaconuauthor=B.+Ballardauthor=M.+Zhangauthor=Y.+Chenauthor=J.+Westauthor=G.+Dottiauthor=B.+Savoldo&title=Inducible+Caspase-9+selectively+modulates+the+toxicities+of+CD19-specific+chimeric+antigen+receptor-modified+T+cells&doi=10.1016%2Fj.ymthe.2017.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells</span></div><div class="casAuthors">Diaconu, Iulia; Ballard, Brandon; Zhang, Ming; Chen, Yuhui; West, John; Dotti, Gianpietro; Savoldo, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">580-592</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0024</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Immunotherapy with T cells expressing the chimeric antigen receptor (CAR) specific for the CD19 antigen (CD19.CAR-Ts) is a very effective treatment in B cell lymphoid malignancies.  However, B cell aplasia and cytokine release syndrome (CRS) secondary to the infusion of CD19.  CAR-Ts remain significant drawbacks.  The inclusion of safety switches into the vector encoding the CAR is seen as the safest method to terminate the effects of CD19.  CAR-Ts in case of severe toxicities or after achieving long-term sustained remissions.  By contrast, the complete elimination of CD19.  CAR-Ts when CRS occurs may jeopardize clin. responses as CRS and antitumor activity seem to concur.  We have demonstrated, in a humanized mouse model, that the inducible caspase-9 (iC9) safety switch can eliminate CD19.  CAR-Ts in a dose-dependent manner, allowing either a selective containment of CD19.  CAR-T expansion in case of CRS or complete deletion on demand granting normal B cell reconstitution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb8U_LN9JImrVg90H21EOLACvtfcHk0ljrI2MBA6dGxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFCltrk%253D&md5=bf490b4d7d31fdb86669d5d4242a77bb</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.ymthe.2017.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymthe.2017.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DDiaconu%26aufirst%3DI.%26aulast%3DBallard%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWest%26aufirst%3DJ.%26aulast%3DDotti%26aufirst%3DG.%26aulast%3DSavoldo%26aufirst%3DB.%26atitle%3DInducible%2520Caspase-9%2520selectively%2520modulates%2520the%2520toxicities%2520of%2520CD19-specific%2520chimeric%2520antigen%2520receptor-modified%2520T%2520cells%26jtitle%3DMol.%2520Ther.%26date%3D2017%26volume%3D25%26spage%3D580%26epage%3D592%26doi%3D10.1016%2Fj.ymthe.2017.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoyos, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoldo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintarelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendravada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heslop, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotti, G.</span></span> <span> </span><span class="NLM_article-title">Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1160</span>– <span class="NLM_lpage">1170</span>, <span class="refDoi"> DOI: 10.1038/leu.2010.75</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1038%2Fleu.2010.75" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=20428207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFShs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=1160-1170&author=V.+Hoyosauthor=B.+Savoldoauthor=C.+Quintarelliauthor=A.+Mahendravadaauthor=M.+Zhangauthor=J.+Veraauthor=H.+E.+Heslopauthor=C.+M.+Rooneyauthor=M.+K.+Brennerauthor=G.+Dotti&title=Engineering+CD19-specific+T+lymphocytes+with+interleukin-15+and+a+suicide+gene+to+enhance+their+anti-lymphoma%2Fleukemia+effects+and+safety&doi=10.1038%2Fleu.2010.75"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety</span></div><div class="casAuthors">Hoyos, V.; Savoldo, B.; Quintarelli, C.; Mahendravada, A.; Zhang, M.; Vera, J.; Heslop, H. E.; Rooney, C. M.; Brenner, M. K.; Dotti, G.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1160-1170</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">T lymphocytes expressing a chimeric antigen receptor (CAR) targeting the CD19 antigen (CAR.19) may be of value for the therapy of B-cell malignancies.  Because the in vivo survival, expansion and anti-lymphoma activity of CAR.19+ T cells remain suboptimal even when the CAR contains a CD28 costimulatory endodomain, we generated a novel construct that also incorporates the interleukin-15 (IL-15) gene and an inducible caspase-9-based suicide gene (iC9/CAR.19/IL-15).  We found that compared with CAR.19+ T cells, iC9/CAR.19/IL-15+ T cells had: (1) greater numeric expansion upon antigen stimulation (10-fold greater expansion in vitro, and 3- to 15-fold greater expansion in vivo) and reduced cell death rate (Annexin-V+/7-AAD+ cells 10±6% for iC9/CAR.19/IL-15+ T cells and 32±19% for CAR.19+ T cells); (2) reduced expression of the programmed death 1 (PD-1) receptor upon antigen stimulation (PD-1+ cells <15% for iC9/CAR.19/IL-15+ T cells vs. >40% for CAR.19+ T cells); and (3) improved antitumor effects in vivo (from 4.7- to 5.4-fold reduced tumor growth).  In addn., iC9/CAR.19/IL-15+ T cells were efficiently eliminated upon pharmacol. activation of the suicide gene.  In summary, this strategy safely increases the anti-lymphoma/leukemia effects of CAR.19-redirected T lymphocytes and may be a useful approach for treatment of patients with B-cell malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgBL73xQZmE7Vg90H21EOLACvtfcHk0ljrI2MBA6dGxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFShs74%253D&md5=387f9927dd7154744dea7cd9294ce721</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1038%2Fleu.2010.75&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2010.75%26sid%3Dliteratum%253Aachs%26aulast%3DHoyos%26aufirst%3DV.%26aulast%3DSavoldo%26aufirst%3DB.%26aulast%3DQuintarelli%26aufirst%3DC.%26aulast%3DMahendravada%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DVera%26aufirst%3DJ.%26aulast%3DHeslop%26aufirst%3DH.%2BE.%26aulast%3DRooney%26aufirst%3DC.%2BM.%26aulast%3DBrenner%26aufirst%3DM.%2BK.%26aulast%3DDotti%26aufirst%3DG.%26atitle%3DEngineering%2520CD19-specific%2520T%2520lymphocytes%2520with%2520interleukin-15%2520and%2520a%2520suicide%2520gene%2520to%2520enhance%2520their%2520anti-lymphoma%252Fleukemia%2520effects%2520and%2520safety%26jtitle%3DLeukemia%26date%3D2010%26volume%3D24%26spage%3D1160%26epage%3D1170%26doi%3D10.1038%2Fleu.2010.75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Budde, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frayo, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouns, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Till, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Press, O. W.</span></span> <span> </span><span class="NLM_article-title">Combining a CD20 chimeric antigen receptor and an inducible Caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e82742</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0082742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1371%2Fjournal.pone.0082742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=24358223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKnsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=L.+E.+Buddeauthor=C.+Bergerauthor=Y.+Linauthor=J.+Wangauthor=X.+Linauthor=S.+E.+Frayoauthor=S.+A.+Brounsauthor=D.+M.+Spencerauthor=B.+G.+Tillauthor=M.+C.+Jensenauthor=S.+R.+Riddellauthor=O.+W.+Press&title=Combining+a+CD20+chimeric+antigen+receptor+and+an+inducible+Caspase+9+suicide+switch+to+improve+the+efficacy+and+safety+of+T+cell+adoptive+immunotherapy+for+lymphoma&doi=10.1371%2Fjournal.pone.0082742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma</span></div><div class="casAuthors">Budde, Lihua E.; Berger, Carolina; Lin, Yukang; Wang, Jinjuan; Lin, Xubin; Frayo, Shani E.; Brouns, Shaunda A.; Spencer, David M.; Till, Brian G.; Jensen, Michael C.; Riddell, Stanley R.; Press, Oliver W.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e82742/1-e82742/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Modification of T cells with chimeric antigen receptors (CAR) has emerged as a promising treatment modality for human malignancies.  Integration of co-stimulatory domains into CARs can augment the activation and function of genetically targeted T cells against tumors.  However, the potential for insertional mutagenesis and toxicities due to the infused cells have made development of safe methods for removing transferred cells an important consideration.  We have genetically modified human T cells with a lentiviral vector to express a CD20-CAR contg. both CD28 and CD137 co-stimulatory domains, a "suicide gene" relying on inducible activation of caspase 9 (iC9), and a truncated CD19 selectable marker.  Rapid expansion (2000 fold) of the transduced T cells was achieved in 28 days after stimulation with artificial antigen presenting cells.  Transduced T cells exhibited effective CD20-specific cytotoxic activity in vitro and in a mouse xenograft tumor model.  Activation of the iC9 suicide switch resulted in efficient removal of transduced T cells both in vitro and in vivo.  Our work demonstrates the feasibility and promise of this approach for treating CD20+ malignancies in a safe and more efficient manner.  A phase I clin. trial using this approach in patients with relapsed indolent B-NHL is planned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrctGCj_X1de7Vg90H21EOLACvtfcHk0ljrI2MBA6dGxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKnsrw%253D&md5=bfde2750cf44fbcc030be0b937be9c3c</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0082742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0082742%26sid%3Dliteratum%253Aachs%26aulast%3DBudde%26aufirst%3DL.%2BE.%26aulast%3DBerger%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DFrayo%26aufirst%3DS.%2BE.%26aulast%3DBrouns%26aufirst%3DS.%2BA.%26aulast%3DSpencer%26aufirst%3DD.%2BM.%26aulast%3DTill%26aufirst%3DB.%2BG.%26aulast%3DJensen%26aufirst%3DM.%2BC.%26aulast%3DRiddell%26aufirst%3DS.%2BR.%26aulast%3DPress%26aufirst%3DO.%2BW.%26atitle%3DCombining%2520a%2520CD20%2520chimeric%2520antigen%2520receptor%2520and%2520an%2520inducible%2520Caspase%25209%2520suicide%2520switch%2520to%2520improve%2520the%2520efficacy%2520and%2520safety%2520of%2520T%2520cell%2520adoptive%2520immunotherapy%2520for%2520lymphoma%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0082742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krance, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamble, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durett, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakhova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoldo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Stasi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grilley, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heslop, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, M. K.</span></span> <span> </span><span class="NLM_article-title">Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">4103</span>– <span class="NLM_lpage">4113</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-02-628354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1182%2Fblood-2015-02-628354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=25977584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlersrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=4103-4113&author=X.+Zhouauthor=G.+Dottiauthor=R.+A.+Kranceauthor=C.+A.+Martinezauthor=S.+Naikauthor=R.+T.+Kambleauthor=A.+G.+Durettauthor=O.+Dakhovaauthor=B.+Savoldoauthor=A.+Di+Stasiauthor=D.+M.+Spencerauthor=Y.+F.+Linauthor=H.+Liuauthor=B.+J.+Grilleyauthor=A.+P.+Geeauthor=C.+M.+Rooneyauthor=H.+E.+Heslopauthor=M.+K.+Brenner&title=Inducible+caspase-9+suicide+gene+controls+adverse+effects+from+alloreplete+T+cells+after+haploidentical+stem+cell+transplantation&doi=10.1182%2Fblood-2015-02-628354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation</span></div><div class="casAuthors">Zhou, Xiaoou; Dotti, Gianpietro; Krance, Robert A.; Martinez, Caridad A.; Naik, Swati; Kamble, Rammurti T.; Durett, April G.; Dakhova, Olga; Savoldo, Barbara; Di Stasi, Antonio; Spencer, David M.; Lin, Yu-Feng; Liu, Hao; Grilley, Bambi J.; Gee, Adrian P.; Rooney, Cliona M.; Heslop, Helen E.; Brenner, Malcolm K.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">4103-4113</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">To test the feasibility of a single T-cell manipulation to eliminate alloreactivity while sparing antiviral and antitumor T cells, we infused 12 haploidentical hematopoietic stem cell transplant patients with increasing nos. of alloreplete haploidentical T cells expressing the inducible caspase 9 suicide gene (iC9-T cells).  We detd. whether the iC9-T cells produced immune reconstitution and if any resultant graft-vs.-host disease (GVHD) could be controlled by administration of a chem. inducer of dimerization (CID; AP1903/Rimiducid).  All patients receiving >104 alloreplete iC9-T lymphocytes per kg achieved rapid reconstitution of immune responses toward 5 major pathogenic viruses and concomitant control of active infections.  Four patients received a single AP1903 dose.  CID infusion eliminated 85% to 95% of circulating CD3+CD19+ T cells within 30 min, with no recurrence of GVHD within 90 days.  In one patient, symptoms and signs of GVHD-assocd. cytokine release syndrome (CRS-hyperpyrexia, high levels of proinflammatory cytokines, and rash) resolved within 2 h of AP1903 infusion.  One patient with varicella zoster virus meningitis and acute GVHD had iC9-T cells present in the cerebrospinal fluid, which were reduced by >90% after CID.  Notably, virus-specific T cells recovered even after AP1903 administration and continued to protect against infection.  Hence, alloreplete iC9-T cells can reconstitute immunity posttransplant and administration of CID can eliminate them from both peripheral blood and the central nervous system (CNS), leading to rapid resoln. of GVHD and CRS.  The approach may therefore be useful for the rapid and effective treatment of toxicities assocd. with infusion of engineered T lymphocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4Vmr9e0JVl7Vg90H21EOLACvtfcHk0lgKZKVWaFW9wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlersrzK&md5=96cc02907194c066252fec9f44308598</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-02-628354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-02-628354%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DDotti%26aufirst%3DG.%26aulast%3DKrance%26aufirst%3DR.%2BA.%26aulast%3DMartinez%26aufirst%3DC.%2BA.%26aulast%3DNaik%26aufirst%3DS.%26aulast%3DKamble%26aufirst%3DR.%2BT.%26aulast%3DDurett%26aufirst%3DA.%2BG.%26aulast%3DDakhova%26aufirst%3DO.%26aulast%3DSavoldo%26aufirst%3DB.%26aulast%3DDi%2BStasi%26aufirst%3DA.%26aulast%3DSpencer%26aufirst%3DD.%2BM.%26aulast%3DLin%26aufirst%3DY.%2BF.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DGrilley%26aufirst%3DB.%2BJ.%26aulast%3DGee%26aufirst%3DA.%2BP.%26aulast%3DRooney%26aufirst%3DC.%2BM.%26aulast%3DHeslop%26aufirst%3DH.%2BE.%26aulast%3DBrenner%26aufirst%3DM.%2BK.%26atitle%3DInducible%2520caspase-9%2520suicide%2520gene%2520controls%2520adverse%2520effects%2520from%2520alloreplete%2520T%2520cells%2520after%2520haploidentical%2520stem%2520cell%2520transplantation%26jtitle%3DBlood%26date%3D2015%26volume%3D125%26spage%3D4103%26epage%3D4113%26doi%3D10.1182%2Fblood-2015-02-628354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendravada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinners, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crisostomo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collinson-Pautz, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pentcheva-Hoang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayle, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slawin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, D. M.</span></span> <span> </span><span class="NLM_article-title">Regulated expansion and survival of chimeric antigen receptor-modified T cells using small molecule-dependent inducible MyD88/CD40</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2176</span>– <span class="NLM_lpage">2188</span>, <span class="refDoi"> DOI: 10.1016/j.ymthe.2017.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.ymthe.2017.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=28697888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKlsbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=2176-2188&author=A.+E.+Fosterauthor=A.+Mahendravadaauthor=N.+P.+Shinnersauthor=W.+C.+Changauthor=J.+Crisostomoauthor=A.+Luauthor=M.+Khalilauthor=E.+Morschlauthor=J.+L.+Shawauthor=S.+Sahaauthor=M.+T.+Duongauthor=M.+R.+Collinson-Pautzauthor=D.+L.+Torresauthor=T.+Rodriguezauthor=T.+Pentcheva-Hoangauthor=J.+H.+Bayleauthor=K.+M.+Slawinauthor=D.+M.+Spencer&title=Regulated+expansion+and+survival+of+chimeric+antigen+receptor-modified+T+cells+using+small+molecule-dependent+inducible+MyD88%2FCD40&doi=10.1016%2Fj.ymthe.2017.06.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40</span></div><div class="casAuthors">Foster, Aaron E.; Mahendravada, Aruna; Shinners, Nicholas P.; Chang, Wei-Chun; Crisostomo, Jeannette; Lu, An; Khalil, Mariam; Morschl, Eva; Shaw, Joanne L.; Saha, Sunandan; Duong, My Linh T.; Collinson-Pautz, Matthew R.; Torres, David L.; Rodriguez, Tania; Pentcheva-Hoang, Tsvetelina; Bayle, J. Henri; Slawin, Kevin M.; Spencer, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2176-2188</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0024</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Anti-tumor efficacy of T cells engineered to express chimeric antigen receptors (CARs) is dependent on their specificity, survival, and in vivo expansion following adoptive transfer.  Toll-like receptor (TLR) and CD40 signaling in T cells can improve persistence and drive proliferation of antigen-specific CD4+ and CD8+ T cells following pathogen challenge or in graft-vs.-host disease (GvHD) settings, suggesting that these costimulatory pathways may be co-opted to improve CAR-T cell persistence and function.  Here, we present a novel strategy to activate TLR and CD40 signaling in human T cells using inducible MyD88/CD40 (iMC), which can be triggered in vivo via the synthetic dimerizing ligand, rimiducid, to provide potent costimulation to CAR-modified T cells.  Importantly, the concurrent activation of iMC (with rimiducid) and CAR (by antigen recognition) is required for interleukin (IL)-2 prodn. and robust CAR-T cell expansion and may provide a user-controlled mechanism to amplify CAR-T cell levels in vivo and augment anti-tumor efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8afsIgYOqCLVg90H21EOLACvtfcHk0lgKZKVWaFW9wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKlsbjI&md5=0c50ee62a00a32ec903b311ae253e9a1</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ymthe.2017.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymthe.2017.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DFoster%26aufirst%3DA.%2BE.%26aulast%3DMahendravada%26aufirst%3DA.%26aulast%3DShinners%26aufirst%3DN.%2BP.%26aulast%3DChang%26aufirst%3DW.%2BC.%26aulast%3DCrisostomo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DA.%26aulast%3DKhalil%26aufirst%3DM.%26aulast%3DMorschl%26aufirst%3DE.%26aulast%3DShaw%26aufirst%3DJ.%2BL.%26aulast%3DSaha%26aufirst%3DS.%26aulast%3DDuong%26aufirst%3DM.%2BT.%26aulast%3DCollinson-Pautz%26aufirst%3DM.%2BR.%26aulast%3DTorres%26aufirst%3DD.%2BL.%26aulast%3DRodriguez%26aufirst%3DT.%26aulast%3DPentcheva-Hoang%26aufirst%3DT.%26aulast%3DBayle%26aufirst%3DJ.%2BH.%26aulast%3DSlawin%26aufirst%3DK.%2BM.%26aulast%3DSpencer%26aufirst%3DD.%2BM.%26atitle%3DRegulated%2520expansion%2520and%2520survival%2520of%2520chimeric%2520antigen%2520receptor-modified%2520T%2520cells%2520using%2520small%2520molecule-dependent%2520inducible%2520MyD88%252FCD40%26jtitle%3DMol.%2520Ther.%26date%3D2017%26volume%3D25%26spage%3D2176%26epage%3D2188%26doi%3D10.1016%2Fj.ymthe.2017.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Stasi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tey, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krance, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durett, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoldo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grilley, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heslop, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotti, G.</span></span> <span> </span><span class="NLM_article-title">Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">3895</span>– <span class="NLM_lpage">3905</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-01-551671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1182%2Fblood-2014-01-551671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=24753538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWhu7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2014&pages=3895-3905&author=X.+Zhouauthor=A.+Di+Stasiauthor=S.+K.+Teyauthor=R.+A.+Kranceauthor=C.+Martinezauthor=K.+S.+Leungauthor=A.+G.+Durettauthor=M.+F.+Wuauthor=H.+Liuauthor=A.+M.+Leenauthor=B.+Savoldoauthor=Y.+F.+Linauthor=B.+J.+Grilleyauthor=A.+P.+Geeauthor=D.+M.+Spencerauthor=C.+M.+Rooneyauthor=H.+E.+Heslopauthor=M.+K.+Brennerauthor=G.+Dotti&title=Long-term+outcome+after+haploidentical+stem+cell+transplant+and+infusion+of+T+cells+expressing+the+inducible+caspase+9+safety+transgene&doi=10.1182%2Fblood-2014-01-551671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene</span></div><div class="casAuthors">Zhou, Xiaoou; Di Stasi, Antonio; Tey, Siok-Keen; Krance, Robert A.; Martinez, Caridad; Leung, Kathryn S.; Durett, April G.; Wu, Meng-Fen; Liu, Hao; Leen, Ann M.; Savoldo, Barbara; Lin, Yu-Feng; Grilley, Bambi J.; Gee, Adrian P.; Spencer, David M.; Rooney, Cliona M.; Heslop, Helen E.; Brenner, Malcolm K.; Dotti, Gianpietro</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">3895-3905</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Adoptive transfer of donor-derived T lymphocytes expressing a safety switch may promote immune reconstitution in patients undergoing haploidentical hematopoietic stem cell transplant (haplo-HSCT) without the risk for uncontrolled graft vs. host disease (GvHD).  Thus, patients who develop GvHD after infusion of allodepleted donor-derived T cells expressing an inducible human caspase 9 (iC9) had their disease effectively controlled by a single administration of a small-mol. drug (AP1903) that dimerizes and activates the iC9 transgene.  We now report the long-term follow-up of 10 patients infused with such safety switch-modified T cells.  We find long-term persistence of iC9-modified (iC9-T) T cells in vivo in the absence of emerging oligoclonality and a robust immunol. benefit, mediated initially by the infused cells themselves and subsequently by an apparently accelerated reconstitution of endogenous naive T lymphocytes.  As a consequence, these patients have immediate and sustained protection from major pathogens, including cytomegalovirus, adenovirus, BK virus, and Epstein-Barr virus in the absence of acute or chronic GvHD, supporting the beneficial effects of this approach to immune reconstitution after haplo-HSCT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos7VrzIKSizrVg90H21EOLACvtfcHk0lgKZKVWaFW9wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWhu7nM&md5=53358083fbcf274c5112b4c0648ca466</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-01-551671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-01-551671%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DDi%2BStasi%26aufirst%3DA.%26aulast%3DTey%26aufirst%3DS.%2BK.%26aulast%3DKrance%26aufirst%3DR.%2BA.%26aulast%3DMartinez%26aufirst%3DC.%26aulast%3DLeung%26aufirst%3DK.%2BS.%26aulast%3DDurett%26aufirst%3DA.%2BG.%26aulast%3DWu%26aufirst%3DM.%2BF.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLeen%26aufirst%3DA.%2BM.%26aulast%3DSavoldo%26aufirst%3DB.%26aulast%3DLin%26aufirst%3DY.%2BF.%26aulast%3DGrilley%26aufirst%3DB.%2BJ.%26aulast%3DGee%26aufirst%3DA.%2BP.%26aulast%3DSpencer%26aufirst%3DD.%2BM.%26aulast%3DRooney%26aufirst%3DC.%2BM.%26aulast%3DHeslop%26aufirst%3DH.%2BE.%26aulast%3DBrenner%26aufirst%3DM.%2BK.%26aulast%3DDotti%26aufirst%3DG.%26atitle%3DLong-term%2520outcome%2520after%2520haploidentical%2520stem%2520cell%2520transplant%2520and%2520infusion%2520of%2520T%2520cells%2520expressing%2520the%2520inducible%2520caspase%25209%2520safety%2520transgene%26jtitle%3DBlood%26date%3D2014%26volume%3D123%26spage%3D3895%26epage%3D3905%26doi%3D10.1182%2Fblood-2014-01-551671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span> <span> </span><span class="NLM_article-title">A Chemical Switch System to Modulate Chimeric Antigen Receptor T Cell Activity through Proteolysis-Targeting Chimaera Technology</span>. <i>ACS Synth. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">987</span>– <span class="NLM_lpage">992</span>, <span class="refDoi"> DOI: 10.1021/acssynbio.9b00476</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acssynbio.9b00476" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotFCkt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=987-992&issue=5&author=S.+M.+Leeauthor=C.+H.+Kangauthor=S.+U.+Choiauthor=Y.+Kimauthor=J.+Y.+Hwangauthor=H.+G.+Jeongauthor=C.+H.+Park&title=A+Chemical+Switch+System+to+Modulate+Chimeric+Antigen+Receptor+T+Cell+Activity+through+Proteolysis-Targeting+Chimaera+Technology&doi=10.1021%2Facssynbio.9b00476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">A Chemical Switch System to Modulate Chimeric Antigen Receptor T Cell Activity through Proteolysis-Targeting Chimaera Technology</span></div><div class="casAuthors">Lee, So Myoung; Kang, Chung Hyo; Choi, Sang Un; Kim, Yeongrin; Hwang, Jong Yeon; Jeong, Hye Gwang; Park, Chi Hoon</div><div class="citationInfo"><span class="NLM_cas:title">ACS Synthetic Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">987-992</span>CODEN:
                <span class="NLM_cas:coden">ASBCD6</span>;
        ISSN:<span class="NLM_cas:issn">2161-5063</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite the excellent efficacy of chimeric antigen receptor (CAR T) cell therapy, concerns about its safety have been constantly raised.  The side effects of CAR T cells result from an aberrantly upregulation of CAR T cell activity.  Therefore, it is crucial to control the CAR T cell activity whenever the patient is at risk.  For this purpose, the iCas9 system, which induces apoptosis in CAR T cell through caspase-9 dimerization by compd., has been invented and is currently going under clin. trial.  However, the iCas9 system is irreversible, as the entire CAR T cell population is removed from the patient.  Thus, CAR T cells, which are very expensive, should be reinfused to the patients after they recovered from the side-effect.  Here, we propose a new CAR T cell safety strategy, which targets CAR "protein", not CAR "T cell".  In this system, the CAR construct is modified to bear a bromodomain (BD).  The addn. of a BD in the CAR protein did not interfere with the original CAR functions, such as cytokine secretion and target cell lysis.  Our data showed that the use of a proteolysis-targeting chimaera (PROTAC) compd. against BD successfully degraded the BD-contg. CAR protein.  Moreover, the CAR expression is recovered when the PROTAC compd. is removed from the cell, demonstrating that our system is reversible.  In a target cell lysis assay, the PROTAC compd. successfully suppressed the lytic activity of CAR T cells by degrading the CAR protein.  In conclusion, we developed a new safety system in which CAR T cells can be "reversibly" controlled by a compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcEdqIGfaX97Vg90H21EOLACvtfcHk0lhMVBloeMidNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotFCkt7c%253D&md5=13fb6d56c3d4dbc74d6954f48e3c48ce</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facssynbio.9b00476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facssynbio.9b00476%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BM.%26aulast%3DKang%26aufirst%3DC.%2BH.%26aulast%3DChoi%26aufirst%3DS.%2BU.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DHwang%26aufirst%3DJ.%2BY.%26aulast%3DJeong%26aufirst%3DH.%2BG.%26aulast%3DPark%26aufirst%3DC.%2BH.%26atitle%3DA%2520Chemical%2520Switch%2520System%2520to%2520Modulate%2520Chimeric%2520Antigen%2520Receptor%2520T%2520Cell%2520Activity%2520through%2520Proteolysis-Targeting%2520Chimaera%2520Technology%26jtitle%3DACS%2520Synth.%2520Biol.%26date%3D2020%26volume%3D9%26issue%3D5%26spage%3D987%26epage%3D992%26doi%3D10.1021%2Facssynbio.9b00476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nandakumar, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.</span></span> <span> </span><span class="NLM_article-title">Design and pharmaceutical applications of proteolysis-targeting chimeric molecules</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">114211</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2020.114211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.bcp.2020.114211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=32866456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVSmsLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2020&pages=114211&author=Y.+Liangauthor=K.+S.+Nandakumarauthor=K.+Cheng&title=Design+and+pharmaceutical+applications+of+proteolysis-targeting+chimeric+molecules&doi=10.1016%2Fj.bcp.2020.114211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Design and pharmaceutical applications of proteolysis-targeting chimeric molecules</span></div><div class="casAuthors">Liang, Yuqing; Nandakumar, Kutty Selva; Cheng, Kui</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">114211</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Proteolysis-targeting chimeras (PROTACs), the hetero-bifunctional compds. contg. a specific ligand to bind the target protein, a suitable linker, and an E3 ubiquitin ligase substrate, are being developed for therapeutic applications.  PROTACs hijack the catalytic activity of ubiquitin E3 ligases to mediate proteasome dependent degrdn. of selected protein of interest (POI), by bringing the ligase and POI into close spatial proximity and initiating the poly-ubiquitination process.  Compared to the traditional small-mol. drugs, PROTACs reduce the problems of dosage, drug resistance, side effects and undruggable targets that could not be targeted pharmacol.  In this review, all the POIs, and peptide to small-mol. based PROTACs developed during the past two decades are summarized and directions for future development are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolWEaC4ysC07Vg90H21EOLACvtfcHk0lhMVBloeMidNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVSmsLvI&md5=1c3c88f438675db747b36683e511d242</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2020.114211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2020.114211%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DNandakumar%26aufirst%3DK.%2BS.%26aulast%3DCheng%26aufirst%3DK.%26atitle%3DDesign%2520and%2520pharmaceutical%2520applications%2520of%2520proteolysis-targeting%2520chimeric%2520molecules%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2020%26volume%3D182%26spage%3D114211%26doi%3D10.1016%2Fj.bcp.2020.114211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varshavsky, A.</span></span> <span> </span><span class="NLM_article-title">N-degron and C-degron pathways of protein degradation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">366</span>, <span class="refDoi"> DOI: 10.1073/pnas.1816596116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1073%2Fpnas.1816596116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=30622213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVKgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=358-366&author=A.+Varshavsky&title=N-degron+and+C-degron+pathways+of+protein+degradation&doi=10.1073%2Fpnas.1816596116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">N-degron and C-degron pathways of protein degradation</span></div><div class="casAuthors">Varshavsky, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">358-366</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A review.  This perspective is partly review and partly proposal.  N-degrons and C-degrons are degrdn. signals whose main determinants are, resp., the N-terminal and C-terminal residues of cellular proteins.  N-degrons and C-degrons include, to varying extents, adjoining sequence motifs, and also internal lysine residues that function as polyubiquitylation sites.  Discovered in 1986, N-degrons were the first degrdn. signals in short-lived proteins.  A particularly large set of C-degrons was discovered in 2018.  We describe multifunctional proteolytic systems that target N-degrons and C-degrons.  We also propose to denote these systems as "N-degron pathways" and "C-degron pathways.".  The former notation replaces the earlier name "N-end rule pathways.".  The term "N-end rule" was introduced 33 years ago, when only some N-terminal residues were thought to be destabilizing.  However, studies over the last three decades have shown that all 20 amino acids of the genetic code can act, in cognate sequence contexts, as destabilizing N-terminal residues.  Advantages of the proposed terms include their brevity and semantic uniformity for N-degrons and C-degrons.  In addn. to being topol. analogous, N-degrons and C-degrons are related functionally.  A proteolytic cleavage of a subunit in a multisubunit complex can create, at the same time, an N-degron (in a C-terminal fragment) and a spatially adjacent C-degron (in an N-terminal fragment).  Consequently, both fragments of a subunit can be selectively destroyed through attacks by the N-degron and C-degron pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr80d0bxpecnLVg90H21EOLACvtfcHk0liW5VFWjtMNIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVKgtQ%253D%253D&md5=c9a7b5260caf96d886af0376e0d92a26</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1816596116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1816596116%26sid%3Dliteratum%253Aachs%26aulast%3DVarshavsky%26aufirst%3DA.%26atitle%3DN-degron%2520and%2520C-degron%2520pathways%2520of%2520protein%2520degradation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26volume%3D116%26spage%3D358%26epage%3D366%26doi%3D10.1073%2Fpnas.1816596116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouchnak, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Wijk, K. J.</span></span> <span> </span><span class="NLM_article-title">N-Degron Pathways in Plastids</span>. <i>Trends Plant Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.1016/j.tplants.2019.06.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.tplants.2019.06.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=31300194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlWnsLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=917-926&author=I.+Bouchnakauthor=K.+J.+van+Wijk&title=N-Degron+Pathways+in+Plastids&doi=10.1016%2Fj.tplants.2019.06.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">N-Degron Pathways in Plastids</span></div><div class="casAuthors">Bouchnak, Imen; van Wijk, Klaas J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Plant Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">917-926</span>CODEN:
                <span class="NLM_cas:coden">TPSCF9</span>;
        ISSN:<span class="NLM_cas:issn">1360-1385</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein amino (N) termini are major determinants of protein stability in the cytosol of eukaryotes and prokaryotes, conceptualized in the N-end rule pathway, lately referred to as N-degron pathways.  Here we argue for the existence of N-degron pathways in plastids of apicomplexa, algae, and plants.  The prokaryotic N-degron pathway depends on a caseinolytic protease (CLP) S recognin (adaptor) for the recognition and delivery of N-degron-bearing substrates to CLP chaperone-protease systems.  Diversified CLP systems are found in chloroplasts and nonphotosynthetic plastids, including CLPS homologs that specifically interact with a subset of N-terminal residues and stromal proteins.  Chloroplast N-terminome data show enrichment of classic stabilizing residues [Ala (A), Ser (S), Val (V), Thr (T)] and avoidance of charged and large hydrophobic residues.  We outline exptl. test strategies for plastid N-degron pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqWt_-Ft_KmrVg90H21EOLACvtfcHk0liW5VFWjtMNIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlWnsLbM&md5=b43b80eedbf2cf6c28789f585687202c</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.tplants.2019.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tplants.2019.06.013%26sid%3Dliteratum%253Aachs%26aulast%3DBouchnak%26aufirst%3DI.%26aulast%3Dvan%2BWijk%26aufirst%3DK.%2BJ.%26atitle%3DN-Degron%2520Pathways%2520in%2520Plastids%26jtitle%3DTrends%2520Plant%2520Sci.%26date%3D2019%26volume%3D24%26spage%3D917%26epage%3D926%26doi%3D10.1016%2Fj.tplants.2019.06.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabek, N.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin ligases: structure, function, and regulation</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1146/annurev-biochem-060815-014922</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1146%2Fannurev-biochem-060815-014922" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=28375744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsFShsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2017&pages=129-157&author=N.+Zhengauthor=N.+Shabek&title=Ubiquitin+ligases%3A+structure%2C+function%2C+and+regulation&doi=10.1146%2Fannurev-biochem-060815-014922"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin Ligases: Structure, Function, and Regulation</span></div><div class="casAuthors">Zheng, Ning; Shabek, Nitzan</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">129-157</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  Ubiquitin E3 ligases control every aspect of eukaryotic biol. by promoting protein ubiquitination and degrdn.  At the end of a three-enzyme cascade, ubiquitin ligases mediate the transfer of ubiquitin from an E2 ubiquitin-conjugating enzyme to specific substrate proteins.  Early investigations of E3s of the RING (really interesting new gene) and HECT (homologous to the E6AP carboxyl terminus) types shed light on their enzymic activities, general architectures, and substrate degron-binding modes.  Recent studies have provided deeper mechanistic insights into their catalysis, activation, and regulation.  In this review, we summarize the current progress in structure-function studies of ubiquitin ligases as well as exciting new discoveries of novel classes of E3s and diverse substrate recognition mechanisms.  Our increased understanding of ubiquitin ligase function and regulation has provided the rationale for developing E3-targeting therapeutics for the treatment of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq6AYlt-T3-bVg90H21EOLACvtfcHk0liW5VFWjtMNIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsFShsb0%253D&md5=3e9fde71ba7871385290f118fc4a768a</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1146%2Fannurev-biochem-060815-014922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-biochem-060815-014922%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DN.%26aulast%3DShabek%26aufirst%3DN.%26atitle%3DUbiquitin%2520ligases%253A%2520structure%252C%2520function%252C%2520and%2520regulation%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2017%26volume%3D86%26spage%3D129%26epage%3D157%26doi%3D10.1146%2Fannurev-biochem-060815-014922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yesbolatova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tominari, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanemaki, M. T.</span></span> <span> </span><span class="NLM_article-title">Ligand-induced genetic degradation as a tool for target validation</span>. <i>Drug Discovery Today: Technol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1016/j.ddtec.2018.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.ddtec.2018.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=31200864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BB3M3mvFWrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2019&pages=91-98&author=A.+Yesbolatovaauthor=Y.+Tominariauthor=M.+T.+Kanemaki&title=Ligand-induced+genetic+degradation+as+a+tool+for+target+validation&doi=10.1016%2Fj.ddtec.2018.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-induced genetic degradation as a tool for target validation</span></div><div class="casAuthors">Yesbolatova Aisha; Tominari Yusuke; Kanemaki Masato T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today. Technologies</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">91-98</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Targeted protein degraders, known as proteolysis targeting chimeras (PROTACs), are drawing more attention as next-generation drugs to target currently undruggable proteins.  As drug discovery of functional degraders involves time- and cost-consuming laborious processes, we propose employing a ligand-induced genetic degradation system to validate candidate proteins before degrader development.  Genetic degradation mimics degrader treatment by depleting a degron-fused protein in the presence of a defined ligand.  All genetic systems use a combination of a degron and defined ligand that enables a protein of interest fused with the degron to be recruited to an E3 ubiquitin ligase for ubiquitylation and subsequent degradation by the proteasome.  However, these events are based on different principles and have different features.  We review the dTAG, HaloTag-based, auxin-inducible degron (AID), and destabilizing domain (DD) systems and discuss a strategy for degrader discovery against novel target proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQCRHissLLXoXy-c-E1v-fmfW6udTcc2eYAgNGmkNb1frntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3mvFWrug%253D%253D&md5=5ef6a19eda7b6714683b019ac7a0e521</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2018.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2018.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DYesbolatova%26aufirst%3DA.%26aulast%3DTominari%26aufirst%3DY.%26aulast%3DKanemaki%26aufirst%3DM.%2BT.%26atitle%3DLigand-induced%2520genetic%2520degradation%2520as%2520a%2520tool%2520for%2520target%2520validation%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2019%26volume%3D31%26spage%3D91%26epage%3D98%26doi%3D10.1016%2Fj.ddtec.2018.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busser, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temburni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirot, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchateau, P.</span></span> <span> </span><span class="NLM_article-title">Modulation of chimeric antigen receptor surface expression by a small molecule switch</span>. <i>BMC Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">44</span>, <span class="refDoi"> DOI: 10.1186/s12896-019-0537-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1186%2Fs12896-019-0537-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=31269942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BB3MzjvVSgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=44&author=A.+Juilleratauthor=D.+Tkachauthor=B.+W.+Busserauthor=S.+Temburniauthor=J.+Valtonauthor=A.+Duclertauthor=L.+Poirotauthor=S.+Depilauthor=P.+Duchateau&title=Modulation+of+chimeric+antigen+receptor+surface+expression+by+a+small+molecule+switch&doi=10.1186%2Fs12896-019-0537-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of chimeric antigen receptor surface expression by a small molecule switch</span></div><div class="casAuthors">Juillerat Alexandre; Tkach Diane; Busser Brian W; Temburni Sonal; Valton Julien; Duclert Aymeric; Poirot Laurent; Depil Stephane; Duchateau Philippe</div><div class="citationInfo"><span class="NLM_cas:title">BMC biotechnology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Engineered therapeutic cells have attracted a great deal of interest due to their potential applications in treating a wide range of diseases, including cancer and autoimmunity.  Chimeric antigen receptor (CAR) T-cells are designed to detect and kill tumor cells that present a specific, predefined antigen.  The rapid expansion of targeted antigen beyond CD19, has highlighted new challenges, such as autoactivation and T-cell fratricide, that could impact the capacity to manufacture engineered CAR T-cells.  Therefore, the development of strategies to control CAR expression at the surface of T-cells and their functions is under intense investigations.  RESULTS:  Here, we report the development and evaluation of an off-switch directly embedded within a CAR construct (SWIFF-CAR).  The incorporation of a self-cleaving degradation moiety controlled by a protease/protease inhibitor pair allowed the ex vivo tight and reversible control of the CAR surface presentation and the subsequent CAR-induced signaling and cytolytic functions of the engineered T-cells using the cell permeable Asunaprevir (ASN) small molecule.  CONCLUSIONS:  The strategy described in this study could, in principle, be broadly adapted to CAR T-cells development to circumvent some of the possible hurdle of CAR T-cell manufacturing.  This system essentially creates a CAR T-cell with an integrated functional rheostat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR1CKVhGP9EQmyYR5VtavbzfW6udTcc2eYtwFMyVT0Zjrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzjvVSgug%253D%253D&md5=f6bbb44e0e41a0b470027b61c8f480d6</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1186%2Fs12896-019-0537-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12896-019-0537-3%26sid%3Dliteratum%253Aachs%26aulast%3DJuillerat%26aufirst%3DA.%26aulast%3DTkach%26aufirst%3DD.%26aulast%3DBusser%26aufirst%3DB.%2BW.%26aulast%3DTemburni%26aufirst%3DS.%26aulast%3DValton%26aufirst%3DJ.%26aulast%3DDuclert%26aufirst%3DA.%26aulast%3DPoirot%26aufirst%3DL.%26aulast%3DDepil%26aufirst%3DS.%26aulast%3DDuchateau%26aufirst%3DP.%26atitle%3DModulation%2520of%2520chimeric%2520antigen%2520receptor%2520surface%2520expression%2520by%2520a%2520small%2520molecule%2520switch%26jtitle%3DBMC%2520Biotechnol.%26date%3D2019%26volume%3D19%26spage%3D44%26doi%3D10.1186%2Fs12896-019-0537-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, K. G.</span></span> <span> </span><span class="NLM_article-title">PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">7124</span>– <span class="NLM_lpage">7129</span>, <span class="refDoi"> DOI: 10.1073/pnas.1521738113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1073%2Fpnas.1521738113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=27274052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC28Xptlyqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=7124-7129&issue=26&author=K.+Rainaauthor=J.+Luauthor=Y.+Qianauthor=M.+Altieriauthor=D.+Gordonauthor=A.+M.+Rossiauthor=J.+Wangauthor=X.+Chenauthor=H.+Dongauthor=K.+Siuauthor=J.+D.+Winklerauthor=A.+P.+Crewauthor=C.+M.+Crewsauthor=K.+G.+Coleman&title=PROTAC-induced+BET+protein+degradation+as+a+therapy+for+castration-resistant+prostate+cancer&doi=10.1073%2Fpnas.1521738113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer</span></div><div class="casAuthors">Raina, Kanak; Lu, Jing; Qian, Yimin; Altieri, Martha; Gordon, Deborah; Rossi, Ann Marie K.; Wang, Jing; Chen, Xin; Dong, Hanqing; Siu, Kam; Winkler, James D.; Crew, Andrew P.; Crews, Craig M.; Coleman, Kevin G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7124-7129</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Prostate cancer has the second highest incidence among cancers in men worldwide and is the second leading cause of cancer deaths of men in the United States.  Although androgen deprivation can initially lead to remission, the disease often progresses to castration-resistant prostate cancer (CRPC), which is still reliant on androgen receptor (AR) signaling and is assocd. with a poor prognosis.  Some success against CRPC has been achieved by drugs that target AR signaling, but secondary resistance invariably emerges, and new therapies are urgently needed.  Recently, inhibitors of bromodomain and extra-terminal (BET) family proteins have shown growth-inhibitory activity in preclin. models of CRPC.  Here, we demonstrate that ARV-771, a small-mol. pan-BET degrader based on proteolysis-targeting chimera (PROTAC) technol., demonstrates dramatically improved efficacy in cellular models of CRPC as compared with BET inhibition.  Unlike BET inhibitors, ARV-771 results in suppression of both AR signaling and AR levels and leads to tumor regression in a CRPC mouse xenograft model.  This study is, to our knowledge, the first to demonstrate efficacy with a small-mol. BET degrader in a solid-tumor malignancy and potentially represents an important therapeutic advance in the treatment of CRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD7QtYgZVig7Vg90H21EOLACvtfcHk0liP0fWiTyYquQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xptlyqs7s%253D&md5=34218e685ad72950f3eb85586110c43d</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1521738113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1521738113%26sid%3Dliteratum%253Aachs%26aulast%3DRaina%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DAltieri%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DD.%26aulast%3DRossi%26aufirst%3DA.%2BM.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DSiu%26aufirst%3DK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26aulast%3DColeman%26aufirst%3DK.%2BG.%26atitle%3DPROTAC-induced%2520BET%2520protein%2520degradation%2520as%2520a%2520therapy%2520for%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26issue%3D26%26spage%3D7124%26epage%3D7129%26doi%3D10.1073%2Fpnas.1521738113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">755</span>– <span class="NLM_lpage">763</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2015.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.chembiol.2015.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=26051217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWrtbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=755-763&issue=6&author=J.+Luauthor=Y.+Qianauthor=M.+Altieriauthor=H.+Dongauthor=J.+Wangauthor=K.+Rainaauthor=J.+Hinesauthor=J.+D.+Winklerauthor=A.+P.+Crewauthor=K.+Colemanauthor=C.+M.+Crews&title=Hijacking+the+E3+ubiquitin+ligase+cereblon+to+efficiently+target+BRD4&doi=10.1016%2Fj.chembiol.2015.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4</span></div><div class="casAuthors">Lu, Jing; Qian, Yimin; Altieri, Martha; Dong, Hanqing; Wang, Jing; Raina, Kanak; Hines, John; Winkler, James D.; Crew, Andrew P.; Coleman, Kevin; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">755-763</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">BRD4, a bromodomain and extraterminal domain (BET) family member, is an attractive target in multiple pathol. settings, particularly cancer.  While BRD4 inhibitors have shown some promise in MYC-driven malignancies such as Burkitt's lymphoma (BL), we show that BRD4 inhibitors lead to robust BRD4 protein accumulation, which may account for their limited suppression of MYC expression, modest antiproliferative activity, and lack of apoptotic induction.  To address these limitations we designed ARV-825, a hetero-bifunctional PROTAC (Proteolysis Targeting Chimera) that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degrdn. of BRD4 in all BL cell lines tested.  Consequently, ARV-825 more effectively suppresses c-MYC levels and downstream signaling than small-mol. BRD4 inhibitors, resulting in more effective cell proliferation inhibition and apoptosis induction in BL.  Our findings provide strong evidence that cereblon-based PROTACs provide a better and more efficient strategy in targeting BRD4 than traditional small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Ol4grCG2RbVg90H21EOLACvtfcHk0ljFtbH22JbVZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWrtbrM&md5=a64675e7a0cd006a8737be9730f447e3</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2015.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2015.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DAltieri%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DRaina%26aufirst%3DK.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DColeman%26aufirst%3DK.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DHijacking%2520the%2520E3%2520ubiquitin%2520ligase%2520cereblon%2520to%2520efficiently%2520target%2520BRD4%26jtitle%3DChem.%2520Biol.%26date%3D2015%26volume%3D22%26issue%3D6%26spage%3D755%26epage%3D763%26doi%3D10.1016%2Fj.chembiol.2015.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khire, U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albelda, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milone, M. C.</span></span> <span> </span><span class="NLM_article-title">Ligand-induced degradation of a CAR permits reversible remote control of CAR T cell activity in vitro and in vivo</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1600</span>– <span class="NLM_lpage">1613</span>, <span class="refDoi"> DOI: 10.1016/j.ymthe.2020.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.ymthe.2020.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=32559430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlKktrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=1600-1613&author=S.+A.+Richmanauthor=L.-C.+Wangauthor=E.+K.+Moonauthor=U.+R.+Khireauthor=S.+M.+Albeldaauthor=M.+C.+Milone&title=Ligand-induced+degradation+of+a+CAR+permits+reversible+remote+control+of+CAR+T+cell+activity+in+vitro+and+in+vivo&doi=10.1016%2Fj.ymthe.2020.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity In Vitro and In Vivo</span></div><div class="casAuthors">Richman, Sarah A.; Wang, Liang-Chuan; Khire, Uday R.; Albelda, Steven M.; Milone, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1600-1613</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0024</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Chimeric antigen receptor (CAR)-modified T cells are endowed with novel antigen specificity and are most often administered to patients without an engineered mechanism to control the CAR T cells once infused.  "Suicide switches" such as the small mol.-controlled, inducible caspase-9 (iCas9) system afford the ability to selectively eliminate engineered T cells; however, these approaches are designed for all-or-none, irreversible termination of an ongoing immune response.  In order to permit reversible and adjustable modulation, we have created a CAR that is capable of on-demand downregulation by fusing the CAR to a previously developed ligand-induced degrdn. (LID) domain.  Addn. of a small mol. ligand triggers exposure of a cryptic degron within the LID domain, resulting in proteasomal degrdn. of the CAR-LID fusion protein and loss of CAR on the surface of T cells.  This fusion construct allowed for reversible and "tunable" inhibition of CAR T cell activity in vitro.  Delivery of the triggering mol. in CAR-LID-treated tumor-bearing mice temporarily reduced CAR activity through modulation of CAR surface expression.  The ability to more flexibly modulate CAR T cell expression through a small mol. provides a platform for controlling possible adverse side effects, as well as preclin. investigations of CAR T cell biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh1TTSO6Te2rVg90H21EOLACvtfcHk0ljFtbH22JbVZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlKktrjE&md5=a88451f909e111847690b616a0c52862</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.ymthe.2020.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymthe.2020.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DRichman%26aufirst%3DS.%2BA.%26aulast%3DWang%26aufirst%3DL.-C.%26aulast%3DMoon%26aufirst%3DE.%2BK.%26aulast%3DKhire%26aufirst%3DU.%2BR.%26aulast%3DAlbelda%26aufirst%3DS.%2BM.%26aulast%3DMilone%26aufirst%3DM.%2BC.%26atitle%3DLigand-induced%2520degradation%2520of%2520a%2520CAR%2520permits%2520reversible%2520remote%2520control%2520of%2520CAR%2520T%2520cell%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Ther.%26date%3D2020%26volume%3D28%26spage%3D1600%26epage%3D1613%26doi%3D10.1016%2Fj.ymthe.2020.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weichsel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wooldridge, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenton-May, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewell, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zezula, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gostick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einsele, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seggewiss, R.</span></span> <span> </span><span class="NLM_article-title">Profound inhibition of antigen-specific T-cell effector functions by dasatinib</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2484</span>– <span class="NLM_lpage">2491</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-4393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1158%2F1078-0432.CCR-07-4393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=18413841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvFGmur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=2484-2491&issue=8&author=R.+Weichselauthor=C.+Dixauthor=L.+Wooldridgeauthor=M.+Clementauthor=A.+Fenton-Mayauthor=A.+K.+Sewellauthor=J.+Zezulaauthor=E.+Greinerauthor=E.+Gostickauthor=D.+A.+Priceauthor=H.+Einseleauthor=R.+Seggewiss&title=Profound+inhibition+of+antigen-specific+T-cell+effector+functions+by+dasatinib&doi=10.1158%2F1078-0432.CCR-07-4393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib</span></div><div class="casAuthors">Weichsel, Ralf; Dix, Carolin; Wooldridge, Linda; Clement, Matthew; Fenton-May, Angharad; Sewell, Andrew K.; Zezula, Josef; Greiner, Elisabeth; Gostick, Emma; Price, David A.; Einsele, Hermann; Seggewiss, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2484-2491</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The dual BCR-ABL/SRC kinase inhibitor dasatinib entered the clinic for the treatment of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia.  Because SRC kinases are known to play an important role in physiol. T-cell activation, we analyzed the immunobiol. effects of dasatinib on T-cell function.  The effect of dasatinib on multiple T-cell effector functions was examd. at clin. relevant doses (1-100 nmol/L); the promiscuous tyrosine kinase inhibitor staurosporine was used as a comparator.  Purified human CD3+ cells and virus-specific CD8+ T cells from healthy blood donors were studied directly ex vivo; antigen-specific effects were confirmed in defined T-cell clones.  Functional outcomes included cytokine prodn. (interleukin-2, IFNγ, and tumor necrosis factor α), degranulation (CD107a/b mobilization), activation (CD69 up-regulation), proliferation (carboxyfluorescein diacetate succinimidyl ester diln.), apoptosis/necrosis induction, and signal transduction.  Both dasatinib and staurosporine inhibited T-cell activation, proliferation, cytokine prodn., and degranulation in a dose-dependent manner.  Mechanistically, this was mediated by the blockade of early signal transduction events and was not due to loss of T-cell viability.  Overall, CD4+ T cells seemed to be more sensitive to these effects than CD8+ T cells, and naive T cells more sensitive than memory T-cell subsets.  The inhibitory effects of dasatinib were so profound that all T-cell effector functions were shut down at therapeutically relevant concns.  These findings indicate that caution is warranted with use of this drug in the clin. setting and provide a rationale to explore the potential of dasatinib as an immunosuppressant in the fields of transplantation and T-cell-driven autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLsnjesiG2xrVg90H21EOLACvtfcHk0lhsPMb3GTNzsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvFGmur0%253D&md5=9260418b1ccea3b8d3a99caab450c762</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-4393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-4393%26sid%3Dliteratum%253Aachs%26aulast%3DWeichsel%26aufirst%3DR.%26aulast%3DDix%26aufirst%3DC.%26aulast%3DWooldridge%26aufirst%3DL.%26aulast%3DClement%26aufirst%3DM.%26aulast%3DFenton-May%26aufirst%3DA.%26aulast%3DSewell%26aufirst%3DA.%2BK.%26aulast%3DZezula%26aufirst%3DJ.%26aulast%3DGreiner%26aufirst%3DE.%26aulast%3DGostick%26aufirst%3DE.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DEinsele%26aufirst%3DH.%26aulast%3DSeggewiss%26aufirst%3DR.%26atitle%3DProfound%2520inhibition%2520of%2520antigen-specific%2520T-cell%2520effector%2520functions%2520by%2520dasatinib%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26issue%3D8%26spage%3D2484%26epage%3D2491%26doi%3D10.1158%2F1078-0432.CCR-07-4393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riesenberg, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Development of molecular and pharmacological switches for chimeric antigen receptor T cells</span>. <i>Exp. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">27</span>, <span class="refDoi"> DOI: 10.1186/s40164-019-0151-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1186%2Fs40164-019-0151-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=31709128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A280%3ADC%252BB3Mjntl2isA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=27&author=B.+X.+Wuauthor=N.+J.+Songauthor=B.+P.+Riesenbergauthor=Z.+Li&title=Development+of+molecular+and+pharmacological+switches+for+chimeric+antigen+receptor+T+cells&doi=10.1186%2Fs40164-019-0151-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Development of molecular and pharmacological switches for chimeric antigen receptor T cells</span></div><div class="casAuthors">Wu Bill X; Song No-Joon; Riesenberg Brian P; Li Zihai</div><div class="citationInfo"><span class="NLM_cas:title">Experimental hematology & oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27</span>
        ISSN:<span class="NLM_cas:issn">2162-3619</span>.
    </div><div class="casAbstract">The use of chimeric antigen receptor (CAR) T cell technology as a therapeutic strategy for the treatment blood-born human cancers has delivered outstanding clinical efficacy.  However, this treatment modality can also be associated with serious adverse events in the form of cytokine release syndrome.  While several avenues are being pursued to limit the off-target effects, it is critically important that any intervention strategy has minimal consequences on long term efficacy.  A recent study published in Science Translational Medicine by Dr.  Hudecek's group proved that dasatinib, a tyrosine kinase inhibitor, can serve as an on/off switch for CD19-CAR-T cells in preclinical models by limiting toxicities while maintaining therapeutic efficacy.  In this editorial, we discuss the recent strategies for generating safer CAR-T cells, and also important questions surrounding the use of dasatinib for emergency intervention of CAR-T cell mediated cytokine release syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeAtUkKoWv1wwxfk_AGB-EfW6udTcc2eb3OWUPyBx7aLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mjntl2isA%253D%253D&md5=6997da39a387268a330c523e8796a837</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1186%2Fs40164-019-0151-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40164-019-0151-z%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%2BX.%26aulast%3DSong%26aufirst%3DN.%2BJ.%26aulast%3DRiesenberg%26aufirst%3DB.%2BP.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DDevelopment%2520of%2520molecular%2520and%2520pharmacological%2520switches%2520for%2520chimeric%2520antigen%2520receptor%2520T%2520cells%26jtitle%3DExp.%2520Hematol.%2520Oncol.%26date%3D2019%26volume%3D8%26spage%3D27%26doi%3D10.1186%2Fs40164-019-0151-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mestermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giavridis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rydzek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nerreter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mades, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadelain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einsele, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudecek, M.</span></span> <span> </span><span class="NLM_article-title">The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">eaau5907</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aau5907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1126%2Fscitranslmed.aau5907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=31270272" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&author=K.+Mestermannauthor=T.+Giavridisauthor=J.+Weberauthor=J.+Rydzekauthor=S.+Frenzauthor=T.+Nerreterauthor=A.+Madesauthor=M.+Sadelainauthor=H.+Einseleauthor=M.+Hudecek&title=The+tyrosine+kinase+inhibitor+dasatinib+acts+as+a+pharmacologic+on%2Foff+switch+for+CAR+T+cells&doi=10.1126%2Fscitranslmed.aau5907"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aau5907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aau5907%26sid%3Dliteratum%253Aachs%26aulast%3DMestermann%26aufirst%3DK.%26aulast%3DGiavridis%26aufirst%3DT.%26aulast%3DWeber%26aufirst%3DJ.%26aulast%3DRydzek%26aufirst%3DJ.%26aulast%3DFrenz%26aufirst%3DS.%26aulast%3DNerreter%26aufirst%3DT.%26aulast%3DMades%26aufirst%3DA.%26aulast%3DSadelain%26aufirst%3DM.%26aulast%3DEinsele%26aufirst%3DH.%26aulast%3DHudecek%26aufirst%3DM.%26atitle%3DThe%2520tyrosine%2520kinase%2520inhibitor%2520dasatinib%2520acts%2520as%2520a%2520pharmacologic%2520on%252Foff%2520switch%2520for%2520CAR%2520T%2520cells%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26doi%3D10.1126%2Fscitranslmed.aau5907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynn, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotillo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lattin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackall, C. L.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic control of CAR-T cell function using dasatinib</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">717</span>, <span class="refDoi"> DOI: 10.1182/bloodadvances.2018028720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1182%2Fbloodadvances.2018028720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=30814055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslyhtrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&pages=711-717&author=E.+W.+Weberauthor=R.+C.+Lynnauthor=E.+Sotilloauthor=J.+Lattinauthor=P.+Xuauthor=C.+L.+Mackall&title=Pharmacologic+control+of+CAR-T+cell+function+using+dasatinib&doi=10.1182%2Fbloodadvances.2018028720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic control of CAR-T cell function using dasatinib</span></div><div class="casAuthors">Weber, Evan W.; Lynn, Rachel C.; Sotillo, Elena; Lattin, John; Xu, Peng; Mackall, Crystal L.</div><div class="citationInfo"><span class="NLM_cas:title">Blood Advances</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">711-717</span>CODEN:
                <span class="NLM_cas:coden">BALDBA</span>;
        ISSN:<span class="NLM_cas:issn">2473-9537</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Chimeric antigen receptor (CAR) T-cell therapy mediates high response rates in relapsed/refractory B-cell malignancies.  Given the similarities in the manner in which TCRs and CARs transduce intracellular signals, the author hypothesized that dasatinib would suppress CAR-T cell activation and function.  To assess the effects of dasatinib on human CAR-T cell activation, CD19.28ζ or CD19.BBζ CAR-T cells with CD19+ Nalm6-GL target cells was cocultured with escalating concns. of dasatinib.  The results provide a compelling basis for testing dasatinib in the treatment of CAR-assocd. neurotoxicity (CRES).  In summary, the novel observation that a com. available, well-tolerated oral agent directly and reversibly modulating CAR-T cell functionality has been reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprc5E8M13uR7Vg90H21EOLACvtfcHk0lhsPMb3GTNzsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslyhtrfP&md5=27226fdcf4b1394c890a1449bc2fc1a7</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2018028720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2018028720%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DE.%2BW.%26aulast%3DLynn%26aufirst%3DR.%2BC.%26aulast%3DSotillo%26aufirst%3DE.%26aulast%3DLattin%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DMackall%26aufirst%3DC.%2BL.%26atitle%3DPharmacologic%2520control%2520of%2520CAR-T%2520cell%2520function%2520using%2520dasatinib%26jtitle%3DBlood%2520Adv.%26date%3D2019%26volume%3D3%26spage%3D711%26epage%3D717%26doi%3D10.1182%2Fbloodadvances.2018028720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blake, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayrhofer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, A. B.</span></span> <span> </span><span class="NLM_article-title">The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro</span>. <i>Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>127</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">330</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1016/j.clim.2008.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=10.1016%2Fj.clim.2008.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=18395492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmt12ru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2008&pages=330-339&issue=3&author=S.+Blakeauthor=T.+P.+Hughesauthor=G.+Mayrhoferauthor=A.+B.+Lyons&title=The+Src%2FABL+kinase+inhibitor+dasatinib+%28BMS-354825%29+inhibits+function+of+normal+human+T-lymphocytes+in+vitro&doi=10.1016%2Fj.clim.2008.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro</span></div><div class="casAuthors">Blake, Stephen; Hughes, Timothy P.; Mayrhofer, Graham; Lyons, A. Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">330-339</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Dasatinib (BMS-354825) is a Src/ABL tyrosine kinase inhibitor currently approved for the treatment of chronic myeloid leukemia.  Dasatinib has increased potency against ABL compared to the current therapy imatinib, and is effective in many cases where disease is resistant to imatinib.  Dasatinib also inhibits many Src-family tyrosine kinases.  We have demonstrated in this study that dasatinib is able to block the function of normal human T-lymphocytes in vitro at clin. relevant concns.  T-cell functions including proliferation, activation and cytokine prodn. were all uniformly inhibited in the presence of dasatinib.  We also demonstrated inhibition of TCR signaling through Src-family kinase LCK, and predicted that inhibition of LCK and other kinases involved in T-cell signaling by dasatinib is responsible for the suppression of T-cell function.  These findings raise the concern about potential T-cell inhibition in patients taking dasatinib, and suggest a possible application for the treatment of T-cell mediated immune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon59yxL66SFLVg90H21EOLACvtfcHk0lh86QTdsLsL5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmt12ru7c%253D&md5=59574b5a4a2bf4e774a152e74d57850e</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2008.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2008.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DT.%2BP.%26aulast%3DMayrhofer%26aufirst%3DG.%26aulast%3DLyons%26aufirst%3DA.%2BB.%26atitle%3DThe%2520Src%252FABL%2520kinase%2520inhibitor%2520dasatinib%2520%2528BMS-354825%2529%2520inhibits%2520function%2520of%2520normal%2520human%2520T-lymphocytes%2520in%2520vitro%26jtitle%3DClin.%2520Immunol.%26date%3D2008%26volume%3D127%26issue%3D3%26spage%3D330%26epage%3D339%26doi%3D10.1016%2Fj.clim.2008.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c02054&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c02054%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-14" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c02054" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67990e2bbb173ce2","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
